



(86) **Date de dépôt PCT/PCT Filing Date:** 2013/03/15
(87) **Date publication PCT/PCT Publication Date:** 2013/09/19
(85) **Entrée phase nationale/National Entry:** 2014/09/11
(86) **N° demande PCT/PCT Application No.:** US 2013/032686
(87) **N° publication PCT/PCT Publication No.:** 2013/138795
(30) **Priorité/Priority:** 2012/03/15 (US61/611,493)

(51) **Cl.Int./Int.Cl. C07K 19/00** (2006.01),
C07K 14/00 (2006.01), **C07K 14/50** (2006.01),
C07K 16/00 (2006.01), **C07K 16/18** (2006.01),
C07K 16/44 (2006.01)

(71) **Demandeur/Applicant:**
PERMEON BIOLOGICS, INC., US

(72) **Inventeurs/Inventors:**
VOGAN, ERIK M., US;
FRANZUSOFF, ALEX, US;
EDWARDS, JOHN, US;
DEWITT, ANN, US

(74) **Agent:** SMART & BIGGAR

(54) **Titre : COMPOSITIONS PENETRANT LES CELLULES POUR L'ADMINISTRATION D'ANTICORPS INTRACELLULAIRES ET DE
GROUPES FONCTIONNELS INTRACELLULAIRES SEMBLABLES AUX ANTICORPS, ET PROCEDES D'UTILISATION**
(54) **Title: CELL PENETRATING COMPOSITIONS FOR DELIVERY OF INTRACELLULAR ANTIBODIES AND ANTIBODY-LIKE
MOIETIES AND METHODS OF USE**

(57) **Abrégé/Abstract:**

The disclosure relates to a complex comprising a Surf+ Penetrating Polypeptide and an AAM moiety for intracellular delivery, and methods of use.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2013 (19.09.2013)

(10) International Publication Number
WO 2013/138795 A1

(51) International Patent Classification:

C07K 19/00 (2006.01) C07K 16/44 (2006.01)
C07K 16/00 (2006.01) C07K 14/50 (2006.01)
C07K 14/00 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2013/032686

(22) International Filing Date:

15 March 2013 (15.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/611,493 15 March 2012 (15.03.2012) US

(71) Applicant: PERMEON BIOLOGICS, INC. [US/US];
One Kendall Square, Cambridge, MA 02139 (US).

(72) Inventors; and

(71) Applicants (for US only): VOGAN, Erik, M. [US/US];
250 East Border Road, Medford, MA 02155 (US). FRAN-
ZUSOFF, Alex [US/US]; 80 Little Nahant Road, Nahant,
MA 01908 (US). EDWARDS, John [US/US]; 2700 North
Ocean Drive, Singer Island, FL 33404 (US). DEWITT,
Ann [US/US]; 1578 Cambridge Street #6, Cambridge, MA
02138 (US).

(74) Agents: VARMA, Anita et al.; Ropes & Gray LLP,
Prudential Tower, 800 Boylston Street, Boston, MA 02199
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: CELL PENETRATING COMPOSITIONS FOR DELIVERY OF INTRACELLULAR ANTIBODIES AND ANTI-
BODY-LIKE MOIETIES AND METHODS OF USE

(57) Abstract: The disclosure relates to a complex comprising a Surf+ Penetrating Polypeptide and an AAM moiety for intracellular
delivery, and methods of use.

WO 2013/138795 A1

5

**CELL PENETRATING COMPOSITIONS FOR DELIVERY OF
INTRACELLULAR ANTIBODIES AND ANTIBODY-LIKE MOIETIES AND
METHODS OF USE**

10

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application 61/611,493, filed March 15, 2012, the entire contents of which are incorporated herein by reference

15

BACKGROUND OF THE DISCLOSURE

The effectiveness of an agent intended for use as a therapeutic, diagnostic, or in other applications is often highly dependent on its ability to penetrate cellular membranes or tissues to access a target and/or induce a desired change in biological activity. Although many therapeutic drugs, diagnostic or other product candidates, whether protein, nucleic acid, small organic molecule, or small inorganic molecule, show promising biological activity *in vitro*, many fail to reach or penetrate target cells to achieve the desired effect, often due to physiochemical properties that result in inadequate biodistribution *in vivo*. Adequate delivery into a cell or cellular compartment of interest is a particularly acute problem for larger molecules, such as antibodies and antibody-like moieties.

In general, absent a specific receptor-mediated mechanism, proteins, such as antibodies, do not penetrate cells well. It is of great interest for protein-based therapeutics, diagnostics and biological assays to identify methods and compositions that facilitate delivery of polypeptides into a cell.

30

SUMMARY OF THE DISCLOSURE

The present disclosure provides compositions and methods for delivering antibodies and antibody-mimic moieties (referred to herein as “AAM moieties” or “an AAM moiety”) into a cell. Without being bound by theory, the present disclosure is based, at least in part, on the discovery that an AAM moiety can be delivered into a cell by complexing the AAM moiety with a cell penetrating polypeptide having surface positive charge (referred to herein as a “Surf+ Penetrating Polypeptide”).

5 The present disclosure is exemplary of the important applications of Intraphilin technology. Also provided are complexes, as well as methods for making and using such complexes comprising a Surf+ Penetrating Polypeptide portion and an AAM moiety portion.

10 In one aspect, the disclosure provides a complex comprising a Surf+ Penetrating Polypeptide and an AAM moiety that binds an intracellular target. In certain embodiments, the AAM moiety binds to an intracellular target distinct from the Surf+ Penetrating Polypeptide. In other words, the the target of the AAM moiety is not the Surf+ Penetrating Polypeptide to which that AAM moiety is complexed to.

15 In a related aspect, the disclosure provides a complex comprising (or consisting of) a first portion comprising a Surf+ Penetrating Polypeptide and a second portion comprising an AAM moiety that binds an intracellular target. In certain embodiments, the AAM moiety binds to an intracellular target distinct from the Surf+ Penetrating Polypeptide. In other words, the the target of the AAM moiety is not the the Surf+ Penetrating Polypeptide to which that AAM moiety is complexed to.

20 In another aspect, the disclosure provides a fusion protein comprising a Surf+ Penetrating Polypeptide and an AAM moiety that binds an intracellular target. In a related aspect, the disclosure provides a fusion protein comprising a first polypeptide portion comprising a Surf+ Penetrating Polypeptide and a second polypeptide portion comprising an AAM moiety that binds to an intracellular target. In some 25 embodiments, the fusion protein is a single polypeptide chain.

In another aspect, the disclosure provides a complex comprising (a) a polypeptide selected from the group consisting of: agouti-signaling protein precursor, band 3 anion transport protein, B-cell lymphoma 6 protein isoform 1, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, beta-defensin 1 30 preproprotein, cathepsin E isoform a preproprotein, charged multivesicular body protein 6, cpG-binding protein isoform 2, C-X-C motif chemokine 10 precursor, epidermal growth factor receptor isoform a precursor, histone acetyltransferase MYST3, histone acetyltransferase p300, homeobox protein Nkx-3.1, lethal(3)malignant brain tumor-like protein 2, male-specific lethal 3 homolog isoform 35 a, Na(+)/H(+) exchange regulatory cofactor NHE-RF1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, peptidyl-prolyl cis-trans isomerase NIMA-interacting

5 1, POU domain class 2-associating factor 1, prostatic acid phosphatase isoform PAP precursor, receptor tyrosine-protein kinase erbB-2 isoform b, receptor tyrosine-protein kinase erbB-3 isoform 1 precursor, receptor tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor, RING1 and YY1-binding protein, sterol regulatory element-binding protein 2, stromal cell-derived factor 1 isoform gamma, talin-1, T-cell surface
 10 glycoprotein CD4 isoform 1 precursor, transcription factor AP-1, transcription factor NF-E2 45 kDa subunit isoform 2, transcription factor Sp1 isoform b, voltage-dependent L-type calcium channel subunit alpha-1C isoform 23, zinc finger protein 224, zinc finger protein 268 isoform c, zinc finger protein 28 homolog, zinc finger protein 32, zinc finger protein 347 isoform a, zinc finger protein 347 isoform b, and
 15 zinc finger protein 40 and (b) an AAM moiety. In certain embodiments, the AAM moiety binds to an intracellular target distinct from the polypeptide associated with the AAM moiety in said complex and/or the complex is a fusion protein. In other words, the the target of the AAM moiety is not the the Surf+ Penetrating Polypeptide to which that AAM moiety is complexed to. Complexes and fusion proteins include,
 20 in certain embodiments, a single polypeptide chain.

In another aspect, the disclosure provides a complex comprising (a) a polypeptide selected from the group consisting of: agouti-signaling protein precursor, band 3 anion transport protein, B-cell lymphoma 6 protein isoform 1, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, beta-defensin 1
 25 preproprotein, cathepsin E isoform a preproprotein, charged multivesicular body protein 6, cpG-binding protein isoform 2, C-X-C motif chemokine 10 precursor, epidermal growth factor receptor isoform a precursor, histone acetyltransferase MYST3, histone acetyltransferase p300, homeobox protein Nkx-3.1, lethal(3)malignant brain tumor-like protein 2, male-specific lethal 3 homolog isoform
 30 a, Na(+)/H(+) exchange regulatory cofactor NHE-RF1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, POU domain class 2-associating factor 1, prostatic acid phosphatase isoform PAP precursor, receptor tyrosine-protein kinase erbB-2 isoform b, receptor tyrosine-protein kinase erbB-3 isoform 1 precursor, receptor tyrosine-protein kinase erbB-4 isoform
 35 JM-a/CVT-2 precursor, RING1 and YY1-binding protein, sterol regulatory element-binding protein 2, stromal cell-derived factor 1 isoform gamma, talin-1, T-cell surface

5 glycoprotein CD4 isoform 1 precursor, transcription factor AP-1, transcription factor NF-E2 45 kDa subunit isoform 2, transcription factor Sp1 isoform b, voltage-dependent L-type calcium channel subunit alpha-1C isoform 23, zinc finger protein 224, zinc finger protein 268 isoform c, zinc finger protein 28 homolog, zinc finger protein 32, zinc finger protein 347 isoform a, zinc finger protein 347 isoform b, or
 10 zinc finger protein 40, or a domain of any of the foregoing having surface positive charge, a mass of at least 4kDa and a charge/molecular weight ratio of at least 0.75 and (b) an AAM moiety. In certain embodiments, the AAM moiety binds to an intracellular target distinct from the polypeptide associated with the AAM moiety in said complex and/or the complex is a fusion protein. In other words, the target of the
 15 AAM moiety is not the the Surf+ Penetrating Polypeptide to which that AAM moiety is complexed to. Complexes and fusion proteins include, in certain embodiments, a single polypeptide chain.

In another aspect, the disclosure provides a complex comprising (a) a polypeptide comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%,
 20 98%, 99%, or 100% identical to any of the amino acid sequences set forth in Section 2 of the sequence listing and identified in such sequence listing by PDB identifier, or a domain thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75 and (b) an AAM moiety. In certain embodiments, the AAM moiety binds to an intracellular target distinct from the
 25 polypeptide associated with the AAM moiety in said complex and/or the complex is a fusion protein. In other words, the target of the AAM moiety is not the the Surf+ Penetrating Polypeptide to which that AAM moiety is complexed to. In certain embodiments, the polypeptide of (a) comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions relative to the sequence of any of the amino acid sequences set forth
 30 in Section 2 of the sequence listing and identified in such sequence listing by PDB identifier, or a domain thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75. In certain embodiments, the amino acid substitutions are conservative substitutions. In other embodiments, at least half of the substitutions are conservative substitutions. In certain embodiments,
 35 the substitutions do not alter the net charge and/or charge/molecular weight of the polypeptide. In certain embodiments, the substitutions are intended to supercharge

5 the polypeptide. Complexes and fusion proteins include, in certain embodiments, a single polypeptide chain.

In another aspect, the disclosure provides a complex comprising (a) a polypeptide comprising an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of the amino acid sequences set forth in
10 Section 1 of the sequence listing and identified in such sequence listing by GenBank accession number, or a domain thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75 and (b) an AAM moiety. In certain embodiments, the AAM moiety binds to an intracellular target distinct from the polypeptide associated with the AAM moiety in said complex and/or
15 the complex is a fusion protein. In other words, the target of the AAM moiety is not the the Surf+ Penetrating Polypeptide to which that AAM moiety is complexed to. In certain embodiments, the polypeptide of (a) comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions relative to the sequence any of the amino acid sequences set forth in Section 1 of the sequence listing and identified in such sequence listing by
20 GenBank accession number, or a domain thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75. In certain embodiments, the amino acid substitutions are conservative substitutions. In other embodiments, at least half of the substitutions are conservative substitutions. In certain embodiments, the substitutions do not alter the net charge and/or
25 charge/molecular weight of the polypeptide. In certain embodiments, the substitutions are intended to supercharge the polypeptide.

In certain embodiments of any of the foregoing or following aspects or embodiments described herein, the complex comprises a linker (e.g., 1, 2, 3, 4, more than 4 linkers). For example, a linker may interconnect the first and second portions
30 of the complex. Additionally or alternatively a linker may interconnect portions of the AAM moiety, such as a VH and VL domains of an scFv.

In certain embodiments of any of the foregoing or following aspects or embodiments described herein, the Surf+ Penetrating Polypeptide is a human polypeptide. In other embodiments, the Surf+ Penetrating Polypeptide is a non-
35 human polypeptide (e.g., mouse, rat, non-human primate) or is a non-naturally occurring protein or is a prokaryotic protein. In certain embodiments, the Surf+

5 Penetrating Polypeptide is a full-length, naturally occurring human polypeptide. In other embodiments, the Surf+ Penetrating Polypeptide is a domain of a full length, naturally occurring human polypeptide. In certain embodiments, the domain of a full length, naturally occurring human polypeptide has a charge/molecular weight ratio greater than that of the full length, naturally occurring human polypeptide. In other
10 embodiments, the domain has a charge/molecular weight ratio of at least 0.75 but the full length, naturally occurring human polypeptide has a charge/molecular weight ratio of less than 0.75. In still other embodiments, the domain has a charge/molecular weight of at least 0.75 but the full length, naturally occurring polypeptide has a net negative charge. In addition to comparisons based on charge/molecular weight,
15 domains (e.g., fragments have some level of structure) of full length polypeptide may be compared to their full length polypeptide based on differences in net charge (e.g., the domain has a greater or lesser net charge; the domain has a net positive charge where the full length polypeptide has a net negative charge).

In certain embodiments of any of the foregoing or following aspects or
20 embodiments described herein, the Surf+ Penetrating Polypeptide is a domain of a full length, naturally occurring human protein, and the complex does not include the full length, naturally occurring human protein. In other embodiments, the Surf+ Penetrating Polypeptide is a domain of a full length, naturally occurring human protein, and wherein the complex does not include sufficient additional amino acid
25 sequence from said full length, naturally occurring human protein contiguous with said domain such that the charge/molecular weight of the first portion would be less than 0.75.

In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the Surf+ Penetrating Polypeptide is a domain of a full
30 length polypeptide, and the domain is less than or about 300, 250, 200, 175, 150, 140, 130, 125, 120, 110, or less than 100 amino acid residues. In other embodiments, the Surf+ Penetrating Polypeptide is a domain of a full length polypeptide, and the domain is less than or about 90, 80, 75, 70, 65, 60, 55, 50, or 45 amino acid residues. Of course, Surf+ Penetrating Polypeptides have a minimal mass of 4 kDa, and thus a
35 suitable domain for use as a Surf+ Penetrating Polypeptide has a mass of at least 4 kDa. Moreover, Surf Penetrating Polypeptides have surface positive charge and

5 charge/molecular weight ratio of at least 0.75. Thus, suitable domains for use as a Surf+ Penetrating Polypeptide also meet this criteria. Numerous exemplary domains are identified herein.

In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the size of the first portion of a complex of the
10 disclosure can be described. For example, the first portion may be less than or about
500, 450, 400, 350, 300, 250, 200, 175, 150, 140, 130, 125, 120, 110, or less than 100
amino acid residues. In other embodiments, the first portion may be less than or
about 90, 80, 75, 70, 65, 60, 55, 50, or 45 amino acid residues. Of course, the first
portion of the complex comprises a Surf+ Penetrating Polypeptide. Thus, although
15 additional amino acid residues may be present, a region of the first portion will have
the characteristics of a Surf+ Penetrating Polypeptide – even if those characteristics
are not applicable when considered over the entire first portion (e.g., the Surf+
Penetrating Polypeptide region of the first portion has a charge/molecular weight ratio
of at least 0.75, but the entire first portion does not). It should be noted that the
20 foregoing sizes are exemplary, and Surf+ Penetrating Polypeptides or first portions that
are larger are also contemplated.

In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the Surf+ Penetrating Polypeptide has an endogenous
function. For example, in certain embodiments, the Surf+ Penetrating Polypeptide is
25 a polypeptide having endogenous function as a DNA binding protein or is a domain of
a full length polypeptide that has endogenous function as a DNA binding protein. In
other embodiments, the Surf+ Penetrating Polypeptide is a polypeptide having
endogenous function as an RNA binding protein or is a domain of a full length
polypeptide, which full length polypeptide has endogenous function as an RNA
30 binding protein. In still other embodiments, Surf+ Penetrating Polypeptide is a
polypeptide having endogenous function as a heparin binding protein or is a domain
of a full length polypeptide, which full length polypeptide has endogenous function as
a heparin binding protein. In other embodiments, the Surf+ Penetrating Polypeptide is
a polypeptide having endogenous function as a C-C or C-X-C class of chemokine or
35 is a domain of a full length polypeptide, which full length polypeptide has
endogenous function as a C-C or C-X-C class of chemokine.

5 In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, complexes do not include Surf+ Penetrating
Polypeptides having certain characteristics, as described in detail herein. For
example, in certain embodiments, the Surf+ Penetrating Polypeptide is not an
antibody or an antigen binding fragment of an antibody.

10 In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the AAM for use in a complex is a full length
antibody molecule or an antigen binding fragment thereof, or a bispecific antibody or
antibody fragment. In other embodiments, the AAM moiety is a camelid antibody, an
IgNAR, or an antibody like molecule comprising a target binding domain engineered
15 into an Fc domain of the antibody like molecule. In certain embodiment, the AAM
moiety comprises an antibody-mimic comprising a protein scaffold, such as a
fibronectin-based scaffold. In certain embodiments, the AAM moiety comprises a
DARPin polypeptide, an Adnectin[®] polypeptide or an Anticalin[®] polypeptide. In
other embodiments, the AAM moiety comprises: a target binding scaffold from Src
20 homology domains (e.g. SH2 or SH3 domains), PDZ domains, beta-lactamase, high
affinity protease inhibitors, an EGF-like domain, a Kringle-domain, a PAN domain, a
Gla domain, a SRCR domain, a Kunitz/Bovine pancreatic trypsin Inhibitor domain, a
Kazal-type serine protease inhibitor domain, a Trefoil (P-type) domain, a von
Willebrand factor type C domain, an Anaphylatoxin-like domain, a CUB domain, a
25 thyroglobulin type I repeat, LDL-receptor class A domain, a Sushi domain, a Link
domain, a Thrombospondin type I domain, a C-type lectin domain, a MAM domain, a
von Willebrand factor type A domain, a Somatomedin B domain, a WAP-type four
disulfide core domain, a F5/8 type C domain, a Hemopexin domain, a Laminin-type
EGF-like domain, or a C2 domain.

30 In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the two portions or components of the complex are
associated non-covalently. In other embodiments, they are associated covalently.
Associations may be direct or via a linker, including via a cleavable linker. The two
portions of the complex may be associated via both covalent and non-covalent
35 interactions.

5 In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the complex is a fusion protein (e.g., the Surf+
Penetrating Polypeptide or portion comprising the Surf+ Penetrating Polypeptide is
fused, directly or via a linker, to the AAM moiety or portion comprising the AAM
moiety). Suitable fusion proteins include, for example, fusion as a single polypeptide
10 chain.

In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the Surf+ Penetrating Polypeptide has an overall net
positive charge of +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16,
+17, +18, +19, +20, or greater than +20. In other embodiments, the Surf+ Penetrating
15 Polypeptide has an overall net charge of +5 to +17, +4-+10, +3-+8, +5-+14, +7-+15,
and the like. Similarly, Surf+ Penetrating Polypeptides with a range of
charge/molecular weight ratios, as well as a range of mass are also contemplated. For
example, in certain embodiments, the Surf+ Penetrating Polypeptide has a mass of
about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or about 15 kDa. However, larger Surf+
20 Penetrating Polypeptides are also contemplated and described herein.

In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the Surf+ Penetrating Polypeptide is a domain of
naturally occurring ataxin-7 isoform a, C-C motif chemokine 24 precursor or
cytochrome c, which domain has surface positive charge and a charge/molecular
25 weight ratio greater than that of its corresponding naturally occurring, full length
polypeptide. An exemplary domain is provided in Figures 1 and 2. However, other
suitable domains include a small domain of any of those described in Figure 1 or 2
having a mass of 4 kDa, surface positive charge, and charge/molecular weight ratio of
at least 0.75.

30 In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the Surf+ Penetrating Polypeptide is a naturally
occurring protein selected from C-C motif chemokine 24 precursor, beta-defensin 103
precursor, cytochrome c, fibroblast growth factor 10 precursor, signal recognition
particle 14 kDa protein, C-X-C chemokine 14 precursor or fibroblast growth factor 8
35 isoform B precursor, or a domain of any of the foregoing, which domain has surface
positive charge and a charge/molecular weight ratio of at least 0.75. An exemplary

5 domain is provided in Figures 1 and 2. However, other suitable domains include a small domain of any of those described in Figure 1 or 2 having a mass of 4 kDa, surface positive charge, and charge/molecular weight ratio of at least 0.75.

In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the Surf+ Penetrating Polypeptide is: a full length
10 polypeptide or a domain of C-C motif chemokine 26 precursor; a domain of HB-EGF (proheparin-binding EGF-like growth factor precursor); a domain of protein DEK isoform 1; a domain of hepatocyte growth factor isoform 1 preprotein; a full length polypeptide or a domain of cytochrome c; a full length polypeptide or domain of C-X-C motif chemokine 24 precursor; or a domain of ataxin 7 isoform a.

15 In certain embodiments of any of the foregoing or following aspects or embodiments described herein, the Surf+ Penetrating Polypeptide is a domain of any of the following, which domain has a charge per molecular weight ratio of at least 0.75 but for which the corresponding full length naturally occurring polypeptide has a charge/molecular weight ratio of less than 0.75: histone-lysine N-methyltransferase
20 MLL isoform 1 precursor; transcription factor AP-1; proheparin-binding EGF-like growth factor precursor; protein DEK isoform 1; hepatocyte growth factor isoform 1 preprotein; epidermal growth factor receptor isoform a precursor; forkhead box protein K2; pre-mRNA-processing factor 40 homolog A; ataxin-7 isoform a, E3 SUMO-protein ligase PIAS1; platelet factor 4 precursor; advanced glycosylation end
25 product-specific receptor isoform 2 precursor; serol regulatory element-binding protein 2; histone acetyltransferase p300; U1 small nuclear ribonucleoprotein A; pre-B-cell leukemia transcription factor 1 isoform 2; homeobox protein Nkx 3.1; homeobox protein Hox-A9; B-cell lymphoma 6 protein isoform 1; ETS domain-containing protein Elk-4 isoform a; pituitary homeobox 3; granulysin isoform NKG5;
30 general transcription factor IIF subunit 1; histone deacetylase complex subunit SAP30; heterochromatin protein 1-binding protein 3; lethal(3)malignant brain tumor-like protein 2; CCAAT/enhancer-binding protein beta; troponin T, cardiac muscle isoform 2; CREB-binding protein isoform B; cyclic AMP-dependent transcription factor ATF-2; cathepsin E isoform a preprotein; glycine receptor subunit alpha-1
35 isoform 1 precursor; CREB-binding protein isoform b; pituitary adenylate cyclase-activating polypeptide precursor; mastermind-like protein 1; BCL2/adenovirus E1B

5 19 kDa protein-interacting protein 3; cathelicidin antimicrobial peptide; epidermal growth factor receptor isoform a precursor; transcription factor NF-E2 45 kDa subunit isoform 2; integrin beta-1 isoform 1D precursor.

In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the Surf+ Penetrating Polypeptide is a domain of
10 charged multivesicular body protein 6; homeobox protein Nkx3.1; B-cell lymphoma 6 protein isoform 1; lethal(3)malignant brain tumor-like protein 2; cathepsin E isoform a preprotein; BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; cathelicidin antimicrobial peptide.

In certain embodiments of any of the foregoing or following aspects or
15 embodiments described herein, the Surf+ Penetrating Polypeptide is a domain of heparin-binding EGF-like growth factor precursor (HBEGF), which domain has surface positive charge and a molecular weight of about 8.9 kDa.

Numerous exemplary domains and full length polypeptides having the structural and functional attributes of a Surf+ Penetrating Polypeptide are provided
20 herein. Similarly, fragments of the expressly exemplified domains having the appropriate functional and structural characteristics of a Surf+ Penetrating Polypeptide are also domains within the scope of the disclosure and suitable for use in a complex of the disclosure.

In certain embodiments of any of the foregoing or following aspects or
25 embodiments described herein, the Surf+ Penetrating Polypeptide is a naturally occurring human polypeptide that is modified to increase its overall net charge (e.g., it is supercharged). For example, the Surf+ Penetrating Polypeptide may be a polypeptide engineered to comprise an overall charge from about +10 to about +40. Supercharging can also be described as the change in charge relative to what it was
30 prior to supercharging. Thus, the disclosure contemplates embodiments in which a polypeptide was supercharged by increasing its net charge from negative to positive, such as by increasing by +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +20, etc. Alternatively, the disclosure contemplates embodiments in which a polypeptide is supercharged to increase the net charge on an already positively
35 charged polypeptide. For example, supercharging may increase the net charge by +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +20, etc.

5 In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the AAM moiety binds to a target and the target is a
kinase, a transcription factor, or an oncoprotein. In other embodiments, the AAM
moiety binds to a target and the target is NFAT-2, calcineurin, JAK-1, JAK-2,
SOCS1, SOCS3, ras or Erk. In certain embodiments, the AAM moiety binds to a
10 target which localizes to a subcompartment of a cell (e.g., nucleus, mitochondria,
cytoplasm, or cytoplasmic face of cell membrane.

In certain embodiments of any of the foregoing or following aspects or
embodiments described herein, the complex is a fusion protein comprising the Surf+
Penetrating Polypeptide and the AAM moiety, and wherein the Surf+ Penetrating
15 Polypeptide is N-terminal to the AAM moiety. In other embodiments, the complex is
a fusion protein comprising the Surf+ Penetrating Polypeptide and the AAM moiety,
and wherein the Surf+ Penetrating Polypeptide is C-terminal to the AAM moiety.

In another aspect, the disclosure provides a nucleic acid comprising a
nucleotide sequence encoding any of the Surf+ Penetrating Polypeptides disclosed
20 herein, or a nucleotide sequence encoding a polypeptide portion comprising a Surf+
Penetrating Polypeptide disclosed herein. Similarly, the disclosure provides a nucleic
acid comprising a nucleotide sequence encoding any of the AAM moieties disclosed
herein. Moreover, the disclosure provides a nucleic acid comprising a nucleotide
sequence encoding a fusion protein comprising a complex of the disclosure.

25 In another aspect, the disclosure provides vectors comprising any of the
nucleic acids of the disclosure, as well as host cells comprising such vectors, and
methods of making polypeptides and complexes.

In another aspect, the disclosure provides methods of delivering an AAM
moiety into a cell. The method is applicable to any of the complexes discussed
30 herein. Such a complex is provided, and cells are contacted with the complex.
Following such contact, the AAM moiety is delivered into the cell.

Similarly, the disclosure provides methods of inhibiting the activity of an
intracellular target in a cell and methods of binding an intracellular target in a cell.
Any of the complexes described herein, including complexes formed from any
35 combination of Surf+ Penetrating Polypeptide portions and AAM moiety portions are
suitable for use in such methods.

5 In another aspect, the disclosure provides a composition comprising a complex of the disclosure and a pharmaceutically acceptable carrier. Any of the complexes described herein, including complexes formed from any combination of Surf+ Penetrating Polypeptide portions and AAM moiety portions are suitable for use in such a composition.

10 In certain embodiments of any of the foregoing or following, a complex of the disclosure can penetrate a cell. Similarly, in certain embodiments, a complex of the disclosure binds to the target via the AAM moiety.

The disclosure contemplates all combinations of any of the foregoing aspects and embodiments, as well as combinations with any of the embodiments set forth in
15 the detailed description and examples.

Unless explained otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure,
20 suitable methods and materials are described herein. The materials, methods, and examples are illustrative only and not intended to be limiting. Other features of the disclosure are apparent from the following detailed description and the claims.

DESCRIPTION OF THE DRAWINGS

25 FIG. 1 is table of human polypeptides.

FIG. 2 is a table of a subset of the human polypeptides presented in FIG. 1.

DETAILED DESCRIPTION OF THE DISCLOSURE

Provided herein are complexes comprising (i) a cell penetrating polypeptide
30 having surface positive charge, called a Surf+ Penetrating Polypeptide, and (ii) an antibody or antibody-mimic molecule, such as a polypeptide comprising a protein scaffold, called an AAM moiety that binds to an intracellular target. Also provided are nucleic acid molecules encoding such protein complexes or encoding the Surf+ Penetrating Polypeptide or AAM moiety portion of such protein complexes, as well as
35 methods of making and using such complexes. Without being bound by theory, the Surf+ Penetrating Polypeptide penetrates cells and, when complexed with the AAM

5 moiety, promotes delivery of the AAM moiety into a cell (e.g., promotes internalization of the AAM moiety into cells). Once inside a cell (e.g., in the cytosol, nucleus, or other cellular compartment), the AAM moiety can bind its intracellularly expressed or localized target molecule and impact cellular activity based on its affect on the target molecule. By way of example, an AAM moiety may bind to an
10 intracellular target, such as a polypeptide or peptide, and alter the activity of the target and/or the activity of the cell via one or more of the following mechanisms (i) inhibit one or more functions of the target; (ii) activate one or more functions of the target; (iii) increase or decrease the activity of the target; (iv) promote or inhibit degradation of the target; (v) change the localization of the target; and (vi) prevent binding
15 between the target and another protein (e.g., prevent binding between the target and a binding partner). Thus, the proteins and complexes described herein are provided for delivery of AAM moieties, e.g., therapeutic, diagnostic and research agents, to cells *in vivo*, *ex vivo*, or *in vitro*.

As described in greater detail herein, the portions of the complexes of the
20 disclosure may be associated via covalent or non-covalent interactions. Exemplary interconnections include fusions (direct or via a linker) via a peptide bond and fusions via chemical methods (direct or via a linker). Moreover, as described in greater detail herein, the association between the two portions of the molecule may persist following internalization into a cell or may be transient. For example, if the two
25 portions of a complex are covalently linked via a cleavable linker, the association may be disrupted after the Surf+ Penetrating Polypeptide portion successfully delivers the AAM moiety into a cell (e.g., once inside the cell, the complex may optionally be disrupted).

This disclosure provides an exemplary application of Intraphilin[™] technology
30 in which a member of a class of Surf+ Penetrating Polypeptides is delivered into a cell or is used to deliver a cargo molecule into a cell. In the present application, certain Surf+ Penetrating Polypeptides are complexed with an AAM moiety, and these complexes are useful for delivering the AAM moiety into cells.

Before continuing to describe the present disclosure in further detail, it is to be
35 understood that this disclosure is not limited to specific compositions or process steps, as such may vary. It must be noted that, as used in this specification and the

5 appended claims, the singular form “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine
10 and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.

15 Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

The numbering of amino acids in the variable domain, complementarity
20 determining region (CDRs) and framework regions (FR), of an antibody follow, unless otherwise indicated, the Kabat definition as set forth in Kabat et al. Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids
25 corresponding to a shortening of, or insertion into, a FR or CDR of the variable domain. For example, a heavy chain variable domain may include a single amino acid insertion (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (*e.g.* residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues may be determined for a given
30 antibody by alignment at regions of homology of the sequence of the antibody with a "standard" Kabat numbered sequence. Maximal alignment of framework residues frequently requires the insertion of “spacer” residues in the numbering system, to be used for the Fv region. In addition, the identity of certain individual residues at any given Kabat site number may vary from antibody chain to antibody chain due to
35 interspecies or allelic divergence.

5 The term “complex of the disclosure” is used to refer to a complex comprising a Surf+ Penetrating Polypeptide portion, such as any of the Surf+ Penetrating Polypeptides described herein, associated with at least one AAM moiety portion. The AAM moiety, which may be an antibody or an antibody-mimic, binds a target expressed or otherwise present in a cell, and the Surf+ Penetrating Polypeptide
10 functions to deliver the AAM moiety into a cell.

As used herein, the terms “antibody” and “antibodies”, also known as immunoglobulins, encompass monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies formed from at least two different epitope binding fragments (*e.g.*, bispecific antibodies), human
15 antibodies, humanized antibodies, camelised antibodies, chimeric antibodies, murine or other non-human antibodies, single-chain Fvs (scFv), Fab fragments, F(ab')₂ fragments, antibody fragments that exhibit the desired biological activity (*e.g.* the antigen binding portion), disulfide-linked Fvs (dsFv), and anti-idiotypic (anti-Id) antibodies (including, *e.g.*, anti-Id antibodies to antibodies of the disclosure),
20 intrabodies, and epitope-binding fragments of any of the above. Immunoglobulins include functional fragments accepted in the art, such as Fc, Fab, scFv, Fv, or other derivatives or combinations of the immunoglobulins, domains of the heavy and light chains of the variable region (such as Fd, Vl, Vk, Vh) and the constant region of an intact antibody such as CH1, CH2, CH3, CH4, C1 and Ck, as well as mini-domains
25 consisting of two beta-strands of an immunoglobulin domain connected by a structural loop. In particular, antibodies include immunoglobulin molecules and immunologically active or other functional fragments of immunoglobulin molecules, *i.e.*, molecules that contain at least one antigen-binding. Immunoglobulin molecules can be of any isotype (*e.g.*, IgG, IgE, IgM, IgD, IgA and IgY), subisotype (*e.g.*, IgG1,
30 IgG2, IgG3, IgG4, IgA1 and IgA2) or allotype (*e.g.*, Gm, *e.g.*, G1m(f, z, a or x), G2m(n), G3m(g, b, or c), Am, Em, and Km(1, 2 or 3)). Antibodies may be derived from any mammal, including, but not limited to, humans, monkeys, pigs, horses, rabbits, dogs, cats, mice, etc., or other animals such as birds (*e.g.* chickens).

As used herein, the term "about" in the context of a given value or range refers
35 to a value or range that is within 20%, preferably within 10%, and more preferably within 5% of the given value or range.

5 It is convenient to point out here that “and/or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example “A and/or B” is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.

 As used herein, the terms “associated with,” or “associate by” when used with
10 respect to the Surf+ Penetrating Polypeptide and AAM moiety portions of a complex of the disclosure, means that these portions are physically associated or connected with one another, either directly or via one or more additional moieties, including moieties that serve as a linking agent, to form a structure that is sufficiently stable so that the AAM moiety is delivered into a cell. The association may be via
15 non-covalent interactions (*e.g.*, electrostatic interactions; affinity or avidity; etc.) and/or via covalent interconnections. In either case, the association may be direct or via a linker moiety or via additional polypeptide sequence. Moreover, the association may be disruptable, such as by cleavage of a linker that interconnects the portions of the complex. The complex may be a fusion protein in which the Surf+ Penetrating
20 Polypeptide portion and the AAM moiety portion are connected by a peptide bond as a fusion protein, either directly or via a linker or other additional polypeptide sequence. In certain embodiments, the fusion protein is a single polypeptide chain. In certain embodiments, the AAM moiety binds to an intracellular target (*e.g.*, a target expressed or present intracellularly) that is distinct from the Surf+ Penetrating
25 Polypeptide present in the complex. In other words, although human Surf+ Penetrating Polypeptides may be expressed endogenously inside a cell, in certain embodiments, the target molecule for the AAM moiety is not a Surf+ Penetrating Polypeptide and/or is not the same Surf+ Penetrating Polypeptide as present in that complex. In certain embodiments, the Surf+ Penetrating Polypeptide portion of a
30 complex of the disclosure is not an antibody or antigen-binding fragment of an antibody. In certain embodiments, the Surf+ Penetrating Polypeptide portion of a complex of the disclosure is not an antibody mimic molecule.

 As used herein, the term “supercharge” refers to any modification of a protein, the primary purpose of which is to increase the net charge or the surface charge of the
35 protein to make that protein suitable for or to improve its suitability for use as a Surf+ Penetrating Polypeptide. Modifications include, but are not limited to, alterations in

5 amino acid sequence or addition of positively charged moieties.

Surf+ Penetrating Polypeptides

A “Surf+ Penetrating Polypeptide”, as used herein, is a polypeptide capable of promoting entry into a cell and having, at least, the following characteristics: mass of
10 at least 4 kDa, charge/molecular weight ratio of at least 0.75, and presence of surface positive charge such that the polypeptide is capable of promoting entry into a cell. The Surf+ Penetrating Polypeptide can itself enter into a cell and/or can be associated with an agent, such as an antibody or antibody mimic, such that it also promotes entry into the cell of the agent. In addition to having surface positive charge, the Surf+
15 Penetrating Polypeptide has a net positive charge. In certain embodiments, Surf+ Penetrating Polypeptides have a mass of at least 4 kDa and a charge/molecular weight ratio of greater than 0.75. A Surf+ Penetrating Polypeptide may be a human polypeptide, including a full length, naturally occurring human polypeptide or a variant of a full length, naturally occurring human polypeptide having one or more
20 amino acid additions, deletions, or substitutions. Moreover, such human polypeptides include domains of full length naturally occurring human polypeptides or a variant of such a domain having one or more amino acid additions, deletions, or substitutions. For the avoidance of doubt, the term “human polypeptide” includes domains (e.g., structural and functional fragments) unless otherwise specified. Further, Surf+
25 Penetrating Polypeptides include human or non-human proteins engineered to have one or more regions of surface positive charge and a charge/molecular weight ratio of at least 0.75, including supercharged polypeptides. The present disclosure provides numerous examples of Surf+ Penetrating Polypeptides, as well as numerous examples of sub-categories of Surf+ Penetrating Polypeptides. The disclosure contemplates that
30 any of the sub-categories of Surf+ Penetrating Polypeptides, as well as any of the specific polypeptides described herein may be provided as part of a complex comprising an AAM moiety. Moreover, any such complexes may be used to deliver an AAM moiety into a cell.

In the present context, a “variant of a human polypeptide” is a polypeptide that
35 differs from a naturally occurring (full length or domain) human polypeptide by one or more amino acid substitutions, additions or deletions. In certain embodiments,

5 these changes in amino acid sequence may be to increase the overall net charge of the polypeptide and/or to increase the surface charge of the polypeptide (e.g., to supercharge a polypeptide). Alternatively, changes in amino acid sequence may be for other purposes, such as to provide a suitable site for pegylation or to facilitate production. Regardless of the specific changes made, the variant of the human
10 polypeptide will be sufficiently similar based on sequence and/or structure to its naturally occurring human polypeptide such that the variant is more closely related to the naturally occurring human protein than it is to a protein from a non-human organism. In certain embodiments, the amino acid sequence of the variant is at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to a naturally occurring human
15 protein. In certain embodiments, the variant of the naturally occurring human polypeptide is a Surf+ Penetrating Polypeptide having cell penetrating activity and a charge/molecular weight ratio of at least 0.75 or of greater than 0.75, but the naturally occurring human polypeptide from which the variant is derived does not have cell penetrating activity and/or has a charge/molecular weight ratio of less than 0.75. In
20 certain embodiments, the variant does not result in further supercharging of the polypeptide. For example, the variant results in a change in amino acid sequence but not a change in the net charge, surface charge and/or charge/molecular weight ratio of the polypeptide.

In certain embodiments, the Surf+ Penetrating Polypeptide is a human
25 polypeptide having surface positive charge, mass of at least 4 kDa and charge/molecular weight ratio of at least 0.75 or of greater than 0.75. Such a human polypeptide may be a naturally occurring human polypeptide (which may also be a fragment of a naturally occurring human polypeptide), or a variant thereof having one or more amino acid additions, substitutions, deletions, such as additions, substitutions or
30 deletions that increase (or that do not change) surface positive charge, charge/molecular weight ratio or net positive charge.

In certain embodiments, the Surf+ Penetrating Polypeptide is a human polypeptide that is a domain of a naturally occurring human polypeptide. In addition to having surface positive charge and the ability to penetrate cells, the domain of a
35 naturally occurring human polypeptide has a mass of at least 4 kDa and a charge/molecular weight ratio of at least 0.75 or of greater than 0.75. In certain

5 embodiments, the Surf+ Penetrating Polypeptide for use in the disclosure is a domain
of a naturally occurring human polypeptide that has a charge/molecular weight ratio
of at least 0.75 or of greater than 0.75, but the corresponding, full length, naturally
occurring human protein has a charge/molecular weight ratio of less than 0.75.
Additionally or alternatively, in certain embodiments, such a domain has an overall
10 net positive charge greater than that of the corresponding, full length, naturally
occurring human protein.

 In certain embodiments, a Surf+ Penetrating Polypeptide has a mass of at least
4, 5, 6, 10, 20, 50, 100, 200 kDa or 250 kDa. For example, a Surf+ Penetrating
Polypeptide may have a mass of about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
15 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 kDa. By way of another example, a Surf+
Penetrating Polypeptide may have a mass of about 4-30 kDa, about 5-25 kDa, about
4-20 kDa, about 5-18 kDa, about 5-15 kDa, about 4-12 kDa, about 5-10 kDa, and the
like. In still other embodiments, the molecular weight of a Surf+ Penetrating
Polypeptide (*e.g.*, a naturally occurring or modified Surf+ Penetrating Polypeptide
20 protein) ranges from approximately 5 kDa to approximately 250 kDa, such as 10 to
250kDa, 50 to 250kDa, or 50 to 100kDa. For example, in certain embodiments, the
molecular weight of the Surf+ Penetrating Polypeptide ranges from approximately
4 kDa to approximately 100 kDa. In certain embodiments, the molecular weight of the
Surf+ Penetrating Polypeptide ranges from approximately 10 kDa to approximately
25 45 kDa. In certain embodiments, the molecular weight of the Surf+ Penetrating
Polypeptide ranges from approximately 5 kDa to approximately 50 kDa. In certain
embodiments, the molecular weight of the Surf+ Penetrating Polypeptide ranges from
approximately 5 kDa to approximately 27kDa. In certain embodiments, the molecular
weight of the Surf+ Penetrating Polypeptide ranges from approximately 10 kDa to
30 approximately 60 kDa. In certain embodiments, the molecular weight of the Surf+
Penetrating Polypeptide is about 5 kD, about 7.5 kDa, about 10 kDa, about 12.5 kDa,
about 15 kDa, about 17.5 kDa, about 20 kDa, about 22.5 kDa, about 25 kDa, about
27.5 kDa, about 30 kDa, about 32.5 kDa, or about 35 kDa. It should be understood
that the mass of the Surf+ Penetrating Polypeptide, including the minimal mass of 4
35 kDa, refers to monomer mass. However, in certain embodiments, a Surf+ Penetrating

5 Polypeptide for use as part of a complex is a dimer, trimer, tetramer, or a higher order multimer.

In certain embodiments, a Surf+ Penetrating Polypeptide for use in the present disclosure is selected to minimize the number of disulfide bonds. In other words, the Surf+ Penetrating Polypeptide may have not more than 2 or 3 or 4 disulfide bonds
10 (e.g., the polypeptide has 0, 1, 2, 3 or 4 disulfide bonds). A Surf+ Penetrating Polypeptide for use in the present disclosure may also be selected to minimize the number of cysteines. In other words, the Surf+ Penetrating Polypeptide may have not more than 2 cysteines, or not more than 4 cysteines, not more than 6 cysteines or not more than 8 cysteines (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8 cysteines). A Surf+ Penetrating
15 Polypeptide for use in the present disclosure may also be selected to minimize glycosylation sites. In other words, the polypeptide may have not more than 1 or 2 or 3 glycosylation sites (e.g., N-linked or O-linked glycosylation; 0, 1, 2 or 3 sites).

As defined above, a Surf+ Penetrating Polypeptide has surface positive charge. The Surf+ Penetrating Polypeptide also has an overall net positive charge under
20 physiological conditions. Note that when the Surf+ Penetrating Polypeptide is a domain of a naturally occurring polypeptide, the overall net positive charge is that of the domain. For example, in certain embodiments, the Surf+ Penetrating Polypeptide has an overall net positive charge of at least +4, +5, +10, +15, +20, +25, +30, +35, +40, or +50. By way of further example, a Surf+ Penetrating Polypeptide may have
25 an overall net positive charge of about +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20, +21, +22, +23, +24, +25, or greater than +25. In certain embodiments, under physiological conditions, the Surf+ Penetrating Polypeptide has a pI greater than or equal to 9, such as a pI of about 9 to about 13 or a pI of between 9 and 13 (inclusive or exclusive). In other embodiments, under
30 physiological conditions, the Surf+ Penetrating Polypeptide has a pI greater than 9 or greater than 9.5, but less than 10. In other embodiments, under physiological conditions, the Surf+ Penetrating Polypeptide has a pI of about 9-9.5, or about 9-10, or about 9.5-10, or about 10-10.5, or about 10-10.3. In other embodiments, under physiological conditions, the Surf+ Penetrating Polypeptide has a pI of about 10-11,
35 about 10.5-11, about 11-12, about 11.5-12, about 12-13, or about 12.5-13. Note that a Surf+ Penetrating Polypeptide may be a polypeptide that has been modified, such as

5 to increase surface charge and/or overall net positive charge as compared to the unmodified protein, and the modified polypeptide may have increased stability and/or increased cell penetrating ability in comparison to the unmodified polypeptide. In some cases, the modified polypeptide may have cell penetrating ability where the unmodified polypeptide did not.

10 Theoretical net charge serves as a convenient short hand. In certain embodiments, the theoretical net charge on the Surf+ Penetrating Polypeptide (*e.g.*, the naturally occurring Surf+ Penetrating Polypeptide or the modified Surf+ Penetrating Polypeptide) is at least +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20, +21, +22, +23, +24, +25, +30, +35, +40 or
15 +50. In other embodiments, the theoretical net charge on the Surf+ Penetrating Polypeptide (*e.g.*, the naturally occurring Surf+ Penetrating Polypeptide or the modified Surf+ Penetrating Polypeptide) is about +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20, +21, +22, +23, +24, +25, +30, +35, +40 or +50. For example, the theoretical net charge on the naturally
20 occurring Surf+ Penetrating Polypeptide can be, *e.g.*, at least +1, at least +2, at least +3, at least +4, at least +5, at least +10, at least +15, at least +20, at least +25, at least +30, at least +35, at least +40 or at least +50 or about +1 to +5, +1 to +10, +5 to +10, +5 to +15, +10 to +20, +15 to +20, +20 to +30, +30 to +40, or +40 to +50 and the like. Note that a Surf+ Penetrating Polypeptide may be a polypeptide that has been
25 modified, such as to increase surface charge and/or overall net positive charge as compared to the unmodified protein, and the modified polypeptide may have increased stability and/or increased cell penetrating ability in comparison to the unmodified polypeptide. In some cases, the modified polypeptide may have cell penetrating ability where the unmodified polypeptide did not.

30 In certain embodiments, the Surf+ Penetrating Polypeptide has a charge:molecular weight ratio (*e.g.*, also referred to as charge/MW or charge/molecular weight) of at least approximately 0.75, 0.8, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, or 3.0. This ratio is the ratio of the theoretical net charge of the Surf+ Penetrating Polypeptide to its molecular weight in kilodaltons. In
35 certain embodiments, the charge/molecular weight is about 0.75-2.0. In certain embodiments, the charge/molecular weight ratio of the Surf+ Penetrating Polypeptide

5 is greater than 0.75. In certain embodiments, the Surf+ Penetrating Polypeptide is a domain of a naturally occurring human polypeptide where the domain has a charge/molecular weight ratio of at least 0.75 or of greater than 0.75, but the corresponding full length, naturally occurring human polypeptide has a charge/molecular weight of less than 0.75.

10 For example, in certain embodiments, the Surf+ Penetrating Polypeptide has a charge:molecular weight ratio of at least approximately 0.75 or of greater than 0.75. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 0.8. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 1.0. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 1.2. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 1.4. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 1.5. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 1.6. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 1.7. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 1.8. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 1.9. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 2.0. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 2.5. In certain embodiments, the Surf+ Penetrating Polypeptide has a charge: molecular weight ratio of at least approximately 3.0.

30 In certain embodiments, the Surf+ Penetrating Polypeptide is a naturally occurring human polypeptide or a domain of a naturally occurring human polypeptide, and it is selected based on the endogenous function of the full length, naturally occurring human polypeptide. By way of example, a Surf+ Penetrating Polypeptide for use in this disclosure may have an endogenous function as, for example, a DNA binding protein, an RNA binding protein or a heparin binding

35

5 protein. Accordingly, in certain embodiments, the disclosure provides complexes in which the Surf+ Penetrating Polypeptide Portion is (i) a domain of a naturally occurring human polypeptide having a charge/molecular weight ratio of at least 0.75 or of greater than 0.75 but for which its naturally occurring, full length human polypeptide does not have a charge/molecular weight ratio of at least 0.75 and (ii) the
10 domain is from a naturally occurring human polypeptide having an endogenous, natural function as a DNA binding protein, an RNA binding protein or a heparin binding protein. In other embodiments, the Surf+ Penetrating Polypeptide does not have an endogenous function as, for example, a DNA binding protein, an RNA binding protein or a heparin binding protein. In certain embodiments, the Surf+
15 Penetrating Polypeptide does not have an endogenous function as a histone or histone-like protein. In certain embodiments, the Surf+ Penetrating Polypeptide does not have an endogenous function as a homeodomain containing protein.

In certain embodiments, the Surf+ Penetrating Polypeptide has tertiary structure. The presence of such tertiary structure distinguishes Surf+ Penetrating
20 Polypeptides from unstructured, short cell penetrating peptides (CPPs) such as poly-arginine and poly-lysine and also distinguishes Surf+ Penetrating Polypeptides from cell penetrating peptides that have some secondary structure but no tertiary structure, such as penetratin and antenapedia.

In certain embodiments, the Surf+ Penetrating Polypeptide is not an antibody
25 or an antigen-binding fragment of an antibody. As noted above, Surf+ Penetrating Polypeptides are distinguishable based on numerous characteristics from various short cell penetrating peptides known in the art. For example, Surf+ Penetrating Polypeptides are distinguishable based on size, shape and structure, charge distribution and the like. Moreover, in certain embodiments, Surf+ Penetrating
30 Polypeptides and complexes comprising a Surf+ Penetrating Polypeptide have improved cell penetration characteristics compared to short CPPs or complexes comprising short CPPs. Nevertheless, to provide further clarity, in certain embodiments, complexes of the disclosure do not further include a short CPP. Additional exemplary support is provided herein.

35 In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include a full

5 length sequence for HIV-Tat, or the portion thereof known in the art as imparting cell penetration activity. In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not contain the protein transduction domain of HIV-Tat, for example, does not contain the contiguous amino acid sequence YGRKKRRQRRR (SEQ ID NO: 612). In certain
10 embodiments, a complex of the disclosure comprising a Surf+ Penetrating Polypeptide penetrates cells more efficiently than a complex comprising all or a portion of HIV-Tat fused to the same cargo.

In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include the
15 protein transduction domain of an antennapedia protein, such as the Drosophila antennapedia protein or a mammalian ortholog thereof. In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include the protein transduction domain of the h-region of fibroblast growth factor 4 (FGF-4). In other embodiments, a complex of the
20 disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include an FGF polypeptide or a 16 residue cell penetrating polypeptide fragment thereof.

In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include the 16
25 amino acid residue sequence referred to as penetratin: RQIKIWFQNRRMKWKK (SEQ ID NO: 613). In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include the 19 amino acid residue sequence referred to as SynB1: RGGRLSYSRRRFSTSTGRA. In certain embodiments, a complex of the disclosure
30 and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include the following amino acid sequence referred to as transportan: GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 614).

In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include the
35 following amino acid sequence RKMLKSTRRQRR. In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a

- 5 complex of the disclosure does not include the amino acid sequence selected from one or more of the following amino acid sequences: YGRKKRRQRRR (SEQ ID NO: 615); WLRRIKAWLRRIKA (SEQ ID NO: 616); WLRRIKAWLRRIKAWLRRIKA (SEQ ID NO: 617); KLALKLALKALKALKLA (SEQ ID NO: 618); KETWWETWWTEWSQPKKKRKV (SEQ ID NO: 619);
- 10 AGGGGYGRKKRRQRRR (SEQ ID NO: 620); KETWWETWWTEWSQPKKKRKV (SEQ ID NO: 621); GLWRALWRLLRSLWRLWKA (SEQ ID NO: 622); GLWRALWRALWRSLWKLKRKV (SEQ ID NO: 623); GLWRALWRALRSLWKLKRKV (SEQ ID NO: 624);
- 15 GLWRALWRGLRSLWKLKRKV (SEQ ID NO: 625); GLWRALWRGLRSLWKKKRKV (SEQ ID NO: 626); GLWRALWRLLRSLWRLWKA (SEQ ID NO: 627); GLWRALWRALWRSLWKLKWKV (SEQ ID NO: 628); GLWRALWRALWRSLWKS KRKV (SEQ ID NO: 629);
- 20 GLWRALWRALWRSLWKKKRKV (SEQ ID NO: 630); GLWRALWRLLRSLWRLWSQ (SEQ ID NO: 631); TRSSRAGLQFPVGRVHRLLRK (SEQ ID NO: 632); RKKRRRESRKKRRRES (SEQ ID NO: 633); GRPRESGKKRKRKRLKP (SEQ ID NO: 634); GKRKKKGKLGKKRDP (SEQ ID NO: 635);
- 25 GKRKKKGKLGKKRPRSR (SEQ ID NO: 636); RKKRRRESRRARRSPRHL (SEQ ID NO: 637); SRRARRSPRESGKKRKRKR (SEQ ID NO: 638); VKRGLKLRHVRPRVTRMDV (SEQ ID NO: 639); VKRGLKLRHVRPRVTRDV (SEQ ID NO: 640); SRRARRSPRHLGSG (SEQ ID NO: 641); LRRERQSRLRRERQSR
- 30 GAYDLRRRERQSRLRRRERQSR (SEQ ID NO: 642); WEAALAEALAEALAEHLAEALAEALAA KGSWYSMRKMSMKIRPFFPQQ (SEQ ID NO: 643); KTRYYSMKKTTMKIIPFNRL (SEQ ID NO: 644); RGADYSLRAVRMKIRPLVTQ (SEQ ID NO: 645);
- 35 LGTYTQDFNKFHTFPQTAIGVGAP (SEQ ID NO: 646); TSPLNIHNGQKL (SEQ ID NO: 647); and NSAAFEDLRVLS (SEQ ID NO: 648)

5 In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include HSV-1 structural protein Vp22 (DAATATRGRSAASRPTEPRAPARSASRPRRPVE) (SEQ ID NO: 649). In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include 10 9 (or, optionally, does not include 7 or 8) consecutive arginine residues (e.g., poly-Arg9). In other embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include 9 (or, optionally, does not include 7 or 8) consecutive lysine residues (e.g., poly-Lys9). In certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include the PTD of mouse transcription factor Mph-1 (YARVRRRGPRR) (SEQ ID NO: 650), Sim-2 (AKAARQAAR) (SEQ ID NO: 651), HIV-1 viral protein Tat (YGRKKRRQRRR) (SEQ ID NO: 652), Antennapedia protein (Antp) of Drosophila (RQIKIWFQNRRMKWKK) (SEQ ID NO: 653), MTS 20 (AAVALLPAVLLALLAPAAADQNQLMP) (SEQ ID NO: 654), and short amphipathic peptide carriers Pep-1 (KETWWETWWTEWSQPKKKRKV) (SEQ ID NO: 655) and Pep-2 (KETWFETWFTEWSQPKKKRKV) (SEQ ID NO: 656).

In certain embodiments, the Surf+ Penetrating Polypeptide is not a toxin. In certain embodiments, the Surf+ Penetrating Polypeptide is not a homeodomain. In 25 certain embodiments, a complex of the disclosure and/or the Surf+ Penetrating Polypeptide portion of a complex of the disclosure does not include a homeodomain.

The foregoing provides description for characteristics of Surf+ Penetrating Polypeptides and sub-categories of Surf+ Penetrating Polypeptides. The disclosure contemplates that any Surf+ Penetrating Polypeptide for use in the present disclosure 30 may be described based on presence or absence of any one or any combination of any of the foregoing features. Additional features and specific examples of polypeptides having such features are described in greater detail below. Such features and combinations of features (including combinations with features set forth above) may also be used to describe the Surf+ Penetrating Polypeptide for use in accordance with 35 the claimed disclosure. Any such polypeptides or categories or sub-categories may be

5 used as part of a complex of the disclosure (e.g., the disclosure provides complexes comprising any such polypeptides).

Exemplary Surf+ Penetrating Polypeptides

10 This section provides examples of Surf+ Penetrating Polypeptides and categories of Surf+ Penetrating Polypeptides.

Surf+ Penetrating Polypeptides that may be used, *e.g.*, in a complex with an AAM moiety and/or to deliver an AAM moiety into a cell as described herein, include nucleic acid binding proteins, *e.g.*, DNA binding proteins, RNA binding proteins or heparin binding proteins. In other words, naturally occurring proteins that can
15 function as Surf+ Penetrating Polypeptides may have a natural, endogenous function, such as an endogenous function as a DNA, RNA or heparin binding protein. In some embodiments, Surf+ Penetrating Polypeptides that may be used in the delivery of an AAM moiety, such as a non-antibody protein scaffold (e.g., an antibody mimic or an antibody-like molecule) or an antibody molecule, can be a DNA binding protein, such
20 as a histone component or a histone-like protein. In certain embodiments, the Surf+ Penetrating Polypeptide portion comprises the histone component is histone linker H1. In certain embodiments, the Surf+ Penetrating Polypeptide portion comprises the histone component is core histone H2A. In certain embodiments, the Surf+ Penetrating Polypeptide portion comprises the histone component is core histone
25 H2B. In certain embodiments, the Surf+ Penetrating Polypeptide portion comprises the histone component is core histone H3. In certain embodiments, the Surf+ Penetrating Polypeptide portion comprises the histone component is core histone H4. In certain embodiments, the the Surf+ Penetrating Polypeptide portion comprises the archael histone-like protein, HPhA. In certain embodiments, the the Surf+ Penetrating
30 Polypeptide portion comprises the bacterial histone-like protein, TmHU. In other embodiments, the Surf+ Penetrating Polypeptide portion does not comprise a protein select from any of the foregoing histone components or histone-like proteins. It should be noted that the foregoing proteins have endogenous, natural function as DNA binding proteins. When used as a Surf+ Penetrating Polypeptide according to
35 the disclosure, the disclosure contemplates the use of human polypeptides, including full length polypeptides and domains of full length polypeptides, regardless of

5 whether the domain with cell penetration function is also a domain that modulates DNA binding activity.

In some embodiments, a Surf+ Penetrating Polypeptide that is used to deliver an AAM moiety, such as a non-antibody protein scaffold (e.g., an antibody mimic or an antibody-like molecule) or an antibody molecule, is an RNA binding protein, such as a ribosomal protein (e.g., L11, S7, S9, or a small nucleolar protein (snoRNP), such as nucleolin, fibrillarin, NOP77P), an RNA polymerase (e.g., RNA polymerase I or II), an RNase, a transcription factor (e.g., a transcriptional U protein (tUTP)), a histone acetyl transferase (hALP), an upstream binding factor (UBF), a splicing protein (e.g., a snRNP (e.g., U1 or U2) or an SR factor), a La protein, or an hnRNP (heterogeneous ribonuclear protein) (e.g., hnRNP A1, hnRNP M or hnRNP L). In other words, in certain embodiments, the Surf+ Penetrating Polypeptide portion comprises any of the foregoing RNA binding proteins. In other embodiments, the Surf+ Penetrating Polypeptide portion does not comprise a protein select from any of the foregoing RNA binding proteins. It should be noted that the foregoing proteins have endogenous, natural function as RNA binding proteins. When used as a Surf+ Penetrating Polypeptide according to the disclosure, the disclosure contemplates the use of human polypeptides, including full length polypeptides and domains of full length polypeptides, regardless of whether the domain with cell penetration function is also a domain that modulates RNA binding activity.

25 In certain embodiments, the Surf+ Penetrating Polypeptide portion comprises a naturally occurring polypeptide, such as a naturally occurring human polypeptide. Examples of such naturally occurring polypeptides (and UniProt identification numbers) include, but are not limited to, DEK (ID No.: P35659), HB-EGF (ID No.: Q99075), or c-Jun (ID No.: P05412); HGF (ID No.: P14210); cyclon (ID No.: Q9H6F5); PNRC1 (ID No.: Q12796); RNPS1 (ID No.: Q15287); SURF6 (ID No.: O75683); AR6P (ID No.: Q66PJ3); NKAP (ID No.: Q8N5F7); EBP2 (ID No.: Q99848); LSM11 (ID No.: P83369); RL4 (ID No.: P36578); KRR1 (ID No.: Q13601); RY-1 (ID No.: Q8WVK2); BriX (ID No.: Q8TDN6); MNDA (ID No.: P41218); H1b (ID No.: P16401); cyclin (ID No.: Q9UK58); MDK (ID No.: P21741); Midkine (ID No.: P21741); PROK (ID No.: Q9HC23); FGF5 (ID No.: P12034); SFRS (ID No.: Q8N9Q2); AKIP (ID No.: Q9NWT8); CDK (ID No.:

5 Q8N726); beta-defensin (ID No.: P81534); Defensin 3 (ID No.: P81534); PAVAC (ID No.: P18509); PACAP (ID No.: P18509); eotaxin-3 (ID No.: Q9Y258); histone H2A (ID No.: Q7L7L0); HMGB1 (ID No.: P09429); TERF 1 (ID No.: P54274); PIAS 1 (ID No.: O75925); Ku70 (ID No.: P12956); HRX (ID No.: Q03164). In certain embodiments, the complex comprises a Surf+ Penetrating Polypeptide portion

10 comprising one of the following: U4/U6.U5 tri-snRNP-associated protein 3 (ID No.: Q8WVK2); beta-defensin (ID No.: P81534); Protein SFRS12IP1 (ID No.: Q8N9Q2); midkine (ID No.: P21741); C-C motif chemokine 26 (ID No.: Q9Y258); surfet locus protein 6 (ID No.: O75683); Aurora kinase A-interacting protein (ID No.: Q9NWT8); NF-kappa-B-activating protein (ID No.: Q8N5F7); histone H1.5

15 (ID No.: P16401); histone H2A type 3 (ID No.: Q7L7L0); 60S ribosomal protein L4 (ID No.: P36578); isoform 1 of RNA-binding protein with serine-rich domain 1 (ID No.: Q15287-1); isoform 4 of cyclin-dependent kinase inhibitor 2A (ID No.: Q8N726-1); isoform 1 of prokineticin-2 (ID No.: Q9HC23-1); isoform 1 of ADP-ribosylation factor-like protein 6-interacting protein 4 (ID No.: Q66PJ3-1); isoform

20 long of fibroblast growth factor 5 (ID No.: P12034-1); or isoform 1 of cyclin-L1 (ID No.: Q9UK58-1).

Additional exemplary Surf+ Penetrating Polypeptides are provided in Figures 1 and 2. The disclosure contemplates that any of the polypeptides, or fragments thereof, may be used in a complex of the disclosure. Moreover, additional suitable

25 domains are described herein. Thus, the disclosure contemplates complexes comprising a Surf+ Penetrating Polypeptide-containing portion. This portion of the complex may comprise any of the Surf+ Penetrating Polypeptides provided in Figures 1 or 2, or a full length or near full length naturally occurring polypeptide provided in Figures 1 or 2, or a domain of any of the foregoing having a mass of at least 4 kDa,

30 surface positive charge, and a charge/molecular weight ratio of at least 0.75. Figure 1 provides information for exemplary domains of naturally occurring human proteins that are Surf+ Penetrating Polypeptides and can be used in the instant disclosure (e.g., in a complex and/or to deliver an AAM moiety into a cell). Figure 2 provides similar information for a subset of the proteins provided in Figure 1. For each entry, a PDB

35 ID number (and chain) is provided, as well as the terminal residues of the fragment, relative to the full length sequence provided in GenBank (e.g., the subsequence start

5 and subsequence end entries). The amino acid sequence for the full length protein sequences provided in GenBank are reproduced herein below in Section 1 of the sequence listing. The amino acid sequence for the particular domains identified by PDB ID number and chain are reproduced below in Section 2 of the sequence listing. The five columns to the right of the protein name provide information for the

10 exemplified fragment (e.g., for the fragment of a naturally occurring human polypeptide, which fragment is a Surf+ Penetrating Polypeptide). For example, these columns indicate the charge/molecular weight, mass, net positive charge, length (# of amino acid residues) of the fragment, and the size of the fragment relative to its corresponding full length protein (% FL). The next column, just to the left of the Gen

15 Bank accession number for the full length protein, indicates the size of the full length protein. The four columns to the right of the Ref seq column (the accession number for the full length protein) provide information for the full length, naturally occurring protein from which the fragment is derived. This information includes the charge/molecular weight of the full length protein, the molecular weight of the full

20 length protein, the net charge (which, in some cases, may be negative) for the full length protein. As is clear from Figure 1, for several proteins, non-overlapping domains that may be used as a Surf+ Penetrating Polypeptide were identified for a given naturally occurring human protein.

As can be seen upon review of Figure 1, in some cases, both the full length,

25 naturally occurring protein and a domain have characteristics indicative of a Surf+ Penetrating Polypeptide (e.g., surface positive charge, charge/molecular weight ratio of at least 0.75, etc.). However, in other cases, the full length protein does not have such characteristics, while a domain of the protein does. In certain embodiments, the disclosure provides complexes in which the Surf+ Penetrating Polypeptide has at least

30 the following characteristics: surface positive charge, mass of at least 4 kDa, charge/molecular weight ratio of at least 0.75 or of greater than 0.75, and is a domain of a naturally occurring human polypeptide. In certain embodiments, the selected domain has a charge per molecular weight ratio greater than that of the corresponding full length, naturally occurring human polypeptide. In other embodiments, the

35 selected domain has a charge per molecular weight ratio of at least 0.75 or greater than 0.75, but the full length, naturally occurring human polypeptide has a charge per

5 molecular weight ratio of less than 0.75. In other embodiments, the selected domain has a net theoretical charge greater than that of the corresponding full length, naturally occurring human polypeptide. In other embodiments, the selected domain has a net positive charge and the corresponding, full length, naturally occurring human polypeptide has a net negative charge. The disclosure contemplates the use of any of
10 the specified domains of full length, naturally occurring human proteins, as well as other domains having the charge and molecular weight characteristics of a Surf+ Penetrating Polypeptide. Moreover, the disclosure contemplates the use of full length, naturally occurring human polypeptides having the charge and molecular weight characteristics of a Surf+ Penetrating Polypeptide. Further, the disclosure
15 contemplates that complexes may comprise a full length naturally occurring human polypeptide, even though only a domain of said human polypeptide functions as a Surf+ Penetrating Polypeptide. In such cases, the additional polypeptide sequence can optionally be used to interconnect the Surf+ Penetrating Polypeptide to the AAM moiety. Thus, in certain embodiments, the disclosure provides complexes comprising
20 a first polypeptide portion that comprises a Surf+ Penetrating Polypeptide. Such a Surf+ Penetrating Polypeptide may optionally be provided with additional sequence endogenously present in, for example, the naturally occurring polypeptide from which the Surf+ Penetrating Polypeptide is a domain or may be present without additional sequence endogenously present in the naturally occurring polypeptide from which the
25 Surf+ Penetrating Polypeptide is a domain. In certain embodiments, the presence of additional sequence from the same naturally occurring polypeptide does not result in the portion comprising the Surf+ Penetrating Polypeptide having a charge/molecular weight ratio of less than 0.75. However, in certain embodiments, the presence of additional sequence from the same naturally occurring polypeptide results in the
30 portion comprising the Surf+ Penetrating Polypeptide having a charge/molecular weight ratio of less than 0.75. For the avoidance of doubt, the “portion comprising a Surf+ Penetrating Polypeptide” refers to the Surf+ Penetrating Polypeptide and additional sequence from the same or similar naturally or non-naturally occurring polypeptide. This portion does not include heterologous linker sequence, nuclear
35 localization signals, or additional portions intended to have an independent and distinct biological function (e.g., a moiety to increase the half life of the complex).

5 The foregoing are exemplary of sub-categories of Surf+ Penetrating Polypeptides that can be used as part of the complexes of the disclosure. For the avoidance of doubt, it should be understood that domains of the naturally occurring human proteins may be modified, such as by introducing one or more amino acid substitutions, deletions or additions. The resulting domain will still be considered a
10 domain of a naturally occurring human polypeptide as long as the domain is readily identifiable based on sequence and/or structure as a domain of that naturally occurring human protein.

 In certain embodiments, the Surf+ Penetrating Polypeptide portion comprises (or consists of) a full length naturally occurring polypeptide or a domain of a full
15 length polypeptide presented in Figure 2. In certain embodiments, the disclosure provides a complex comprising an AAM moiety associated with a human polypeptide (full length or domain) presented in Figure 2. However, as should be noted, the domains depicted in the figures are merely exemplary. Having identified a suitable domain, such as the domains identified by PDB in figures 1 and 2, suitable sub-
20 domains or non-overlapping domains can be readily identified. Thus, in certain embodiments, the disclosure contemplates the use of any of the domains set forth in Figure 1 or 2, as well as a fragment (sub-domain; also considered a domain) thereof having a mass of at least 4kDa, surface positive charge and charge/molecular weight ratio of at least 0.75.

25 To further illustrate, in certain embodiments, the Surf+ Penetrating Polypeptide is a full length or a domain of C-C motif chemokine 26 precursor (e.g., such as a fragment of about 71 amino acid residues beginning at position 24 of the full length protein, a net charge of +13, and having a charge/MW of 1.55), a domain of HB-EGF (proheparin-binding EGF-like growth factor precursor, such as, a fragment
30 of about 79 amino acid residues beginning at position 72 of the full length protein, a net positive charge of +12, and a charge/molecular weight of 1.35), a domain of protein DEK isoform 1 (e.g., such as a fragment of about 131 amino acid residues beginning at position 78 of the full length protein, a net positive charge of +19, and a charge/molecular weight of 1.26), a domain of hepatocyte growth factor isoform 1
35 preprotein (e.g., such as a fragment of about 131 amino acid residues beginning at position 31 of the full length protein, a net positive charge of + 14, and a

5 charge/molecular weight of 1.23), a full length or a domain of cytochrome c (e.g.,
 such as a fragment of about 104 amino acid residues beginning at position 2 of the full
 length protein, a net positive charge of +9, and a charge per molecular weight of
 0.77), a full length or domain of C-X-C motif chemokine 24 precursor (e.g., such as a
 10 fragment of about 78 amino acid residues beginning at position 34 of the full length
 protein, a net positive charge of +13, and a charge per molecular weight of 1.37), or a
 domain of ataxin 7 isoform a (e.g., such as a fragment of about 74 amino acid residues
 beginning at position 330, a net positive charge of +9, and a charge/molecular weight
 of 1.03). In certain embodiments, the disclosure provides a complex comprising an
 AAM moiety and any of the foregoing full length, naturally occurring human
 15 polypeptides, or a domain thereof, which domain has the charge and charge/molecular
 weight characteristics of a Surf+ Penetrating Polypeptide. In certain embodiments,
 the complex (a complex of the disclosure) comprises a domain of the full length,
 naturally occurring human polypeptide, but the complex does not comprise the full
 length, naturally occurring human polypeptide.

20 To further illustrate, in other embodiments, the Surf+ Penetrating Polypeptide
 is a domain of any of the following, which domain has a charge per molecular weight
 ratio of at least 0.75 but for which the corresponding full length naturally occurring
 polypeptide has a charge/molecular weight ratio of less than 0.75: histone-lysine N-
 methyltransferase MLL isoform 1 precursor; transcription factor AP-1; proheparin-
 25 binding EGF-like growth factor precursor; protein DEK isoform 1; hepatocyte growth
 factor isoform 1 preprotein; epidermal growth factor receptor isoform a precursor;
 forkhead box protein K2; pre-mRNA-processing factor 40 homolog A; ataxin-7
 isoform a, E3 SUMO-protein ligase PIAS1; platelet factor 4 precursor; advanced
 glycosylation end product-specific receptor isoform 2 precursor; serol regulatory
 30 element-binding protein 2; histone acetyltransferase p300; U1 small nuclear
 ribonucleoprotein A; pre-B-cell leukemia transcription factor 1 isoform 2; homeobox
 protein Nkx 3.1; homeobox protein Hox-A9; B-cell lymphoma 6 protein isoform 1;
 ETS domain-containing protein Elk-4 isoform a; pituitary homeobox 3; granulysin
 isoform NKG5; general transcription factor IIF subunit 1; histone deacetylase
 35 complex subunit SAP30; heterochromatin protein 1-binding protein 3;
 lethal(3)malignant brain tumor-like protein 2; CCAAT/enhancer-binding protein beta;

5 troponin T, cardiac muscle isoform 2; CREB-binding protein isoform B; cyclic AMP-dependent transcription factor ATF-2; cathepsin E isoform a preprotein; glycine receptor subunit alpha-1 isoform 1 precursor; CREB-binding protein isoform b; pituitary adenylate cyclase-activating polypeptide precursor; mastermind-like protein 1; BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; cathelicidin

10 antimicrobial peptide; epidermal growth factor receptor isoform a precursor; transcription factor NF-E2 45 kDa subunit isoform 2; integrin beta-1 isoform 1D precursor; C-C motif chemokine 5 precursor; forkhead box protein O1, O3 or O4; talin 1; TATA-box binding protein isoform 1 or 2; telomeric repeat-binding factor 1 or 2; or lactotransferrin isoform 1 precursor. For each of the foregoing, a suitable

15 fragment is provided in Figure 1. Moreover, other examples of this sub-category of Surf+ Penetrating Polypeptides are provided in and are immediately apparent from Figure 1. In certain embodiments, the disclosure provides a complex comprising an AAM moiety and any of the foregoing full length, naturally occurring human polypeptides, or a domain thereof, which domain has the charge and charge/molecular

20 weight characteristics of a Surf+ Penetrating Polypeptide. In certain embodiments, the complex (a complex of the disclosure) comprises a domain of the full length, naturally occurring human polypeptide, but the complex does not comprise the full length, naturally occurring human polypeptide. In certain embodiments, the complex and/or the Surf+ Penetrating Polypeptide portion does not include one of the

25 polypeptides or specific fragments provided in Figure 1. In certain embodiments, the complex and/or the Surf+ Penetrating Polypeptide portion does not include HRX (Uniprot number Q03164 or fragment identified at PDB 2J2S. In certain embodiments, the complex and/or the Surf+ Penetrating Polypeptide portion does not include c-Jun (Uniprot number P05412 or fragment identified at PDB 1JNM. In

30 certain embodiments, the complex and/or the Surf+ Penetrating Polypeptide portion does not include defensin 3 (Uniprot number P81534 or fragment identified at PDB 1KJ6. In certain embodiments, the complex and/or the Surf+ Penetrating Polypeptide portion does not include HBEGF (Uniprot number Q99075 or fragment identified at PDB 1XDT. In certain embodiments, the complex and/or the Surf+ Penetrating

35 Polypeptide portion does not include N-Dek (Uniprot number P35659 or fragment identified at PDB 2JX3. In certain embodiments, the complex and/or the Surf+

5 Penetrating Polypeptide portion does not include HGF (Uniprot number P14210 or fragment identified at PDB 2HGF. In certain embodiments, the complex and/or the Surf+ Penetrating Polypeptide portion does not include HIST4 (Uniprot number P62805 or fragment identified at PDB 2CV5.

To further illustrate, in other embodiments, the Surf+ Penetrating Polypeptide
 10 is a domain of: charged multivesicular body protein 6 (e.g., a fragment of about 39 amino acid residues having a charge/molecular weight of 1.07); homeobox protein Nkx3.1 (e.g., a fragment of about 69 amino acid residue having a charge/molecular weight of 0.96); B-cell lymphoma 6 protein isoform 1 (e.g., a fragment of about 74 amino acid residues having a charge per molecular weight of 0.93); lethal(3)malignant
 15 brain tumor-like protein 2 (e.g., a fragment of about 43 amino acid residues having a charge/molecular weight of 0.87); cathepsin E isoform a preprotein (e.g., a fragment of about 35 amino acid residues having a charge/molecular weight of 1.66); BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (e.g., a fragment of about 45 amino acid residues have a charge/molecular weight of 1.02); cathelicidin
 20 antimicrobial peptide (e.g., a fragment of about 37 amino acid residues having a charge/molecular weight of 1.34). In certain embodiments, the disclosure provides a complex comprising an AAM moiety and any of the foregoing full length, naturally occurring human polypeptides, or a domain thereof, which domain has the charge and charge/molecular weight characteristics of a Surf+ Penetrating Polypeptide. In certain
 25 embodiments, the complex (a complex of the disclosure) comprises a domain of the full length, naturally occurring human polypeptide, but the complex does not comprise the full length, naturally occurring human polypeptide.

To further illustrate, in other embodiments, the Surf+ Penetrating Polypeptide is selected from a domain of any of: agouti-signaling protein precursor, band 3 anion
 30 transport protein, B-cell lymphoma 6 protein isoform 1, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, beta-defensin 1 preproprotein, cathepsin E isoform a preproprotein, charged multivesicular body protein 6, cpG-binding protein isoform 2, C-X-C motif chemokine 10 precursor, epidermal growth factor receptor isoform a precursor, histone acetyltransferase MYST3, histone acetyltransferase p300,
 35 homeobox protein Nkx-3.1, lethal(3)malignant brain tumor-like protein 2, male-specific lethal 3 homolog isoform a, Na(+)/H(+) exchange regulatory cofactor NHE-

5 RF1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, peptidyl-prolyl cis-trans
isomerase NIMA-interacting 1, POU domain class 2-associating factor 1, prostatic
acid phosphatase isoform PAP precursor, receptor tyrosine-protein kinase erbB-2
isoform b, receptor tyrosine-protein kinase erbB-3 isoform 1 precursor, receptor
tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor, RING1 and YY1-
10 binding protein, sterol regulatory element-binding protein 2, stromal cell-derived
factor 1 isoform gamma, talin-1, T-cell surface glycoprotein CD4 isoform 1 precursor,
transcription factor AP-1, transcription factor NF-E2 45 kDa subunit isoform 2,
transcription factor Sp1 isoform b, voltage-dependent L-type calcium channel subunit
alpha-1C isoform 23, zinc finger protein 224, zinc finger protein 268 isoform c, zinc
15 finger protein 28 homolog, zinc finger protein 32, zinc finger protein 347 isoform a,
zinc finger protein 347 isoform b, or zinc finger protein 40. In certain embodiments,
the selected domain is a domain presented in Figure 2, or a variant thereof. In certain
embodiments, the complex (a complex of the disclosure) comprises a domain of the
full length, naturally occurring human polypeptide, but the complex does not
20 comprise the full length, naturally occurring human polypeptide.

In certain embodiments, the disclosure provides a complex comprising an
AAM moiety and any of the following full length (or substantially full length),
naturally occurring human polypeptides: agouti-signaling protein precursor, band 3
anion transport protein, B-cell lymphoma 6 protein isoform 1, BCL2/adenovirus E1B
25 19 kDa protein-interacting protein 3, beta-defensin 1 preproprotein, cathepsin E
isoform a preproprotein, charged multivesicular body protein 6, cpG-binding protein
isoform 2, C-X-C motif chemokine 10 precursor, epidermal growth factor receptor
isoform a precursor, histone acetyltransferase MYST3, histone acetyltransferase p300,
homeobox protein Nkx-3.1, lethal(3)malignant brain tumor-like protein 2, male-
30 specific lethal 3 homolog isoform a, Na(+)/H(+) exchange regulatory cofactor NHE-
RF1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, peptidyl-prolyl cis-trans
isomerase NIMA-interacting 1, POU domain class 2-associating factor 1, prostatic
acid phosphatase isoform PAP precursor, receptor tyrosine-protein kinase erbB-2
isoform b, receptor tyrosine-protein kinase erbB-3 isoform 1 precursor, receptor
35 tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor, RING1 and YY1-
binding protein, sterol regulatory element-binding protein 2, stromal cell-derived

5 factor 1 isoform gamma, talin-1, T-cell surface glycoprotein CD4 isoform 1 precursor, transcription factor AP-1, transcription factor NF-E2 45 kDa subunit isoform 2, transcription factor Sp1 isoform b, voltage-dependent L-type calcium channel subunit alpha-1C isoform 23, zinc finger protein 224, zinc finger protein 268 isoform c, zinc
 10 zinc finger protein 28 homolog, zinc finger protein 32, zinc finger protein 347 isoform a, zinc finger protein 347 isoform b, or zinc finger protein 40.

Figure 1 provides specific examples of domains that are Surf+ Penetrating Polypeptides. It should be appreciated that other fragments of the corresponding naturally occurring human proteins may also be suitable, such as an overlapping fragment that retains the surface positive charge of the recited fragment but is shorter
 15 or longer (e.g., the starting or ending residue is different but the functional core of surface positive charge is retained; the fragment retains the essential structure of the recited fragment). Fragments that retain the essential structure but differ in length may differ in mass, length, and/or charge/molecular weight. However, essential structure, surface charge and charge/molecular weight of at least 0.75 are maintained.
 20 Additionally, Figure 1 provides examples for several human polypeptides of more than one non-overlapping domain that may be used as a Surf+ Penetrating Polypeptide.

In certain embodiments, the Surf+ Penetrating Polypeptide portion of a complex of the disclosure is or comprises a domain of a human polypeptide, such as a
 25 domain of a naturally occurring human polypeptide. A complex may comprise the domain outside of its context in its full length, naturally occurring protein (e.g., the complex does not include the full length human polypeptide from which the domain is a portion). Alternatively, the domain may be provided in the context of its full length polypeptide or in the context of additional polypeptide sequence (but less than all)
 30 from the naturally occurring protein from which the Surf+ Penetrating Polypeptide is a domain (e.g., the complex does include the full length human polypeptide from which the domain is an identified portion).

In some embodiments, a complex of the disclosure (e.g., a complex comprising an AAM moiety associated with the polypeptide) comprises a polypeptide
 35 listed in Table 1 below. In other words, in some embodiments, a complex comprises a portion comprising a Surf+ Penetrating Polypeptide and the portion comprising a

- 5 Surf+ Penetrating Polypeptide is selected from a polypeptide listed in Table 1. In certain embodiments, the complex includes at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 100% of the full length polypeptide, provided as contiguous amino acid residues.

10

Table 1. Exemplary naturally occurring molecules that may be used in a complex of the disclosure

<u>Protein Name</u>	<u>Refseq^a</u>
60S ribosomal protein L10	NP_006004.2
advanced glycosylation end product-specific receptor isoform 2 precursor	NP_001193858.1
ataxin-7 isoform a	NP_000324.1
B-cell lymphoma 6 protein isoform 1	NP_001124317.1
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3	NP_004043.2
cathelicidin antimicrobial peptide	NP_004336.2
cathepsin E isoform a preproprotein	NP_001901.1
C-C motif chemokine 13 precursor	NP_005399.1
C-C motif chemokine 24 precursor	NP_002982.2
C-C motif chemokine 5 precursor	NP_002976.2
C-C motif chemokine 7 precursor	NP_006264.2
CCAAT/enhancer-binding protein beta	NP_005185.2
charged multivesicular body protein 6	NP_078867.2
CREB-binding protein isoform b	NP_001073315.1
C-X-C motif chemokine 14 precursor	NP_004878.2
C-X-C motif chemokine 2	NP_002080.1
cyclic AMP-dependent transcription factor ATF-2	NP_001871.2
cytochrome c	NP_061820.1
E3 SUMO-protein ligase PIAS1	NP_057250.1
eotaxin precursor	NP_002977.1
epidermal growth factor receptor isoform a precursor	NP_005219.2
epidermal growth factor receptor isoform a precursor	NP_005219.2
ETS domain-containing protein Elk-4 isoform a	NP_001964.2
fibroblast growth factor 10 precursor	NP_004456.1
fibroblast growth factor 8 isoform B precursor	NP_006110.1
forkhead box protein K2	NP_004505.2
forkhead box protein O1	NP_002006.2
forkhead box protein O3	NP_963853.1

forkhead box protein O4 isoform 1	NP_005929.2
general transcription factor IIF subunit 1	NP_002087.2
glycine receptor subunit alpha-1 isoform 1 precursor	NP_001139512.1
granulysin isoform NKG5	NP_006424.2
heparin-binding growth factor 2	NP_001997.5
hepatocyte growth factor isoform 1 preproprotein	NP_000592.3
heterochromatin protein 1-binding protein 3	NP_057371.2
histone acetyltransferase MYST3	NP_001092883.1
histone acetyltransferase p300	NP_001420.2
histone deacetylase complex subunit SAP30	NP_003855.1
histone H3-like centromeric protein A isoform a	NP_001800.1
homeobox protein Hox-A9	NP_689952.1
homeobox protein Hox-B1	NP_002135.2
homeobox protein NANOG	NP_079141.2
homeobox protein Nkx-3.1	NP_006158.2
integrin beta-1 isoform 1D precursor	NP_391988.1
lethal(3)malignant brain tumor-like protein 2	NP_113676.2
liver-expressed antimicrobial peptide 2 precursor	NP_443203.1
lymphotactin precursor	NP_002986.1
major centromere autoantigen B	NP_001801.1
male-specific lethal 3 homolog isoform a	NP_523353.2
mastermind-like protein 1	NP_055572.1
max dimerization protein 1 isoform 2	NP_001189442.1
nucleolar transcription factor 1 isoform a	NP_055048.1
parathyroid hormone-related protein isoform 2 preproprotein	NP_945315.1
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	NP_006212.1
pituitary adenylate cyclase-activating polypeptide precursor	NP_001108.2
pituitary homeobox 3	NP_005020.1
platelet factor 4 precursor	NP_002610.1
POU domain class 2-associating factor 1	NP_006226.2
POU domain, class 2, transcription factor 1 isoform 3	NP_001185715.1
pre-B-cell leukemia transcription factor 1 isoform 2	NP_001191890.1
pre-mRNA-processing factor 40 homolog A	NP_060362.3
RAF proto-oncogene serine/threonine-protein kinase	NP_002871.1
receptor tyrosine-protein kinase erbB-2 isoform b	NP_001005862.1
receptor tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor	NP_001036064.1
retinoblastoma-associated protein	NP_000312.2
ribonuclease H1	NP_002927.2
RING1 and YY1-binding protein	NP_036366.3
RNA-binding motif protein, Y chromosome, family 1 member B	NP_001006121.1
SAM pointed domain-containing Ets transcription factor	NP_036523.1

serine/arginine-rich splicing factor 1 isoform 1	NP_008855.1
serum response factor	NP_003122.1
sex-determining region Y protein	NP_003131.1
signal recognition particle 14 kDa protein	NP_003125.3
small nuclear ribonucleoprotein Sm D2 isoform 1	NP_004588.1
small nuclear ribonucleoprotein Sm D3	NP_004166.1
sterol regulatory element-binding protein 1 isoform a	NP_001005291.1
sterol regulatory element-binding protein 2	NP_004590.2
stromal cell-derived factor 1 isoform gamma	NP_001029058.1
talin-1	NP_006280.3
TATA-box-binding protein isoform 1	NP_003185.1
TATA-box-binding protein isoform 2	NP_001165556.1
T-cell leukemia homeobox protein 2	NP_057254.1
T-cell surface glycoprotein CD4 isoform 1 precursor	NP_000607.1
T-cell surface glycoprotein CD4 isoform 3	NP_001181946.1
telomeric repeat-binding factor 1 isoform 1	NP_059523.2
telomeric repeat-binding factor 2	NP_005643.1
THAP domain-containing protein 1 isoform 1	NP_060575.1
transcription factor AP-1	NP_002219.1
transcription factor NF-E2 45 kDa subunit isoform 2	NP_001129495.1
transcription factor SOX-2	NP_003097.1
transcription factor Sp1 isoform b	NP_003100.1
transcriptional activator Myb isoform 1	NP_001123645.1
transcriptional activator Myb isoform 4	NP_001155128.1
troponin T, cardiac muscle isoform 2	NP_001001430.1
tumor necrosis factor receptor superfamily member 13C	NP_443177.1
U1 small nuclear ribonucleoprotein A	NP_004587.1
voltage-dependent L-type calcium channel subunit alpha-1C isoform 23	NP_001161097.1
zinc finger Ran-binding domain-containing protein 2 isoform 2	NP_005446.2

- 5 ^a“Refseq” is the NCBI Reference Sequence ID on the web at [ncbi.nlm.nih.gov/ RefSeq/ RSfaq.html#background](http://ncbi.nlm.nih.gov/RefSeq/RSfaq.html#background).

Regardless of the specific Surf+ Penetrating Polypeptide or category of Surf+ Penetrating Polypeptide used in a complex, the disclosure contemplates embodiments
10 in which the complex comprises a domain of a full length, naturally occurring human protein, but does not include the full length, naturally occurring human protein as a contiguous amino acid sequence. However, even when a domain of a full length, naturally occurring human protein is providing the Surf+ Penetrating Polypeptide

5 function for a complex, the disclosure contemplates embodiments in which that domain is provided in the context of the full length (or substantially full length), naturally occurring protein – such that the complex comprises the full length, naturally occurring human protein, or when the Surf+ Polypeptide portion includes additional polypeptide sequence (more sequence than is necessary or sufficient to
10 achieve cell penetration).

In some embodiments, a complex comprises a portion comprising a Surf+ Penetrating Polypeptide and the portion comprising a Surf+ Penetrating Polypeptide is selected from a polypeptide listed in Figure 1 or 2. In certain embodiments, the complex includes at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%,
15 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 100% of the full length polypeptide from which the Surf+ Penetrating polypeptide is a domain, provided as contiguous amino acid residues.

For illustrative purposes, the disclosure has provided numerous exemplary Surf+ Penetrating Polypeptides, including numerous human polypeptides. However,
20 Surf+ Penetrating Polypeptides suitable for use also include polypeptides from other species, such as mouse, rat, monkey, etc. Accordingly, the disclosure contemplates use of naturally occurring polypeptides (and domains thereof having characteristics of Surf+ Penetrating Polypeptides) from these other organisms. Accordingly, in one embodiment, the disclosure provides a complex comprising a Surf+ Penetrating
25 Polypeptide, which is a naturally occurring mammalian polypeptide (such as mouse, rat, monkey, etc.) or domain thereof associated with an AAM moiety.

Supercharging

In addition, in certain embodiments, Surf+ Penetrating Polypeptides include
30 naturally occurring or non-human proteins that may be or have been further modified to increase positive charge (e.g., supercharged). These include polypeptides that, prior to supercharging, have a charge/molecular weight ratio of at least 0.75 or of greater than 0.75, as well as polypeptides that do not have a charge/molecular weight ratio of at least 0.75 prior to supercharging. An example is the +52 streptavidin
35 described in the Examples in which streptavidin has been supercharged to have a net

5 positive charge of +52. Another example is the +36 GFP described in the Examples in which GFP has been supercharged to have a net positive charge of +36.

Surf+ Penetrating Polypeptides can be naturally-occurring, or can be produced by changing one or more conserved or non-conserved amino acids on or near the surface of a protein to more polar or charged amino acid residues. The amino acid
10 residues to be modified may be hydrophobic, hydrophilic, charged, or a combination thereof. Surf+ Penetrating Polypeptides can also be produced by the attachment of charged moieties to the protein in order to supercharge the protein.

Natural as well as unnatural proteins (*e.g.*, engineered proteins) may be modified, *e.g.*, to increase the net charge of the protein. Examples of proteins that
15 may be modified include receptors, membrane bound proteins, transmembrane proteins, enzymes, transcription factors, extracellular proteins, therapeutic proteins, cytokines, messenger proteins, DNA-binding proteins, RNA-binding proteins, proteins involved in signal transduction, structural proteins, cytoplasmic proteins, nuclear proteins, hydrophobic proteins, hydrophilic proteins, *etc.*

20 A naturally occurring Surf+ Penetrating Polypeptides, or a protein to be modified for supercharging, may be derived from any species of plant, animal, and/or microorganism. In certain embodiments, the protein is a mammalian protein. In certain embodiments, the protein is a human protein. In certain embodiments, the naturally occurring Surf+ Penetrating Polypeptide, or the protein to be modified, is
25 derived from an organism typically used in research. For example, the naturally occurring Surf+ Penetrating Polypeptide, or the protein to be modified, may be from a primate (*e.g.*, ape, monkey), rodent (*e.g.*, rabbit, hamster, gerbil), pig, dog, cat, fish (*e.g.*, *Danio rerio*), nematode (*e.g.*, *C. elegans*), yeast (*e.g.*, *Saccharomyces cerevisiae*), or bacteria (*e.g.*, *E. coli*). In certain embodiments, the protein is non-
30 immunogenic. In other certain embodiments, the protein is non-antigenic. In certain embodiments, the protein does not have inherent biological activity or has been modified to have no biological activity. In certain embodiments, the protein is chosen based on its targeting ability.

In certain embodiments of the disclosure, the term supercharging is used to
35 refer to changes made to the Surf+ Penetrating Polypeptide or changes made to a polypeptide such that it functions as and meets the definition of a Surf+ Penetrating

5 Polypeptide, but do not include changes in charge or charge density that result from association with the AAM moiety.

In some embodiments, the naturally occurring Surf+ Penetrating Polypeptides, or the protein to be modified is one whose structure has been characterized, for example, by NMR or X-ray crystallography. In some embodiments, the naturally
10 occurring Surf+ Penetrating Polypeptides, or the protein to be modified, is one whose structure has been predicted, for example, by threading homology modeling or de novo structure prediction. In some embodiments, the naturally occurring Surf+ Penetrating Polypeptides, or the protein to be modified, is one whose structure has been correlated and/or related to biochemical activity (*e.g.*, enzymatic activity,
15 protein-protein interactions, *etc.*). In certain embodiments, the inherent biological activity of a modified protein is reduced or eliminated to reduce the risk of deleterious and/or undesired effects. Alternatively, the biological activity of the modified protein can be increased or potentiated, or a non-naturally occurring biological activity of the protein may be generated as a result of the charge modification concomitant with the
20 creation of the charged-modified Surf+ Penetrating Polypeptides.

For embodiments in which a protein is modified to generate a Surf+ Penetrating Polypeptides, the surface residues of a protein to be modified may be identified using any method known in the art. In certain embodiments, surface residues are identified by computer modeling of the protein. In certain embodiments,
25 the three-dimensional structure of the protein is known and/or determined, and surface residues are identified by visualizing the structure of the protein. Homology modeling and *de novo* structure prediction are two methods for modeling the 3-D structure of a protein; such methods are particularly useful in the absence of an NMR or crystal structure. In some embodiments, surface residues are predicted using
30 computer software. In certain particular embodiments, an Accessible Surface Area (ASA) is used to predict surface exposure. A high ASA value indicates a surface exposed residue, whereas a low ASA value indicates the exclusion of solvent interactions with the residue. In certain particular embodiments, an Average Neighbor Atoms per Sidechain Atom (AvNAPSA) value is used to predict surface
35 exposure. AvNAPSA is an automated measure of surface exposure which has been implemented as a computer program. A low AvNAPSA value indicates a surface

5 exposed residue, whereas a high value indicates a residue in the interior of the protein. In certain embodiments, the software is used to predict the secondary structure and/or tertiary structure of a protein, and surface residues or near-surface residues are identified based on this prediction. In some embodiments, the prediction of surface residues is based on hydrophobicity and hydrophilicity of the residues and their
10 clustering in the primary sequence of the protein. Besides *in silico* methods, surface residues of the protein may also be identified using various biochemical techniques, for example, protease cleavage, surface modification, derivatization, labeling, hydrogen-deuterium exchange experiments, *etc.* We note that such modeling is also useful for identifying domains of a full length protein that possess characteristics of s
15 Surf+ Penetrating Polypeptide.

Optionally, of the surface residues, it is then determined which are conserved or important to the functioning of the protein. However, conserved amino acids may be modified even if the underlying biological activity of the protein is to be retained, reduced, enhanced or augmented by one or more non-naturally occurring biological
20 activities. Identification of conserved residues can be determined using any method known in the art. In certain embodiments, conserved residues are identified by aligning the primary sequence of the protein of interest with related proteins. These related proteins may be from the same family of proteins. Related proteins may also be the same protein from a different species. For example, conserved residues may be
25 identified by aligning the sequences of the same protein from different species. For example, proteins of similar function or biological activity may be aligned. Preferably, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 different sequences are used to determine the conserved amino acids in the protein. In certain embodiments, a residue is considered conserved if over 50%, over 60%, over 70%, over 75%, over
30 80%, over 90%, or over 95% of the sequences have the same amino acid in a particular position. In other embodiments, the residue is considered conserved if over 50%, over 60%, over 70%, over 75%, over 80%, over 90%, or over 95% of the sequences have the same or a similar (*e.g.*, valine, leucine, and isoleucine; glycine and alanine; glutamine and asparagine; or aspartate and glutamate) amino acid in a
35 particular position. Many software packages are available for aligning and comparing protein sequences as described herein. As would be appreciated by one of skill in the

5 art, either the conserved residues may be determined first or the surface residues may be determined first. The order does not matter. In certain embodiments, a computer software package may determine surface residues and/or conserved residues, and may optionally do so simultaneously. Important residues in the protein may also be identified by mutagenesis of the protein. For example, alanine scanning of the protein
10 can be used to determine the important amino acid residues in the protein. In some embodiments, site-directed mutagenesis may be used. In certain embodiments, conserving the original biological activity of the protein is not important, and therefore, the steps of identifying the conserved residues and preserving them are not performed.

15 Each of the surface residues is identified as hydrophobic or hydrophilic. In certain embodiments, residues are assigned a hydrophobicity score. For example, each surface residue may be assigned an octanol/water logP value. Other hydrophobicity parameters may also be used. Such scales for amino acids have been discussed in: Janin, 1979, *Nature*, 277:491; Wolfenden *et al.*, 1981, *Biochemistry*,
20 20:849; Kyte *et al.*, 1982, *J. Mol. Biol.*, 157:105; Rose *et al.*, 1985, *Science*, 229:834; Cornette *et al.*, 1987, *J. Mol. Biol.*, 195:659; Charton and Charton, 1982, *J. Theor. Biol.*, 99:629; each of which is incorporated by reference. Any of these hydrophobicity parameters may be used in the inventive method to determine which residues to modify. In certain embodiments, hydrophilic or charged residues are
25 identified for modification. Near-surface residues are residues that are either a) not surface residues but immediately adjacent in primary amino acid sequence or within a three-dimensional structure or b) not surface residues that can become surface residues upon the alteration of a polypeptide's tertiary structure. The contribution of near-surface residues in a Surf+ Penetrating Polypeptide is determined using the
30 methods described herein.

In certain embodiments, for generation of Surf+ Penetrating Polypeptides, at least one identified surface residue or near-surface residue is chosen for modification. In certain embodiments, hydrophobic residue(s) are chosen for modification. In other embodiments, hydrophilic and/or charged residue(s) are chosen for modification. In
35 certain embodiments, more than one residue is chosen for modification. In certain embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 of the identified residues are

5 chosen for modification. In certain embodiments, over 10, over 15, over 20, or over 25 residues are chosen for modification.

In certain embodiments, multiple variants of a protein, each with different modifications, are produced and tested to determine the best variant in terms of delivery of a biological moiety to a cell, pharmacokinetics, stability, biocompatibility, and/or biological activity, or a biophysical property such as expression level. In some
10 embodiments, a library of protein variants is generated in an *in vivo* system containing an expression host such as phage, bacteria, yeast or mammalian cells, or in an *in vitro* system such as mRNA display, ribosome display, or polysome display. Such a library may contain 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , or over 10^9 , possible variants
15 (including substitutions, deletions of one or more residues, and insertion of one or more residues). By testing the variants resulting from this library, Surf+ Penetrating Polypeptides may be created from polypeptides for which no structural information such as crystal structure is known or available.

In certain embodiments, residues chosen for modification are mutated into
20 more hydrophilic residues (including positively charged residues). Typically, residues are mutated into more hydrophilic natural amino acids. In certain embodiments, residues are mutated into amino acids that are positively charged at physiological pH. For example, a residue may be changed to an arginine, or lysine, or histidine. In certain embodiments, all the residues to be modified are changed into the
25 same alternate residue. For example, all the chosen residues are changed to an arginine residue, a lysine residue or a histidine residue. In other embodiments, the chosen residues are changed into different residues; however, all the final residues are positively charged at physiological pH. In certain embodiments, to create a positively charged protein, all the residues to be mutated are converted to arginine or lysine or
30 histidine residues, or a combination thereof. To give but another example, all the chosen residues for modification are aspartate, glutamate, asparagine, and/or glutamine, and these residues are mutated into arginine, lysine or histidine.

In some embodiments, a protein may be modified to increase the overall net charge on the protein. In certain embodiments, the theoretical net charge is increased,
35 relative to its unmodified protein, by at least +1, at least +2, at least +3, at least +4, at least +5, at least +10, at least +15, at least +20, at least +25, at least +30, at least +35,

5 or at least +40. In certain embodiments, the chosen amino acids are changed into non-ionic, polar residues (*e.g.*, cysteine, serine, threonine, tyrosine, glutamine, and asparagine). In some embodiments, increasing the overall net charge comprises increasing the total number of positively charged residues on or near the surface.

10 In certain embodiments, the amino acid residues mutated to charged amino acids residues are separated from each other by at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, or at least 25 amino acid residues in the primary amino acid sequence. In certain embodiments, the amino acid residues mutated to positively charged amino acids residues (*e.g.*, arginine, lysine or histidine) are separated from each other by at least 1,
15 at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, or at least 25 amino acid residues in the primary amino acid sequence. In certain embodiments, fewer than two or only two, three, four or five consecutive amino acids are modified to generate a charge-modified Surf+ Penetrating Polypeptide. Alternatively, wherein a surface projection is present in the
20 polypeptide, more than two, three, four, five, six, seven, eight, nine, or ten consecutive amino acids are modified to generate a charged-modified Surf+ Penetrating Polypeptide.

In certain embodiments, a surface exposed loop, helix, turn, or other secondary structure may contain only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or
25 more than 30 charged residues. Distributing the charged residues over the surface of the protein may allow for more stable proteins. In certain embodiments, only 1, 2, 3, 4, or 5 residues per 15-20 amino acids of the primary sequence are mutated to charged amino acids (*e.g.*, arginine, lysine or histidine). In certain embodiments, on average only 1, 2, 3, 4, or 5 residues per 10 amino acids of the primary sequence are mutated
30 to charged amino acids (*e.g.*, arginine, lysine or histidine). In certain embodiments, on average only 1, 2, 3, 4, or 5 residues per 15 amino acids of the primary sequence are mutated to charged amino acids (*e.g.*, arginine, lysine or histidine). In certain embodiments, on average only 1, 2, 3, 4, or 5 residues per 20 amino acids of the primary sequence are mutated to charged amino acids (*e.g.*, arginine, lysine or
35 histidine). In certain embodiments, on average only 1, 2, 3, 4, or 5 residues per 25 amino acids of the primary sequence are mutated to charged amino acids (*e.g.*,

5 arginine, lysine or histidine). In certain embodiments, on average only 1, 2, 3, 4, or 5 residues per 30 amino acids of the primary sequence are mutated to charged amino acids (*e.g.*, arginine, lysine or histidine).

In certain embodiments, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the mutated charged amino acid residues of a charge-modified
10 Surf+ Penetrating Polypeptide are solvent exposed. In certain embodiments, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the mutated charged amino acids residues of the charge-modified Surf+ Penetrating Polypeptide are on the surface of the protein. In certain embodiments, less than 5%, less than 10%, less than 20%, less than 30%, less than 40%, less than 50% of the mutated charged amino acid
15 residues are not solvent exposed. In certain embodiments, less than 5%, less than 10%, less than 20%, less than 30%, less than 40%, less than 50% of the mutated charged amino acid residues are internal amino acid residues.

In some embodiments, amino acids are selected for modification using one or more predetermined criteria. For example, to generate a superpositively charged
20 protein, ASA or AvNAPSA values may be used to identify aspartic acid, glutamic acid, asparagine, and/or glutamine residues with ASA values above a certain threshold value or AvNAPSA values below a certain threshold value, and one or more (*e.g.*, all) of these residues may be changed to arginine, lysine or histidine. In some
25 embodiments, to generate a superpositively charged protein, ASA calculations are used to identify aspartic acid, glutamic acid, asparagine, and/or glutamine residues with ASA above a certain threshold value, and one or more (*e.g.*, all) of these are changed to arginine, lysine or histidine. In some embodiments, to generate a
30 superpositively charged protein, AvNAPSA is used to identify aspartic acid, glutamic acid, asparagine, and/or glutamine residues with AvNAPSA below a certain threshold value, and one or more (*e.g.*, all) of these are changed to arginines. In some
embodiments, to generate a superpositively charged protein, AvNAPSA is used to identify aspartic acid, glutamic acid, asparagine, and/or glutamine residues with
AvNAPSA below a certain threshold value, and one or more (*e.g.*, all) of these are changed to lysines. In other embodiments, to generate a superpositively charged
35 protein, AvNAPSA is used to identify aspartic acid, glutamic acid, asparagine, and/or glutamine residues with AvNAPSA below a certain threshold value, and one or more

5 (e.g., all) of these are changed to histidines.

In some embodiments, solvent-exposed residues are identified by the number of neighbors. In general, residues that have more neighbors are less solvent-exposed than residues that have fewer neighbors. In some embodiments, solvent-exposed residues are identified by half sphere exposure, which accounts for the direction of the amino acid side chain (Hamelryck, 2005, *Proteins*, 59:8-48; incorporated herein by
10 reference). In some embodiments, solvent-exposed residues are identified by computing the solvent exposed surface area, accessible surface area, and/or solvent excluded surface of each residue. See, e.g., Lee *et al.*, *J. Mol. Biol.* 55(3):379-400, 1971; Richmond, *J. Mol. Biol.* 178:63-89, 1984; each of which is incorporated herein
15 by reference.

The desired modifications or mutations in the protein may be accomplished using any techniques known in the art. Recombinant DNA techniques for introducing such changes in a protein sequence are well known in the art. In certain embodiments, the modifications are made by site-directed mutagenesis of the
20 polynucleotide encoding the protein. Other techniques for introducing mutations are discussed in *Molecular Cloning: A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch, and Maniatis (Cold Spring Harbor Laboratory Press: 1989); the treatise, *Methods in Enzymology* (Academic Press, Inc., N.Y.); Ausubel *et al.* *Current Protocols in Molecular Biology* (John Wiley & Sons, Inc., New York, 1999); each of
25 which is incorporated herein by reference. The modified protein is expressed and tested. In certain embodiments, a series of variants is prepared, and each variant is tested to determine its biological activity and its stability. The variant chosen for subsequent use may be the most stable one, the most active one, or the one with the greatest overall combination of activity and stability. After a first set of variants is
30 prepared an additional set of variants may be prepared based on what is learned from the first set. Variants are typically created and over-expressed using recombinant techniques known in the art.

As would be appreciated by one of skill in the art, protein fragments, functional protein domains, and homologous proteins are also considered to be within
35 the scope of this disclosure. For example, provided herein is any protein fragment of a reference protein (meaning a polypeptide sequence at least one amino acid residue

5 shorter than a reference polypeptide sequence but otherwise identical) 10, 20, 30, 40,
50, 60, 70, 80, 90, 100 or greater than 100 amino acids in length. In another example,
any protein that includes a stretch of about 20, about 30, about 40, about 50, or about
100 amino acids which are about 40%, about 50%, about 60%, about 70%, about
80%, about 90%, about 95%, or about 100% identical to any of the sequences
10 described herein can be utilized in accordance with the disclosure. In certain
embodiments, a protein sequence to be utilized in accordance with the disclosure
includes 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations as shown in any of the sequences
provided or referenced herein.

15 **Antibody or Antibody-Mimic Moiety (AAM Moiety)**

The disclosure provides complexes comprising a Surf+ Penetrating
Polypeptide portion, as described above, and an antibody or antibody-mimic moiety
(AAM moiety) portion that is associated with the Surf+ Penetrating Polypeptide
portion. This section of the application describes the AAM moiety portion of
20 complexes of the disclosure and provides numerous representative examples. The
disclosure contemplates that any such AAM moiety may be associated with any Surf+
Penetrating Polypeptide or category of Surf+ Penetrating Polypeptide to form a
complex (e.g., may be associated to a portion comprising or consisting of a Surf+
Penetrating Polypeptide). Such a complex has cell penetrating ability (e.g., cell
25 penetrating ability provided by the Surf+ Penetrating Polypeptide portion) and
promotes delivery of the AAM moiety into a cell. As described in greater detail
below, AAM moieties for use in the context of the present disclosure bind to
intracellular targets (e.g., bind to targets expressed or otherwise present inside a cell).
Accordingly, the present disclosure provides complexes and methods for delivering
30 the AAM moiety into a cell where it can bind its target molecule.

As used herein, an “AAM moiety” is an antibody or an antibody mimic
molecule that specifically binds to a target molecule expressed or otherwise present
intracellularly (an intracellular target). An antibody-mimic molecule is also referred
to as an antibody-like molecule. An antibody-mimic binds to a target molecule, but
35 binding is mediated by binding units other than antigen binding portions comprising
at least a variable heavy or variable light chain of an antibody. Thus, in an antibody

5 mimic, binding to target is mediated by a different antigen-binding unit, such as a protein scaffold or other engineered binding unit. Numerous categories of antibody-mimics are well known in the art and are described in further detail below.

The term “target” refers to a molecule expressed or otherwise present inside a cell to which an AAM moiety specifically binds (e.g., binds with affinity and
10 specificity distinct from non-specific interactions). In certain embodiments, the target is a peptide or polypeptide, including peptides or polypeptides that are glycosylated, phosphorylated or otherwise post-translationally modified. The term “intracellular target” refers to molecules expressed or otherwise present in a cell so that the target can be contacted while inside the cell by an AAM moiety. For example, a secreted
15 polypeptide that is taken up by a cell is, for some period of time, present inside a cell. Thus, while present inside a cell, such a secreted polypeptide may be an intracellular target available to be contacted by an AAM moiety. In certain embodiments, the intracellular target is a target whose endogenous localization is inside a cell (e.g., the target is not secreted).

20 In certain embodiments, the AAM moiety binds to a target expressed or otherwise present intracellularly, and that target is distinct from the Surf+ Penetrating Polypeptide to which the AAM moiety is complexed. In other words, the Surf+ Penetrating Polypeptide or Surf+ Penetrating Polypeptide portion to which the AAM moiety is complexed is not also the endogenous target of the AAM moiety. However,
25 in certain embodiments, it is possible that the Surf+ Penetrating Polypeptide may itself bind to or have some affinity for the same target. This, however, is permissible and is not intended to be excluded by the foregoing description.

In certain embodiments, a complex of the disclosure comprises an AAM moiety, wherein the AAM moiety is an antibody that binds to a target molecule
30 expressed inside a cell. In certain embodiments, a complex of the disclosure comprises an AAM moiety, wherein the AAM moiety is an antibody-mimic (e.g., a protein comprising a protein scaffold or other binding unit that binds to a target expressed inside a cell). In certain embodiments, the AAM moiety binds to its target, and that target is a polypeptide expressed in a cell. In certain embodiments, the AAM
35 moiety binds its target molecule, such as a polypeptide, with high affinity (e.g., with an affinity of at least 10^{-6} , 10^{-7} , 10^{-8} , 10^{-9} , 10^{-10} , or 10^{-11} M, or with an affinity in the

5 range of 10^{-6} to 10^{-8} , 10^{-7} to 10^{-10} , or 10^{-9} to 10^{-11} M). In certain embodiments, the AAM moiety binds to its target with an affinity at least 100, at least 1000, or at least 10000 times tighter than its affinity for another polypeptide. Regardless of the affinity with which an AAM moiety binds its target, binding is understood to not include nonspecific binding (e.g., binding due to background or general stickiness of
10 polypeptides).

It should be appreciated that the target may also be expressed extracellularly. However, in the context of the present disclosure, the primary aim is to facilitate delivery of the AAM moiety into a cell to promote binding of the AAM moiety to target expressed inside a cell. Nevertheless, the fact that the target moiety, such as a
15 polypeptide, is also expressed extracellularly does not limit its suitability as a target. Non-limiting examples of target polypeptides are described in greater detail in the portion of the disclosure entitled "Applications". However, these serve only as examples.

Binding of an AAM moiety to a target is generally intended to have one or
20 more biological consequences or utilities. For example, binding of an AAM moiety may be useful for inhibiting the activity of the target, such as by preventing binding to another protein, by promoting degradation of the target, or by sequestering the target away from its necessary site of action. Binding of an AAM moiety may also be useful for labeling a target to facilitate visualization or monitoring of cells expressing
25 the target. Given a particular known target polypeptide, numerous methods exist for identifying AAM moieties that bind to the target and that have a desired function, e.g., that inhibit activity of the target or that bind to the target without altering activity (so as to serve as a suitable labeling agent). Exemplary methods of making and testing AAM moieties that bind a target are described herein.

30 In certain embodiments, an AAM moiety is an antibody-mimic comprising a protein scaffold. Scaffold-based AAM moieties have positioning or structural components and target-contacting components in which the target contacting residues are largely concentrated. Thus, in an embodiment, a scaffold-based AAM moiety comprises a scaffold comprising two types of regions, structural and target contacting.
35 The target contacting region shows more variability than does the structural region when a scaffold-based AAM moiety to a first target is compared with a scaffold-based

5 AAM moiety of a second target (where both AAM moieties are of the same category, *e.g.*, both are Adnectins or both are Anticalins[®]). The structural region tends to be more conserved across AAM moieties that bind different targets. This is analogous to the CDRs and framework regions of antibodies. In the case of an Anticalin[®], the first class corresponds to the loops, and the second class corresponds to the anti-parallel
10 strands.

In certain embodiments the AAM moiety is a subunit-based AAM moiety. These AAM moieties are based on an assembly of subunits which provide distributed points of contact with the target that form a domain that binds with high affinity to the target (*e.g.* as seen with DARPin).

15 In certain embodiments an AAM moiety for use as part of a complex of the disclosure has a molecular weight of 5-250, 10-200, 5-15, 10-30, 15-30, 20-25 kD. AAM moieties can comprise one or more polypeptide chains.

AAM moieties can be antibody-based or non-antibody-based.

AAM moieties suitable for use in the compositions and methods featured in
20 the disclosure include antibody molecules, such as full-length antibodies and antigen-binding fragments thereof, and single domain antibodies, such as camelids. For example, an antibody molecule is complexed with an Surf+ Penetrating Polypeptide for delivery of the antibody molecule into a cell. The antibody molecule binds an intracellular target, *e.g.*, an intracellular polypeptide, such as to inhibit, label or
25 activate the target, *e.g.*, for treatment of a disorder, for labeling to monitor expression or as a diagnostic, for research or clinical purposes.

Other suitable AAM moieties include polypeptides engineered to contain a scaffold protein, such as a DARPin, an Adnectin[®], or an Anticalin[®]. These are exemplary of antibody-mimic moieties that, in the context of the disclosure, may be
30 complexed with a Surf+ Penetrating Polypeptide to promote delivery of the AAM moiety into a cell. The scaffold protein (*e.g.*, the AAM moiety portion of the complex) binds an intracellular target, *e.g.*, an intracellular polypeptide, such as to inhibit, label or activate the target, *e.g.*, for treatment of a disorder, for labeling to monitor expression or as a diagnostic, for research purposes. Inhibition can be, *e.g.*,
35 by steric inhibition, *e.g.*, by blocking protein interaction with a substrate, or inhibition can be, *e.g.*, by causing target protein degradation.

5 An AAM moiety for delivery into a cell can be, *e.g.*, an agent for treatment, prophylaxis, diagnosis, imaging, or labeling. In some embodiments, the AAM moiety has a desirable activity in a target cell, but the Surf+ Penetrating Polypeptide that delivers the AAM moiety is inert, *i.e.*, the Surf+ Penetrating Polypeptide has no observable biological function in the cell other than to deliver the agent to the interior
10 of the cell. In other embodiments, the Surf+ Penetrating Polypeptide has at least one desired biological activity, *e.g.*, the polypeptide modifies (*e.g.*, enhances) the effect of the AAM moiety on a target molecule, or the Surf+ Penetrating Polypeptide binds to and affects the activity of a second target molecule that is separate from the first molecule targeted by the high affinity binding ligand.

15 Before describing exemplary AAM moieties and sub-categories of AAM moieties in greater detail, it should be understood that the AAM moiety itself has charge, size and charge distribution characteristics. However, such charge or charge distribution characteristics are not considered when describing the charge characteristics of the Surf+ Penetrating Polypeptide portion or when evaluating
20 whether the Surf+ Penetrating Polypeptide portion has been supercharged or modified. Rather, supercharging refers to changes to Surf+ Penetrating Polypeptide – other than occur simply by complexing to an AAM moiety.

Antibody Molecules

25 As used herein, the term “antibody” or “antibody molecule” refers to a protein that includes sufficient sequence (*e.g.*, antibody variable region sequence) to mediate binding to a target, and in embodiments, includes at least one immunoglobulin variable region or an antigen binding fragment thereof.

An antibody molecule can be, for example, a full-length, mature antibody, or
30 an antigen binding fragment thereof. An antibody molecule, also known as an antibody or an immunoglobulin, encompass monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies formed from at least two different epitope binding fragments (*e.g.*, bispecific antibodies), human antibodies, humanized antibodies, camelised antibodies, chimeric antibodies,
35 single-chain Fvs (scFv), Fab fragments, F(ab')₂ fragments, antibody fragments that exhibit the desired biological activity (*e.g.* the antigen binding portion), disulfide-

5 linked Fvs (dsFv), and anti-idiotypic (anti-Id) antibodies (including, *e.g.*, anti-Id antibodies to antibodies of the disclosure), intrabodies, and epitope-binding fragments of any of the above. In particular, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, *i.e.*, molecules that contain at least one antigen-binding site. Immunoglobulin molecules can be of any

10 isotype (*e.g.*, IgG, IgE, IgM, IgD, IgA and IgY), subisotype (*e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or allotype (*e.g.*, Gm, *e.g.*, G1m(f, z, a or x), G2m(n), G3m(g, b, or c), Am, Em, and Km(1, 2 or 3)). Antibodies may be derived from any mammal, including, but not limited to, humans, monkeys, pigs, horses, rabbits, dogs, cats, mice, etc., or other animals such as birds (*e.g.* chickens). The antibody molecule can be a

15 single domain antibody, *e.g.*, a nanobody, such as a camelid, or a llama- or alpaca-derived single domain antibody, or a shark antibody (IgNAR). The single domain antibody comprises, *e.g.*, only a variable heavy domain (VHH). An antibody molecule can also be a genetically engineered single domain antibody. Typically, the antibody molecule is a human, humanized, chimeric, camelid, shark or *in vitro*

20 generated antibody.

Examples of fragments include (i) an Fab fragment having a VL, VH, constant light chain domain (CL) and constant heavy chain domain 1 (CH1) domains; (ii) an Fd fragment having VH and CH1 domains; (iii) an Fv fragment having VL and VH domains of a single antibody; (iv) a dAb fragment (Ward, E.S. et al., Nature 341, 544-546 (1989); McCafferty et al (1990) Nature, 348, 552-55; and Holt et al (2003) Trends in Biotechnology 21, 484-490), having a VH or a VL domain; (v) isolated CDR regions; (vi) F(ab')₂ fragments, a bivalent fragment comprising two linked Fab fragments (vii) single chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to

30 form an antigen binding site (Bird et al, Science, 242, 423-426, 1988 and Huston et al, PNAS USA, 85, 5879-5883, 1988) (viii) bispecific single chain Fv dimers (for example as disclosed in WO 1993/011161) and (ix) "diabodies", multivalent or multispecific fragments constructed by gene fusion (for example as disclosed in WO94/13804 and Holliger, P. et al, Proc. Natl. Acad. Sci. USA 90 6444-6448, 1993).

35 Fv, scFv or diabody molecules may be stabilized by the incorporation of disulphide bridges linking the VH and VL domains (Reiter, Y. et al, Nature Biotech, 14, 1239-

5 1245, 1996). Minibodies comprising a scFv joined to a CH3 domain may also be
made (Hu, S. et al, Cancer Res., 56, 3055-3061, 1996). Other examples of binding
fragments are Fab', which differs from Fab fragments by the addition of a few
residues at the carboxyl terminus of the heavy chain CH1 domain, including one or
more cysteines from the antibody hinge region, and Fab'-SH, which is a Fab'
10 fragment in which the cysteine residue(s) of the constant domains bear a free thiol
group. These antibody fragments are obtained using conventional techniques known
to those with skill in the art, and the fragments are screened for utility in the same
manner as are intact antibodies. Suitable fragments may, in certain embodiments, be
obtained from human or rodent antibodies.

15 The term "antibody molecule" includes intact molecules as well as functional
fragments thereof. Constant regions of the antibody molecules can be altered, *e.g.*,
mutated, to modify the properties of the antibody (*e.g.*, to increase or decrease one or
more of: Fc receptor binding, antibody glycosylation, the number of cysteine
residues, effector cell function, or complement function). In certain embodiments,
20 antibodies for use in the present disclosure are labelled, modified to increase half-life,
and the like. For example, in certain embodiments, the antibody is chemically
modified, such as by PEGylation, or by incorporation in a liposome.

Antibody molecules can also be single domain antibodies. Single domain
antibodies can include antibodies whose complementary determining regions are part
25 of a single domain polypeptide. Examples include, but are not limited to, heavy chain
antibodies, antibodies naturally devoid of light chains, light chains devoid of heavy
chains, single domain antibodies derived from conventional 4-chain antibodies, and
engineered antibodies and single domain scaffolds other than those derived from
antibodies. Single domain antibodies may be any of the art, or any future single
30 domain antibodies. Single domain antibodies may be derived from any species
including, but not limited to mouse, human, camel, llama, fish, shark, goat, rabbit, and
bovine. In one aspect of the disclosure, a single domain antibody can be derived from
a variable region of the immunoglobulin found in fish, such as, for example, that
which is derived from the immunoglobulin isotype known as Novel Antigen Receptor
35 (NAR) found in the serum of shark. Methods of producing single domain antibodies
derived from a variable region of NAR ("IgNARs") are described in WO 03/014161

5 and Streltsov (2005) *Protein Sci.* 14:2901-2909. According to another aspect, a single domain antibody is a naturally occurring single domain antibody known as a heavy chain antibody devoid of light chains. Such single domain antibodies are disclosed in WO 9404678, for example. For clarity reasons, this variable domain derived from a heavy chain antibody naturally devoid of light chain is known herein as a VHH or
10 nanobody to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from antibodies raised in Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides Camelidae may produce heavy chain antibodies naturally devoid of light chain; and such VHHs are within the scope of the disclosure.

15 The VH and VL regions can be subdivided into regions of hypervariability, termed “complementarity determining regions“ (CDR), interspersed with regions that are more conserved, termed “framework regions“ (FR). The extent of the framework region and CDRs has been precisely defined by a number of methods (see, Kabat, E. A., *et al.* (1991) *Sequences of Proteins of Immunological Interest*, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia, C. *et al.* (1987) *J. Mol. Biol.* 196:901-917; and the AbM definition used by Oxford Molecular’s AbM antibody modelling software. See, generally, *e.g.*, *Protein Sequence and Structure Analysis of Antibody Variable Domains*. In: *Antibody Engineering Lab Manual* (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). Each VH
20 and VL typically includes three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

The VH or VL chain of the antibody molecule can further include all or part of a heavy or light chain constant region, to thereby form a heavy or light immunoglobulin chain, respectively. In one embodiment, the antibody molecule is a
30 tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains. The heavy and light immunoglobulin chains can be connected by disulfide bonds. The heavy chain constant region typically includes three constant domains, CH1, CH2 and CH3. The light chain constant region typically includes a CL domain. The variable region of the heavy and light chains contains a binding domain that interacts with an
35 antigen. The constant regions of the antibody molecules typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune

5 system (*e.g.*, effector cells) and the first component (Clq) of the classical complement system.

The term “immunoglobulin” comprises various broad classes of polypeptides that can be distinguished biochemically. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (γ , μ , α , δ , ϵ) with
10 some subclasses among them (*e.g.*, $\gamma 1$ - $\gamma 4$). It is the nature of this chain that determines the “class” of the antibody as IgG, IgM, IgA, IgD, or IgE, respectively. The immunoglobulin subclasses (isotypes) *e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1, *etc.* are well characterized and are known to confer functional specialization. Modified
15 versions of each of these classes and isotypes are readily discernable to the skilled artisan in view of the instant disclosure and, accordingly, are within the scope of the present disclosure. All immunoglobulin classes are also within the scope of the present disclosure. Light chains are classified as either kappa or lambda (κ , λ). Each heavy chain class may be bound with either a kappa or lambda light chain.

The term “antigen-binding fragment” refers to one or more fragments of a full-
20 length antibody that retain the ability to specifically bind to a target of interest. Examples of binding fragments encompassed within the term “antigen-binding fragment” of a full length antibody include (i) a Fab fragment, a monovalent fragment having VL, VH, CL and CH1 domains; (ii) a F(ab')₂ fragment, a bivalent fragment including two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an
25 Fd fragment having VH and CH1 domains; (iv) an Fv fragment having VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, (1989) Nature 341:544-546), which has a VH domain; and (vi) an isolated complementarity determining region (CDR) that retains functionality. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be
30 joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules known as single chain Fv (scFv). See *e.g.*, Bird *et al.* (1988) Science 242:423-426; and Huston *et al.* (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883.

The term “antigen-binding site” refers to the part of an antibody molecule that
35 comprises determinants that form an interface that binds to a target antigen, or an epitope thereof. With respect to proteins (or protein mimetics), the antigen-binding

5 site typically includes one or more loops (of at least four amino acids or amino acid mimics) that form an interface that binds to the target antigen or epitope thereof. Typically, the antigen-binding site of an antibody molecule includes at least one or two CDRs, or more typically at least three, four, five or six CDRs.

Regardless of the type of antibody used, in certain embodiments, the antibody
10 may comprise replacing one or more amino acid residue(s) with a non-naturally occurring or non-standard amino acid, modifying one or more amino acid residue into a non-naturally occurring or non-standard form, or inserting one or more non-naturally occurring or non-standard amino acid into the sequence. Examples of numbers and locations of alterations in sequences are described elsewhere herein.

15 Naturally occurring amino acids include the 20 “standard” L-amino acids identified as G, A, V, L, I, M, P, F, W, S, T, N, Q, Y, C, K, R, H, D, E by their standard single-letter codes. Non-standard amino acids include any other residue that may be incorporated into a polypeptide backbone or result from modification of an existing amino acid residue. Non-standard amino acids may be naturally occurring or non-
20 naturally occurring. Several naturally occurring non-standard amino acids are known in the art, such as 4-hydroxyproline, 5-hydroxylysine, 3-methylhistidine, N-acetylserine, etc. (Voet & Voet, *Biochemistry*, 2nd Edition, (Wiley) 1995). Those amino acid residues that are derivatised at their N-alpha position will only be located at the N-terminus of an amino-acid sequence. Normally, an amino acid is an L-amino
25 acid, but it may be a D-amino acid. Alteration may therefore comprise modifying an L-amino acid into, or replacing it with, a D-amino acid. Methylated, acetylated and/or phosphorylated forms of amino acids are also known, and amino acids in the present disclosure may be subject to such modification.

In certain embodiments, the antibodies used in the claimed methods are
30 generated using random mutagenesis of one or more selected VH and/or VL genes to generate mutations within the entire variable domain. Such a technique is described by Gram et al., 1992, Proc. Natl. Acad. Sci., USA, 89:3576-3580 who used error-prone PCR. In some embodiments one or two amino acid substitutions are made within an entire variable domain or set of CDRs.

5 Another method that may be used is to direct mutagenesis to CDR regions of VH or VL genes. Such techniques are disclosed by Barbas et al., 1994, Proc. Natl. Acad. Sci., USA, 91:3809-3813 and Schier et al., 1996, J. Mol. Biol. 263:551-567.

Preparation of Antibodies

10 Suitable antibodies for use as an AAM moiety can be prepared using methods well known in the art. For example, antibodies can be generated recombinantly, made using phage display, produced using hybridoma technology, etc. Non-limiting examples of techniques are described briefly below.

In general, for the preparation of monoclonal antibodies or their functional
15 fragments, especially of murine origin, it is possible to refer to techniques which are described in particular in the manual “Antibodies“ (Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor N.Y., pp. 726, 1988) or to the technique of preparation from hybridomas described by Köhler and Milstein, Nature, 256:495-497, 1975.

20 Monoclonal antibodies can be obtained, for example, from a cell obtained from an animal immunized against the target antigen, or one of its fragments. Suitable fragments and peptides or polypeptides comprising them may be used to immunise animals to generate antibodies against the target antigen.

The monoclonal antibodies can, for example, be purified on an affinity column
25 on which the target antigen or one of its fragments containing the epitope recognized by said monoclonal antibodies, has previously been immobilized. More particularly, the monoclonal antibodies can be purified by chromatography on protein A and/or G, followed or not followed by ion-exchange chromatography aimed at eliminating the residual protein contaminants as well as the DNA and the lipopolysaccharide (LPS), in
30 itself, followed or not followed by exclusion chromatography on Sepharose™ gel in order to eliminate the potential aggregates due to the presence of dimers or of other multimers. In one embodiment, the whole of these techniques can be used simultaneously or successively.

It is possible to take monoclonal and other antibodies and use techniques of
35 recombinant DNA technology to produce other antibodies or chimeric molecules that bind the target antigen. Such techniques may involve introducing DNA encoding the

5 immunoglobulin variable region, or the CDRs, of an antibody to the constant regions,
or constant regions plus framework regions, of a different immunoglobulin. See, for
instance, EP-A-184187, GB 2188638A or EP-A-239400, and a large body of
subsequent literature. A hybridoma or other cell producing an antibody may be
subject to genetic mutation or other changes, which may or may not alter the binding
10 specificity of antibodies produced.

Further techniques available in the art of antibody engineering have made it
possible to isolate human and humanised antibodies. For example, human hybridomas
can be made as described by Kontermann, R & Dubel, S, *Antibody Engineering*,
Springer-Verlag New York, LLC; 2001, ISBN: 3540413545. Phage display, another
15 established technique for generating antagonists has been described in detail in many
publications, such as Kontermann & Dubel, supra and WO92/01047 (discussed
further below), and US patents US 5,969,108, US 5,565,332, US 5,733,743, US
5,858,657, US 5,871,907, US 5,872,215, US 5,885,793, US 5,962,255, US 6,140,471,
US 6,172,197, US 6,225,447, US 6,291,650, US 6,492,160 and US 6,521,404.

20 Transgenic mice in which the mouse antibody genes are inactivated and
functionally replaced with human antibody genes while leaving intact other
components of the mouse immune system, can be used for isolating human antibodies
Mendez, M. et al. (1997) Nature Genet, 15(2): 146–156. Humanised antibodies can be
produced using techniques known in the art such as those disclosed in, for example,
25 WO91/09967, US 5,585,089, EP592106, US 5,565,332 and WO93/17105. Further,
WO2004/006955 describes methods for humanising antibodies, based on selecting
variable region framework sequences from human antibody genes by comparing
canonical CDR structure types for CDR sequences of the variable region of a non-
human antibody to canonical CDR structure types for corresponding CDRs from a
30 library of human antibody sequences, e.g. germline antibody gene segments. Human
antibody variable regions having similar canonical CDR structure types to the non-
human CDRs form a subset of member human antibody sequences from which to
select human framework sequences. The subset members may be further ranked by
amino acid similarity between the human and the non-human CDR sequences. In the
35 method of WO2004/006955, top ranking human sequences are selected to provide the
framework sequences for constructing a chimeric antibody that functionally replaces

5 human CDR sequences with the non-human CDR counterparts using the selected subset member human frameworks, thereby providing a humanized antibody of high affinity and low immunogenicity without need for comparing framework sequences between the non-human and human antibodies. Chimeric antibodies made according to the method are also disclosed.

10 Synthetic antibody molecules may be created by expression from genes generated by means of oligonucleotides synthesized and assembled within suitable expression vectors, for example as described by Knappik et al. J. Mol. Biol. (2000) 296, 57-86 or Krebs et al. Journal of Immunological Methods 254 2001 67-84.

Note that regardless of how an antibody of interest is initially identified or
15 made, any such antibody can be subsequently produced using recombinant techniques. For example, a nucleic acid sequence encoding the antibody may be expressed in a host cell. Such methods include expressing nucleic acid sequence encoding the heavy chain and light chain from separate vectors, as well as expressing the nucleic acid sequences from the same vector. These and other techniques using a
20 variety of cell types are well known in the art.

Using these and other techniques known in the art, antibodies that specifically bind to any target can be made. Once made, antibodies can be tested to confirm that they bind to the desired target antigen and to select antibodies having desired properties. Such desired properties include, but are not limited to, selecting
25 antibodies having the desired affinity and cross-reactivity profile. Given that large numbers of candidate antibodies can be made, one of skill in the art can readily screen a large number of candidate antibodies to select those antibodies suitable for the intended use. Moreover, the antibodies can be screened using functional assays to identify antibodies that bind the target and have a particular function, such as the
30 ability to inhibit an activity of the target or the ability to bind to the target without inhibiting its activity. Thus, one can readily make antibodies that bind to a target and are suitable for an intended purpose.

The nucleic acid (*e.g.*, the gene) encoding an antibody can be cloned into a vector that expresses all or part of the nucleic acid. For example, the nucleic acid can
35 include a fragment of the gene encoding the antibody, such as a single chain antibody (scFv), a F(ab')₂ fragment, a Fab fragment, or an Fd fragment.

5 Antibodies may also include modifications, *e.g.*, modifications that alter Fc function, *e.g.*, to decrease or remove interaction with an Fc receptor or with C1q, or both. For example, the human IgG4 constant region can have a Ser to Pro mutation at residue 228 to fix the hinge region.

10 In another example, the human IgG1 constant region can be mutated at one or more residues, *e.g.*, one or more of residues 234 and 237, *e.g.*, according to the numbering in U.S. Patent No. 5,648,260. Other exemplary modifications include those described in U.S. Patent No. 5,648,260.

15 For some antibodies that include an Fc domain, the antibody production system may be designed to synthesize antibodies in which the Fc region is glycosylated. In another example, the Fc domain of IgG molecules is glycosylated at asparagine 297 in the CH2 domain. This asparagine is the site for modification with biantennary-type oligosaccharides. This glycosylation participates in effector functions mediated by Fcγ receptors and complement C1q (Burton and Woof (1992) *Adv. Immunol.* 51:1-84; Jefferis *et al.* (1998) *Immunol. Rev.* 163:59-76). The Fc domain can be produced in a mammalian expression system that appropriately glycosylates the residue corresponding to asparagine 297. The Fc domain can also include other eukaryotic post-translational modifications.

25 Antibodies can be modified, *e.g.*, with a moiety that improves its stabilization and/or retention in circulation, *e.g.*, in blood, serum, lymph, bronchoalveolar lavage, or other tissues, *e.g.*, by at least 1.5, 2, 5, 10, or 50 fold.

30 For example, an antibody generated by a method described herein can be associated with a polymer, *e.g.*, a substantially non-antigenic polymer, such as a polyalkylene oxide or a polyethylene oxide. Suitable polymers will vary substantially by weight. Polymers having molecular number average weights ranging from about 200 to about 35,000 daltons (or about 1,000 to about 15,000, and 2,000 to about 12,500) can be used.

35 For example, an antibody generated by a method described herein can be conjugated to a water soluble polymer, *e.g.*, a hydrophilic polyvinyl polymer, *e.g.* polyvinylalcohol or polyvinylpyrrolidone. A non-limiting list of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block

5 copolymers thereof, provided that the water solubility of the block copolymers is maintained. Additional useful polymers include polyoxyalkylenes such as polyoxyethylene, polyoxypropylene, and block copolymers of polyoxyethylene and polyoxypropylene (Pluronics); polymethacrylates; carbomers; branched or unbranched polysaccharides that comprise the saccharide monomers D-mannose,
10 D- and L-galactose, fucose, fructose, D-xylose, L-arabinose, D-glucuronic acid, sialic acid, D-galacturonic acid, D-mannuronic acid (*e.g.* polymannuronic acid, or alginic acid), D-glucosamine, D-galactosamine, D-glucose and neuraminic acid including homopolysaccharides and heteropolysaccharides such as lactose, amylopectin, starch, hydroxyethyl starch, amylose, dextrane sulfate, dextran, dextrans, glycogen, or the
15 polysaccharide subunit of acid mucopolysaccharides, *e.g.* hyaluronic acid; polymers of sugar alcohols such as polysorbitol and polymannitol; heparin or heparon.

Antibody-Mimic Molecules

Antibody-mimic molecules are antibody-like molecules comprising a protein
20 scaffold or other non-antibody target binding region with a structure that facilitates binding with target molecules, *e.g.*, polypeptides. When an antibody mimic comprises a scaffold, the scaffold structure of an antibody-mimic is reminiscent of antibodies, but antibody-mimics do not include the CDR and framework structure of immunoglobulins. Like antibodies, however, a pool of scaffold proteins having
25 different amino acid sequence (but having the same basic scaffold structure) can be made and screened to identify the antibody-mimic molecule having the desired features (*e.g.*, ability to bind a particular target; ability to bind a particular target with a certain affinity; ability to bind a particular target to produce a certain result, such as to inhibit activity of the target). In this way, antibody-mimics molecules that bind a
30 target and that have a desired function can be readily made and tested in much the same way that antibodies can be. There are numerous examples of classes of antibody-mimic molecules; each of which is characterized by a unique scaffold structure. Any of these classes of antibody-mimic molecules may be used as the AAM moiety portion of a complex of the disclosure. Exemplary classes are described
35 below and include, but are not limited to, DARPin polypeptides, Adnectins[®] polypeptides, and Anticalins[®] polypeptides.

5 In certain embodiments, an antibody-mimic moiety molecule can comprise binding site portions that are derived from a member of the immunoglobulin superfamily that is not an immunoglobulin (e.g., a T-cell receptor or a cell-adhesion protein such as CTLA-4, N-CAM, and telokin). Such molecules comprise a binding site portion which retains the conformation of an immunoglobulin fold and is capable
10 of specifically binding to the target antigen or epitope. In some embodiments, antibody-mimic moiety molecules of the disclosure also comprise a binding site with a protein topology that is not based on the immunoglobulin fold (e.g., such as ankyrin repeat proteins or fibronectins) but which nonetheless are capable of specifically binding to a target antigen or epitope.

15 Antibody-mimic moiety molecules may be identified by selection or isolation of a target-binding variant from a library of binding molecules having artificially diversified binding sites. Diversified libraries can be generated using completely random approaches (e.g., error-prone PCR, exon shuffling, or directed evolution) or aided by art-recognized design strategies. For example, amino acid positions that are
20 usually involved when the binding site interacts with its cognate target molecule can be randomized by insertion of degenerate codons, trinucleotides, random peptides, or entire loops at corresponding positions within the nucleic acid which encodes the binding site (see e.g., U.S. Pub. No. 20040132028). The location of the amino acid positions can be identified by investigation of the crystal structure of the binding site
25 in complex with the target molecule. Candidate positions for randomization include loops, flat surfaces, helices, and binding cavities of the binding site. In certain embodiments, amino acids within the binding site that are likely candidates for diversification can be identified by their homology with the immunoglobulin fold. For example, residues within the CDR-like loops of fibronectin may be randomized to
30 generate a library of fibronectin binding molecules (see, e.g., Koide et al., J. Mol. Biol., 284: 1141-1151 (1998)). Other portions of the binding site which may be randomized include flat surfaces. Following randomization, the diversified library may then be subjected to a selection or screening procedure to obtain binding molecules with the desired binding characteristics. For example, selection can be
35 achieved by art-recognized methods such as phage display, yeast display, or ribosome display.

5 In one embodiment, an antibody-mimic molecule of the disclosure comprises a binding site from a fibronectin binding molecule. Fibronectin binding molecules (e.g., molecules comprising the Fibronectin type I, II, or III domains) display CDR-like loops which, in contrast to immunoglobulins, do not rely on intra-chain disulfide bonds. The FnIII loops comprise regions that may be subjected to random mutation
10 and directed evolutionary schemes of iterative rounds of target binding, selection, and further mutation in order to develop useful therapeutic tools. Fibronectin-based “addressable” therapeutic binding molecules (“FATBIM”) may be developed to specifically or preferentially bind the target antigen or epitope. Methods for making fibronectin binding polypeptides are described, for example, in WO 01/64942 and in
15 U.S. Pat. Nos. 6,673,901, 6,703,199, 7,078,490, and 7,119,171, which are incorporated herein by reference.

 FATBIMs include, for example, the species of fibronectin-based binding molecules termed Adnectins[®]. As used herein “Adnectins[®],” also called “monobodies,” are genetically engineered proteins that functionally mimic antibodies
20 and that typically exhibit highly specific and high-affinity target protein binding. In some embodiments, an Adnectin[®] comprises far fewer amino acid residues than does an antibody, and in other embodiments, the Adnectin[®] is approximately the size as a single variable domain of an antibody. In one embodiment, the Adnectin[®] comprises approximately 90 amino acids, e.g., 94 amino acids, and has a molecular mass of
25 about 10 kDa, which is fifteen times smaller than an IgG type antibody, and comparable to the size of a single variable domain of an antibody. In certain embodiments the structure of an Adnectin[®] is based on the structure of human fibronectin, and more specifically on the structure of the tenth extracellular type III domain of human fibronectin. This domain has a structure analogous to antibody
30 variable domains, with seven beta sheets forming a barrel and three exposed loops on each side, which are analogous to the three complementarity determining regions. Unlike antibodies, however, Adnectins[®] typically lack binding sites for metal ions and a central disulfide bond. Adnectins[®] can be engineered to have specificity for different target proteins by modifying the loops between the second and third beta
35 sheets, and between the sixth and seventh beta sheets (*i.e.*, by modifying loops BC and FG of the tenth extracellular type III domain of fibronectin). Adnectins[®] are

5 described in, e.g., U.S. Patent No. 7,115,396. In certain embodiments, the disclosure provides a complex comprising a Surf+ Penetrating Polypeptide associated with an Adnectin (e.g., a antibody-mimic based on the structure of human fibronectin), wherein the Adnectin binds to an intracellularly expressed target. In other words, in certain embodiments, complexes of the disclosure comprise an AAM moiety portion
10 comprising a scaffold structure based on fibronectin, such as the tenth extracellular type III domain of fibronectin.

In another embodiment, an antibody-mimic molecule of the disclosure comprises a binding site from an affibody. As used herein “Affibody[®]” molecules are derived from the immunoglobulin binding domains of staphylococcal Protein A
15 (SPA) (see e.g., Nord et al., Nat. Biotechnol., 15: 772-777 (1997)). An Affibody[®] is an antibody mimic that has unique binding sites that bind specific targets. Affibody[®] molecules can be small (e.g., consisting of three alpha helices with 58 amino acids and having a molar mass of about 6 kDa), have an inert format (no Fc function), and have been successfully tested in humans as targeting moieties. Affibody[®] molecules
20 have been shown to withstand high temperatures (90 °C) or acidic and alkaline conditions (pH 2.5 or pH 11, respectively). Affibody[®] binding sites employed in the disclosure may be synthesized by mutagenizing an SPA-related protein (e.g., Protein Z) derived from a domain of SPA (e.g., domain B) and selecting for mutant SPA-related polypeptides having binding affinity for a target antigen or epitope. Other
25 methods for making affibody binding sites are described in U.S. Pat. Nos. 6,740,734 and 6,602,977 and in WO 00/63243, each of which is incorporated herein by reference. In certain embodiments, the disclosure provides a complex comprising a Surf+ Penetrating Polypeptide associated with an Affibody, wherein the Affibody binds to an intracellularly expressed target.

30 In another embodiment, an antibody-mimic molecule of the disclosure comprises a binding site from an anticalin. As used herein, “Anticalins[®]” are antibody functional mimetics derived from human lipocalins. Lipocalins are a family of naturally-occurring binding proteins that bind and transport small hydrophobic molecules such as steroids, bilins, retinoids, and lipids. The main structure of
35 Anticalins[®] is similar to wild type lipocalins. The central element of this protein architecture is a beta-barrel structure of eight antiparallel strands, which supports four

5 loops at its open end. These loops form the natural binding site of the lipocalins and can be reshaped *in vitro* by extensive amino acid replacement, thus creating novel binding specificities.

Anticalins[®] possess high affinity and specificity for their prescribed ligands as well as fast binding kinetics, so that their functional properties are similar to those of
10 antibodies. Anticalins[®] however, have several advantages over antibodies, including smaller size, composition of a single polypeptide chain, and a simple set of four hypervariable loops that can be easily manipulated at the genetic level. Anticalins[®], for example, are about eight times smaller than antibodies with a size of about 180 amino acids and a mass of about 20 kDa. Anticalins[®] have better tissue penetration
15 than antibodies and are stable at temperatures up to 70 °C, and also unlike antibodies, Anticalins[®] can be produced in bacterial cells (*e.g.*, *E. coli* cells) in large amounts. Further, while antibodies and most other antibody mimetics can only be directed at macromolecules like proteins, Anticalins[®] are able to selectively bind to small molecules as well. Anticalins[®] are described in, *e.g.*, U.S. Patent No. 7,723,476. In
20 certain embodiments, the disclosure provides a complex comprising a Surf+ Penetrating Polypeptide associated with an Affibody, wherein the Affibody binds to an intracellularly expressed target.

In another embodiment, an antibody-mimic molecule of the disclosure comprises a binding site from a cysteine-rich polypeptide. Cysteine-rich domains
25 employed in the practice of the present disclosure typically do not form an alpha-helix, a beta-sheet, or a beta-barrel structure. Typically, the disulfide bonds promote folding of the domain into a three-dimensional structure. Usually, cysteine-rich domains have at least two disulfide bonds, more typically at least three disulfide bonds. An exemplary cysteine-rich polypeptide is an A domain protein. A-domains
30 (sometimes called “complement-type repeats”) contain about 30-50 or 30-65 amino acids. In some embodiments, the domains comprise about 35-45 amino acids and in some cases about 40 amino acids. Within the 30-50 amino acids, there are about 6 cysteine residues. Of the six cysteines, disulfide bonds typically are found between the following cysteines: C1 and C3, C2 and C5, C4 and C6. The A domain constitutes
35 a ligand binding moiety. The cysteine residues of the domain are disulfide linked to form a compact, stable, functionally independent moiety. Clusters of these repeats

5 make up a ligand binding domain, and differential clustering can impart specificity with respect to the ligand binding. Exemplary proteins containing A-domains include, e.g., complement components (e.g., C6, C7, C8, C9, and Factor I), serine proteases (e.g., enteropeptidase, matriptase, and corin), transmembrane proteins (e.g., ST7, LRP3, LRP5 and LRP6) and endocytic receptors (e.g. Sortilin-related receptor, LDL-
10 receptor, VLDLR, LRP1, LRP2, and ApoER2). Methods for making A-domain proteins of a desired binding specificity are disclosed, for example, in WO 02/088171 and WO 04/044011, each of which is incorporated herein by reference.

In another embodiment, an antibody-mimic molecule of the disclosure comprises a binding site from a repeat protein. Repeat proteins are proteins that
15 contain consecutive copies of small (e.g., about 20 to about 40 amino acid residues) structural units or repeats that stack together to form contiguous domains. Repeat proteins can be modified to suit a particular target binding site by adjusting the number of repeats in the protein. Exemplary repeat proteins include designed ankyrin repeat proteins (i.e., a DARPins) (see e.g., Binz et al., Nat. Biotechnol., 22: 575-582
20 (2004)) or leucine-rich repeat proteins (i.e., LRRPs) (see e.g., Pancer et al., Nature, 430: 174-180 (2004)).

As used here, “DARPins” are genetically engineered antibody mimetic proteins that typically exhibit highly specific and high-affinity target protein binding. DARPins were first derived from natural ankyrin proteins. In certain embodiments,
25 DARPins comprise three, four or five repeat motifs of an ankyrin protein. In certain embodiments, a unit of an ankyrin repeat consists of 30-34 amino acid residues and functions to mediate protein-protein interactions. In certain embodiments, each ankyrin repeat exhibits a helix-turn-helix conformation, and strings of such tandem repeats are packed in a nearly linear array to form helix-turn-helix bundles connected
30 by relatively flexible loops. In certain embodiments, the global structure of an ankyrin repeat protein is stabilized by intra- and inter-repeat hydrophobic and hydrogen bonding interactions. The repetitive and elongated nature of the ankyrin repeats provides the molecular bases for the unique characteristics of ankyrin repeat proteins in protein stability, folding and unfolding, and binding specificity. While not wishing
35 to be bound by theory, it is believed that the ankyrin repeat proteins do not recognize specific sequences, and interacting residues are discontinuously dispersed into the

5 whole molecules of both the ankyrin repeat protein and its target protein. In addition, the availability of thousands of ankyrin repeat sequences has made it feasible to use rational design to modify the specificity and stability of an ankyrin repeat domain for use as a DARPin to target any number of proteins. The molecular mass of a DARPin domain is typically about 14 or 18 kDa for four- or five-repeat DARPins,
10 respectively. DARPins are described in, e.g., U.S. Patent No. 7,417,130. All so far determined tertiary structures of ankyrin repeat units share a characteristic composed of a beta-hairpin followed by two antiparallel alpha-helices and ending with a loop connecting the repeat unit with the next one. Domains built of ankyrin repeat units are formed by stacking the repeat units to an extended and curved structure. LRRP
15 binding sites from part of the adaptive immune system of sea lampreys and other jawless fishes and resemble antibodies in that they are formed by recombination of a suite of leucine-rich repeat genes during lymphocyte maturation. Methods for making DARPin or LRRP binding sites are described in WO 02/20565 and WO 06/083275, each of which is incorporated herein by reference.

20 Another example of an AAM moiety suitable for use in the present disclosure is based on technology in which binding regions are engineered into the Fc domain of an antibody molecule. These antibody-like molecules are another example of AAM moieties for use in the present disclosure. In certain embodiments, antibody mimics include all or a portion of an antibody like molecule, comprising the CH2 and CH3
25 domains of an immunoglobulin, engineered with non-CDR loops of constant and/or variable domains, thereby mediating binding to an epitope via the non-CDR loops. Exemplary technology includes technology from F-Star, such as antigen binding Fc molecules (termed FcabTM) or full length antibody like molecules with dual functionality (mAb² TM). FcabTM (antigen binding Fc) are a “compressed” version of
30 these antibody like molecules. These molecules include the CH2 and CH3 domains of the Fc portion of an antibody, naturally folded as a homodimer (50kDa). Antigen binding sites are engineered into the CH3 domains, but the molecules lack traditional antibody variable regions.

Similar antibody like molecules are referred to as mAb² TM molecules. Full
35 length IgG antibodies with additional binding domains (such as two) engineered into the CH3 domains. Depending on the type of additional binding sites engineered into

5 the CH3 domains, these molecules may be bispecific or multispecific or otherwise facilitate tissue targeting.

This technology is described in, for example, WO08/003103, WO12/007167, and US application 20090298195, the disclosures of which are hereby incorporated by reference.

10 In other embodiments, an antibody-mimic molecule of the disclosure comprises binding sites derived from Src homology domains (e.g. SH2 or SH3 domains), PDZ domains, beta-lactamase, high affinity protease inhibitors, or small disulfide binding protein scaffolds such as scorpion toxins. Methods for making binding sites derived from these molecules have been disclosed in the art, see e.g.,
15 Panni et al., J. Biol. Chem., 277: 21666-21674 (2002), Schneider et al., Nat. Biotechnol., 17: 170-175 (1999); Legendre et al., Protein Sci., 11:1506-1518 (2002); Stoop et al., Nat. Biotechnol., 21: 1063-1068 (2003); and Vita et al., PNAS, 92: 6404-6408 (1995). Yet other binding sites may be derived from a binding domain selected from the group consisting of an EGF-like domain, a Kringle-domain, a PAN domain,
20 a Gla domain, a SRCR domain, a Kunitz/Bovine pancreatic trypsin Inhibitor domain, a Kazal-type serine protease inhibitor domain, a Trefoil (P-type) domain, a von Willebrand factor type C domain, an Anaphylatoxin-like domain, a CUB domain, a thyroglobulin type I repeat, LDL-receptor class A domain, a Sushi domain, a Link domain, a Thrombospondin type I domain, an Immunoglobulin-like domain, a C-type
25 lectin domain, a MAM domain, a von Willebrand factor type A domain, a Somatomedin B domain, a WAP-type four disulfide core domain, a F5/8 type C domain, a Hemopexin domain, a Laminin-type EGF-like domain, a C2 domain, and other such domains known to those of ordinary skill in the art, as well as derivatives and/or variants thereof. Exemplary antibody-mimic moiety molecules, and methods of
30 making the same, can also be found in Stemmer et al., "Protein scaffolds and uses thereof", U.S. Patent Publication No. 20060234299 (Oct. 19, 2006) and Hey, et al., Artificial, Non-Antibody Binding Proteins for Pharmaceutical and Industrial Applications, TRENDS in Biotechnology, vol. 23, No. 10, Table 2 and pp. 514-522 (October 2005).

35 In one embodiment, an antibody-mimic molecule comprises a Kunitz domain. "Kunitz domains" as used herein, are conserved protein domains that inhibit certain

5 proteases, *e.g.*, serine proteases. Kunitz domains are relatively small, typically being about 50 to 60 amino acids long and having a molecular weight of about 6 kDa. Kunitz domains typically carry a basic charge and are characterized by the placement of two, four, six or eight or more that form disulfide linkages that contribute to the compact and stable nature of the folded peptide. For example, many Kunitz domains
10 have six conserved cysteine residues that form three disulfide linkages. The disulfide-rich α/β fold of a Kunitz domain can include two, three (typically), or four or more disulfide bonds.

Kunitz domains have a pear-shaped structure that is stabilized the, *e.g.*, three disulfide bonds, and that contains a reactive site region featuring the principal
15 determinant P1 residue in a rigid confirmation. These inhibitors competitively prevent access of a target protein (*e.g.*, a serine protease) for its physiologically relevant macromolecular substrate through insertion of the P1 residue into the active site cleft. The P1 residue in the proteinase-inhibitory loop provides the primary specificity determinant and dictates much of the inhibitory activity that particular Kunitz protein
20 has toward a targeted proteinase. Typically, the N-terminal side of the reactive site (P) is energetically more important than the P' C-terminal side. In most cases, lysine or arginine occupy the P1 position to inhibit proteinases that cleave adjacent to those residues in the protein substrate. Other residues, particularly in the inhibitor loop region, contribute to the strength of binding. Generally, about 10-12 amino acid
25 residues in the target protein and 20-25 residues in the proteinase are in direct contact in the formation of a stable proteinase-inhibitor complex and provide a buried area of about 600 to 900 Å. By modifying the residues in the P site and surrounding residues Kunitz domains can be designed to target and inhibit or activate a protein of choice, *e.g.*, an intracellular protein of choice. Kunitz domains are described in, *e.g.*, U.S.
30 Patent No. 6,057,287.

In another embodiment, an antibody-mimic molecule of the disclosure is an Affilin[®]. As used herein "Affilin[®]" molecules are small antibody-mimic proteins which are designed for specific affinities towards proteins and small compounds. New Affilin[®] molecules can be very quickly selected from two libraries, each of
35 which is based on a different human derived scaffold protein. Affilin[®] molecules do not show any structural homology to immunoglobulin proteins. There are two

5 commonly-used Affilin[®] scaffolds, one of which is gamma crystalline, a human structural eye lens protein and the other is “ubiquitin” superfamily proteins. Both human scaffolds are very small, show high temperature stability and are almost resistant to pH changes and denaturing agents. This high stability is mainly due to the expanded beta sheet structure of the proteins. Examples of gamma crystalline derived
10 proteins are described in WO200104144 and examples of “ubiquitin-like” proteins are described in WO2004106368.

In another embodiment, an antibody-mimic moiety molecule of the disclosure is an Avimer. Avimers are evolved from a large family of human extracellular receptor domains by in vitro exon shuffling and phage display, generating
15 multidomain proteins with binding and inhibitory properties. Linking multiple independent binding domains has been shown to create avidity and results in improved affinity and specificity compared with conventional single-epitope binding proteins. In certain embodiments, Avimers consist of two or more peptide sequences of 30 to 35 amino acids each, connected by linker peptides. The individual sequences
20 are derived from A domains of various membrane receptors and have a rigid structure, stabilised by disulfide bonds and calcium. Each A domain can bind to a certain epitope of the target protein. The combination of domains binding to different epitopes of the same protein increases affinity to this protein, an effect known as avidity (hence the name). Other potential advantages include simple and efficient
25 production of multitarget-specific molecules in *Escherichia coli*, improved thermostability and resistance to proteases. Avimers with sub-nanomolar affinities have been obtained against a variety of targets. Alternatively, the domains can be directed against epitopes on different target proteins. This approach is similar to the one taken in the development of bispecific monoclonal antibodies. In a study, the
30 plasma half-life of an anti-interleukin 6 avimer could be increased by extending it with an anti-immunoglobulin G domain. Additional information regarding Avimers can be found in U.S. patent application Publication Nos. 2006/0286603, 2006/0234299, 2006/0223114, 2006/0177831, 2006/0008844, 2005/0221384, 2005/0164301, 2005/0089932, 2005/0053973, 2005/0048512, 2004/0175756, all of
35 which are hereby incorporated by reference in their entirety.

5 The foregoing provides numerous examples of classes of antibody-mimics. In certain embodiments, the disclosure provides complexes in which the AAM moiety portion is an antibody-mimic that binds to an intracellular target, such as any of the foregoing classes antibody-mimics. Any of these antibody-mimics may be complexed with a Surf+ Penetrating Polypeptide or a portion comprising a Surf+ Penetrating Polypeptide, including any of the sub-categories or specific examples of Surf+ Penetrating Polypeptides.

Formation of Complexes

15 The present disclosure provides complexes comprising (i) a Surf+ Penetrating Polypeptide portion and (ii) an AAM moiety portion (e.g., at least one AAM moiety) associated with the Surf+ Penetrating Polypeptide portion. The complexes are useful, for example, for delivery into a cell, and thus facilitate delivery of the AAM moiety into a cell where it can bind its intracellular target. Below are provided examples of complexes of the disclosure and how the portions of the complexes are associated and/or made. The present disclosure provides complexes comprising (i) a Surf+ Penetrating Polypeptide portion and (ii) an AAM moiety portion (e.g., at least one AAM moiety) associated with the Surf+ Penetrating Polypeptide portion. The AAM moiety portion binds to an intracellular target and the Surf+ Penetrating Polypeptide portion facilitates entry of the complex, and thus entry of the AAM moiety, into cells. 25 Once inside the cell, the AAM moiety portion can bind the intracellularly expressed target. In certain embodiments, the association between the AAM moiety and the Surf+ Penetrating Polypeptide is disruptable. Thus, in certain embodiments, once the complex enters the cell, the association can be disrupted and the AAM moiety alone can bind or continue binding to the target. However, the association need not be disrupted, and the complex may remain intact after entry into the cell. 30

 Complexes of the disclosure may, in certain embodiments, include portions in addition to the Surf+ Penetrating Polypeptide portion and the AAM moiety portion. For example, the complexes may include one or more linkers, the complexes may include sequence that helps localize the complex to a sub-cellular location, and/or the 35 complex may include tags to facilitate detection and/or purification of the complex or a portion of the complex. These additional sequences may be located at the N-

5 terminus, at the C-terminus or internally. Moreover, additional portions may be interconnected to the Surf+ Polypeptide portion to the AAM moiety portion or to both.

Complexes of the disclosure, including fusion proteins, comprises a Surf+ Penetrating Polypeptide that penetrates cells associated with an AAM moiety that
10 binds to an intraceelular target. When provided as a complex, such as a fusion protein, these complexes penetrate cells and bind to the intracellular target via the AAM moiety. When provided as a complex or fusion protein (e.g., when the Surf+ Penetrating Polypeptide and the AAM moiety are associate), the complex penetrates cells and the AAM moiety is able to bind to its intracellular target. By way of
15 example, an AAM moiety may bind to an intracellular target, such as a polypeptide or peptide, and alter the activity of the target and/or the activity of the cell via one or more of the following mechanisms (i) inhibit one or more functions of the target; (ii) activate one or more functions of the target; (iii) increase or decrease the activity of the target; (iv) promote or inhibit degradation of the target; (v) change the localization
20 of the target; and (vi) prevent binding between the target and another protein.

In certain embodiments, the Surf+ Penetrating Polypeptide and AAM moiety portions of the complex are associated covalently. For example, these two portions may be fused (e.g., the complex comprises a fusion protein). Covalent interactions may be direct or indirect (via a linker). Additional interactions, such as non-covalent
25 interactions, may also be involved in the association between the two portions. Thus, in some embodiments, such covalent interactions are mediated by one or more linkers. In some embodiments, the linker is a cleavable linker. In certain embodiments, the cleavable linker comprises an amide, an ester, or a disulfide bond. For example, the linker may be an amino acid sequence that is cleavable by a cellular enzyme. In
30 certain embodiments, the enzyme is a protease. In other embodiments, the enzyme is an esterase. In some embodiments, the enzyme is one that is more highly expressed in certain cell types than in other cell types. For example, the enzyme may be one that is more highly expressed in tumor cells than in non- tumor cells. Exemplary sequences that can be used in linkers and enzymes that cleave those linkers are
35 presented in Table 2.

5 Table 2. Exemplary cleavable linker sequences.

Cleavable sequencer	SEQ ID NO:	Enzymes that Target the Linker
X-AGVF-X	670	Lysosomal thiol proteinases (see, <i>e.g.</i> , Duncan <i>et al.</i> , Biosci. Rep., 2:1041-46, 1982; incorporated herein by reference)
X-GFLG-X	671	Lysosomal cysteine proteinases (see, <i>e.g.</i> , Vasey <i>et al.</i> , Clin. Canc. Res., 5:83-94, 1999; incorporated herein by reference)
X-FK-X	672	Cathepsin B-ubiquitous, overexpressed in many solid tumors, such as breast cancer (see, <i>e.g.</i> , Dubowchik <i>et al.</i> , Bioconjugate Chem., 13:855-69, 2002; incorporated herein by reference)
X-A*L-X	673	Lysosomal hydrolases (see, <i>e.g.</i> , Trouet <i>et al.</i> , Proc. Natl. Acad. Sci., USA, 79:626-29, 1982; incorporated herein by reference)
X-A*LA*L-X	674	Cathepsin B-ubiquitous, overexpressed in many solid tumors, such as breast cancer (see, <i>e.g.</i> , Schmid <i>et al.</i> , Bioconjugate Chemistry, 18:702-16, 2007; incorporated herein by reference)
X-AL*AL*A-X	675	Cathepsin D-ubiquitous (see, <i>e.g.</i> , Czerwinski <i>et al.</i> , Proc. Natl. Acad. Sci. USA, 95:11520-25, 1998; incorporated herein by reference)

“X” denotes the Surf+ Penetrating Polypeptide or AAM moiety.

“*” refers to observed cleavage site.

Other exemplary linkers include flexible linkers, such as one or more repeats
10 of glycine and serine (Gly/Ser linkers). In certain embodiments, the flexible linker comprises glycine, alanine and/or serine amino acid residues. Simple amino acids (*e.g.*, amino acids with simple side chains (*e.g.*, H, CH₃ or CH₂OH) and/or unbranched) provide greater flexibility (*e.g.*, two-dimensional or three-dimensional flexibility) within the linker. Further, alternating the glycine, alanine and/or serine residues may
15 provide even greater flexibility within the linker. The amino acids can alternate/repeat in any manner consistent with the linker remaining functional (*e.g.*, resulting in expressed and/or active fusion protein). Exemplary flexible linkers include linkers comprising repeats of gly-gly-gly-gly-ser, gly-ser, ala-ser, and ala-gly. Other combinations are also possible.

5 In certain embodiments, the Surf+ Penetrating Polypeptide and the AAM moiety are fused by using a construct that comprises an intein, which is self-spliced out to join the Surf+ Penetrating Polypeptide and the AAM moiety via a peptide bond.

 In another embodiment, *e.g.*, where expression of a fusion construction is not practical (*e.g.*, is inefficient) or not possible, the Surf+ Penetrating Polypeptide and
10 the AAM moiety are synthesized by using a viral 2A peptide construct that comprises the Surf+ Penetrating Polypeptide and the AAM moiety for bicistronic expression. In this embodiment, the Surf+ Penetrating Polypeptide and the AAM moiety genes may be expressed on the bicistronic construct, and the 2A peptide results in cotranslational “cleavage” of the two proteins (Trichas *et al.*, BMC Biology 6:40, 2008).

15 The disclosure contemplates complexes in which the Surf+ Penetrating Polypeptide and the AAM moiety portions are associated by a covalent or non-covalent linkage. In either case, the association may be direct or via one or more additional intervening liners or moieties.

 In some embodiments, a Surf+ Penetrating Polypeptide and an AAM moiety
20 are associated through chemical or proteinaceous linkers or spacers. Exemplary linkers and spacers include, but are not restricted to, substituted or unsubstituted alkyl chains, polyethylene glycol derivatives, amino acid spacers, sugars, or aliphatic or aromatic spacers common in the art.

 Suitable linkers include, for example, homobifunctional and
25 heterobifunctional cross-linking molecules. The homobifunctional molecules have at least two reactive functional groups, which are the same. The reactive functional groups on a homobifunctional molecule include, for example, aldehyde groups and active ester groups. Homobifunctional molecules having aldehyde groups include, for example, glutaraldehyde and subaraldehyde.

30 Homobifunctional linker molecules having at least two active ester units include esters of dicarboxylic acids and N-hydroxysuccinimide. Some examples of such N-succinimidyl esters include disuccinimidyl suberate and dithio-bis-(succinimidyl propionate), and their soluble bis-sulfonic acid and bis-sulfonate salts such as their sodium and potassium salts.

35 Heterobifunctional linker molecules have at least two different reactive groups. Examples of heterobifunctional reagents containing reactive disulfide bonds

5 include N-succinimidyl 3-(2-pyridyl-dithio)propionate (Carlsson *et al.*, 1978. Biochem. J., 173:723-737), sodium S-4-succinimidyloxycarbonyl-alpha-methylbenzylthiosulfate, and 4-succinimidyloxycarbonyl-alpha-methyl-(2-pyridyldithio)toluene. Examples of heterobifunctional reagents comprising reactive groups having a double bond that reacts with a thiol group include succinimidyl 4-(N-
10 maleimidomethyl)cyclohexane-1-carboxylate and succinimidyl m-maleimidobenzoate. Other heterobifunctional molecules include succinimidyl 3-(maleimido)propionate, sulfosuccinimidyl 4-(p-maleimido-phenyl)butyrate, sulfosuccinimidyl 4-(N-maleimidomethyl-cyclohexane)-1-carboxylate, maleimidobenzoyl-5N-hydroxy-succinimide ester.

15 Other means of cross-linking proteins utilize affinity molecule binding pairs, which selectively interact with acceptor groups. One entity of the binding pair can be fused or otherwise linked to the Surf+ Penetrating Polypeptide and the other entity of the binding pair can be fused or otherwise linked to the AAM moiety. Exemplary affinity molecule binding pairs include biotin and streptavidin, and derivatives
20 thereof; metal binding molecules; and fragments and combinations of these molecules. Exemplary affinity binding pairs include StreptTag (WSHPQFEK) (SEQ ID NO: 657) / SBP (streptavidin binding protein), cellulose binding domain/ cellulose, chitin binding domain/ chitin, S-peptide/ S-fragment of RNaseA, calmodulin binding peptide/ calmodulin, and maltose binding protein/ amylose.

25 In one embodiment, the Surf+ Penetrating Polypeptide and the AAM moiety are linked by ubiquitin (and ubiquitin-like) conjugation.

The disclosure also provides nucleic acids encoding a Surf+ Penetrating Polypeptide and an AAM moiety, such as an antibody molecule, or a non-antibody molecule scaffold, such as a DARPin, an Adnectin[®], an Anticalin[®], or a Kunitz
30 domain polypeptide. The complex of a Surf+ Penetrating Polypeptide and an AAM moiety can be expressed as a fusion protein, optionally separated by a peptide linker. The peptide linker can be cleavable or not cleavable. A nucleic acid encoding a fusion protein can express the fusion in any orientation. For example, the nucleic acid can express an N-terminal Surf+ Penetrating Polypeptide fused to a C-terminal AAM
35 moiety (*e.g.*, antibody), or can express an N-terminal AAM moiety fused to a C-terminal Surf+ Penetrating Polypeptide.

5 A nucleic acid encoding an Surf+ Penetrating Polypeptide can be on a vector that is separate from a vector that carries a nucleic acid encoding a AAM moiety. The Surf+ Penetrating Polypeptide and the AAM moiety can be expressed separately, and complexed (including chemically linked) prior to introduction to a cell for intracellular delivery. The isolated complex can be formulated for administration to a
10 subject, as a pharmaceutical composition.

The disclosure also provides host cells comprising a nucleic acid encoding the Surf+ Penetrating Polypeptide or the AAM moiety, or comprising the complex as a fusion protein. The host cells can be, for example, prokaryotic cells (*e.g.*, *E. coli*) or eukaryotic cells.

15 In certain embodiments, the recombinant nucleic acids encoding an complex, or the portions thereof, may be operably linked to one or more regulatory nucleotide sequences in an expression construct. Regulatory nucleotide sequences will generally be appropriate for a host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety
20 of host cells. Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the disclosure. The
25 promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An expression construct may be present in a cell on an episome, such as a plasmid, or the expression construct may be inserted in a chromosome. In a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selectable
30 marker genes are well known in the art and will vary with the host cell used. In certain aspects, this disclosure relates to an expression vector comprising a nucleotide sequence encoding a complex of the disclosure (*e.g.*, a complex comprising a Surf+ Penetrating Polypeptide portion and an AAM moiety portion) polypeptide and operably linked to at least one regulatory sequence. Regulatory sequences are art-
35 recognized and are selected to direct expression of the encoded polypeptide. Accordingly, the term regulatory sequence includes promoters, enhancers, and other

5 expression control elements. Exemplary regulatory sequences are described in
Goeddel; *Gene Expression Technology: Methods in Enzymology*, Academic Press,
San Diego, CA (1990). It should be understood that the design of the expression
vector may depend on such factors as the choice of the host cell to be transformed
and/or the type of protein desired to be expressed. Moreover, the vector's copy
10 number, the ability to control that copy number and the expression of any other
protein encoded by the vector, such as antibiotic markers, should also be considered.

The disclosure also provides host cells comprising or transfected with a
nucleic acid encoding the complex as a fusion protein. The host cells can be, for
example, prokaryotic cells (*e.g.*, *E. coli*) or eukaryotic cells. Other suitable host cells
15 are known to those skilled in the art.

In addition to the nucleic acid sequence encoding the complex or portions of
the complex, a recombinant expression vector may carry additional nucleic acid
sequences, such as sequences that regulate replication of the vector in a host cells
(*e.g.*, origins of replication) and selectable marker genes. The selectable marker gene
20 facilitates selection of host cells into which the vector has been introduced.
Exemplary selectable marker genes include the ampicillin and the kanamycin
resistance genes for use in *E. coli*.

The present disclosure further pertains to methods of producing fusion
proteins of the disclosure. For example, a host cell transfected with an expression
25 vector can be cultured under appropriate conditions to allow expression of the
polypeptide to occur. The polypeptide may be secreted and isolated from a mixture of
cells and medium containing the polypeptides. Alternatively, the polypeptides may
be retained in the cytoplasm or in a membrane fraction and the cells harvested, lysed
and the protein isolated. A cell culture includes host cells, media and other
30 byproducts. Suitable media for cell culture are well known in the art. The
polypeptides can be isolated from cell culture medium, host cells, or both using
techniques known in the art for purifying proteins, including ion-exchange
chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and
immunoaffinity purification with antibodies specific for particular epitopes of the
35 polypeptides. In a preferred embodiment, the polypeptide is a fusion protein
containing a domain which facilitates its purification.

5 A nucleic acid encoding a Surf+ Penetrating Polypeptide can be on a vector that is separate from a vector that carries a nucleic acid encoding an AAM moiety. The portions of the complex can be expressed separately, and complexed prior to introduction to a cell for intracellular delivery. The isolated complex can be formulated for administration to a subject, as a pharmaceutical composition.

10 Recombinant nucleic acids of the disclosure can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells (yeast, avian, insect or mammalian), or both. Expression vehicles for production of a recombinant polypeptide include plasmids and other vectors. For instance, suitable vectors include plasmids of the types:

15 pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*. The preferred mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The

20 pcDNAI/amp, pcDNAI/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and

25 eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papilloma virus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. The various methods employed in the preparation of the plasmids and transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and

30 eukaryotic cells, as well as general recombinant procedures, see *Molecular Cloning A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press, 1989) Chapters 16 and 17. In some instances, it may be desirable to express the recombinant polypeptide by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL-

35 derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors

5 (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended
10 termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out
15 using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 1992).

It should be understood that fusion polypeptides or protein of the present
20 disclosure can be made in numerous ways. For example, a Surf+ Penetrating Polypeptide and an AAM moiety can be made separately, such as recombinantly produced in two separate cell cultures from nucleic acid constructs encoding their respective proteins. Once made, the proteins can be chemically conjugated directly or via a linker. By way of another example, the fusion polypeptide can be made as an
25 inframe fusion in which the entire fusion polypeptide, optionally including one or more linker, tag or other moiety, is made from a nucleic acid construct that includes nucleotide sequence encoding both a Surf+ Penetrating Polypeptide portion and an AAM moiety portion of the complex.

In certain embodiments, a complex of the disclosure is formed under
30 conditions where the linkage (*e.g.*, by a covalent or non-covalent linkage) is formed, while the activity of the AAM moiety is maintained.

To minimize the effect of linkage on AAM moiety activity (*e.g.*, target binding), any linkage to the AAM moiety can be at a site on the protein that is distant from the target-interacting region of the AAM moiety.

35 Further, in the case of a cleavable linker, an enzyme that cleaves a linker between the a Surf+ Penetrating Polypeptide and an AAM moiety does not have an

5 effect on the AAM moiety, such that the structure of the AAM moiety remains intact and the AAM moiety retains its target binding activity.

In other embodiments, the Surf+ Penetrating Polypeptide and AAM moiety portions of the complex are separated, *e.g.*, within the cell, under conditions where the linkage (*e.g.*, a covalent or non-covalent linkage) is dissociated, while the activity of
10 the AAM moiety is maintained. For example, the Surf+ Penetrating Polypeptide and AAM moiety can be joined by a cleavable peptide linker that is subject to a protease that does not interfere with activity of the AAM moiety.

In some embodiments the Surf+ Penetrating Polypeptide portion and AAM moiety portion are separated in the endosome due to the lower pH of the endosome.
15 Thus in these embodiments, the linker is cleaved or broken in response to the lower pH, but the activity of the AAM moiety is not affected.

In some embodiments, the AAM moiety binds and inhibits (or activates) activity of the intracellular target while the AAM moiety is still complexed with the Surf+ Penetrating Polypeptide. Thus the complex does not dissociate in the cell, prior
20 to the activity of the AAM moiety on the target protein. While in other embodiments, the Surf+ Penetrating Polypeptide and AAM moiety dissociate following delivery into the cell and, for example, the AAM moiety may interact with its intracellular target after dissociation from the Surf+ Penetrating Polypeptide.

It should be noted that the disclosure contemplates that the foregoing
25 description of complexes is applicable to any of the embodiments and combinations of embodiments described herein. For example, the description is applicable in the context of complexes in which the AAM moiety portion is associated with a portion comprising a Surf+ Penetrating Polypeptide presented in the context of additional sequence, such as additional sequence from its own naturally occurring polypeptide.
30 In this context, any interconnection is via the two portions of the complex (the AAM portion and the Surf+ Penetrating Polypeptide portion), but the interconnection may not be directly between the Surf+ Penetrating Polypeptide and the AAM moiety.

5

Modifications

As detailed above, the disclosure contemplates that Surf+ Penetrating Polypeptides (naturally occurring or generated by protein modification) may be modified chemically or biologically. For example one or more amino acids may be added, deleted, or changed from the primary sequence. This includes changes intended to supercharge a polypeptide (e.g., to increase surface positive charge, net charge or charge/molecular weight). However, modifications to the Surf+ Penetrating Polypeptides also include variation that is not intended to supercharge the protein.

In this section, additional modifications are described. The modifications may be modifications to a complex of the disclosure, and the modification may be appended directly or indirectly to either or both of the Surf+ Penetrating Polypeptide portion or the AAM moiety portion. For example, a polyhistidine tag or other tag may be added to the complex or to either polypeptide portion of the complex to aid in the purification of the complex or of either portion of the complex. Other peptides, protein or small molecules may be added onto the complex to alter the biological, biochemical, and/or biophysical properties of the complex. For example, a targeting peptide may be added to the primary sequence of the Surf+ Penetrating Polypeptides or complex.

Other modifications of the Surf+ Penetrating Polypeptides or complex include, but are not limited to, post-translational or post-production modifications (*e.g.*, glycosylation, phosphorylation, acylation, lipidation, farnesylation, acetylation, proteolysis, *etc.*). In certain embodiments, the Surf+ Penetrating Polypeptides or complex may be modified to reduce its immunogenicity. In certain embodiments, the Surf+ Penetrating Polypeptides or complex may be modified to improve half-life or bioavailability.

In certain embodiments, the complex or either portion of the complex may be conjugated to a soluble polymer or carbohydrate, *e.g.*, to increase serum half life of the Surf+ Penetrating Polypeptide, AAM moiety and/or complex. For example, the Surf+ Penetrating Polypeptides, AAM moiety or complex may be conjugated to a polyethylene glycol (PEG) polymer, *e.g.*, a monomethoxy PEG. Other polymers useful as stabilizing materials may be of natural, semi-synthetic (modified natural) or

5 synthetic origin. Exemplary natural polymers include naturally occurring polysaccharides, such as, for example, arabinans, fructans, fucans, galactans, galacturonans, glucans, mannans, xylans (such as, for example, inulin), levan, fucoidan, carrageenan, galatocarloose, pectic acid, pectins, including amylose, pullulan, glycogen, amylopectin, cellulose, dextran, dextrin, dextrose, glucose, polyglucose, polydextrose, pustulan, chitin, agarose, keratin, chondroitin, dermatan, hyaluronic acid, alginic acid, xanthin gum, starch and various other natural homopolymer or heteropolymers, such as those containing one or more of the following aldoses, ketoses, acids or amines: erythrose, threose, ribose, arabinose, xylose, lyxose, allose, altrose, glucose, dextrose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, mannitol, sorbitol, lactose, sucrose, trehalose, maltose, cellobiose, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, glucuronic acid, gluconic acid, glucaric acid, galacturonic acid, mannuronic acid, glucosamine, galactosamine, and neuraminic acid, and naturally occurring derivatives thereof. Accordingly, suitable polymers include, for example, proteins, such as albumin, polyalginates, and polylactide-coglycolide polymers. Exemplary semi-synthetic polymers include carboxymethylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, methylcellulose, and methoxycellulose. Exemplary synthetic polymers include polyphosphazenes, hydroxyapatites, fluoroapatite polymers, polyethylenes (such as, for example, polyethylene glycol (including for example, the class of compounds referred to as PLURONICTM, commercially available from BASF, Parsippany, N.J.), polyoxyethylene, and polyethylene terephthalate), polypropylenes (such as, for example, polypropylene glycol), polyurethanes (such as, for example, polyvinyl alcohol (PVA), polyvinyl chloride and polyvinylpyrrolidone), polyamides including nylon, polystyrene, polylactic acids, fluorinated hydrocarbon polymers, fluorinated carbon polymers (such as, for example, polytetrafluoroethylene), acrylate, methacrylate, and polymethylmethacrylate, and derivatives thereof.

One of skill in the art can envision a multitude of ways of modifying the Surf+ Penetrating Polypeptides, AAM moieties or complexes of the disclosure without departing from the scope of the present disclosure. In certain embodiments, the

5 primary purpose of the modification is a purpose other than to further supercharge the complex versus that of the unmodified complex. The disclosure contemplates that any of the foregoing modifications may be to the Surf+ Penetrating Polypeptide portion of a complex or to the AAM moiety portion of a complex. Moreover, the modification may be made prior to complex formation, concurrently with complex, 10 such as fusion protein formation, or as a post-production step following complex (such as fusion protein) formation.

Additional examples of modifications include localization domains to facilitate localization of the complex to the intended intracellular location. Once again, the localization domain may be appended directly or indirectly to the Surf+ 15 Penetrating Polypeptide portion or to the AAM moiety portion. Exemplary localization domains include, for example, nuclear localization signal, a mitochondrial matrix localization signal, and the like. In certain embodiments, it may be preferable to append the localization domain to the AAM moiety so that, in the event that the association between the Surf+ Penetrating Polypeptide and the AAM moiety is 20 disrupted (such as by cleavage of a cleavable linker) after entry into the cell, the AAM moiety will still include the localization domain.

The foregoing are merely exemplary of modification of the complexes of the disclosure whose primary purpose is other than to further supercharge the complex, relative to the unmodified complex.

25

Detectable Moieties

It is further contemplated that complexes of the disclosure can be modified to comprise a detectable moiety. Detectable moieties include fluorescent or otherwise detectable polypeptides, peptide, radioactive or other moieties which allow for 30 detection of the complex or the portions of the complex. Such detectable moieties can be included in the polypeptide sequence of the complex, or operably linked thereto, such as in a fusion protein, or by covalent or non-covalent linkages. The disclosure contemplates that the detectable moiety may be appended directly or indirectly to the Surf+ Penetrating Polypeptide portion of the complex and/or the AAM moiety portion 35 of the complex and/or to any linker portion.

Exemplary fluorescent proteins include green fluorescent protein, blue

5 fluorescent protein, cyan fluorescent protein or yellow fluorescent protein. Other exemplary fluorescent proteins include, but are not limited to, enhanced green fluorescent protein (EGFP), split GFP, AcGFP, TurboGFP, Emerald, Azami Green, ZsGreen, EBFP, Sapphire, T-Sapphire, ECFP, mCFP, Cerulean, CyPet, AmCyan1, Midori-Ishi Cyan, mTFP1 (Teal), enhanced yellow fluorescent protein (EYFP),
10 Topaz, Venus, mCitrine, YPet, PhiYFP, ZsYellow1, mBanana, Kusabira Orange, mOrange, dTomato, dTomato-Tandem, DsRed, DsRed2, DsRed-Express (T1), DsRed-Monomer, mTangerine, mStrawberry, AsRed2, mRFP1, JRed, mCherry, HcRed1, mRaspberry, HcRed1, HcRed-Tandem, mPlum, and AQ143.

Additional suitable labels that can be used in accordance with the disclosure
15 include, but are not limited to, fluorescent, chemiluminescent, chromogenic, phosphorescent, and/or radioactive labels. In addition, when an epitope tag is included in a complex, the complex is detectable using an antibody that is immunoreactive with the epitope tag.

20 Any complex of the disclosure can be readily tested to confirm that, following complex formation, the complex retains the ability to penetrate cells and the AAM moiety retains the ability to specifically bind its target. This testing can be done regardless of whether the complex is a fusion protein (directly or via a linker) or a chemical fusion or otherwise associated. By way of example, the Surf+ Penetrating
25 Polypeptide may be tested for cell penetration activity alone and the AAM moiety may be tested for specific binding (in vitro or ex vivo) to its target. After confirming that the selected Surf+ Penetrating Polypeptide does penetrate cells and the AAM moiety does bind its target, a complex is generated using any suitable method. Following complex formation, cell penetration activity is again assessed to confirm
30 that complex formation did not interfere with cell penetration activity, and that the Surf+ Penetrating Polypeptide penetrates cells in association with this cargo. Additionally, following complex formation, specific binding of the AAM moiety (present in the complex) is tested to confirm complex formation does not interfere with the ability of the AAM moiety to specifically bind its target.

35

5 Applications

 The present disclosure provides complexes comprising (i) a Surf+ Penetrating Polypeptide portion and (ii) an AAM moiety portion, wherein the Surf+ Penetrating Polypeptide portion is associated with the AAM moiety portion. The present disclosure also provides methods for using such complexes. As detailed throughout, the AAM moiety binds to a target expressed in a cell and providing the AAM moiety as a complex promotes delivery of the AAM moiety into the cell (e.g., due to the cell penetrating ability of the Surf+ Penetrating Polypeptide). Once inside the cell, the AAM moiety can bind to its target. Such binding may occur while the AAM moiety remained complexed to the Surf+ Penetrating Polypeptide portion, or such binding may occur after cleavage or dissociation of the two portions of the complex. Additionally, binding may initially occur while the AAM moiety is complexed to the Surf+ Penetrating Polypeptide, but the complex may then be disrupted or cleaved so that, subsequently, the AAM moiety alone is bound to the target (e.g., the target polypeptide or peptide expressed in the cell).

 Any AAM moiety may be provided as a complex with a Surf+ Penetrating Polypeptide and delivered to a cell using the inventive system. Given the ability to readily make and test antibodies and antibody-mimics, and thus, to generate AAM moieties capable of binding to a target and having a desired activity (e.g., inhibiting the function of the target, promoting the function of the target, binding without interfering or altering the function of the target), the present system may be used in combination with virtually any target, such as a polypeptide or peptide, expressed in a cell. Accordingly, the complexes of the disclosure have numerous applications, including research uses, therapeutic uses, diagnostic uses, imaging uses, and the like, and such uses are applicable over a wide range of targets and disease indications.

 The following provides specific examples, including examples of specific targets. However, the potential uses of complexes of the disclosure are not limited to specific target polypeptides or peptides. Rather, the generally uses include, at least, the following. Complexes of the disclosure are useful for delivering AAM moieties into cells where they are useful for labeling a target protein, such as for imaging cells, tissues and whole organisms. Labeling may be useful when performing research studies of protein expression, disease progression, cell fate, protein localization and

5 the like. Labeling may be useful diagnostically or prognostically, such as in cases where target expression correlates with a particular condition. In certain embodiments, an AAM moiety intended for labeling may be selected such that it does not interfere with the function of the target (e.g., a moiety that binds to a target but does not alter the activity of the target).

10 In addition, complexes of the disclosure may be used in research setting to study target expression, presence/absence of target in a disease state, impact of inhibiting or promoting target activity, etc. Complexes of the disclosure are suitable for these studies in vitro or in vivo. By promoting delivery of the AAM moiety into cells, complexes of the disclosure help avoid false negative results obtained when an
15 AAM moiety is unable to penetrate a cell (e.g., a non-experiment because the AAM moiety cannot contact a target expressed inside the cell).

Further, complexes of the disclosure have therapeutic uses by promoting delivery of therapeutic AAM moieties into cells in humans or animals (including animal models of a disease or condition). Once again, the use of complexes of the
20 disclosure decrease failure of an AAM moiety due to inability to effectively penetrate cells or due to the inability to effectively penetrate cells at concentrations that are not otherwise toxic to the organism.

Regardless of whether a complex of the disclosure is used in a research, diagnostic, prognostic or therapeutic context, the result is that the AAM moiety is
25 delivered into a cell following contacting the cell with the complex (e.g., either contacting a cell in culture or administered to a subject). Once inside the cells, the AAM moiety binds its intracellular target.

In certain embodiments, the AAM moiety binds a target expressed in the nucleus or in the cytosol of a cell. In some embodiments, AAM moiety binds a
30 membrane associated target, e.g., a target localized on the cytosolic side of the cell membrane, the cytosolic side of the nuclear membrane, or the cytosolic side of the mitochondrial membrane.

In certain embodiment, a Surf+ Penetrating Polypeptide is complexed with an AAM moiety that binds an intracellular target in the nucleus of a cell, such as an
35 NFAT (Nuclear Factor of Activated T cells) (e.g., NFAT-2), a STAT (Signal

5 Transducer and Activator of Transcription) (*e.g.*, STAT-3, STAT-5, or STAT-6) or RORgammaT (retinoic acid-related orphan receptor).

In certain embodiments, a Surf+ Penetrating Polypeptide is complexed with an AAM moiety that binds an intracellular target in the cytosol of the cell, such as FK506, calcineurin, or a Janus Kinase (*e.g.*, JAK-1 or JAK-2).

10 In another embodiment, a Surf+ Penetrating Polypeptide is complexed with an AAM moiety that binds an intracellular target localized on the cytosolic side of the cell membrane, such as ras, a PI3K (phosphoinositide-3-kinase), or fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor).

15 In yet other embodiments, a Surf+ Penetrating Polypeptide is complexed with an AAM moiety that binds an intracellular target localized on the cytosolic side of the mitochondrial membrane, such as Bcl-2.

In some embodiments, the AAM moiety binds a kinase, a transcription factor or an oncoprotein. For example, the AAM moiety can bind a kinase, such as a JAK
20 kinase (*e.g.*, JAK-1 or JAK-2) or b-raf (v-raf murine sarcoma viral oncogene homolog B1) or Erk (mitogen-activated protein kinase 1). By way of further example, the AAM moiety can bind a transcription factor, such as Hif1-alpha, a STAT (*e.g.*, STAT-3, STAT-5 or STAT-6), or IRF-1 (Interferon Regulatory Factor 1). In some
25 embodiments, the AAM moiety binds an oncogene, such as ras, b-raf or Akt (v-akt murine thymoma viral oncogene homolog 1).

In some embodiments, a complex comprising (i) a Surf+ Penetrating Polypeptide portion and (ii) an AAM moiety portion in accordance with the present disclosure may be used for therapeutic purposes, or may be used for diagnostic purposes. The disease or condition that may be treated depends on the target (*e.g.*, the
30 target is one for which binding by an AAM moiety has a therapeutic benefit).

For example, a complex in accordance with the present disclosure may be used for treatment of any of a variety of diseases, disorders, and/or conditions, including but not limited to one or more of the following: autoimmune disorders; inflammatory disorders; and proliferative disorders, including cancers. In one
35 embodiment, the disease treated by the complex is a cardiovascular disorder, or an angiogenic disorder such as macular degeneration. In another embodiment, the

- 5 disease treated by the complex is an eye disease, such as age-related macular degeneration (AMD), diabetic macular edema (DME), retinitis pigmentosa, or uveitis.

In some embodiments, a complex is useful for treating one or more of the following: an infectious disease; a neurological disorder; a respiratory disorder; a digestive disorder; a musculoskeletal disorder; an endocrine, metabolic, or nutritional disorders; a urological disorder; psychological disorder; a skin disorder; a blood and lymphatic disorder; *etc.*

In certain embodiments, the complex of the disclosure binds, via the AAM moiety, a protein set forth in Table 3 (each, an intracellular target). In other words, the AAM moiety portion of the complex binds (e.g., specifically binds) to the target expressed or otherwise located inside the cell (the intracellular target). In certain embodiments, targeting the protein may be useful in the research, diagnosis, prognosis, monitoring or treatment of the listed disease.

Table 3. Exemplary intracellular target proteins.

<u>Diseases</u>	<u>Target</u>	<u>Protein class</u>	<u>Intracellular Location of Target</u>
cancer, age-related macular degeneration, ischemia, rheumtoid arthritis	Hif1-alpha	Txn factor	nuclear
dry eye, psoriasis	Calcineurin	phosphatase	cytosol
psoriasis	peptidylprolyl isomerase A (cyclophilin A)	peptidylprolyl isomerase	cytosol
psoriasis	peptidylprolyl isomerase A (FK506 binding protein/immunophilin)	peptidylprolyl isomerase	cytosol
dry eye, psoriasis	NFATs (NFAT-2)	Txn factor	nuclear
cancer, Transplant Rejection, Restenosis, glycogen storage disease	mechanistic/mammalian target of rapamycin mTOR, FRAP1; (serine/threonine kinase)	serine/threonine kinase	cytosol
myelofibrosis, cancer, inflammation	Janus Kinases (such as JAK-1 and JAK-2)	non-receptor tyrosine kinase	cytosol
inflammatory diseases (rheumatoid arthritis, gout, crohn's disease),	SOCS1, SOCS3 (suppressor of cytokine signaling)	STAT binding protein	cytosol

epilepsy, Huntington Disease			
autoimmune diseases such as multiple sclerosis and cancer, age- related macular degeneration, uveitis	STAT-3 (signal transducer and activator of transcription)	Txn factor	nuclear
cancer (Sezary disease)	STAT-5	Txn factor	nuclear
autoimmune diseases such as atopic dermatitis and emphysema, COPD, lung fibrosis, acute asthma	STAT-6	Txn factor	nuclear
cancer	Ras	GTPase, signal transducing protein	cytosolic-side of cell membrane
cancer such as melanoma	b-raf	serine/threonine kinase	cytosol
cancer, prion diseases such as Creutzfeldt-Jakob Disease	Erk	Txn factor	multiple locations depending on cell- type and disease
cancer	MAP Kinases (mitogen activated kinases)	serine/threonine kinase	cytosol
cancer	Jnk (C-Jun N-terminal kinase)	serine/threonine kinase	cytosol
cancer	MEK (MAP/Erk kinase)	serine/threonine kinase	cytosol
cancer	PI3K (phosphatidyl inositol 3 kinase)	lipid kinase	cytosolic-side of cell membrane
cancer	AKT	serine/threonine kinase	cytosol
inflammatory diseases (arthritis, gout, inflammatory bowel disease), neurodiseases (Huntington Disease, epilepsy) and metabolic diseases such as diabetes type 2 and obesity, cryopyrin- associated periodic syndromes, chronic obstructive	Caspase-1 (cysteine- aspartic proteases)	protease	cytosol

pulmonary disease			
inflammatory diseases such as psoriasis, rheumatoid arthritis, age-related macular degeneration, cancer, duchene muscular dystrophy, ALS, and cachexia-induced cardiac atrophy	NEMO also known as IKK γ (IKK gamma)	regulatory binding protein/adaptor scaffold protein	cytosol
inflammatory diseases (rheumatoid arthritis, gout, crohn's disease), epilepsy, Huntington Disease; pyogenic bacterial infections	MyD88 (Myeloid differentiation primary response)	regulatory binding protein/adaptor scaffold protein	cytosol
inflammatory diseases (arthritis, gout, inflammatory bowel disease), neurodiseases (Huntington Disease, epilepsy) and metabolic diseases such as diabetes type 2 and obesity, cryopyrin-associated periodic syndromes, chronic obstructive pulmonary disease	ASC	regulatory binding protein/adaptor scaffold protein	cytosol
inflammatory diseases (arthritis, gout, inflammatory bowel disease), neurodiseases (Huntington Disease, epilepsy) and metabolic diseases such as	NLRP3 (inflammasome component)	regulatory binding protein/adaptor scaffold protein	cytosol

diabetes type 2 and obesity, cryopyrin-associated periodic syndromes, chronic obstructive pulmonary disease			
inflammatory and autoimmune diseases such as inflammatory bowel disease, multiple sclerosis, Gout, Arthritis, psoriasis	retinoic acid-related orphan receptor (ROR γ T) (RORgammaT)	Txn factor	nuclear
cancer	Thymidylate synthase	metabolic enzyme	cytosol & nucleus
cancer	abl tyrosine kinase; bcr-abl (product of chromosomal translocation)	tyrosine kinase	cytosol
	Interferon Regulatory Factor 1 (IRF-1) - transcription factor	Txn factor	nucleus
cancer	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)	tyrosine kinase	cytosolic-side of cell membrane
cancer	fms-related tyrosine kinase 3	tyrosine kinase	cytosolic-side of cell membrane
cancer	kinase insert domain receptor (a type III receptor tyrosine kinase)	tyrosine kinase	cytosolic-side of cell membrane
cancer	macrophage stimulating 1 receptor (c-met-related tyrosine kinase)	tyrosine kinase	cytosolic-side of cell membrane
cancer, diabetic retinopathy	protein kinase C family (alpha, beta)	serine/threonine kinase	multiple locations depending on cell-type and disease (cytosolic, associated with cell membrane)
Cancer	beta tubulin/microtubule	cytoskeletal structural protein	cytosol
Cancer, Charcot-Marie-Tooth, neurogenerative diseases, eye disorder	kinesins and chromosome-associated KIF	microtubule associated motor protein	cytosol

Cancer, kidney diseases, respiratory diseases, hearing loss	Dynein	microtubule associated motor protein	cytosol
inflammation, pain	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) COX-2	cyclooxygenase	cytosolic face of membranes
cancer	Rho associated protein kinases	serine/threonine kinase	cytosol
cancer	Aurora protein kinases	serine/threonine kinase	nucleus-cytosol (functions before and during nuclear envelope breakdown)
	Insulin receptor substrates (IRS)	regulatory binding protein/adaptor scaffold protein	cytosolic face of plasma membrane
cancer	focal adhesion kinases (PTK2)	tyrosine kinase	cytosol
cancer	cyclin dependent kinases	serine/threonine kinase	nucleus
Cancer	Bcl-2	regulatory binding protein/adaptor scaffold protein	outer mitochondrial membrane
cancer	Telomerase	reverse transcriptase	nuclear
cancer	cytochrome c	electron transport pathway component, regulatory binding protein/adaptor scaffold protein (only in context of stimulating apoptosis)	cytosol (when released from mitochondria)

5

The foregoing are merely exemplary of intracellular targets. The present disclosure is application to any target (e.g., generating complexes comprising an AAM moiety that binds to any intracellular target).

10

Regardless of the target or the particular use, in certain embodiments, a complex is administered to a cell or organism in an effective amount. The term “effective amount” means an amount of an agent to be delivered that is sufficient, when administered to a cell or a subject to have the desired effect. In the context of

5 the present disclosure, an effective amount may be the amount sufficient to promote delivery of the complex into a cell and to promote binding of the AAM moiety to its target. In a therapeutic setting, an effective amount is the amount sufficient to treat (e.g., alleviate, improve or delay onset of one or more symptoms of) a disease, disorder, and/or condition.

10 In one embodiment, the AAM moiety is bispecific, *e.g.*, is a bispecific antibody, or bispecific fragment thereof. A complex comprising a bispecific antibody can bind two different target polypeptides at the same time, or at different times.

A complex of the disclosure may be used in a clinical setting, such as for therapeutic purposes. Therapeutic complexes may include an AAM moiety that binds
15 to and reduces the activity of one or more targets (*e.g.*, polypeptide targets). Such AAM moieties are particularly useful for treating a disease, disorder, and/or condition associated with high levels of one or more particular targets, or high activity levels of one or more particular targets.

In some embodiments, the complex is detectable (*e.g.*, one or both of the
20 Surf+ Penetrating Polypeptide portion and the AAM moiety portion are modified with a detectable label). For example, one or both portions of the complex may include at least one fluorescent moiety. In some embodiments, the Surf+ Penetrating Polypeptide portion has inherent fluorescent qualities. In some embodiments, one or both portions of the complex may be associated with at least one fluorescent moiety
25 (*e.g.*, conjugated to a fluorophore, fluorescent dye, *etc.*). Alternatively or additionally, one or both portions of the complex may include at least one radioactive moiety (*e.g.*, protein may comprise iodine-131 or Yttrium-90; *etc.*). Such detectable moieties may be useful for detecting and/or monitoring delivery of the complex to a target site.

A complex associated with a detectable label can be used in detection,
30 imaging, disease staging, diagnosis, or patient selection. Suitable labels include fluorescent, chemiluminescent, enzymatic labels, colorimetric, phosphorescent, density-based labels, *e.g.*, labels based on electron density, and in general contrast agents, and/or radioactive labels.

In some embodiments, the complexes featured in the disclosure may be used
35 for research purposes, *e.g.*, to efficiently deliver AAM moieties to cells in a research context. In some embodiments, the complexes may be used as research tools to

5 efficiently transduce cells with antibody molecules or with other AAM moieties. In
some embodiments, complexes may be used as research tools to efficiently introduce
an AAM moiety into cells for purposes of studying the effect of the AAM moiety on
cellular activity. In certain embodiments, a complex can be used to deliver an AAM
moiety into a cell for the purpose of studying the biological activity of the target
10 peptide or protein (e.g., what happens if the target is inhibited or agonized, etc.). In
certain embodiments, a complex may be introduced into a cell for the purpose of
studying the biological activity of the AAM moiety (e.g., does it inhibit target
activity, does it promote target activity, etc.).

15 **Pharmaceutical Compositions**

The present disclosure provides complexes of the disclosure (e.g., a Surf+
Penetrating Polypeptide portions-associated with an AAM moiety portion). This
section describes exemplary compositions, such as compositions of a complex of the
disclosure formulated in a pharmaceutically acceptable carrier. Any of the complexes
20 comprising any of the Surf+ Penetrating Polypeptides and any of the AAM moieties
described herein may be formulated in accordance with this section of the disclosure.

Thus, in certain aspects, the present disclosure provides compositions, such as
pharmaceutical compositions, comprising one or more such complexes, and one or
more pharmaceutically acceptable excipients. Pharmaceutical compositions may
25 optionally include one or more additional therapeutically active substances. In
accordance with some embodiments, a method of administering pharmaceutical
compositions comprising one or more Surf+ Penetrating Polypeptide or one or more
complexes of the disclosure (e.g., a complex comprising a Surf+ Penetrating
Polypeptide associated with at least one AAM moiety) to be delivered to a subject in
30 need thereof is provided. In some embodiments, compositions are administered to
humans. For the purposes of the present disclosure, the phrase “active ingredient”
generally refers to an AAM moiety portion complexed with a Surf+ Penetrating
Polypeptide portion to be delivered as described herein.

Although the descriptions of pharmaceutical compositions provided herein are
35 principally directed to pharmaceutical compositions which are suitable for
administration to humans, it will be understood by the skilled artisan that such

5 compositions are generally suitable for administration to animals of all sorts, as well
as suitable or adaptable for research use. Modification of pharmaceutical
compositions suitable for administration to humans in order to render the
compositions suitable for administration to various animals is well understood, and
the ordinarily skilled veterinary pharmacologist can design and/or perform such
10 modification with merely ordinary, if any, experimentation. Subjects or patients to
which administration of the pharmaceutical compositions is contemplated include, but
are not limited to, humans and/or other primates; mammals, including commercially
relevant mammals such as cattle, pigs, horses, sheep, cats, dogs, mice, and/or rats;
and/or birds, including commercially relevant birds such as chickens, ducks, geese,
15 and/or turkeys.

Formulations of the pharmaceutical compositions described herein may be
prepared by any method known or hereafter developed in the art of pharmacology. In
general, such preparatory methods include the step of bringing the active ingredient
into association with an excipient and/or one or more other accessory ingredients, and
20 then, if necessary and/or desirable, shaping and/or packaging the product into a
desired single- or multi-dose unit.

A pharmaceutical composition in accordance with the disclosure may be
prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of
single unit doses. As used herein, a “unit dose” is a discrete amount of the
25 pharmaceutical composition comprising a predetermined amount of the active
ingredient. The amount of the active ingredient is generally equal to the dosage of the
active ingredient which would be administered to a subject and/or a convenient
fraction of such a dosage such as, for example, one-half or one-third of such a dosage.

Relative amounts of the active ingredient, the pharmaceutically acceptable
30 excipient, and/or any additional ingredients in a pharmaceutical composition in
accordance with the disclosure will vary, depending upon the identity, size, and/or
condition of the subject treated and further depending upon the route by which the
composition is to be administered. By way of example, the composition may include
between 0.1% and 100% (w/w) active ingredient.

35 Pharmaceutical formulations may additionally include a pharmaceutically
acceptable excipient, which, as used herein, includes any and all solvents, dispersion

5 media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's *The Science and Practice of Pharmacy*, 21st Edition, A. R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD, 2006; incorporated herein by reference)
10 discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional excipient medium is incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is
15 contemplated to be within the scope of this disclosure.

In some embodiments, a pharmaceutically acceptable excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, an excipient is approved for use in humans and for veterinary use. In some embodiments, an excipient is approved by United States Food and Drug
20 Administration. In some embodiments, an excipient is pharmaceutical grade. In some embodiments, an excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.

Pharmaceutically acceptable excipients used in the manufacture of
25 pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Such excipients may optionally be included in pharmaceutical formulations. Excipients such as cocoa butter and suppository waxes, coloring agents, coating
30 agents, sweetening, flavoring, and/or perfuming agents can be present in the composition, according to the judgment of the formulator.

Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and/or elixirs. In addition to active ingredients, liquid dosage
35 forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol,

5 isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, oral compositions can include adjuvants such
10 as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and/or perfuming agents. In certain embodiments for parenteral administration, compositions are mixed with solubilizing agents such as Cremophor[®], alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and/or combinations thereof.

15 Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing agents, wetting agents, and/or suspending agents. Sterile injectable preparations may be sterile injectable solutions, suspensions, and/or emulsions in nontoxic parenterally acceptable diluents and/or solvents, for example, as a solution in 1,3-butanediol.

20 Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. Fatty acids such as oleic acid can be used in the preparation of injectables.

25 Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, and/or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

 In order to prolong the effect of an active ingredient, it is often desirable to
30 slow the absorption of the active ingredient from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered
35 drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in

5 biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are prepared by entrapping the drug in liposomes or microemulsions which are compatible with
10 body tissues.

Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing compositions with suitable non-irritating excipients such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum
15 or vaginal cavity and release the active ingredient.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, an active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.

20 Dosage forms for topical and/or transdermal administration of a composition may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches. Generally, an active ingredient is admixed under sterile conditions with a pharmaceutically acceptable excipient and/or any needed preservatives and/or buffers as may be required. Additionally, the present disclosure
25 contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms may be prepared, for example, by dissolving and/or dispensing the compound in the proper medium. Alternatively or additionally, rate may be controlled by either providing a rate controlling membrane and/or by dispersing the compound in a polymer matrix
30 and/or gel.

Suitable devices for use in delivering intradermal pharmaceutical compositions described herein include short needle devices such as those described in U.S. Patents 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662. Intradermal compositions may be administered by devices
35 which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 and functional equivalents thereof. Jet

5 injection devices which deliver liquid compositions to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in U.S. Patents 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851; 5,893,397; 5,466,220; 5,339,163; 5,312,335; 10 5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460; and PCT publications WO 97/37705 and WO 97/13537. Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable. Alternatively or additionally, conventional syringes may be used in the classical mantoux method of 15 intradermal administration.

Formulations suitable for topical administration include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions. Topically-administrable formulations may, for example, 20 comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of active ingredient may be as high as the solubility limit of the active ingredient in the solvent.

A pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a 25 formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 nm to about 7 nm or from about 1 nm to about 6 nm. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder and/or using a self propelling 30 solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container. Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nm and at least 95% of the particles by number have a diameter less than 7 nm. Alternatively, at least 95% of the particles by weight have a 35 diameter greater than 1 nm and at least 90% of the particles by number have a diameter less than 6 nm. Dry powder compositions may include a solid fine powder

5 diluent such as sugar and are conveniently provided in a unit dose form.

Pharmaceutical compositions formulated for pulmonary delivery may provide an active ingredient in the form of droplets of a solution and/or suspension. Such formulations may be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising active
10 ingredient, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate. Droplets provided by this route of administration may have
15 an average diameter in the range from about 0.1 nm to about 200 nm.

Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 μm to 500 μm . Such a
20 formulation is administered in the manner in which snuff is taken, *i.e.* by rapid inhalation through the nasal passage from a container of the powder held close to the nose.

Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of active ingredient,
25 and may comprise one or more of the additional ingredients described herein. A pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, 0.1% to 20% (w/w) active ingredient, the balance comprising an orally
30 dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising active ingredient. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may have an average particle and/or
35 droplet size in the range from about 0.1 nm to about 200 nm, and may further comprise one or more of any additional ingredients described herein.

5 A pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1/1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid excipient. Such drops may further comprise buffering agents, salts, and/or one or
10 more other of any additional ingredients described herein. Other ophthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are contemplated as being within the scope of this disclosure.

In certain embodiments, complexes of the disclosure and compositions of the
15 disclosure, including pharmaceutical preparations, are non-pyrogenic. In other words, in certain embodiments, the compositions are substantially pyrogen free. In one embodiment, the formulations of the disclosure are pyrogen-free formulations which are substantially free of endotoxins and/or related pyrogenic substances. Endotoxins include toxins that are confined inside a microorganism and are released only when
20 the microorganisms are broken down or die. Pyrogenic substances also include fever-inducing, thermostable substances (glycoproteins) from the outer membrane of bacteria and other microorganisms. Both of these substances can cause fever, hypotension and shock if administered to humans. Due to the potential harmful effects, even low amounts of endotoxins must be removed from intravenously
25 administered pharmaceutical drug solutions. The Food & Drug Administration ("FDA") has set an upper limit of 5 endotoxin units (EU) per dose per kilogram body weight in a single one hour period for intravenous drug applications (The United States Pharmacopeial Convention, Pharmacopeial Forum 26 (1):223 (2000)). When therapeutic proteins are administered in relatively large dosages and/or over an
30 extended period of time (e.g., such as for the patient's entire life), even small amounts of harmful and dangerous endotoxin could be dangerous. In certain specific embodiments, the endotoxin and pyrogen levels in the composition are less than 10 EU/mg, or less than 5 EU/mg, or less than 1 EU/mg, or less than 0.1 EU/mg, or less than 0.01 EU/mg, or less than 0.001 EU/mg.

35 General considerations in the formulation and/or manufacture of pharmaceutical agents may be found, for example, in *Remington: The Science and*

- 5 *Practice of Pharmacy* 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference).

Administration

10 The present disclosure provides methods for delivering an AAM moiety into a cell. Cells or tissues are contacted with a complex comprising an AAM moiety and a Surf+ Penetrating Polypeptide, thereby promoting delivery of the AAM moiety into the cell.

The present disclosure provides methods comprising administering Surf+ Penetrating Polypeptide/AAM moiety complexes to a subject in need thereof, as well as methods of contacting cells or cells in culture with such complexes. The disclosure contemplates that any of the complexes of the disclosure (e.g., complexes including a Surf+ Penetrating Polypeptide Portion and a AAM moiety portion) may be administered, such as described herein. Complexes of the disclosure, including as pharmaceutical compositions, may be administered or otherwise used for research, diagnostic, imaging, prognostic, or therapeutic purposes, and may be used or administered using any amount and any route of administration effective for preventing, treating, diagnosing, researching or imaging a disease, disorder, and/or condition. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular composition, its mode of administration, its mode of activity, and the like. Compositions in accordance with the disclosure are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment.

30 The specific therapeutically effective, prophylactically effective, or appropriate imaging dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration

35 of the treatment; drugs used in combination or coincidental with the specific

5 compound employed; and like factors well known in the medical arts.

Surf+ Penetrating Polypeptide/AAM moiety complexes (e.g., complexes of the disclosure) comprising at least one agent to be delivered and/or pharmaceutical, prophylactic, diagnostic, research or imaging compositions thereof may be administered to animals, such as mammals (e.g., humans, domesticated animals, cats,
10 dogs, mice, rats, *etc.*). In some embodiments, complexes of the disclosure comprising at least one agent to be delivered, and/or pharmaceutical, prophylactic, diagnostic, research or imaging compositions thereof are administered to humans.

Complexes of the disclosure comprising at least one agent to be delivered and/or pharmaceutical, prophylactic, research diagnostic, or imaging compositions
15 thereof in accordance with the present disclosure may be administered by any route and may be formulated in a manner suitable for the selected route of administration or in vitro application. In some embodiments, complexes of the disclosure, and/or pharmaceutical, prophylactic, diagnostic, or imaging compositions thereof, are administered by one or more of a variety of routes, including oral, intravenous,
20 intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, intradermal, rectal, intravaginal, intraperitoneal, topical (e.g. by powders, ointments, creams, gels, lotions, and/or drops), mucosal, nasal, buccal, enteral, vitreal, intratumoral, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; as an oral spray, nasal spray, and/or aerosol, and/or
25 through a portal vein catheter. Other devices suitable for administration include, e.g., microneedles, intradermal specific needles, Foley's catheters (e.g., for bladder instillation), and pumps, e.g., for continuous release.

In some embodiments, complexes of the disclosure, and/or pharmaceutical, prophylactic, diagnostic, research or imaging compositions thereof, are administered
30 by systemic intravenous injection. In specific embodiments, complexes of the disclosure and/or pharmaceutical, prophylactic, research diagnostic, or imaging compositions thereof may be administered intravenously and/or orally. In specific embodiments, complexes of the disclosure, and/or pharmaceutical, prophylactic, research diagnostic, or imaging compositions thereof, may be administered in a way
35 which allows the complex to cross the blood-brain barrier, vascular barrier, or other epithelial barrier.

5 Complexes of the disclosure comprising at least one AAM moiety to be delivered may be used in combination with one or more other therapeutic, prophylactic, diagnostic, research or imaging agents. By “in combination with,” it is not intended to imply that the agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the
10 scope of the disclosure. Compositions of the disclosure can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics, other reagents or medical procedures. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. In some embodiments, the disclosure encompasses the delivery of pharmaceutical, prophylactic, diagnostic,
15 research or imaging compositions in combination with agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.

 It will further be appreciated that therapeutic, prophylactic, diagnostic, research or imaging active agents utilized in combination may be administered
20 together in a single composition or administered separately in different compositions. In general, it is expected that agents utilized in combination will be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.

25 The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, a composition useful for treating cancer in
30 accordance with the disclosure may be administered concurrently with a chemotherapeutic agent), or they may achieve different effects (*e.g.*, control of any adverse effects).

Kits

35 The disclosure provides a variety of kits (or pharmaceutical packages) for conveniently and/or effectively carrying out methods of the present disclosure.

5 Typically kits will comprise sufficient amounts and/or numbers of components to allow a user to perform multiple treatments of a subject(s) and/or to perform multiple experiments for desired uses (e.g., laboratory or diagnostic uses). Alternatively, a kit may be designed and intended for a single use. Components of a kit may be disposable or reusable.

10 In some embodiments, kits include one or more of (i) a Surf+ Penetrating Polypeptide as described herein and an AAM moiety to be delivered; and (ii) instructions (or labels) for forming complexes comprising the Surf+ Penetrating Polypeptide associated with the AAM moiety (e.g., with at least one AAM moiety). Optionally, such kits may further include instructions for using the complex in a
15 research, diagnostic or therapeutic setting.

In some embodiments, a kit includes one or more of (i) a Surf+ Penetrating Polypeptide portion as described herein and an AAM moiety portion to be delivered or a complex of such Surf+ Penetrating Polypeptide associated with such AAM moiety; (ii) at least one pharmaceutically acceptable excipient; (iii) a syringe, needle,
20 applicator, *etc.* for administration of a pharmaceutical, prophylactic, diagnostic, or imaging composition to a subject; and (iv) instructions and/or a label for preparing the pharmaceutical composition and/or for administration of the composition to the subject.

In some embodiments, a kit includes one or more of (i) a pharmaceutical
25 composition comprising a complex of the disclosure (e.g., a Surf+ Penetrating Polypeptide portion as described herein associated with an AAM moiety portion to be delivered); (ii) a syringe, needle, applicator, *etc.* for administration of the pharmaceutical, prophylactic, diagnostic, or imaging composition to a subject; and (iii) instructions and/or a label for administration of the pharmaceutical, prophylactic,
30 diagnostic, or imaging composition to the subject. Optionally, the kit need not include the syringe, needle, or applicator, but instead provides the composition in a vial, tube or other container suitable for long or short term storage until use.

In some embodiments, a kit includes one or more components useful for modifying proteins of interest, such as by supercharging the protein, to produce a
35 Surf+ Penetrating Polypeptide. These kits typically include all or most of the reagents needed. In certain embodiments, such a kit includes computer software to aid a

5 researcher in designing the engineered or otherwise modified Surf+ Penetrating Polypeptide an in accordance with the disclosure. In certain embodiments, such a kit includes reagents necessary for performing site-directed mutagenesis.

In some embodiments, a kit may include additional components or reagents. For example, a kit may include buffers, reagents, primers, oligonucleotides,
10 nucleotides, enzymes, buffers, cells, media, plates, tubes, instructions, vectors, *etc.*

In some embodiments, a kit comprises two or more containers. In certain embodiments, a kit may include one or more first containers which comprise a Surf+ Penetrating Polypeptide, and optionally, at least one AAM moiety molecule to be delivered, or a complex comprising a Surf+ Penetrating Polypeptide and at least one
15 AAM moiety to be delivered for diagnosing or prognosing a disease, disorder or condition or for research use; and the kit also includes one or more second containers which comprise one or more other prophylactic or therapeutic agents useful for the prevention, management or treatment of the same disease, disorder or condition, or useful for the same research application.

20 In some embodiments, a kit includes a number of unit dosages of a pharmaceutical, prophylactic, diagnostic, or imaging composition comprising a complex of the disclosure or comprising a Surf+ Penetrating Polypeptide, and optionally, at least one AAM moiety to be delivered. In some embodiments, the unit dosage form is suitable for intravenous, intramuscular, intranasal, oral, topical or
25 subcutaneous delivery. Thus, the disclosure herein encompasses solutions, preferably sterile solutions, suitable for each delivery route. A memory aid may be provided, for example in the form of numbers, letters, and/or other markings and/or with a calendar insert, designating the days/times in the treatment schedule in which dosages can be administered. Placebo dosages, and/or calcium dietary supplements, either in a form
30 similar to or distinct from the dosages of the pharmaceutical, prophylactic, diagnostic, or imaging compositions, may be included to provide a kit in which a dosage is taken every day.

In some embodiments, the kit may further include a device suitable for administering the composition according to a specific route of administration or for
35 practicing a screening assay.

5 Kits may include one or more vessels or containers so that certain of the individual components or reagents may be separately housed. Exemplary containers include, but are not limited to, vials, bottles, pre-filled syringes, IV bags, blister packs (comprising one or more pills). A kit may include a means for enclosing individual containers in relatively close confinement for commercial sale (*e.g.*, a plastic box in
10 which instructions, packaging materials such as styrofoam, *etc.*, may be enclosed). Kit contents can be packaged for convenient use in a laboratory.

 In the case of kits sold for laboratory and/or diagnostic use, the kit may optionally contain a notice indicating appropriate use, safety considerations, and any limitations on use. Moreover, in the case of kits sold for laboratory and/or diagnostic
15 use, the kit may optionally comprise one or more other reagents, such as positive or negative control reagents, useful for the particular diagnostic or laboratory use.

 In the case of kits sold for therapeutic and/or diagnostic use, a kit may also contain a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice
20 reflects (a) approval by the agency of manufacture, use or sale for human administration, (b) directions for use, or both.

 These and other aspects of the present disclosure will be further appreciated upon consideration of the following Examples, which are intended to illustrate certain
25 particular embodiments of the disclosure but are not intended to limit its scope, as defined by the claims.

EXAMPLE

 The disclosure now being generally described, it will be more readily
30 understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present disclosure, and are not intended to limit the disclosure.

Example 1: A Microtubule Localizing Complex

 In one exemplification, an antibody to tubulin is biotinylated at the sulfhydryl
35 groups on one or more cysteines and conjugated to a supercharged streptavidin (+52SAV). +52SAV is an example of a Surf+ Penetrating Polypeptide. It has high

5 net positive charge, surface positive charge and penetrates cells. +52SAV is a tetramer of four monomers, each of which has a net charge of +13. The mass of each monomer is 16.54 kDa and the charge/molecular weight ratio of the tetramer is 0.79.

Each monomer of the +52SAV tetramer has the following amino acid sequence:

10 DPSKDSKAQVSAAKAGITGTWYNQLGSTFIVTAGAKGALTGTYESAVGNAK
 SRYVLTGRYDSAPATKSGGTALGWTVAWKNKYRNAHSATTWSGQYVGGA
 KARINTQWLLTSGTTKAKAWKSTLVGHDTFTKVKPSAASIDAACKAGVNNG
 NPLDAVQQ (SEQ ID NO: 658).

For *in vitro* analysis of this complex, cells in culture are contacted with the
 15 +52SAV-tubulin antibody complex. The complex is internalized by the cells. Once inside a cell, the tubulin antibody binds its target (e.g., tubulin expressed by microtubules in the cell), which is detected by immunofluorescence with antibodies to the tubulin antibody after cell fixation and permeabilization.

For *in vivo* studies, the +52SAV-tubulin antibody complex is injected
 20 subcutaneously into rats and, following a punch biopsy and/or harvest of various tissue samples, immunohistochemistry is performed with antibodies to the tubulin antibody to detect tissue penetration and biodistribution.

Suitable controls are conducted and include the use of an anti-tubulin antibody alone to confirm that the AAM moiety alone does not efficiently penetrate non-
 25 permeabilized cells or does so at levels substantially less than that of the complex, as well as the use of the Surf+ Penetrating Polypeptide alone to confirm that it does not independently bind specifically to the intracellular target.

+52SAV expression and purification: His6x-tagged +52SAV was expressed in BL21(DE3) cells, grown in Terrific Broth media (Boston Bioproducts, Ashland,
 30 MA), and induced with 1 mM IPTG for 4 hours at 37°C. Cells were lysed with 5 mL of lysis buffer (1X Bugbuster® (EMD Chemicals, Rockland, MA), 20mM Hepes pH 7.5, 150mM NaCl, 25 U/mL Benzonase (EMD Chemicals, Rockland, MA), 0.1mg/mL lysozyme and EDTA-free 1Xprotease inhibitors (Roche, South San Francisco, CA)) per gram of cell paste. The resulting inclusion body pellet from
 35 centrifugation of the lysate was washed three times with lysis buffer, then resuspended in 6M guanidinium hydrochloride, pH 1.5 and dialyzed against the same

5 buffer overnight. The denatured protein was refolded by dialysis against 50mM Hepes pH 7.5, 150mM NaCl, and 0.3M guanidinium hydrochloride. Affinity purification of refolded +52SAV was carried out using Iminobiotin Agarose according to the manufacturer's instructions (Pierce®, Thermo Fisher Scientific Inc., Rockford, IL).

Biotinylation of antibody: Disulfide bonds of commercially available anti-
10 tubulin antibody (sheep polyclonal; Cytoskeleton, Inc., Denver, CO) were reduced by 1 hour incubation with 10mM beta-mercaptoethanol at 37°C. Residual beta-mercaptoethanol was removed from the antibody using Zeba™ Spin Desalting Columns (Pierce®, Thermo Fisher Scientific Inc., Rockford, IL) according to the manufacturer's instructions. The resulting reduced antibody was biotinylated on the
15 free sulfhydryl groups using EZ-Link® BMCC-Biotin (Pierce®, Thermo Fisher Scientific Inc., Rockford, IL) according to the manufacturer's instructions. The level of biotinylation (usually 1-2 biotin molecules per antibody) was determined using a Fluorescence Biotin Quantitation kit (Pierce®, Thermo Fisher Scientific Inc., Rockford, IL).

20 Generation of the antibody/+52SAV complex: +52SAV was incubated with biotinylated antibody and free biotin to generate a 1:1 molar ratio of antibody bound to +52SAV. This complex was then purified using a cation exchange resin (SP sepharose, fast flow; GE Healthcare).

Cell uptake and visualization: HeLa cells (ATCC, Manassas, VA) were plated
25 at a density of 10^4 cells per well of a 96-well dish one day prior to treatment with protein. Uptake and binding of tubulin antibody to intracellular microtubules will be assessed by dose ranging (0.05 to 2 μ M) and time course incubation of the antibody/+52SAV complex with cells. After treatment, cells are fixed with 4% paraformaldehyde followed by permeabilization with 0.5% saponin. The fixed and
30 permeabilized cells are incubated with a fluorescent labeled secondary antibody and visualized by fluorescence microscopy.

In the foregoing example, +52SAV may be replaced by a human Surf+ Penetrating Polypeptide, such as a fragment of a naturally occurring polypeptide set forth in Figure 1 or Figure 2, including specific domains identified by PDB number,
35 or fragments thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75. Amino acid sequence information for

5 full length proteins identified in Figures 1 and 2 by GenBank Accession number are provided in Section 1 of the Sequence Listing. Amino acid sequence information for domains of protein identified in Figures 1 and 2 by PDB identifier are provided in Section 2 of the Sequence Listing.

Moreover, the commercially available anti-tubulin antibody may be replaced
10 by a recombinantly produced anti-tubulin antibody. Use of a recombinantly produced antibody facilitates generating complexes as fusion proteins comprising a Surf+ Penetrating Polypeptide portion and an AAM moiety portion. Such replacement of the specific embodiments set forth in these examples with other suitable embodiments is specifically contemplated.

15 Example 2: A Nuclear Pore Localizing Complex

In another exemplification, antibody to nucleoporin (mouse monoclonal [QE5]; Abcam, Cambridge, MA) is biotinylated at the sulfhydryl groups at one or more cysteines and conjugated to a supercharged streptavidin (+52SAV).

For *in vitro* analysis of this complex, cells in culture are contacted with the
20 +52SAV-nucleoporin antibody complex. The complex is internalized by the cells. Once inside a cell, the nucleoporin antibody binds to the nuclear pore in the cell (e.g., binds to its target nucleoporin expressed by the nuclear pore), which is detected by immunofluorescence with antibodies to the nucleoporin antibody after cell fixation and permeabilization.

25 For *in vivo* studies, the +52SAV-nucleoporin antibody complex is injected subcutaneously into rats and, following a punch biopsy and/or harvest of various tissue samples, immunohistochemistry is performed with antibodies to the nucleoporin antibody to detect tissue penetration and biodistribution. Methods for preparation and testing of the +52SAV-antibody complex will be followed as
30 described above.

In the foregoing example, +52SAV may be replaced by a human Surf+ Penetrating Polypeptide, such as a fragment of a naturally occurring polypeptide set forth in Figure 1 or Figure 2, including specific domains identified by PDB number, or fragments thereof having surface positive charge, a mass of at least 4 kDa, and a
35 charge/molecular weight ratio of at least 0.75. Amino acid sequence information for full length proteins identified in Figures 1 and 2 by GenBank Accession number are

5 provided in Section 1 of the Sequence Listing. Amino acid sequence information for domains of protein identified in Figures 1 and 2 by PDB identifier are provided in Section 2 of the Sequence Listing.

Moreover, the commercially available antibody may be replaced by a recombinantly produced antibody. Use of a recombinantly produced antibody
10 facilitates generating complexes as fusion proteins comprising a Surf+ Penetrating Polypeptide portion and an AAM moiety portion. Such replacement of the specific embodiments set forth in these examples with other suitable embodiments is specifically contemplated.

Example 3: A Golgi Localizing Complex

15 In another exemplification, antibody to p58 Golgi protein (mouse monoclonal [58K-9]; Abcam) is biotinylated at the sulfhydryl groups at one or more cysteines and conjugated to a supercharged streptavidin (+52SAV).

For *in vitro* analysis of this complex, cells in culture are contacted with the +52SAV-p58 Golgi antibody complex. The complex is internalized by the cells.
20 Once inside a cell, the p58 Golgi antibody binds to the perinuclear Golgi apparatus in the cell, which is detected by immunofluorescence with antibodies to the p58 Golgi antibody after cell fixation and permeabilization.

For *in vivo* studies, the +52SAV-p58 Golgi antibody complex is injected subcutaneously into rats and, following a punch biopsy and/or harvest of various
25 tissue samples, immunohistochemistry is performed with antibodies to the p58 Golgi antibody to detect tissue penetration and biodistribution. Methods for preparation and testing of the +52SAV-antibody complex will be followed as described above.

In the foregoing example, +52SAV may be replaced by a human Surf+ Penetrating Polypeptide, such as a fragment of a naturally occurring polypeptide set
30 forth in Figure 1 or Figure 2, including specific domains identified by PDB number, or fragments thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75. Amino acid sequence information for full length proteins identified in Figures 1 and 2 by GenBank Accession number are provided in Section 1 of the Sequence Listing. Amino acid sequence information for
35 domains of protein identified in Figures 1 and 2 by PDB identifier are provided in Section 2 of the Sequence Listing.

5 Moreover, the commercially available antibody may be replaced by a
recombinantly produced antibody. Use of a recombinantly produced antibody
facilitates generating complexes as fusion proteins comprising a Surf+ Penetrating
Polypeptide portion and an AAM moiety portion. Such replacement of the specific
embodiments set forth in these examples with other suitable embodiments is
10 specifically contemplated.

Example 4: An Inhibitory Complex

 In another exemplification, a neutralizing antibody to caspase1 (mouse
monoclonal [D57A2]; Cell Signaling Technology, Inc.®, Danvers, MA) is
biotinylated at the sulfhydryl groups at one or more cysteines and conjugated to a
15 supercharged streptavidin (+52SAV).

 For *in vitro* analysis of this complex, cells in culture are contacted with the
+52SAV-caspase antibody complex. The complex is internalized by the cells.
Internalization is confirmed, as described above, using immunofluorescence with
secondary antibodies to the caspase 1 antibody. The functional activity of the
20 caspase1 antibody inside the cell is assayed by, for example, measuring the effect on
inhibition of pro-IL-1 β processing and reduction in levels of secreted active IL-1 β ,
which can be monitored by an immunoassay of the cell supernatant such as an ELISA
assay, for which a commercially available kit is available (Pierce®, Thermo Fisher
Scientific Inc., Rockford, IL). Such an assay is used to confirm that once delivered
25 into cells, the neutralizing antibody to caspase1 maintains its function (e.g., the
antibody inhibits an activity of caspase1).

 For *in vivo* studies, mice are injected intraarticularly with monosodium urate
crystals plus C18 free fatty acids to induce joint swelling. Such joint swelling may be
monitored by macroscopic scoring, by ^{99m}Tc uptake, by local IL-1 β levels and/or by
30 quantifying immune cell influx into the joint, and each of these methods have been
previously described (Joosten LA, *et al.* (2010) *Arthritis & Rheumatism* 62:3237-
3248). Given that the neutralizing caspase1 antibody reduces IL-1 β levels, the
complex is evaluated for its ability to alleviate symptoms caused, in whole or in part,
by elevated local IL-1 β levels. The +52SAV-caspase 1 antibody complex is injected
35 intraarticularly with dose ranging and time course (including prior to, concomitant
with and post injection of urate crystals plus C18 free fatty acids) studies. Following

5 injection, treated mice are evaluated for inhibition of joint swelling in comparison to untreated mice.

In the foregoing example, +52SAV may be replaced by a human Surf+ Penetrating Polypeptide, such as a fragment of a naturally occurring polypeptide set forth in Figure 1 or Figure 2, including specific domains identified by PDB number,
10 or fragments thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75. Amino acid sequence information for full length proteins identified in Figures 1 and 2 by GenBank Accession number are provided in Section 1 of the Sequence Listing. Amino acid sequence information for domains of protein identified in Figures 1 and 2 by PDB identifier are provided in
15 Section 2 of the Sequence Listing.

Moreover, the commercially available antibody may be replaced by a recombinantly produced antibody. Use of a recombinantly produced antibody facilitates generating complexes as fusion proteins comprising a Surf+ Penetrating Polypeptide portion and an AAM moiety portion. Such replacement of the specific
20 embodiments set forth in these examples with other suitable embodiments is specifically contemplated.

Example 5: Complexes Comprising Naturally Occurring Surf+ Penetrating Polypeptides

In another exemplification, a naturally occurring human Surf+ Penetrating
25 Polypeptide, such as a cell penetrating fragment of HBEGF, are fused in frame for expression of a chimeric fusion protein to an AAM moiety, such as an Adnectin[®], DARPin, nanobody, scFv or single VH or VL domain antibody. Although HBEGF and the AAM moiety can be directly linked, in this example the two moieties are interconnected via a linker, such as a (G₄S)₃ (*i.e.*, a (Gly-Gly-Gly-Gly-Ser)₃) linker. A
30 suitable HBEGF fragment is set forth in PDB ID 1XDT and is a polypeptide of about 79 amino acid residues (*e.g.*, includes about amino acid residues 72-147 of the full length HBEGF protein). This HBEGF domain is an example of a naturally occurring human Surf+ Penetrating Polypeptide. It has surface positive charge, charge/molecular weight of at least 0.75, and a molecular weight of at least 4 kDa.
35 Specifically, this polypeptide has a molecular weight of about 8.9 kDa, a net charge of +12, and a charge/molecular weight of 1.35. Moreover, this HBEGF fragment is

5 exemplary of Surf+ Penetrating Polypeptides having a charge/molecular weight of at least 0.75, but for which the charge/molecular weight of the full length naturally occurring protein is less than 0.75 (e.g., charge/molecular weight of full length HBEGF is about 0.52). Subdomains (e.g., smaller functional fragments) of HBEGF having surface positive charge, a mass of at least 4kDa, a charge/molecular weight
10 ratio of at least 0.75, and cell penetrating capability may also be used.

Optionally, the complex includes one or more tags to facilitate detection and/or purification. In one example, a 10 amino acid sequence including the 6xHis tag is appended to the N-terminus of the fusion protein (MGHHHHHHGG) (SEQ ID NO: 659) and a 9 amino acid myc epitope tag plus two glycines as a linker sequence
15 (GGEQKLISEEDL) (SEQ ID NO: 660) is appended to the C-terminus of the fusion protein.

For in vitro analysis, this His-HBEGF-linker-AAM moiety-myc fusion protein is contacted with and internalized by a cell. Accumulation in the cell is monitored by immunofluorescence with an anti-myc antibody (mouse monoclonal [9E10]; Abcam,
20 Cambridge, MA).

The AAM moiety may be an scFv that binds tubulin. The His-HBEGF-linker-tubulin scFv-myc fusion protein is contacted with and internalized by a cell and the myc-tagged tubulin scFv binds to microtubules in the cell, which can be subsequently detected by immunofluorescence with anti-myc tag antibody following fixation,
25 permeabilization.

For this and other examples, the order of the fusion protein may be altered so that the Surf+ Penetrating Polypeptide portion of the complex is located C-terminally to the AAM moiety portion of the complex, e.g. myc-tubulin scFv-linker-HBEGF-His.

30 HBEGF expression and purification: the His-HBEGF-tubulin scFv-myc fusion protein was expressed in SHuffle® cells (New England Biolabs, Ipswich, MA), grown in Progro™ media (Expression Technologies, San Diego, CA), and induced with 0.5mM IPTG for 19 hours at 22°C. Cells were lysed in lysis buffer as described above. The lysate supernatant was subjected to fractionation on a HiTrap™ IMAC
35 column (GE Healthcare, Piscataway, NJ), followed by a SP-HP cation exchange column (GE Healthcare, Piscataway, NJ), and finally a Superdex™ 75 10/300 GL gel

5 filtration column (GE Healthcare, Piscataway, NJ) to purify the fusion protein. The fusion protein is stored in high salt PBS buffer (8 mM sodium phosphate, 2 mM potassium phosphate, 2.7 mM KCl, 0.5 M NaCl, pH 7.4)

Cell uptake and visualization: HeLa cells are plated as above and subjected to dose ranging (0.05 to 2 μ M) and time course studies for uptake of the
 10 His-HBEGF-tubulin scFv-myc fusion protein. After incubation with the fusion protein, cells are fixed and permeabilized as described above. The fixed and permeabilized cells are incubated with a fluorescent labeled secondary antibody and visualized by fluorescent microscopy.

In the foregoing example, the Surf+ Penetrating Polypeptide may be replaced
 15 by a human Surf+ Penetrating Polypeptide, such as a fragment of a naturally occurring polypeptide set forth in Figure 1 or Figure 2, including specific domains identified by PDB number, or fragments thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75. Amino acid sequence information for full length proteins identified in Figures 1 and 2 by
 20 GenBank Accession number are provided in Section 1 of the Sequence Listing. Amino acid sequence information for domains of protein identified in Figures 1 and 2 by PDB identifier are provided in Section 2 of the Sequence Listing.

Example 6: Complexes Comprising an Antibody-Mimic Moiety

In some embodiments, the AAM moiety in the complex is an Adnectin[®]
 25 sequence, such as the naïve, wild type Fn3 Adnectin[®], which has no target binding protein in the cells, but is studied for biophysical and biochemical properties in fusion with a Surf+ Penetrating Polypeptide of the disclosure and for monitoring uptake into cells.

Alternatively, a complex of a Surf+ Penetrating Polypeptide and the HA4 or
 30 7c12 Adnectin[®] sequence is made and studied. These particular AAM moieties bind to the SH2 domain of the Abelson kinase, as described by Grebien, F *et al* (2011) *Cell* 147:306-319. The resulting complex is internalized by cells and binds (via the AAM moiety) to the cytoplasmic Bcr-Abl kinase fusion protein. Either complex is studied in vitro and/or in vivo, such as using assays described above. Additionally, such
 35 complexes will be evaluated in dose ranging and time course studies for ability to inhibit Abl kinase activity and leukemogenesis in mouse BaF3 cells harboring Bcr-

5 Abl kinase, as previously described (Grebien, F *et al* (2011) *Cell* 147:306-319).

Example 7: Complexes Comprising an Antibody-Mimic Moiety

In some embodiments, the AAM moiety complexed to a Surf+ Penetrating Polypeptide (e.g., chemically conjugated or complexed as a fusion protein) is a designed ankyrin repeat protein, or DARPin, such as a naïve DARPin or the 2A1 and
 10 2F6 DARPins that bind to the CC2-LZ domain of IKK γ /NEMO, as previously described (Wyler, E. *et al* (2007) *Protein Science* 16:2013-2022). For any of these complexes, a His tag is optionally appended to the fusion protein to facilitate purification from *E. coli*, and a myc epitope tag is optionally appended to the DARPin
 15 tagged DARPin protein inside the cells.

HEK293T cells are transiently transfected with an NF- κ B reporter plasmid, such as pIgk-luc, and co-transfected with a β -galactosidase expressing reporter plasmid. After 24 hours, cells are stimulated with 10ng/mL TNF- α and cell lysates are assayed for both reporter protein activities, where the β -galactosidase activity is used
 20 to normalize transfection and reporter protein activity. The His-Surf+ Penetrating Polypeptide-linker-DARPin-myc fusion protein is contacted with the cells for dose ranging and time course studies of inhibition of NEMO activity and reduced NF- κ B activation following TNF- α stimulation, as previously described (Wyler, E. *et al* (2007) *Protein Science* 16:2013-2022).

Example 8: Target Subcellular Localization

The present disclosure provides complexes and methods for delivering AAM moieties into cells. The target of the particular AAM moiety may itself be localized in, for example, the nucleus, peroxisome, cytoplasm, mitochondria, cytoplasmic face of the cell membrane, etc.

30 In some embodiments, the target of the particular AAM moiety is localized in the nucleus. Optionally, a nuclear localization sequence (NLS), for instance the peptide sequence DPKKKRKV (SEQ ID NO: 661), is included in the complex, such that the complex has any of the following exemplary structures to facilitate its targeting to the nucleus: His-Surf+ Penetrating Polypeptide-linker-NLS-AAM
 35 moiety-myc; His-Surf+ Penetrating Polypeptide-linker-AAM moiety-NLS-myc; NLS-AAM moiety-linker-Surf+ Penetrating Polypeptide; AAM moiety-NLS-linker-

5 Surf+ Penetrating Polypeptide. As detailed throughout, His and/or myc tags may be present, absent or replaced with another tag. Moreover, additional linkers may be present or absent. After contacting and penetration into the cell, the AAM moiety will transit to and accumulate inside the nucleus. Accumulation in the cell nucleus is monitored by immunofluorescence with an anti-myc antibody and is detected by
10 fluorescence microscopy of live or fixed cells.

In some embodiments, the target is localized in the peroxisome. Optionally, a peroxisomal targeting sequence (PTS) is appended to the C-terminus of the AAM moiety (His-Surf+ Penetrating Polypeptide-linker-myc-AAM moiety-PTS). After contacting and penetration into the cell, the AAM moiety portion will transit to and
15 accumulate inside peroxisomes. Accumulation in the cell is monitored by immunofluorescence with an anti-myc antibody. Alternatively, the PTS may be appended to another portion of the complex, such as to the Surf+ Penetrating Polypeptide portion.

In some embodiments, the target is localized to the cytosolic face of the
20 plasma membrane. Optionally, a plasma membrane localization signal sequence (KLNPPDESGPGCMSCKCVLS) (SEQ ID NO: 662) is appended to the C-terminus of the AAM moiety (His-Surf+ Penetrating Polypeptide-linker-AAM moiety-myc-membrane localization signal) to facilitate its targeting and binding to the cytosolic face of the plasma membrane. After contacting and penetration into the cell, the AAM
25 moiety will transit to and accumulates at the cytosolic face of the plasma membrane, which is monitored by immunofluorescence with an anti-myc antibody and detected by fluorescence microscopy of live or fixed cells. Alternatively, the plasma membrane localization signal may be appended to another portion of the complex, such as to the Surf+ Penetrating Polypeptide portion.

30 In some embodiments, the target is localized in the mitochondrial matrix. Optionally, a mitochondrial matrix localization signal sequence (MLS) is appended to the N-terminus of the AAM moiety, which is followed by the linker sequence and then the Surf+ Penetrating Polypeptide (MLS-AAM moiety-myc-linker-Surf+ Penetrating Polypeptide). After contacting and penetration into the cell, the AAM
35 moiety will transit to and accumulate inside the mitochondrial matrix. Accumulation in the cell is monitored by immunofluorescence with an anti-myc antibody and

5 detected by fluorescence microscopy of live or fixed cells. Alternatively, the MLS may be appended to another portion of the complex, such as to the Surf+ Penetrating Polypeptide portion.

10 Example 9: Surface-charged fusion proteins with single chain antibody (scFv) to huntingtin protein

A complex comprising a supercharged GFP protein (another example of a Surf+ Penetrating Polypeptide, in this case a charge engineered protein) fused via a glycine-serine linker to an AAM moiety (in this case, an scFv that specifically binds huntingtin protein; an intracellular target) was expressed and purified. The complex
15 was also tagged on the N-terminus with a Myc tag and on the C-terminus with a Hisx6 tag. A control lacking the AAM moiety was also expressed and purified. The complexes are fusion protein and can be represented as:

- Myc-+36GFP-(G₄S)₂-C4-His₆;
- Myc-+36GFP-His₆;

20 where “+36GFP” denotes the supercharged GFP portion; “C4” denotes the particular AAM moiety used in this example; and (G₄S)₂ denotes the linker used to link the supercharged GFP portion to the AAM moiety (this linker is also referred to as GS10). In this particular example, the supercharged GFP portion has a net charge of +36. The amino acid sequence of +36GFP is set forth in SEQ ID NO: 663. The AAM
25 moiety in this example is an scFv that specifically binds huntingtin protein; an intracellular target. This single chain Fv, also known as an intrabody because it is an scFv that binds an intracellular target, is denoted “C4”. The C4 scFv binds to the first 17 amino acids of huntingtin protein and has been demonstrated to delay the aggregation phenotype when the gene is delivered in adeno-associated viral vectors
30 (AAV2/1) in mice (J Neuropathol Exp Neurol. 2010. 69(10):1078-1085). In other words, the scFv binds to the intracellular protein and prevents the bound protein from binding to another protein, in this case, another huntington protein molecule. This is an example of one mechanism by which an AAM might impact the activity of an intracellular target. In this example, the AAM is preventing the bound protein from
35 binding its binding partner (a protein) which may be a different protein or another molecule of the same protein.

5 Inability to get penetration of the protein has limited its use to such a viral-based approach.

In this example, the complex is a fusion protein and the GFP and scFv portion are interconnected via a peptide linker. This fusion protein is a single polypeptide chain (e.g., the portions are connected to form a single polypeptide chain). Here, the peptide linker is a ten amino acid linker, specifically (GGGGS)₂. In this particular example, the GFP portion is N-terminal to the scFv. However, in other embodiments, the GFP portion may be C-terminal to the scFv portion. Moreover, the linker sequence and/or length can be varied, and the fusion protein may or may not have a tag. The amino acid sequence for the GFP-scFv fusion protein (Myc-+36GFP-(G₄S)₂-C4-His₆) is set forth in SEQ ID NO: 664. The amino acid sequence of the control complex (Myc-+36GFP-His₆) is set forth in SEQ ID NO: 665.

Example 10: The binding of AMM moiety to its target is maintained when delivered into cells as a fusion protein with a Surf+ Penetrating Polypeptide

20 Experiments were conducted to demonstrate that the complex described in Example 9 (Myc-+36GFP-(G₄S)₂-C4-His₆) can be effectively delivered into cells and disrupt aggregation of mHTT. In other words, does the fusion protein have the ability to penetrate cells and yet retain the ability of the C4 (scFv; AAM moiety) to bind its intracellular target and disrupt the binding of this target to its binding partners (e.g., 25 disrupt binding to another protein – whether that other protein be the same or different).

C4 has been previously shown to block HTT aggregation when delivered by transient transfection using a viral system (Butler and Messer, PLoSOne 2011, 6:e29199). This assay was employed to assess whether C4 maintains its activity when 30 delivered into cells via a Surf+ Penetrating Polypeptide. In this assay a HTT exon 1 protein fragment containing 46 glutamine repeats and a red fluorescence protein tag (HDex1-RFP) was expressed in ST14A cells by transient transfection. ST14A cell are immortalized rat neuron progenitor cells, a cell line representative of immature CNS cells. If left untreated the protein forms punctate aggregates in the cells, which 35 can be visualized by fluorescence microscopy. The assay is as followed:

1. Transfect cells using jetPEI™ with a plasmid encoding HDex1-46Q-RFP

- 5 2. Change media 4 hours post transfection
3. Add purified Myc-+36GFP-(G₄S)₂-C4-His₆ or Myc-+36GFP-His₆ 6 hours post transfection at a concentration of 2 uM.
4. Perform live cell imaging at 48 hours post transfection in green fluorescence, red fluorescence and phase contrast.
- 10 5. Fix a sample of each group for HA labeling.
6. Count the number of aggregates in each sample.

The results indicated that +36GFP-linker-C4 fusion protein reduces aggregation of HDex1-46QRFP (HTT46Q-RFP) by 30% at 48 hours relative to +36GFP alone at 2 micromolar. The number of aggregates formed by HTT46Q-RFP
 15 in the cells was determined by counting the number of aggregates seen when imaging for red fluorescence. Visual counting indicated 30% less aggregates in the +36GFP-linker-C4-treated cells, as compared to the +36GFP-treated cells. These results indicate that +36GFP efficiently delivers C4 to the cytoplasm of ST14A cells, where it is able to bind to and prevent aggregation of HTT.

20 The 30% decrease in aggregation observed in this Example is significant. In an experiment performed by Butler and Messer, where C4 was expressed via viral transfection as an intrabody with a PEST sequence that targets for proteosomal degradation, aggregation was reduced 51% for HDex1-25Q and 78% for HDex1-72Q at 48 hours post-transfection (Butler and Messer, PLoSOne 2011, 6;e29199). In such
 25 an experiment however, the intrabody is likely continuously expressed over the time course and the PEST sequence may further decrease aggregation by targeting HTT for proteosomal degradation. The 30% decrease observed in this Example is notable with a singular administration of protein in which the C4 scFv is fused to a Surf+ Penetrating Polypeptide. The use of a human Surf+ Penetrating Polypeptide is
 30 described below.

Sequences:

Myc-(+36)GFP-His₆ (where the underlined sequence depicts +36 GFP.

35 MEQKLISEEDLGSASKGERLFRGKVPILVELKGDVNGHKFSVRGKGKGDATR
GKLTCLKFICTTGKLPVPWPTLVTTLTYGVCFSRYPKHMKRHDFFKSAMPKG

5 YVQERTISFKKDGKYKTRAEVKFEGRTL VNRIKLKGRDFKEKGNILGHKLRY
NFN SHKVYITADKRKNGIKAKFKIRHNVKDGSVQLADHYQQNTPIGRGPVLL
PRNHYLSTRSKLSKDPKEKRDHMLLEFVTAAGIKHGRDERYKGHGHHHHH
 H (SEQ ID NO: 665)

10 Myc-(+36)GFP-(G₄S)₂-C4_scFv-His6 (where the underlined sequence is, from N- to
 C- terminus, GFP, linker, C4 scFv).

MEQKLISEEDLGSASKGERLFRGKVPILVELKGDVNGHKFSVRGKGKGDATR
 GKLT LKFICTTGKLPVPWPTLVTTLT YGVQCFSRYPKHMKRHDFFKSAMPKG
 YVQERTISFKKDGKYKTRAEVKFEGRTL VNRIKLKGRDFKEKGNILGHKLRY
 15 NFN SHKVYITADKRKNGIKAKFKIRHNVKDGSVQLADHYQQNTPIGRGPVLL
PRNHYLSTRSKLSKDPKEKRDHMLLEFVTAAGIKHGRDERYKGHGGGGGSG
 GGGSQVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEW
 VAVISYDGSNKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR
 DRYFDLWGRGTLVTVSSGGGGSGGGGSGGGGSGSALTQPASVSGSPGQSITIS
 20 CTGTSSDIGAYNYVSWYQQYPGKAPKLLIYDVSNRPSGISNRFSGSKSGDTAS
LTISGLQAEDEADYYCSSFANSGPLFGGGTKVTVLGGHGHHHHHHH (SEQ ID
 NO: 664)

Example 11: Fusion protein comprising a domain of FGF10 fused to an AAM moiety

25 In some embodiments, the Surf+ Penetrating Polypeptide is a domain of
 FGF10 having surface positive charge, an overall net positive charge, and a
 charge/molecular weight ratio greater than that of full length, unprocessed, naturally
 occurring FGF10. An exemplary AAM moiety which can be fused to the Surf+
 Penetrating Polypeptide is an scFv. In such a fusion protein, the FGF10 portion may
 30 be N- or C-terminal to the AAM moiety.

The fusion proteins optionally include a linker that interconnects the FGF10
 portion to the AAM moiety. Suitable linkers include a glycine/serine rich linker.
 When present, the linker may also include a serum-stable proteolytic cleavage site,
 such as a site cleavable by cathepsin class proteases. Cleavable linkers permit the
 35 separation of the AAM moiety from the FGF10 portion following internalization.

The following exemplary fusion protein is generated:

5 Myc-FGF10 portion-GS₁₀-AAM-His₆

Where, for example:

FGF10 portion is a domain of full length, naturally occurring human FGF10;

AAM is the AAM moiety and can be an scFv;

(GS)₁₀ is the linker amino acid sequence “GGGGSGGGGS”;

10 His₆ is the tag “HHHHHH”; and

Myc is the tag “EQKLISEEDL”.

The fusion protein is internalized by cells and binds (via the AAM moiety) to the target of interest. The fusion protein is studied in vitro and/or in vivo, such as using assays described herein.

15 An exemplary fusion protein is a fusion protein made by fusing a domain of FGF10 to a scFv specific for huntingtin protein. The fusion protein is tagged on the N-terminus with a Myc tag and on the C-terminus with a His₆ tag. A control lacking the AAM moiety is also made. The complexes can be represented as:

- Myc-FGF10-His₆
- 20 • Myc-FGF10-GS₁₀-C4-His₆

where “FGF10” denotes the domain of FGF10, “C4” denotes the particular AAM moiety used in this example, as described above; and GS₁₀ denotes the linker (also known as (G₄S)₂ used to link the FGF10 portion to the AAM moiety.

25 In this particular example, the FGF10 portion has the amino acid sequence set forth in SEQ ID NO: 666.

The AAM moiety in this example is an scFv specific for huntingtin protein. This scFv, denoted “C4”, targets the first 17 amino acids of huntingtin protein and has been demonstrated to delay the aggregation phenotype when the gene is delivered in adeno-associated viral vectors (AAV2/1) in mice (J Neuropathol Exp Neurol. 2010.
30 69(10):1078-1085).

Experiments are conducted to demonstrate that the complex Myc-FGF10-GS₁₀-C4-His₆ can be effectively delivered into cells and disrupt aggregation of mHTT. The experimental procedure is as outlined above.

5

Example 12: Fusion protein comprising a variant domain of FGF10 fused to an AAM moiety

A fusion protein is made by fusing a variant domain of FGF10 having one or more amino acid additions, deletions, or substitutions relative to the naturally occurring domain, to an AAM moiety. The complex is tagged on the N-terminus with a Myc tag and on the C-terminus with a His₆ tag. A control lacking the AAM moiety is also made. The complexes can be represented as:

- Myc-FGF10(mut4)-His₆
 - Myc-FGF10(mut4)-GS₁₀-C4-His₆
- where “FGF10(mut4)” denotes the variant domain of FGF10, “C4” denotes the particular AAM moiety used in this example; and GS₁₀ denotes the linker used to link the variant FGF10 portion to the AAM moiety.

In this particular example, the variant FGF10 portion has the amino acid sequence set forth in SEQ ID NO: 667. This variant FGF10 portion has been modified to minimize mitogenic effects and includes the following mutations: R78A/T114R/E158A/K195A. See e.g., Yeh et al. PNAS (2003) 100:2266-71; Ibrahimi et al. Mol Cell Biol. (2005) 25:671-84; and Wang et al. Cytokine (2010) 49:338-43. The amino acid sequence for the FGF10(mut4)-scFv fusion protein (Myc-FGF10(mut4)-GS₁₀-C4-His₆) is set forth in SEQ ID NO: 668. The amino acid sequence of the control complex (Myc-FGF10(mut4)-His₆) is set forth in SEQ ID NO: 669.

The AAM moiety in this example is an scFv specific for huntingtin protein. This scFv, denoted “C4”, targets the first 17 amino acids of huntingtin protein and has been demonstrated to delay the aggregation phenotype when the gene is delivered in adeno-associated viral vectors (AAV2/1) in mice (J Neuropathol Exp Neurol. 2010. 69(10):1078-1085).

Experiments are conducted to demonstrate that the complex Myc-FGF10(mut4)-GS₁₀-C4-His₆ can be effectively delivered into cells and disrupt aggregation of mHTT. Experiments for evaluating activity of the fusion protein are as outlined above.

5

Myc-FGF10(mut4)-His6

MEQKLISEEDLGSGRHVRSYNHLQGDVAWRKLFSFTKYFLKIEKNGKVSG
 TKKENCPYSILEIRSVEIGVVAVKAINSNYLAMNKKGKLYGSKEFNDC
 KLKERIEANGYNTYASFNWQHNGRQMYVALNGKGAPRRGQKTRRANTS
 10 AHFLPMVVHSGHGHGHHHHH (SEQ ID NO: 669)

Myc-FGF10(mut4)-GS10-C4_scFv-His6

MEQKLISEEDLGSGRHVRSYNHLQGDVAWRKLFSFTKYFLKIEKNGKVSG
 TKKENCPYSILEIRSVEIGVVAVKAINSNYLAMNKKGKLYGSKEFNDC
 15 KLKERIEANGYNTYASFNWQHNGRQMYVALNGKGAPRRGQKTRRANTS
 AHFLPMVVHSGHGGGGSGGGGSQVQLQESGGGLVQPGGSLRLSCAASGF
 TFSSYSMSWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNK
 NTLYLQMNSLRAEDTAVYYCARDRYFDLWGRGTLVTVSSGGGGSGGGG
 SGGGGSQSALTQPASVSGSPGQSITISCTGTSSDIGAYNYVSWYQQYPGKA
 20 PKLLIYDVSNRPSGISNRFSGSKSGDTASLTISGLQAEDEADYYCSSFANSG
 PLFGGGTKVTVLGGHGHGHHHHH (SEQ ID NO: 668)

SEQUENCE LISTING INFORMATION

25 The following sequence information is intended to provide a detailed description for
 the amino acid sequences referenced in Figures 1 and 2 by GenBank accession
 number and/or PDB identifier. As such, all such sequence information should be
 considered part of the detailed description of the invention and provides additional
 description for Surf+ Penetrating Polypeptides, as well as polypeptides suitable for
 30 use as a portion of a complex comprising a Surf+ Penetrating Polypeptide.

The disclosure contemplates complexes comprising an amino acid sequence
 selected from amongst any of the amino acid sequences provided in this sequence
 listing, as well as functional fragments thereof (e.g., domains thereof having surface
 positive charge, a mass of at least 4 kDa, a charge/molecular weight ratio of at least
 35 0.75). Such polypeptides are suitable for use in complexes of the disclosure.
 Moreover, in certain embodiments, complexes of the disclosure comprise an amino

- 5 acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any of the foregoing.

Section 1 of Sequence Listing: Amino acid sequence information for full length sequences referenced by GenBank accession number in Figures 1 and 2.

10

**AMINO ACID SEQUENCE INFORMATION DISCLOSED IN GENBANK
FOR NATURALLY OCCURRING PROTEINS IDENTIFIED BY GENBANK
ACCESSION NUMBER IN FIGURE 1**

15

NP_001184033.1 histone-lysine N-methyltransferase MLL isoform 1 precursor
 MAHSCRWRFPARPGTTGGGGGGGRRGLGGAPRQRPALLLPVGGGGPGAPPSPPAVA
 AAAAAAGSSGAGVPGGAAAASAASSSSASSSSSSSSASSGPALLRVGPGFDAALQVSAAGT
 20 NLRFRFRAVFGESGGGGGSGEDEQFLGFGSDEEVRVRSPTSPSVKTSRKPGRGRPSGSDRNS
 AILSDPSVFSPLNKSETKSGDKIKKKDSKSIEKKRGRPPTFPGVKIKITHGKDISELPKGNKEDS
 LKKIKRTPSATFQQATKIKKLKLAGKLSPLKSKFKTGKLGKGRGVQIVRRRGRPPSTERIKTPS
 GLLINSELEKPQKVRKDKEGTPPLTKEDKTVVRQSPRRIKPVRIIPSSKRTDATIAKQLLQRAK
 KGAQKKIEKEAAQLQGRKVKTQVKNIRQFIMPVVSASSRIKTPRRFIEDEDYDPPIKIARLES
 25 TPNSRFSAPSCGSSEKSSAASQHSQMSDSSRSSPSVDTSTDSQASEEIQVLPEERSDTPEVH
 PPLPISQSPENESNDRRSRRYSVSERSFGSRTTKKLSTLQSAPQQQTSSSPPPPLTPPPPLQPAS
 SISDHTPWLMPTIPLASPFLPASTAPMQGKRKSILREPTFRWTSKHSRSEPQYFSSAKYAKE
 GLIRKPIFDNFRPPPLTPEDVGFASGFSASGTAASARLFSPLHSGTRFDMHKRSPLLRAPRFTPS
 EAHSRIFESVTLPSNRTSAGTSSSGVSNRKRKRKFVSPIRSEPRSPSHSMRTRSGRLSSSELSPLT
 30 PPSSVSSSLSISVSPLATSALNPTFTFSPSHSLTQSGESAENQRPRKQTSAPAEFSSSSPTPLFP
 WFTPGSQTERGRNKDKAPEELSKDRDADKSVEKDKSRERDREREKENKRESRKEKRKKKGSE
 IQSSSALYPVGRVSKEKVVGEDVATSSSAKKATGRKKSSSHDSGTDITSVTLGDTTAVKTKIL
 IKKGRGNLEKTNLDLGPTAPSLEKEKTLCLSTPSSSTVKHSTSSIGSMLAQADKLPMTDKRVA
 SLLKKAKAQLCKIEKSKSLKQTDQPKAQQQESDSSETSVRGPRIKHVCRRAAVALGRKRAVF
 35 PDDMPTLSALPWEEREKILSSMGNDDKSSIAGSEDAEPLAPPIKPIKPVTRNKAPQEPPVKKGR
 RSRRCGQCPCGQVPEDCGVCTNCLDKPKFGGRNIKKQCKMRKCQNQLQWMPSKAYLQKQ
 AKAVKKKEKKSKTSEKKDSKESSVVKNVVDSSQKPTPSAREDPAKKSSSEPPPRKPVEEKS
 EEGNVSAPGPESKQATTPASRKSSKQVSQPALVIPPPQPTTGPPRKEVPKTTTPSEPKKKQPPPP
 ESGPEQSKQKKVAPRPSIPVKQKPKEKEKPPPVNKKQENAGTLNLSLNGNSSKQKIPADGV
 40 HRIRVDFKEDCEAENVWEMGGLGILTSVPITPRVVCFLCASSGHVEFVYCQVCCEPFHKFCLE
 ENERPLEDQLENWCCRCKFCHVCGRQHQAQTKQLLECNKCRNSYHPECLGPNYPTKPTKKK
 KVIWICKCVRCKSCGSTTPGKGWDAQWHDHSLCHDCAKLFAKGNFCPLCDKCYDDDDYE
 SKMMQCGKCDRWVHVKCENLSGTEDEMYEILSNLPESVAYTCVNCTERHPAEWRLALEKE
 LQISLKQVLTALLNSRTTSHLLRYRQAAKPPDLNPETEESIPSRSSPEGPDPPVLTEVSKQDDQ
 45 QPLDLEGVKKRMDQGNYSVLEFSDDIVKIIQAAINSDDGGQPEIKKANSMVKSFFIRQMERVF
 PWFSVKKSRFWEPNKKVSSNSGMLPNAVLPPSLDHNYAQWQEREENSHTEQPPLMKKIIPAPK
 PKGPGEPDSPTPLHPPTPPILSTDRSREDSPELNPPPGIEDNRQCALCLTYGDDSDANDAGRLLYI
 GQNEWTHVNCALWSAEVFEDDDGSLKNVHMAVIRGKQLRCEFCQKPGATVGCCLTSCTSN
 YHFMCSRAKNCVFLDDKKVYCQRHRDLIKGEVVPENGFEVFRRVFVDFEGISLRRKFLNGLE
 50 PENIHMMIGSMTIDCLGILNDLSDCEDKLFPIGYQCSR VYWSTTDARKRCVYTCKIVECRPPV
 VEPDINSTVEHDENRTIAHSPTSFTSSSKESQNTAEIISPPSPDRPPHSQTS GSCYYHVISKVPRI
 RTPSYSPTQRSPGCRPLPSAGSPTPTTHEIVTVGDPLLSSGLRSIGSRRHSTSSLSPQRSKLRIMS

5 PMRTGNTYSRNNVSSVSTTGTATDLESSAKVVDHVLGPLNSSTSLGQNTSTSSNLQRTVVTV
 GNKNSHLDGSSSSEMKQSSASDLVSKSSSLKGEKTKVLSSKSSEGSAGHNVAYPGIPKLAPQV
 HNTTSRELVNLSKIGSFAEPSSVSFSSKEALSFPHLHLRGQRNDRDQHTDSTQSANSSPDEDTEV
 KTLKLSGMSNRSSIINEHMGSSSRDRRQKGKKCKETFKHSSKSFLEPGQVTTGEEGNLKP
 EFMDEVLTPEYMGQRPCNNVSSDKIGDKGLSMPGVPKAPPMQVEGSAKELQAPRKRTVKVT
 10 LTPLKMENESQSKNALKESSPASPLQIESTSPTEPISASENPGDGPVAQPSPNNTSCQDSQSN
 YQNLVPQDRNLMLPDGPKPQEDGSFKRRYPRRSARARSNMFFGLTPLYGVRSYGEEDIPFYS
 SSTGKKRGKRSAGQVDGADDLSTSDDDLYYNFRTRTVISSGGEERLASHNLFREEEQCDL
 PKISQLDGVDDGTESDTSVTATTRKSSQIPKRNGKENGTEENLKIDRPEDAGEKEHVTKSSVGH
 KNEPKMDNCHSVSRVKTQGQDSLEAQLSSLESSRRVHTSTPSDKNLLDTYNTELLKSDSDNN
 15 NSDDCGNILPSDIMDFVLKNTPSMQALGESPESSSSSELLNLGEGGLDLSNREKDMGLFEVFSQ
 QLPTTEPVDSSVSSSISAEQFELPLELPDLSVLTTSPVPSQNPSRLAVISDSGEKRVITTEK
 SVASSESDPALLSPGVDPTPEGHMTDPHFIIQGHMDADHISSPPCGSVEQGHGNNQDLTRNSST
 PGLQVPVSPTVPIONQKYVPNSTDSPGPSQISNAAVQTTPPHLKPATEKLIVVNQNMQPLYVL
 QTLPNGVTQKIQLTSSVSSTPSVMETNTSVLGPMGGGLTTLTGLNPSLPTSQSLFPSASKGLLP
 20 MSHHQHLHSFPAATQSSFPNINPPSGLLIGVQPPDPQLLVSESSQRTDLSTTVATPSSGLKK
 RPISRLQTRKNKKLAPSSTPSNIAPSDVVSNMTLINFTPSQLPNHPSLLDLGSLNTSSHRTVPNII
 KRSKSSIMYFEPAPLLPQSVGGTAATAAGTSTISQDTSHLTSGSVSGLASSSSVLNVVSMQTTT
 TPTSSASVPGHVTLTNPRLLGTPDIGSISNLLIKASQQSLGIQDQPVALPPSSGMFPQLGTSQTP
 STAAITAASSICVLPSTQTTGITAASPSGEADEHYQLQHVNQLLASKTGIHSSQRDLDSASGPQ
 25 VSNFTQTVDA PNSMGLEQNKALSSAVQASPTSPGGSPSSPSSGQRSASPSVPGPTKPKPKTKR
 FQLPLDKGNGKKHKVSHLRTSSSEAHIPDQETTSLSGTGTPGAEEQQTASVEQSSQKEC
 GQPAGQVAVLPEVQVTQNPANEQESAEPKTVEEEESNFSSPLMLWLQQEQKRKESITEKKPK
 KGLVFEISSDDGFQICAESIEDAWKSLTDKVQEARSNARLKQLSFAGVNGLRMLGILHDAVV
 FLIEQLSGAKHCRNYKFRFHKPEEANEPLNPHGSARAEVHLRKSADFDMFNFLASKHRQPPE
 30 YNPNDDEEEEVQLKSARRATSM DLPMRFRHLK KTSKEAVGVYRSPIHGRGLFCKRNIDA
 GEMVIEYAGNVIRSIQTDKREKYYDSKGIGCYMFRIDDSEVV DATMHGNAARFINHSCEPNC
 YSRVINIDGQKHIVIFAMRKIYRGEELTYDYKFPIEDASNKLPCNCGAKKCRKFLN (SEQ ID
 NO: 1)

35 NP_002219.1 transcription factor AP-1
 MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSM TLNLADPVGSLKPHLRKNSDLLT
 SPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAEHSQNT
 LPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFPNGALSSGGGA
 PSYGAAGLAFPAQPQQQQPPHLPQQMPVQH PRLQALKEEPQTVPEMPGETPPLSPIDMES
 40 QERIKAEKRMRNRRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQ
 KVMNHVNSGCQLMLTQQQLQTF (SEQ ID NO: 2)

NP_006063.1 C-C motif chemokine 26 precursor
 MMGLSLASAVLLASLLSLHLGTATRGSDISKTC CFQYSHKPLPWTWVRSYEFTSNSCSQR
 45 AVIFTTKRGKKVCTHPRKKWVQKYISLLKTPKQL (SEQ ID NO: 3)

NP_001936.1 proheparin-binding EGF-like growth factor precursor
 MKLLPSVVLKLFLAAVLSALVTGESLERLRRLAAGTSNPDPPTVSTDQLLPLGGGRDRKVR
 DLQEADLDLLRVTLSSKPQALATPNKEEHGKRKKKGKGLGKKRDPCLRKYKDFCIHGECKY
 50 VKELRAPSCICHPGYHGERCHGLSLPVENRLYTYDHTTILAVVAVVLSSVCLLVIVGLLMFR
 YHRRGGYDVENEKVKLGMTNSH (SEQ ID NO: 4)

NP_003463.1 protein DEK isoform 1
 MSASAPAAEGEGTPTQPA SEKEPEMPGPREESEEEEEDEDEEEEEEEKEKSLIVEGKREKKKV
 55 ERLTMQVSSLQREPFTIAQGGKQKLCEIERIHFFLSKKKTDELRLNLHKLLYNRP GTVSSLKKN
 VGQFSGFPFEKGSVQYKKKEEMLKKFRNAMLKSICEVLDLERSGVNSELVKRILNFLMHPKP

- 5 SGKPLPKSKKTCSTGSGSKKERNSSGMARKAKRTKCPEILSDESSSDEDEKKNKEESSDDEDKES
EEPPPKKTAKREKPKQKATSKSKKSVKSANVKKADSSTTKKNQNSSKKESESEDSSDDEPLI
KKLKKPPTDEELKETIKKLLASANLEEVMTKQICKKVYENYPTYDLTERKDFIKTTVKELIS
(SEQ ID NO: 5)
- 10 NP_000592.3 hepatocyte growth factor isoform 1 preproprotein
MWVTKLLPALLLQHVLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIK
TKKVNTADQCANRCTRNGKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYE
NKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEE
GGPWCFTSNPEVRYEVCIPQCSEVECMTNCGESYRGLMDHTESGKICQRWDHQTTPHRHKF
15 LPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCADNTMNDTDVPLETTECI
QQQGEgyRGTVNTIWNIGIPCQRWDSQYPHEHDMTPENFKCKDLRENYCRNPDGSESPWCFT
TDPNIRVGYCSQIPNCDMSHGQDCYRGNGKNYMGNLSQTRSGLTCSMWDKNMEDLHRHIF
WEPDASKLNENYCRNPDDDAHGPWCYTGNPLIPWDYCPISRCEGDTTPTIVNLDHPVISCAL
TKQLRVVNGIPTRTNIGWMVSLRYRNKHICGGLIKESWVLTARQCFPSRDLKDYEAWLGIH
20 DVHGRGDEKCKQVLNVSQLVYGPEGSDLVLMKLARPAVLDDFVSTIDLPNYGCTIPEKTSCS
VYGWGYTGLINYDGLLRVAHLYIMGNEKCSQHHRGKVTLNESEICAGAEKIGSGPCEGDYD
GPLVCEQHKKMRMVLGVIVPGRGCAIPNRPGIFVRVAYYAKWIKIILTYKVPQS (SEQ ID
NO: 6)
- 25 NP_001075020.1 beta-defensin 103 precursor
MRIHYLLFALLFLFLVPVPGHGGIINTLQKYYCRVRGGRCVLSCLPKEEQIGKCSTRGR
KCCRRKK (SEQ ID NO: 7)
- NP_078884.2 Endonuclease VIII-like 1
30 MPEGPHELHLASQFVNEACRALVFGGCVEKSSVSRNPEVPFESSAYRISASARGKELRLIL
SPLPGAQPQQEPLALVFRFGMSGFQLVPREELPRHAHLRFYTAPPGPRLALCFVDIRRF
GRWDLGGKWQPGRGPCVLQEYQQFRENVLRLNADKAFDRPICEALLDQRFENGIGNYLRAE
ILYRLKIPPFKARSVLEALQQHRPSPELTLSQKIRTKLQNPDLLELCHSVPKEVVQLGGKGY
GSESGEEDFAAFRAWLRCYGMPSLQDRHGRTIWFQGDPLAPKGRKSRKKKSKATQL
35 SPEDRVEDALPPSKAPSRTRAKRDLPKRTATQRPEGTSLQQDPEAPTVPKKGRRKGRQAAS
GHCRPRKVKADIPSLEPEGTSAS (SEQ ID NO: 8)
- NP_061820.1 cytochrome c
40 MGDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKTGQAPGYSYTAANKNKGIIW
GEDTLMEYLENPKKYIPGTMIFVGIIKKKEERADLIAYLKATNE (SEQ ID NO: 9)
- NP_004456.1 fibroblast growth factor 10 precursor
MWKWILTHCASAAPHLPGCCCCFLLLFLVSSVPVTCQALGQDMVSPEATNSSSSSFSSP
SSAGRHVRSYNHLQGDVRWRKLFSFTKYFLKIEKNGKVSGTKKENCYPYSILEITSVEIGV
45 VAVKAINSNNYLLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVA
LNGKGAPRRGQKTRRKNTSAHFLPMVVHS (SEQ ID NO: 10)
- NP_002982.2 C-C motif chemokine 24 precursor
MAGLMTIVTSLFLGVCAHHIPTGSVVIPSPCCMFFVSKRIPENRVVSYQLSSRSTCLK
50 AGVIFTTKKGQQFCGDPKQEWVQRYMKNLDAKQKKASPRARAVAVKGPVQRYPGNQTTTC
(SEQ ID NO: 11)
- NP_003125.3 signal recognition particle 14 kDa protein
55 MVLLESEQFLTELTRLFQKCRTSVYITLKKYDGRTKPIPKKGTVEGFEPADNKCLLRA
TDGKKKISTVVSSKEVNKFQMAYSNLLRANMDGLKKRDKKNKTKKTKAAAAAAAAPAA
AATAPTTAATTAATAAQ (SEQ ID NO: 12)

5

NP_005219.2 epidermal growth factor receptor isoform a precursor

MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVV
 LGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLNLQIIRGNMYEYNSYALAVLSN
 YDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLS
 10 CQKCDPSCPNGSCWGAGEENCQKLTIIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRES
 CLVCRKFRDEATCKDTCPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSC
 VRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSSISGDLH
 ILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQ
 FSLAVVSLNITSLGLRSLKEISDGDVHISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSC
 15 KATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPPREFVENSECQCHPE
 CLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCAPAGVMGENNTLVWKYADAGHVCHLCH
 PNCTYGCTGPGLEGCPNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRLRLQ
 ERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELR
 EATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGS
 20 QYLLNWCVQIAKGMNYLEDRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHA
 EGGKVPIKWMALLESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLP
 QPPICTIDVYIMVVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNF
 YRALMDEEDMDDVVDADAYLIPQQGFFSSPSTSRTPLLSSLATSNNSTVACIDRNLQSCPI
 KEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDP
 25 HYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAKGSHQISLDNPDYQQDFFPKEAKPN
 GIFKGSTAENAEYLRVAPQSSEFIGA (SEQ ID NO: 13)

NP_004878.2 C-X-C motif chemokine 14 precursor

MSLLPRRAPPVSMRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYP
 30 HCEEKMVIITTKSVSRYRGQEHCLHPKLQSTKRFIKWYNWNEKRRVYEE (SEQ ID NO: 14)

NP_004505.2 forkhead box protein K2

MAAAAAALSGAGTPPAGGGAGGGGAGGGGSPGGWAVARLEGREFEYLMKKRSVTIGRNS
 SQGSVDVSMGHSSFISRRHLEIFTPPGGGGHGGAAPELPPAQPRPDAGGDFYLRCLGKNGVF
 35 VDGVFQRRGAPPLQLPRVCTFRFPSTNIKITFTALSSEKREKQEASESPVKAVQPHISPLTINIP
 DTMAHLISPLPSPTGTISAANSCSPSRGAGSSGYKVGRVMPSDLNLMADNSQPENEKEASG
 GDSPKDDSKPPYSYAQLIVQAITMAPDKQLTLNGIYTHITKNYPYRTADKGWQNSIRHNL
 LNRYFIKVPRSQEEP GKGSFWRIDPASESKLIEQAFRRRPRGVPCFRTPLGPLSSRSAPASN
 HAGVLSAHSSGAQTPELSREGSPAPLEPEPGAAQPKLAVIQEARFAQSAPGSPLSSQPVLITV
 40 QRQLPQAIKPVITYTVATPVTSTSTQPPVVQTVHVHQPAPVSVTSVAGLAPANTYTVSGQAV
 VTPAAVLAPPKAEAQENGHDHREVKKVVEPIPAIGHATLGTA SRIQTAQTTPVQTVTIVQQAP
 LGQHQLPIKTVTQNGTHVASVPTAVHGVNNAASPLHMLATHASASASLPTKRHNGDQPE
 QPELKRIKTEDGEGIVIALSVDTPPAAVREKGVQN (SEQ ID NO: 15)

45 NP_060362.3 pre-mRNA-processing factor 40 homolog A

MCSGSGRRRSSLSPTRPGTGAERGGLMMGHPGMHYAPMGMHPMGQRANMPPVPHGMM
 PQMMPPMGPPMGQMPGMMSSVMPGMMMSHMSQASMQPALPPGVNSMDVAAGTASGA
 KSMWTEHKSPDGRTYYNTETKQSTWEKPDDLKTPAEQLLSKCPWKEYKSDSGKPYYNS
 QTKESRWAKPKELEDLEGYQNTIVAGSLITKSNLHAMIKAEESKQEECTTTSTAPVPTTEIPT
 50 TMSTMAAAEAAA AVVAAAAAANANASTSASNTVSGTVPVPEPEVTSIVATVV
 DNENTVTISTEEQAQLTSTPAIQDQSVEVSSNTGEETSKQETVADFTPKKEEEESQPAKKTYT
 WNTKEEAKQAFKELLKEKRVPSNASWEQAMKMIINDPRYSALAKLSEKKQAFNAYKVQTE
 KEEKEEARSKYKEAKESFQRFLNHEKMTSTTRYKKAEQMFGEMEVWNAISERDRLEIYED
 VLFFLSKKEKEQAKQLRKRNWEALKNILDNMANVTYSTTWSEAQQYLMNDNPTFAEDEELQ
 55 NMDKEDALICFEEHIRALEKEEEEEKQKSLRERRRQRKNRESFQIFLDELHEHGQLHSMSSW
 MELYPTISSDIRFTNMLGQPGSTALDLFKFYVEDLKARYHDEKKIHKDILKDKGFVVEVNTTF

- 5 EDFVAIISSTKRSTTLDAGNIKLAFNSLLEKAEAREREREKEEARKMKRKESAFKSMLKQAAP
PIELDAVWEDIRERFVKEPAFEDITLESERKRIFKDFMHVLEHECQHHSKNKKHKKKSKKH
HRKRSRSGSDSDDDSHSKKKRQRSESRASEHSSSAESERSYKKSKKHKKKSKKRRHKS
DSPESDAEREKDKKEKDRESEKDRTRQRSESKHKSPKKKTGKDSGNWDTSGSELSEGELEKR
RRTLLEQLDDDQ (SEQ ID NO: 16)
- 10 NP_004166.1 small nuclear ribonucleoprotein Sm D3
MSIGVPIKVLHEAEGHIVTCETNTGEVYRGKLI EAEDNMNCQMSNITVTYRDGRVAQLEQVY
IRGSKIRFLILPDMLKNAPMLKSMKNKNQGSGAGRGKAAILKAQVAARGRGRGMGRGNIFQ
KRR (SEQ ID NO: 17)
- 15 NP_000324.1 ataxin-7 isoform a
MSERAADDVRGEPRRAAAAAGGAAAAAARQQQQQQQQQQPPPPQPQRQQHPPPPRRTRP
EDGGPGAASTSAAAMATVGERRPLPSPEVMLGQSWNLWVEASKLPGKDGTDELDESFKFEGK
NREVMGLCREDMPIFGFCPAHDDFYLVVCNDCNQVVKPQAFQSHYERRHSSSSKPPPLAVPPT
20 SVFSFFPSLSKSKGGSASGSNRSSSGGVLSASSSSSKLLKSPKEKLQLRGNTRPMHPIQQSRVP
HGRIMTPSVKVEKIHPPKMDGTLLKSAVGPTCPATVSSLVKPGLNCPSIPKPTLPSPGQILNGKG
LPAPPTLEKKPEDNSNNRKFLNKRLSEREFDPDIHCGVIDLDTKKPCTRSLTCKTHSLTQRRRA
VQGRRKRFDVLLAEHKNKTREKELIRHPDSQQPPQPLRDPHPAPPRTSQEPHQNPBGVIPSES
KPFVASKPKPHTPSLPRPPGCPAQGGGSAPIDPPPVHESPHPLPATEPASRLSSEEGEGDDKEE
25 SVEKLDCHYSGHHPQPASFCTFGSRQIGRGYYVFDSRWNRRLRCALNLMVEKHLNAQLWKKI
PPVPSTTSPISTRIPHRTNSVPTSQCGVSYLAAATVSTSPVLLSSTCISPNSKSVPAHGTTLNAQP
AASGAMDPVCSMQSRQVSSSSSSPSTPSGLSSVPSSPMSRKPQKLKSSKSLRPKESSGNSTNC
QNASSSTSGGSGKKRKNSSPLL VHSSSSSSSSSSSSSHSMESFRKNCVAHSGPPYPSTVTSSH SIG
LNCVTNKANAVNVRHDQSGRGPPTGSPAESIKRMSVMVNSSDSTLSLGPFIHQSNELPVNSH
30 GSFHSHTPLDKLIGKKRKCSPPSSSINNSSSKPTKVAKVPVAVNNVHMKHTGTIPGAQGLMNS
SLLHQPKARP (SEQ ID NO: 18)
- NP_057250.1 E3 SUMO-protein ligase PIAS1
MADSAELKQMVMSLRVSELQVLLGYAGRKNKHGRKHELLTKALHLLKAGCSPAVQM KIKEL
35 YRRRFPQKIMTPADLSIPNVHSSPMPATLSPSTIPQLTYDGHPASSPLLVP SLLGPKHELELPHL
TSALHPVHPDIKLQKLPHYDLLDELIKPTSLASDNSQRFRETCFAFALTPQQVQQISSSMDISGT
KCDFTVQVQLRFCLSETSCPQEDHFPPNLCVKVNTKPCSLPGYLPPTKNGVEPKRPSRPINIT
LVRLSTTVPN TIVVSWTAEIGRNY SMAVYLVKQLSSTVLLQRLRAKGIRNP DHSRALIKEKLT
ADPDSEIATTS LRVSLLCPLGKMRLTIPCRALTC SHLQCFDATLYIQMNEKKPTWVCPVCDK
40 KAPYEHLIIDGLFMEILKYCTDCDEIQFKEDGTWAPMR SKKEVQEVSASYNGVDGCLSSTLE
HQVASHHQSSNKNKKVEVIDLTIDSSSDEEEEEPSAKRTCPSLSPTSPLNNKGILSLPHQASPV
SRTPSLPAVDTSYINTSLIQDYRHPFHMTMPYDLQGLDFFPFLSGDNQHYNTSLLAAAAAA
VSDDQDLLHSSRFFPYTSSQMFLDQLSAGGSTSLPTTNGSSSGSNSSLVSSNSLRESHSHTVTN
RSTDTASIFGIIPDIISLD (SEQ ID NO: 19)
- 45 NP_002610.1 platelet factor 4 precursor
MSSAAGFCASRPGLLFLGLLLLPLVVAFAFAEAEEDGDLQCLCVKTTSQVRPRHITSLEV
IKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKI IKKLLS (SEQ ID NO: 20)
- 50 NP_001193858.1 advanced glycosylation end product-specific receptor isoform 2 precursor
MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEA
WKVLS PQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKS NYRVRVYQIP
GKPEIVDSASELTAGVPNKVVEESRRSRKRPCEQEVGTCVSEGSYPAGTLSWHLDGKPLVPN
EKGVS VKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVW
55 EPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHW MKDGVPLPLPPSPVLILPEIGPQ

5 DQGTYSVCVATHSSHGPQESRAVSISIIPEGEEGPTAGSVGGSSGLGTLALALGILGGLGTAALLI
GVILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP (SEQ ID NO: 21)

NP_006110.1 fibroblast growth factor 8 isoform B precursor

10 MGSPRSALSCLLLHLLVLCLQAQVTVQSSPNFTQHVREQSLVTDQLSRRLIRTYQLYSRT
SGKHVQVLANKRINAMAEDGDPFAKLIVETDTFGSRVRVRGAETGLYICMNKKGKLIASN
GKGKDCVFTEIVLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQHQRREVHFMKRLPRG
HHTTEQSLRFEFLNYPPFTRSLRGSQRTWAPEPR (SEQ ID NO: 22)

NP_004590.2 sterol regulatory element-binding protein 2

15 MDDSGELGGLETMETLTELGDELTLGDIDEMLQFVSNQVGEFPDLFSEQLCSSFPGSGGSGSS
SGSSGSSSSSSNGRGSSSGAVDPSVQRSFTQVTLPSFSPSAASPQAPTLQVKVSPTSVPSTTPRAT
PILQPRPQPQPQTQLQQQTVMITPTFSTTPQTRIIQQPLIYQNAATSFQVLQPQVQSLVTSSQ
VQPVTIQQQVQTVQAQRVLTQTANGTLQTLAPATVQTVAAPQVQQVPVLVQPQIIKTDSLVL
TTLKTDGSPVMAAVQNPALTALTTPITQTAALQVPTLVGSSGTILTTMPVMMGQEKVPIKQVP
20 GGVKQLEPPKEGERRTTHNIIKRYRSSINDKIIELKDLVMGTDAMHKSGVLRKAIDYIKYL
QQVNHKLRQENMVLKLANQKNKLLKGIDLGSLVDNEVDLKIEDFNQNVLLMSPPASDSGSQ
AGFSPYSIDSEPGSPLLDDAKVKDEPDSPVALGMVDRSRILLCVLTFLCLSFNPLTSLLQWG
GAHDSQHPHSGSGRSVLSFESGSGGWFDWMMPTLLLWLNVGVIVLSVFVKLLVHGEPVIR
PHSRSSVTFWRHRKQADLDLARGDFAAAAGNLQTCLAVLGRALPTSRLDLACSLSWNVIRY
25 SLQKLRLVRWLLKKVFQCRATPATEAGFEDEAKTSARDAALAYHRLHQLHITGKLPAGSA
CSDVHMALCAVNLAECAEEKIPPSTLVEIHLTAAMGLKTRCGGKLGFLASYFLSRAQSLCGP
EHSAPVPSLRWLCHPLGQKFFMERSWSVKSAAKESLYCAQRNPADPIAQVHQAFCKNLLER
AIESLVKPKQAKKKAGDQEEESCEFSALYLLHSFVDSVGVMSPPLSRSSVLKSALGPDIIIC
RWWTSAITVAISWLQGDDAAVRSHFTKVERIPKALEVTESPLVKAIFHACRAMHASLPGKAD
30 GQSSSFCHCERASGHLWSSLNVSGATSDPALNHVVQLLTCDLLSLRTALWQKQASASQAV
GETYHASGAELAGFQRDLGSLRRLAHSFRPAYRKVFLHEATVRLMAGASPTRTHQLLEHSL
RRRTTQSTKHGEVDAWPGQRERATAILLACRHLPLSFLSSPGQRAVLLAEAARTLEKVGDRR
SCNDCQQMIVKLGGGTAAIAAS (SEQ ID NO: 23)

35 NP_078867.2 charged multivesicular body protein 6

MGNLFGRKKQSRVTEQDKAILQLKQQRDKLRQYQKRIAQQLERERALARQLLRDGRKERA
KLLLKKKRYQEQLLDRTENQISSLEAMVQSIEFTQIEMKVMGLQFGNECLNKMHVMSIEE
VERILDETQEA VEYQRQIDELLAGSFTQEDEDAILLELSAITQEQIELPEVPSEPLPE
KIPENVPVKARPRQAEVAAS (SEQ ID NO: 24)

40

NP_001029058.1 stromal cell-derived factor 1 isoform gamma

MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVAR
LKNNNRQVCIDPKLKWIEYLEKALNKGRREEKVGKKEKIGKKKRQKKRKAQAQKRKN
(SEQ ID NO: 25)

45

NP_001420.2 histone acetyltransferase p300

MAENVVEPGPPSAKRPKLSSPALSASASDGTDFGSLFDLEHDLDELINSTEGLTNGGD
INQLQTS LGMVQDAASKHKQLSELLRSGSSPNLNMGVGGPGQVMASQAQQSSPGLGLINSM
VKSPMTQAGLTSPNMGMGTSGPNQGPTQSTGMMNSPVNQPAMGMNTGMNAGMNPGLMA
50 AGNGQGIMPVNQVMNGSIGAGRGRQNMQYPNPGMGSAGNLLTEPLQQGSPQMGGQTGLRG
PQPLKMGMNNPNPYGSPYTQNPGQQIGASGLGLQIQTKTVLSNNLSPFAMDKKAVPGGG
MPNMGQQPAPQVQQPGLVTPVAQGMGSGAHTADPEKRKLIQQQLVLLHAHKCQRREQA
NGEVRQCNLPHCRTMKNVLNHMTHCQSGKSCQVAHCASSRQIISHWKNCTRHDPCVCLPL
KNAGDKRNQQPILTGAPVGLGNPSSLGVGQQSAPNLSTVSQIDPSSIERAYAALGLPYQVNQ
55 MPTQPQVQAKNQNNQQPGQSPQGMRPMSNMSASPMGVNGGVGVQTPSLLSDSMLHSAINS
QNPMMSENASVPSLGPMPTAAQPSTTGIRKQWHEDITQDLRNHLVHKLVAIFPTPDPAALK

5 DRRMENLVAYARKVEGDMYESANNRAEYYHLLAEKIYKIQKELEEKRRTRLQKQNMLPNA
 AGMVPVSMNPGPNMGQPQPGMTSNGPLPDPSMIRGSVPNQMMPRITPQSGLNQFGQMSMA
 QPPIVPRQTPPLQHHGQLAQPGALNPPMGYGPRMQQPSNQGQFLPQTQFPSQGMNVTNIPLA
 PSSGQAPVSQAQMSSSSCPVNSPIMPPGSQGSIIHCPQLPQPALHQNSPSPVPSRTPTPHHTPPS
 IGAQQPPATTIPAPVPTPPAMPPGPQSQUALHPPPRQTPTPTTQLPQQVQPSLPAAPSADQPQQ
 10 QPRSQQSTAASVPTPTAPLLPPQPATPLSQPAVSIEGQVSNPPSTSSTEVSQAIAEKQPSQEVK
 MEAKMEVDQPEPADTQPEDISESKVEDCKMESTETEERSTELKTEIKEEEDQPSTSATQSSPA
 PGQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPLLGIPDYFDIVKSPMDLSTIKR
 KLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCC
 GRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRHYHCEKCFNEIQGESVSLGDDPSQPQTIN
 15 KEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIWPAGFVCDGCLKKSARTRKENKFS
 AKRLPSTRLGTFLENRVNDLRRQNHPESEVTVRVVHASDKTVEVKPGMKARFVDSGEMA
 ESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDVHFFRPKCLRTAV
 YHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAV
 SERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEEERKREENTSNESTD
 20 VTKGDSKNAKKKNNKTSKNKSSLSRGNKKKPGMPNVSNLDSQKLYATMEKHKEVFFVIR
 LIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTARDKHLEFSSLRRAQWSTMCMLVELHTQS
 QDRFVYTCNECKHHVETRWHCTVCEDYDLCTCYNTKNHDKMEKLGLGLDDESNNQQA
 AATQSPGDSRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICK
 QLIALCCYHAKHCQENKCPVPFCLNIKQKLRQQQLQHRLQQAQMLRRRMASMQRTGVVGQ
 25 QQGLPSPTPATPTTPTGQQPTTPQTPQPTSQPQPTPPNSMPPYLPRTQAAGPVSQGAAGQVT
 PPTPPQTAQPPLPGPPAAVEMAMQIQRAAETQRQMAHVQIFQRPIQHQMPPMTMPMAPMGM
 NPPPMTRGPSGHLEPGMGPTGMQQQPPWSQGGLPQPQQQLQSGMPRPAMMSVAQHGGQPLN
 MAPQPGLGQVGISPLKPGTVSQQALQNLRLTLRSPSSPLQQQQVLSILHANPQLLAAFIKQRA
 AKYANSNPQPIPGQPGMPQGQPGLPPTMPGQQGVHSNPAMQNMNPMQAGVQRAGLPQQ
 30 QPQQQLQPPMGGMSPQAQQMNMNHNTMPSQFRDILRRQQMMQQQQQQGAGPGIGPGMA
 NHNQFQQPQGVGYPPQQQQQRMQHMMQQMQQGNMGQIGQLPQALGAEAGASLQAYQQRL
 LQQQMGSPPVQPNPMSPQQHMLPNQAQSPHLQGGQIPNSLSNQVRSPQPVPSPRPQSQPPHSSP
 SPRMQPQPSPHHVSPQTSSPHPLVAAQANPMEQGHFASPDQNSMLSQLASNPGMANLHGA
 SATDLGLSTDNSDLNSNLSQSTLDIH (SEQ ID NO: 26)

35 NP_004587.1 U1 small nuclear ribonucleoprotein A
 MAVPETRPNHTIYINNLEKIKKDELKKSLEYAIFSQFGQILDILVSRSLKMRGQAFVIFK
 EVSSATNALRSMQGFPPFYDKPMRIQYAKTDSDIIAKMKGTFFVERDRKREKRKPKSQETPATK
 KAVQGGGATPVVGAVQGPVPGMPMTQAPRIMHHMPGQPPYMPPPGMIPPPGLAPGQIPPG
 40 AMPPQQLMPGQMPPAQPLSENPPNHILFTNLPEETNELMLSMLFNQFPGFKEVRLVPGRHDI
 AFVEFDNEVQAGAARDALQGFKITQNNAMKISFAKK (SEQ ID NO: 27)

NP_001191890.1 pre-B-cell leukemia transcription factor 1 isoform 2
 MDEQPRLMHSAGVGMAGHPGLSQHLQDAGGTEGEGGRKQDIGDILQQIMTITDQSLDEA
 45 QARKHALNCHRMKPALFNVLCIEKEKTVLSIRGAQEEPTDPQLMRLDNMLLAEGVAGPEK
 GGSAAAAAAAAAASGGAGSDNSVEHSDYRAKLSQIRQIYHTELEKYEQACNEFTTHVMNLL
 REQSRTRPISPKEIERMVSIIHRKFSSIQMQLKQSTCEAVMILRSRFLDARRKRRNFNKQATEIL
 NEYFYSHLSNPYPSEEAKEELAKKCGITVSQVSNWFGNKRIRYKKNIGKFQEEANIYAAKTA
 VTATNVSAHGSQANSPTPNSAGGYSPCYQPDRIQ (SEQ ID NO: 28)

50 NP_006158.2 homeobox protein Nkx-3.1
 MLRVPEPRPGEAKAEGAAPPTPSKPLTSFLIQDILRDGAQRQGGRTSSQRQRDPEPEPEP
 EPEGGRSRAGAQNQLSTGPRAAPEEAETLAETEPERHLGSYLLDSENTSGALPRLPQTP
 KQPQKRSRAAFSHTQVIELERKFHQKYLAPERAHLAKNLKLTETQVKIWFQNRRYKTKRK
 55 QLSSELGDLEKHSSLPALKEEAFSRASLVSVYNSYPYPYLYCVGSWSPAFW (SEQ ID NO:
 29)

5

NP_689952.1 homeobox protein Hox-A9

MATTGALGNYYVDSFLLGADADEL SVGRYAPGTLGQPPRQAATLAEHPDFSPCSFQSKAT
 VFGASWNPVHAAGANAVPAAVYHHHHHPYVHPQAPVAAAAPDGRYMRSWLEPTPGALS
 FAGLPSSRPYGIKPEPLSARRGDCPTLDTHTLSTLDYACGSPVDREKQPSEGAFSENNAENES
 10 GGDKPPIDPNNPAANWLHARSTRKKRCPYTKHQTTLELEKEFLNMYLTRDRRYEVARLLNL
 TERQVKIWFQNRRMKMKKINKDRAKDE (SEQ ID NO: 30)

NP_001124317.1 B-cell lymphoma 6 protein isoform 1

MASPADSCIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTD
 15 QLKCNLSVINLDPEINPEGFCILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTCRKFI
 KASEAEMVSAIKPPREEFLNSRMLMPQDIMAYRGREVENNLPLRSAPGCESRAFAPSLYSG
 LSTPPASYSMYSHLPVSSLLFSDEEFRDVRMPVANPFPKERALPCDSARPVPGEYSRPTLEVSP
 NVCHSNIYSPKETIPEEARSDMHYSVAEGLKPAAPSARNAPYFPCDKASKEEERPSSSEDEIAL
 HFEPNAPLNRKGLVSPQSPQKSDCQPNPTESCSSKNACILQASGSPPAKSPTDPKACNWKK
 20 YKFIVLNSLNQNAKPEGPEQAELGRLSPRAYTAPPACQPPMEPENLDLQSPTKLSASGEDSTIP
 QASRLNNIVNRSMTGSPRSSSESHSPLYMHPPKCTSCGSQSPQHAEMCLHTAGPTFPEEMGET
 QSEYSDSSCENGAFECNECDCRFSEEASLKRHTLQTHSDKPYKCDRCQASFRYKGNLASHKT
 VHTGEKPYRCNICGAQFNRPANLKTHTRIHSGEKPYKCETCGARFVQVAHLRAHVLIHTGEK
 PYPCEICGTRFRHLQTLKSHLRIHTGEKPYHCEKCNLHFRHKSQRLRLHLRQKHGAITNTKVQ
 25 YRVSATDLPELPKAC (SEQ ID NO: 31)

NP_001964.2 ETS domain-containing protein Elk-4 isoform a

MDSAITLWQFLLQLLQKPQNKHMICWTSNDGQFKLLQAEEVARLWGIRKNKPNMNYDKLS
 RALRYYYVKNIIKKVNGQKFVYKFVSYPEILNMDPMTVGRIEGDCESLNFSEVSSSSKDVEN
 30 GGDKPPQPGAKTSSRNDYIHSGLYSSFTLNSLNSSNVKLFKLIK TENPAEKLAEEKSPQEPTP
 SVIKFVTTSPSKKPPVEPVAATISIGPSISPSSEETIQALETLVSPKLPSLEAPTSASNVMTAFATTP
 PISSIPPLQEPPRTPSPPLSSHPDIDTIDSVASQPMELPENLSLEPKDQDSVLLEKDKVNSSRS
 KKPKGLELAPTLVITSSDPSPLGILSPSLPTASLTPAFFSQTPHILTPSPLLSSIHFWSTLSPVAPLS
 PARLQGANTLFQFPSVLNSHGPFTLSGLDGPST
 35 PGPFSPDLQKT (SEQ ID NO: 32)

NP_005020.1 pituitary homeobox 3

MEFGLLSEAEARSPALSLSDAGTPHPQLPEHGCKGQEHS DSEKASASLPGGSPEDGSLKK
 KQRRQRTHFTSQQLQELEATFQRNRYPD MSTREEIAVWTNLTEARVRVWFKNRRRAKWRKR
 40 ERSQQAELCKGSFAAPLGGLVPPYEEVYPGYSYGNWPPKALAPPLAAKTFPFAFNSVNVGPL
 ASQPVFSPSSIAASMVPSAAAAPGTVPGPGALQGLGGGPPGLAPAAVSSGAVSCP YASAAA
 AAAAAASSPYVYRDPCNSSLASRLKAKQHASF SYPAVHGPPPAANLSPCQY AVERPV
 (SEQ ID NO: 33)

45 NP_006424.2 granulysin isoform NKG5

MATWALLLLAAMLLGNPGLVFSRLSPEYYDLARAH LRDEEKSCPCLAQEGPQGDLLTKTQE
 LGRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVC RNFMRRYQSRVTQG
 LVAGETAQQICEDLRLCIPSTGPL (SEQ ID NO: 34)

50 NP_002087.2 general transcription factor IIF subunit 1

MAALGPSSQNVTEYVVRVPKNTTKKYNIMAFNAADKVN FATWNQARLERDLSNKKIYQEE
 EMPESGAGSEFNRLREEARRKKYGIVLKEFRPEDQPWLLRVNGKSGRKFKGIKKGGVTEN
 TSYIIFTQCPDGAFEAFPVHNWYNFTPLARHRTLTAEEAE EEWERRNKVLNHF SIMQQRRLLK
 DQDQDEDEEEKEKRGRRKASELRIH DLEDDLEMSSDASDASGEEGGRVPKAKKKAPLAKGG
 55 RKKKKKKKGSDDEAFEDSDDGDFEGQEVDYMSDGSSSSSQEEPESKAKAPQQEEGPKGVDEQS
 DSSEES EEEKPPEEDKEEEEEKKAPT PQEKKRRKDSSEESDSSEESDIDSEASSALFMAKKKTP

- 5 PKRERKPSGGSSRGNSRPGTPSAEGGSTSSTLRAAASKLEQGKRVSEMPAAKRLRLDTGPQS
LSGKSTPQPPSGKTTTPNSGDVQVTEDAVRRYLTRKPMTTKDLLKKFQTKKTGLSSEQTVNVL
AQILKRLNPERKMINDKMHFSLKE (SEQ ID NO: 35)
- NP_003855.1 histone deacetylase complex subunit SAP30
- 10 MNGFTPDEMRSRGDAAA AVAAVVAAAAAASAGNGTGAGTGAEVPGAGAVSAAGPPGA
AGPGPGQLCCLREDGERCGRAAGNASFSKRIQKSISQKKVKIELDKSARHLYICDYHKNLIQS
VRNRRKRKGSDDDGGDSPVQDIDTPEVDLYQLQVNTLRRYKRHFKLPTRPGLNKAQLVEIV
GCHFRSIPVNEKDTLTYFIYSVKNDKNKSDLKVDSGVH (SEQ ID NO: 36)
- 15 NP_057371.2 heterochromatin protein 1-binding protein 3
MATDTSQGELVHPKALPLIVGAQLIHADKLGEKVEDSTMPIRRTVNSTRETTPPKSKLAEG
EEEKPEPDISSEESVSTVEEQENETPPATSSEAEQPKGEPENEEKEENKSSEETKKDEKD
QSKEKEKKVKKTIPSWATLSASQLARAQKQTPMASSPRPKMDAILTEAIKACFQKSGASVVA
IRKYIIHKYPSLELERRGYLLKQALKRELNRGVIKQVKKGKSGSFVVVQKSRKTPQKSRNR
- 20 KNRSSAVDPEPQVKLEDVLPLAFTRLCEPKEASYSLIRKYVSQYYPKLRVDIRPQLLKNALQR
AVERGQLEQITGKGASGTFQLKKSGEKPLLGGSLMEYAILSAIAAMNEPKTCSTTALKKYVL
ENHPGTNSNYQMHLKKTLQKCEKNGWMEQISGKGFSGTFQLCFPYYPSPGVLFPPKKEPDD
SRDEDEDEDESEEDSEDEEPPPKRRLQKKTPAKSPGKAASVKQRGSKPAPKVSAAQRGKAR
PLPKKAPPAKTPAKKTRPSSTVIKKPSGGSSKKPAT SARKEVKLPKGKSTMKKSFVRVKK
- 25 (SEQ ID NO: 37)
- NP_002977.1 eotaxin precursor
MKVSAALLWLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQK
AVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP (SEQ ID NO: 38)
- 30 NP_443203.1 liver-expressed antimicrobial peptide 2 precursor
MWHLKLCAVLMIFLLLLGQIDGSPIVEVSSAKRRPRRMTPFWRGVSLRPIGASCRDDSEC
ITRLCRKRRCSLSVAQE (SEQ ID NO: 38)
- 35 NP_113676.2 lethal(3)malignant brain tumor-like protein 2
MEKPRSIEETPSSEPMEEEEDDLELFGGYDSFRSYNSSVGSESSSYLEESSEAENEDRE
AGELPTSPLHLLSPGTPRSLDGSSEPAVCEMCGIVGTREAFFSKTKRFCVSCSRSYSS
NSKKASILARLQGKPPTKKAKVLHKAAWSAKIGAFLHSQGTGQLADGTPTGQDALVLGFD
WGKFLKDH SYKAAPVSCFKHVPLYDQWEDVMKGMKVEVLNSDAVLPSRVYWIASVIQTA
- 40 GYRVLLRYEGFENDASHDFWCNLGTVDVHPIGWCAINSKILVPPRTIHAKFTDWKGYLMKR
LVGSRTL PVDFHIKMVESMKYPFRQGMRLLEVVDKSQVSRTRMAVVDTVIGGRLRLLYEDGD
SDDDFWCHMWSPLIHPVGWSRRVGHGIKMSERRSDMAHHPTFRKIYCDAPVYLFKKVRVAV
YTEGGWFEEGMKLEAIDPLNLGNICVATVCKVLLDG YLMICVDGGPSTDGLDWFCYHASSH
AIFPATFCQKNDIELTPPKG YEAQTFN WENYLEKTKSKAAP SRLFNMDCPNHGFKVGMKLE
- 45 AVDLMEPR LICVATVKRVVHRLLSIHFDGWDSEYDQWVDCESPDIYPVGWCELTGYQLQPP
VAAEPATPLKAKEATKKKKKKQFGKKRKRIPTKTRPLRQGSKKP LLEDDPQGARKISSEVP
GEIIAVRVKEEHLDVASPDKASSPELPVSVENIKQETDD (SEQ ID NO: 39)
- NP_002986.1 lymphotactin precursor
- 50 MRLLILALLGICSLTAYIVEGVGSEVSDKRTC VSLTTQRLPVSR IKTYTITEGSLRAVIF
ITKRGLKVCADPQATWVRDVVRSM DRKSNTNRNMIQT KPTGTQQTNTAVTLTG (SEQ ID
NO: 40)
- NP_005185.2 CCAAT/enhancer-binding protein beta
- 55 MQRLVAWDPACLPLPPPPPAFKSMEVANFY YEADCLAAAYGGKAAPAAPPAARPGPRPPAG
ELGSIGDHERAIDFSPYLEPLGAPQAPAPATATDTFEAAPPAPAPAPASSGQH HDFLSDLFSDD

- 5 YGGKNCKKPAEYGYVSLGRLGAAKGALHPGCFAPLHPPPPPPPPPAELKAEPGFEPADCKRK
EEAGAPGGGAGMAAGFPYALRAYLGYQAVPSGSSGSLSTSSSSSPGTPSPADAKAPPTACY
AGAAPAPSQVKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAEN
ERLQKKVEQLSRELSTLRNLFKQLPEPLASSGHC (SEQ ID NO: 41)
- 10 NP_001001430.1 troponin T, cardiac muscle isoform 2
MSDIEEVVEEYEEEEQEEAAVEEQEEAAEEDAEAEAETEETRAEEDEEEEAKEAEDGPMEE
SKPKPRSFMPNLVPPKIPDGERVDFDDIHRKRMEKDLNELQALIEAHFENRKKEEEELVSLKD
RIERRRAERAQQRIRNEREKERQNRLAEERARREEEENRRKAEDEARKKKALSNNMMHFGG
YIQKQAQTERKSGKRQTEREKKKKILAERRKVLAIDLHNLNEDQLREKAKELWQSIYNLEAEKF
15 DLQEKFKQKYEINVLNRINDNQKVSCTRKGAKVTGRWK (SEQ ID NO: 42)
- NP_001073315.1 CREB-binding protein isoform b
MAENLLDGPPNPKRAKLSSPGFSANDSTDFGSLFDLENDLPDELIPNGGELGLLNSGNLV
PDAASKHKQLSELLRGGSGSSINPGIGNVSASSPVQQGLGGQAQGPNSANMASLSAMGKSP
20 LSQGDSSAPSLPKQAASTSGPTPAASQALNPQAQKQVGLATSSPATSTGPGICMNANFNQT
HPGLLNSNSGHSNLNQASQGQAQVMNGSLGAAGRGRGAGMPYPTPAMQGASSSVLAETLT
QVSPQMTGHAGLNTAQAGGMAKMGITGNTSPFGQPFSQAGGQPMGATGVNPQLASKQSM
VNSLPTFPTDIKNTSVTNVPNMSQMQTSVGIVPTQAIATGPTADPEKRKLIQQQLVLLHAHK
CQRREQANGEVRACSLPHCRTMKNVLNTHMTHCQAGKACQAILGSPASGIQNTIGSVGTGQQ
25 NATSLSNPNPIDPSSMQRAYAALGLPYMNQPQTQLQPQVPGQQAQPQTHQQMRTLNLPLGN
NPMNIPAGGITTDQQPPNLISESALPTSLGATNPLMNDGSNSGNIGTLSTIPTAAPPSSSTGVRKG
WHEHVTQDLRSHLVHKLVAIFPTPDPAALKDRRMENLVAYAKKVEGDMYESANSRDEYY
HLLAEKIYKIQKELEEKRRSRLHKQGILGNQPALPAPGAQPPVIPQAQPVRPPNGPLSLPVNR
MQVSQGMNSFNPMISLGNVQLPQAPMGPRASPMPNHSVQMNSMGSVPGMAISPSRMPQPPN
30 MMGAHTNNMMAQAPAQSQFLPQNQFPSSSGAMSVGMGQPPAQTGVSQGVPGAALPNPL
NMLGPQASQLPCPPVTQSPLHPTPPASTAAGMPSLQHTTPPGMTTPPQPAAPTQPSTPVSSSG
QTPTPTPGSVPSATQTQSTPTVQAAAQAQVTPQPQTPVQPPSVATPQSSQQQPTPVHAQPPGT
PLSQAAASIDNRVPTPSSVASAETNSQQPGPDVPVLEMKTETQAEDTEPDGESKGEPRSEM
MEEDLQGASQVKEETDIAEQKSEPMEVDEKKPEVKVEVKEEEESSSNGTASQSTSPSQPRKKI
35 FKPEELRQALMPTLEALYRQDPESLPFRQPVDPLLGIPDYFDIVKNPMDLSTIKRKLDTGQY
QEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLGYCCGRKYEFS
PQTLCCYGKQLCTIPRDAAYYSYQNRHYFCEKCFTEIQGENVTLGDDPSQPQTISKDQFEKK
KNDTLDPEPFVDCKEGRKMHCICVLHYDIIWPSGFVCDNCLKKTGRPRKENKFSKRLQTT
RLGNHLEDVRVNFLLRRQNHPEAGEVFVRVVASDKTVEVKPGMKSRFVDSGEMSESPYRT
40 KALFAFEEIDGVDVCFFGMHVQEYGSDCPPPNTRRVYISYLDLSIHFFRPRCLRTAVYHEILIGY
LEYVKKLGYVTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAFAERIIHDY
KDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEEERKKEESTAASETTEGSQGDS
KNAKKKNNKKTNKNKSSISRANKKKPSMPNVSNLDSQKLYATMEKHKEVFFVIHLHAGPVI
NTLPPIVDPDPLLSCDLMDGRDAFLTARDKHWEFSSLRRSKWSTLCMLVELHTQGQDRFV
45 YTCNECKHHVETRWHCTVCEDYDLCINCYNTKSHAHKMVKWGLGLDDEGSSQGEPQSKSP
QESRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCKQLIALC
CYHAKHCQENKCPVPFCLNIKHKLRRQQQIQHRLQQAQLMRRRMATMNTRNVPQQSLPSPTS
APPGTPTQQPSTPQTPQPPAQPQPSPVSMSPAGFPSVARTQPPTTVSTGKPTSQVPAPPPPAQPP
PAAVEAARQIEREAQQQQHLRYVNINNSMPPGRTGMGTPGSQMAPVSLNVPRPNQVSGPVM
50 PSMPPGQWQQAPLPQQQPMPLPRPVISMQAQAAVAGPRMPSVQPPRSISPSALQDLLRTLK
SPSSPQQQQQVLNILKSNPQLMAAFIKQRTAKYVANQPGMQPQPGLQSQPGMQPQPGMHQQ
PSLQNLNAMQAGVPRPGVPPQQQAMGGLNPQGQALNIMNPGHNPNMASMNPQYREMLRR
QLLQQQQQQQQQQQQQQQQQQQGSAGMAGGMAGHGQFQQPQGGGYPPAMQQQQQRMQQ
HLPLQGSSMGQMAAQMGQLGQMGPGLGADSTPNIQQALQQRILQQQQMKQQIGSPGQPN
55 PMSPQQHMLSGQPQASHLPGQQIATSLSNQVRSPAPVQSPRPQSQPPHSSPSPRIQPQPSPHHV

5 SPQTGSPHPGLAVTMASSIDQGH LGNPEQSAMLPQLNTPSR SALSS ELSLVGDTTGD TLEKFV
EGL (SEQ ID NO: 43)

NP_001871.2 cyclic AMP-dependent transcription factor ATF-2

10 MKFKLHVNSARQYKDLWNMSDDK PFLCTAPGCGQRFTNEDHLAVHKHKHEMTLKFGPAR
NDSVIVADQTPTPTRFLKNCEEVGLF NELASPFENEFFKKASEDDIKKMPLDLSPLATPIIRSKIE
EPSVVETTHQDSPLPHPESTTSDEKEVPLAQTAQPTSAIVRPASLQV PNVLLTSSD
SSVIIQQAVPSPTSSTVITQAPSSNRPIVPVPGPFLL LHL PNGQTMPVAIPASITSSNV
HVPAAVPLVRPVTMVPSVPGIPGPSSPQP VQSEAKMRLKAALTQQHPPVTNGDTVKGHGSG
LVRTQSEESRPQSLQQPATSTTETPASPAHTTPQTQSTSGRRRRAANEDPDEKRRKFLE
15 RNRAAASRCRQKRKVWVQSLEKKAEDLSSLNGQLQSEVTLLRNEVAQLKQLLLAHKDCPV
TAMQKKSGYHTADKDDSSDISVPSSPHTEAIQHSSVSTSNGVSSTS KAEAVATSVLTQMAD
QSTEPALSQIVMAPSSQSQPSGS (SEQ ID NO: 44)

NP_001901.1 cathepsin E isoform a preproprotein

20 MKTLLLLLLLVLLELGEAQGSLHRVPLRRHPSLKKKLRARSQ LSEFWKSHNLDMIQFTESC
SMDQSAKEPLINYLDMEYFGTISIGSPPQNFTVIFDTGSSNLWVPSVYCTSPACKTHSRF
QPSQSSTYSQPGQSFSIQYGTGSLSGIIGADQVSVEGLTVVGQQFGESVTEPGQTFVDAE
FDGILGLGYPSLAVGGVTPVFDNMMAQNLVDLPMFSVYMSSNPEGGAGSELIFGGYDHS HF
SGSLNWVPVTKQAYWQIALDNIQVGGTVMFCSEGCQAIVDTGTSLITGPSDKIKQLQNAIGA
25 APVDGEYAVECANLNVMPDVTFTINGVPYTLSP TAYTLLDFVDGMQFCSSGFQGLDIHPPAG
PLWILGDVFIRQFYSVFDRGNRVGLAPAVP (SEQ ID NO: 45)

NP_001139512.1 glycine receptor subunit alpha-1 isoform 1 precursor

30 MYSFNTLRLYLWETIVFFSLAASKEAEAARSAPKPMSPSDFLDKLMGRTSGYDARIRPNF
KGPPVNVSCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYNEYPDDSLDLDP SMLDS
IWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLTLACPM DLKNFPM DVQTC
IMQLESFGYTMNDLIFEWQEQQGAVQVADGLTLPQFILKEEKDLRYCTKH YNTGKFTCIEARF
HLERQMGGYYLIQMYIPSL LIVILSWISFWINMDAAPARVGLGITT VLTMTTQSSGSRA
SLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVN FVSRQH KELLRFRRKRRHHKSPMLNLFQE
35 DEAGEGRFNFSAYGMGPACLQAKDGISVKGANNSNTTNPP PAPS KSPEEMRKLFIQRAKKID
KISRIGFPM AFLIFNMFYWIIYKIVRREDVHNQ (SEQ ID NO: 46)

NP_001108.2 pituitary adenylate cyclase-activating polypeptide precursor

40 MTMCSGARLALLVYGIIMHSSVYSSPAAAGLRFP GIRPEEEAYGEDGNPLPDFDGSEPPG
AGSPASAPRAAAAWYRPAGRRDVAHGILNEAYRKVLDQLSAGKHLQSLVARGVGGSLGGG
AGDDAEPLSKRHSDGIFTDSYSRYRKQMAVKKYLA AVL GKRYKQRVKNKGRR IAYL (SEQ
ID NO: 47)

NP_055572.1 mastermind-like protein 1

45 MVLPTCPMAEFALPRHS AVMERLRRRIELCRRHHSTCEARYEAVSPERLELERQHTFALH
QRCIQAKAKRAGKHRQPPAATAPAPAAPARLDAADGPEHGRPATHLHDTV KRNLD SATSP
QNGDQQNGYGDLPFGHKKTREAPLGVAISSNGLPPASPLGQSDKPSGADALQSSGKHS LGL
DSL NKKRLADSSLHLNGG SNPSESFPLSLNKELKQEPVEDLPCMITGT VGSISQSNLMPDLNL
NEQEWKELIEELNRSVPDEDMKDLFNEDFEEKKDPESSGSATQTPLAQDINIKTEFSPA AFEQ
50 EQLGSPQVRAGSAGQTFLGPSSAPVSTDSPSLGGSQTLFHTSGQPRADNPSPNLMPASAQAQ
NAQRALAGVVLPSQGPGGASELSSAHQLQQIAAKQKREQMLQNPQQATPAPAPGQMSTWQ
QTGPSHSSLDVPYPMEKPASPSSYKQDFTNSKLLMMPSV NKSSPRPGPYLQPSHVNLLSHQ
PPSNLNQNSANNQGSVLDYGNTKPLSHYKADCGQGSGSGQSKPALMAYLPQQLSHISHEQ
NSLFLMKPKPGNMPFRSLVPPGQE QNPSSVPVQAQATSVGTQPPAVSVASSHNSSPYLSSQQ
55 QAAVMKQHQLLLDQQKQREQQQKHLQQQQFLQRQQHLLAEQEKQQFQRHLTRPPPQYQD
PTQGSFPQQVGQFTGSSAAVPGMNTLGPSNSSCPRVFPQAGNLMPMGPGHASVSSLPTNSGQ
QDRGVAQFPGSQNMPQSSLYGMASGITQIVAQPPPQATNGHAHIPRQTNVGQNTSVSAA YG

- 5 QNSLGSSGLSQQHNKGTLNPGLTKPPVPRVSPAMGGQNSSWQHQGMPNLSGQTPGNSNVSP
FTAASSFHMQQQAHLKMSSPQFSQAVPNRPMAPMSSAAAVGSLLPPVSAQQRTSAPAPAPP
TAPQQGLPGLSPAGPELGAFSQQSPASQMGGGRAGLHCTQAYPVRTAGQELPFAYSGQPGGSGL
SSVAGHTDLIDSLLKNRTSEEWMSDLDDLLGSQ (SEQ ID NO: 48)
- 10 NP_004043.2 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3
MSQNGAPGMQEESLQGSWVELHFSNNGNGGSVPASVSIYNGDMEKILLDAQHESGRSSSKS
SHCDSPPRSQTPQDTNRASETDTHSIGEKNSSQSEEDDIERRKEVESILKKNSDWIWDW
SSRPENIPPKEFLFKHPKRTATLSMRNTSVMKKGGIFSAEFLKVFLPSLLLSHLLAIGLG
IYIGRRLTTSTSTF (SEQ ID NO: 49)
- 15 NP_004336.2 cathelicidin antimicrobial peptide
MKTQRDGHSLGRWSLVLLLLGLVMPLAIIAQVLSYKEAVLRAIDGINQRSSDANLYRLLDL
PRPTMDGDPDTPKPVSTVKEVCPRTTQQSPEDCDFKKDGLVKRCMGTVTLNQARGSFDIS
CDKDNKRFBALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO: 50)
- 20 NP_001181946.1 T-cell surface glycoprotein CD4 isoform 3
MGKKLPLHLTLPQALPQYAGSGNLTALAEAKTGKLHQEVNLVVMRATQLQKNLTCEVWGP
TSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQAERMSQIKRLLSEKKTCQCPHRFQKTCSPI
25 (SEQ ID NO: 51)
- NP_005219.2 epidermal growth factor receptor isoform a precursor
MRPSGTAGAALLALLAALCPASRALEEKVCQGTSNKLTLQGTGFEDHFLSLQRMFNCEVV
LGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLNLQIIRGNMYYENSYALAVLSN
30 YDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLS
CQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRRCRGKSPSDCCHNQCAAGCTGPRES
CLVCRKFRDEATCKDTCPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSC
VRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLH
ILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIRGRTKQHGG
35 FSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSC
KATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPRFVENSECIQCHPE
CLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCH
PNCTYGCTGPGLEGCPNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRLRLQ
ERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELR
40 EATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGS
QYLLNWCVQIAKGMNYLEDRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHA
EGGKVPIKWMALLESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLP
QPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNF
YRALMDEEDMDDVVDADDEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNLQSCPI
45 KEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDP
HYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAKGSHQISLDNPDYQQDFFPKEAKPN
GIFKGSTAENAEYLRVAPQSSEFIGA (SEQ ID NO: 52)
- NP_001129495.1 transcription factor NF-E2 45 kDa subunit isoform 2
50 MSPCPPQQSRNRVIQLSTSELGEMELTWQEIMSITELQGLNAPSEPSFEPQAPAPYLGPP
PPTTYCPCSIHPDSGFPLPPPPYELPASTSHVPDPYSGNMAIPVSKPLSLSGLLSEPL
QDPLALLDIGLPAGPPKPQEDPESDSGLSLNYSDAESLELEGTEAGRRESEYVEMYVVEY
PYSLMPNSLAHSNYTLPAETPLALEPSSGPVRAKPTARGEAGSRDERRALAMKIPFPTD
KIVNLPVDDFNELLARYPLTESQLALVRDIRRRGKNKVAAQNCRKRKLETIVQLERELER
55 LTNERERLLRARGEADRTLEVMRQQLTELYRDIFQHLRDESGNSYSPEEYALQQAADGTI
FLVPRGTKMEATD(SEQ ID NO: 53)

5

NP_008855.1 serine/arginine-rich splicing factor 1 isoform 1

MSGGGVIRGPAGNNDCRIYVGNLPPDIRTKDIEDVFYKYGAIRDIDLKNRRGGPPFAFVE
 FEDPRDAEDAVYGRDGYDYDGYRLRVEFPRSGRGTGRGGGGGGGGGGAPRGRYGPPSRSE
 NRVVVVSGLPPSGSWQDLKDHMREAGDVCYADVYRDGTGVVEFVRKEDMTYAVRKLDNTK
 10 FRSHEGETAYIRVKVDGPRSPSYGRSRSRSRSRSRSRSRSNSRSRSYSPRRSRGSPRYSRHSRS
 RSRT (SEQ ID NO: 54)

NP_945315.1 parathyroid hormone-related protein isoform 2 preproprotein

MQRRLVQQWSVAVFLLSYAVPSCGRSVEGLSRRLKRAVSEHQLLHDKGKSIQDLRRRFFLH
 15 HLIAEIHTAEIRATSEVSPNSKPSNTKNHPVRFSGDDEGRYLTQETNKVETYKEQPLK
 TPGKKKKKGKPGKRKEQEKKRRTRSAWLDSGVTGSGLEGDHLSDTSTTSLELDSR (SEQ ID
 NO: 55)

NP_391988.1 integrin beta-1 isoform 1D

20 precursorMNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQE
 GMPTSARCDDLEALKKKKGCPDDIENPRGSKDIKKKNKNTNRSGTAEKLPEDITQIQPQQ
 LVLRLRSGEPQTFTLKFRAEDYPIDLYYLMDSLYSMKDDLENVKSLGTDLMNEMRRITSDF
 RIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGN
 LDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGIVLPNDGQCHLEN
 25 NMYTMSHYDYDPSIAHLVQKLENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSSANSSNVI
 QLIIDAYNSLSSEVILENGKLSEGVITISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSN
 KCPKKDSDFSFKIRPLGFTEEVEVILQYICECECQSEGIPEPKCHEGNGTFECGACRCNEGRVG
 RHCECSTDEVNSEMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNF
 NCDRSNGLICGGNGVCKCRVCECNPNYTGSA CDCSLDTSTCEASNGQICNGRGICECGVCKC
 30 TDPKFQGTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQ
 PVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLI
 GLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTQENPIYKSPINNFKNPYGRKAGL (SEQ
 ID NO: 56)

35 NP_006004.2 60S ribosomal protein L10

MGRRPARYRYCKNKPYPKSRFCRGVPDAKIRIFDLGRKKAKVDEFPLCGH MVSD EYEQLS
 SEALEAARICANKYMKVSCGKDG FHIRVRLHPFHVIRINKMLSCAGADRLQTGMRGAFGKP
 QGTVARVHIGQVIMSIRTKLQNKEHVIEALRRAKFKFPGRQKIHISKKWGFTKFN ADEFEDM
 VAEKRLIPDGCGVKYIPNRGPLDKWRALHS (SEQ ID NO: 57)

40

NP_001193858.1 advanced glycosylation end product-specific receptor isoform 2 precursor

MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEA
 WKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKS NYRVRVYQIP
 GKPEIVDSASELTAGVPNKVVEESRRSRKRPCEQEVGTCVSEGSYPAGTLSWHLDGKPLVPN
 45 EKGVS VKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVW
 EPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHW MKDGVPLPLPPSPVLILPEIGPQ
 DQGTYS CVATHSSHGPQESRAVSISIIPEGEGPTAGSVGGSGGLGTLALALGILGGLGTAALLI
 GVILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP (SEQ ID NO: 58)

50 NP_005399.1 C-C motif chemokine 13 precursor

MKVSAVLLCLLLMTAAFN PQGLAQP DALNPSTCCFTFSSKKISLQRLKSYVITTSRCPQ
 KAVIFRTKLGKEICADPKEKWVQNYMKHLGRKAHTLKT (SEQ ID NO: 59)

NP_002976.2 C-C motif chemokine 5 precursor

55 MKVSAAALAVILIATALCAPASASPYSSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNP
 AVVFVTRKNRQVCANPEKKWVREYINSLEMS (SEQ ID NO: 60)

- 5 NP_006264.2 C-C motif chemokine 7 precursor
MKASAALLCLLLTAAAFSPQGLAQPVGINSTTCCYRFINKKIPKQRLESYRRTTSSHCP
REAVIFKTKLDKEICADPTQKWVQDFMKHLDKKTQTPKL (SEQ ID NO: 61)
- NP_002080.1 C-X-C motif chemokine 2
10 MARATLSAAPSNPRLLRVALLLLLVAASRRAAGAPLATELRCQCLQTLQGIHLKNIQSV
KVKSPGPHCAQTEVIATLKNGQKACLNPA SP MVKKIIEKMLKNGKSN (SEQ ID NO: 62)
- NP_002006.2 forkhead box protein O1
15 MAEAPQVVEIDPDFEPLRPRRSCTWPLRPEFSQSNSATSSPAPSGSAAANPDAAAGLPS
ASAAAVSADFMSNLSLLEESDFPQAPGSVAAA VAAAAAAAAAATGGLCGDFQGPEAGCLHPA
PPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQ
IYEW MVKSVPYFKDKGDSNSSAGWKNSIRHNLSLH SKFIRVQNEGTGKSSWWMLNPEGGKS
GKSPRRRAASMDNNSKFAKSRRAAKKKASLQSGQEGAGDSPGSQFSKWPASPGSHSNDDE
DNWSTFRPRTSSNASTISGR LSPIMTEQDDLGE G DVHSMVYPPSAAKMASTLPSLSEISNPEN
20 MENLLDNLNLLSSPTSLTVSTQSSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSP
LPQMPIQTLQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSRVLGQN
VMMGPNSVMSTYGSQASHNKMMNPSSHTHPGHAQQTS AVNGRPLPHTVSTMPHTSGMNR
LTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYGRMGLLHQEKLPDLDGMFIERLDCDME
SIIRNDLMDGDTLDFNFDNVLPNQSFPHSVKTTTHSWVSG (SEQ ID NO: 63)
- 25 NP_963853.1 forkhead box protein O3
MAEAPASPAPLSPLEVELDPEFEPQSRPRRSCTWPLQRPELQASPAKPSGETAADS MIPEE
EDDEDDEDGGGRAGSAMAIGGGGGSGTLGSGLLLED SARVLAPGGQDPGSGPATAAGGLSG
GTQALLQPQQPLPPPQPGAAGGSGQPRKCSSRRNAWGNLSYADLITRAIESSPDKRLTLSQIY
30 EWMVRCVPYFKDKGDSNSSAGWKNSIRHNLSLHSR FMRVQNEGTGKSSWWIINPDGGKSG
KAPRRRAVSMDNSNKYTKSRGRAAKKKAALQTAPESADDSPS QLSKWPGSPTSRS SDELDA
WTDFRSRTNSNASTVSGRLSPIMASTELDEVQDDDA PLSPMLYSSSASLSPSVSKPCTVELPR
LTD MAGTMNLNDGLTENLMDDLLDNITLPPSQPSPTGGLMQRSSSFYTTKGSGGLGSPTSSFN
STVFGPSSLNSLRQSPMQTIQENKPATFSSMSHYGNQTLQDLLTSDSLSHSDVMMTQSDPLM
35 SQASTAVSAQNSRRNVMLRNDPMMSF AAQPNQGS LVNQNLHHQHQTQ GALGGSRALSNS
VSNMGLSESSSLGSAKHQQQSPVSQSMQTLSDSLSGSSLYSTSANLPVMGHEKFPSDLDLDM
FNGSLECDMESIIRSELMDADGLDFNFD SLISTQNVVGLNVGNFTGAKQASSQSWVPG (SEQ
ID NO: 64)
- 40 NP_005929.2 forkhead box protein O4 isoform 1
MDPGNENSATEAAAIIDLPDFEPQSRPRRSCTWPLRPEIANQPSEPPEVEPDLGEKVHT
EGRSEPILLPSRLPEPAGGPQPGILGAVTGPRKGGSR RNAWGNQSYAELISQAIESAPEK
RLTLAQIYEW MVRTVPYFKDKGDSNSSAGWKNSIRHNLSLH SKFIKVHNEATGKSSWWML
NPEGGKSGKAPRRRAASMDSSSKLLRGRSKAPKKKPSVLPAPPEGATPTSPVGHFAKWSGSP
45 CSRNREEADMWTTFRPRSSSNASSVSTRLSPLRPESEVLAE EIPASVSSYAGGVPTLNEGLEL
LDGLNLTSSHLLSRSGLSGFS LQHPGVTGPLHTYSSSLFSPAEGPLSAGEGCF
SSSQALEALLTSDTPPPPADVLM TQVDPI LSQAPTL LLLGGLPSSSKLATGVGLCPKPLE
APGPSSLVPTLSMIAPPPVMASAPIPKALGTPVLTPTTEAASQDRMPQDL DLD MYMENLE
CDMDNIISDLMDEGEGLDNFEPDP (SEQ ID NO: 65)
- 50 NP_002087.2 general transcription factor IIF subunit 1
MAALGPSSQNVT EYVVRVPKNTTKKY NIMAFNAADKVN FATWNQARLERDLSNKKIYQEE
EMPESGAGSEFN RKLREEARRKKY GIVLKEFRPEDQPWLLRVNGKSGRKFKGIKKGGVTEN
TSYYIFTQCPDGAF EAFVHNWYNFTPLARHRTLTAEEAE EEWERRNKVLNHF SIMQQRR LK
55 DQDQDEDEEEKEKRGRRKASELRIHDLEDDLEMSSDASDASGEEGGRVPKAKKKAPLAKGG
RKKKKKKKGSDDEAFEDSDDGDFEGQEVDYMSDGSSSSQEEPESKAKAPQQEEGPKGVDEQS

- 5 DSSEESSEEEKPPEEDKEEEEEKKAPTPQEKRRKDSSEESDSSEESDIDSEASSALFMAKKKTP
PKRERKPSGGSSRGNSRPGTPSAEGGSTSSTLRAAASKLEQGKRVSEMPAAKRLRLDTGPQS
LSGKSTPQPPSGKTTTPNSGDVQVTEDAVRRYLTRKPMTTKDLLKKFQTKKTGLSSEQTVNVL
AQILKRLNPERKMINDKMHFSLKE (SEQ ID NO: 66)
- 10 NP_002087.2 general transcription factor IIF subunit 1
MAALGPSSQNVTEYVVRVPKNTTKKYNIMAFNAADKVN FATWNQARLERDLSNKKIYQEE
EMPESGAGSEFNRLREEARRKKYGIVLKEFRPEDQPWLLRVNGKSGRKFKGIKKGGVTEN
TSYYIFTQCPDGAFAFPVHNWYNFTPLARHRTLTAEEAEEEWERRNKVLNHF SIMQQRRLK
DQDQDEDEEEKEKRGRRKASELRIHDLDDLEMSDASDASGEEGGRVPKAKKKAPLAKGG
15 RKKKKKKKGSDDEAFEDSDDGDFEGQEV DYMSDGSSSSQEEPESKAKAPQQEEGPKGVD EQS
DSSEESSEEEKPPEEDKEEEEEKKAPTPQEKRRKDSSEESDSSEESDIDSEASSALFMAKKKTP
PKRERKPSGGSSRGNSRPGTPSAEGGSTSSTLRAAASKLEQGKRVSEMPAAKRLRLDTGPQS
LSGKSTPQPPSGKTTTPNSGDVQVTEDAVRRYLTRKPMTTKDLLKKFQTKKTGLSSEQTVNVL
AQILKRLNPERKMINDKMHFSLKE (SEQ ID NO: 67)
- 20 NP_001997.5 heparin-binding growth factor 2
MVGVGGGDVEDVTPRPGGCQISGRGARGCNGIPGAAAWEAALPRRRPRRHPSVNPRSRAAG
SPRTRGRRTEERPSGSRLGDRGRGRALPGGRLGGRGRGRAPERVGGRRGRGRGT AAPRAAPA
ARGSRPGPAGTMAAGSITTLPALPEDGGSGAFPPGHFKDPKRLYCKNGGFFLRIHPDGRVDG
25 VREKSDPHIKLQLQAEERGVSISIKGVCANRYLAMKEDGRLASKCVTDECFFFERLESNNYN
TYRSRKYTSWYVALKRTGQYKLGSKTGPGQKAILFLPMSAKS (SEQ ID NO: 68)
- NP_000592.3 hepatocyte growth factor isoform 1 preproprotein
MWVTKLLPALLLQHVLHLLLLPIAIPYAEGQRKRNTIHEFKKSAKTTLIKIDPALKIK
30 TKKVNTADQCANRCTR NKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYE
NKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEE
GGPWCFTSNPEVRYEVC DIPQCSEVECMT CNGESYRGLMDHTESGKICQRWDHQT PHRHKF
LPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCADNTMNDTDVPLETTECI
QGGGEGYRGTVNTIWN GIPCQRWDSQYPHEHDMTPENFKCKDLRENYCRNPDGSESPWCFT
35 TDPNIRVG YCSQIPNCDMSHGQDCYRGNGKNYMG NLSQTRSGLTCSMWDKNMEDLHRHIF
WEPDASKLNENYCRNPDDDAHG PWCYTGNPLIPWDYCPISRCEGDTTPTIVNLDHPVISCAK
TKQLRVVNGIPTRTNIGWMVSLRYRNKHICGGS LIKE SWVLTARQCFPSRDLKDYEAWLGIH
DVHGRGDEKCKQVLNVSQ LVYGPEGSDLVLMKLARPAVLDDFVSTIDL PNYGCTIPEKTSCS
VYGWGYTGLINYDGLLRVAHLYIMGNEKCSQHHRGKVT LNESEICAGAEKIGSGPCEGDY G
40 GPLVCEQH KMRMVLGVIVPGRGCAIPNRPGIFVRVAYYAKWIHKIILTYKVPQS (SEQ ID
NO: 69)
- NP_001092883.1 histone acetyltransferase MYST3
MVKLANPLYTEWILEAIKKVKKQKQRPSEERICNAVSSSHGLDRKTVLEQLELSVKDGTI
45 LKVS NKGLNSYKDPDNPGRIALPKPRNHGKLDNKQNV DWNKLIKRAVEGLAESGGSTL KSI
ERFLKGQKDVSALFGGSAASGFHQQLRLAIKRAIGHGRLLKDGPLYRLNTKATNVDGKESCE
SLSCLPPVSLLPHEKDKPVAEPIPICSFCLGTKEQNREKKPEELISCADCGNSGHP SCLKFSPEL
TVRVKALRWQCIECKTCSSCRDQGKNADNMLFCDSCDRGFHMECCDPPLTRMPKGMWICQ
ICRPRKKGRKLLQKKA AQIKRRYTNP IGRPKNRLKKQNTVSKGPFSKVRTGPGRGRKRKITLS
50 SQSASSSSEEGYLERIDGLDFCRDSNVSLKF NKKTKGLIDGLTKFFTPSPDGRKARGEVVDYS
EQYRIRKRGNRKSSTSDWPTDNQDGDGKQENEERLFGS QEIMTEKDMELFRDIQEALQK
VGVTGPPDPQVRCPSVIEFGKYEIHTWYSSPYPQEYSRLPKLYLCEFC LKYMKSRTILQQHMK
KCGWFHPPANEIYRKNNISVFEVDGNVSTIYCQNLCLLAKLFLDHKTLYYDVEPFLFYVLTQ
NDVKGCHLVGYFSKEKHCQQKYNVSCIMILPQYQRKGYGRFLIDFSYLLSKREGQAGSPEKP
55 LSDLGRLSYMAYWKS VILECLYHQNDKQISIKKLSKLTGICPDITSTLHHLRMLDFRSDQFV
IIRREKLIQDHMAKLQLNLRPVDVDPECLRWTPVIVSNSV VSEEEEEEAEEGENEEPQCQERE

5 LEISVGKSVSHENKEQDSYSVESEKKPEVMAPVSSTRLSKQVLPHDSLPA NSQPSRRGRWGR
 KNRKTQERFGDKDSKLLLEETSSAPQEQYGECGEKSEATQEQYTESEEQLVASEEQPSQDGK
 PDLPKRRLSEGVEPWGQLKKSPALKCRLTEGSERLPRRYSEGDRVLRGFSESSEEEEEPE
 SPRSSSPILTKPTLKRKKPFLHRRRRVRKRKHHNSSVVTETISETTEVLDEPFEDSDSERPMR
 LEPTFEIDEEEEEDENELFPREYFRRLSSQDVLRCQSSSKRKSKDEEDEDEESDDADDTPIPKP
 10 VSLLRKRDVKNSPLEP
 DTSTPLKKKKGWPKGKSRKPIHWKKRPGRKPGFKLSREIMPVSTQACVIEPIVSIPKAGR
 KPKIQESEETVEPKEDMPLPEERKEEEEEMQAEAEAEAEEGEEEDAASSEVPAASPADSSNS
 PETETKEPEVEEEEEKPRVSEEQRQSEEEQQELEPEPEEEEEEDAAAETAQNDDHDADDED
 DGHLESTKKKELEEQPTREDVKEEPGVQESFLDANMQKSREKIKDKEETELDSEEEQPSH
 15 DTSVVSEQMAGSEDDHEEDSHTKEELIELKEEEEIPHSELDTVQAVQSLTQEESEHE
 GAYQDCEETLAACQTLQSYTQADEDPQMSMVEDCHASEHNSPISSVQSHPSQSVRSVSSPNV
 PALESGYTQISPEQGSLSAPSMQNMETSPMMDVPSVSDHSQQVVD SGFSDLGSIESTTENYEN
 PSSYDSTMGGSGICGNSSSQSSCSYGGLSSSSSLTQSSCVVTQQMASMGSSCSMMQQSSVQPA
 ANCSIKSPQSCVVERPPSNQQQQPPPPPPQQPQPPPPQPPAPQPPPPQQQPQ
 20 QQPQPQPQPQPQPQPQPPLSQCSMNNSFTPAPMIMEIPESGSTGNISIERIPGDFG
 AGSYSQPSATFSLAKLQQLTNTIMDPHAMPYSHSPAVTSYATSVLSLNTGLAQLAPSHPL
 AGTPQAQATMTPPPNLASTTMNLTSPLLQCNMSATNIGIPHTQRLQGQMPVKGHISIRSK
 SAPLPSAAAHQQQLYGRSPSAVAMQAGPRALAVQRGMNMGVNLMPTPAYNVNSMNMNTL
 NAMNSYRMTQPMMNSSYHSNPAYMNQTAQYPMQMGMGMMGSQAYTQQPMQPNPHGN
 25 MMYTGPSHHSYMNAAGVPKQSLNGPYMRR (SEQ ID NO: 70)

NP_001800.1 histone H3-like centromeric protein A isoform a

MGPRRRSRKPEAPRRRSPSPTPTGPSRRGPSLGASSHQHSRRRQGWLKEIRKLQKSTHL
 LIRKLFP SRLAREICVKFTRGVDFNWQAQALLALQEAAEAFLVHLFEDAYLLTLHAGRVTLF
 30 PKDVQLARRIRGLEEGLG (SEQ ID NO: 71)

NP_002135.2 homeobox protein Hox-B1

MDYNRMNSFLEYPLCNRGPSAYS AHSAPTSFPPSSAQAVDSYASEGRYGGGLSSPAFQQNSG
 YPAQQPPSTLGVPFPSSAPSGYAPAAACSPSYGPSQYYPLGQSEG DGGYFHPSSYGAQLGGLSD
 35 GYGAGGAGPGPYPPQHPPYGNEQTASFAPAYADLLSEDKETPCPSEPNTPTARTFDWMKVK
 RNPPKTAKVSEPGLGSPSGLRTNFTTRQLTELEKEFHFNKYLSRARRVEIAATLELNETQVKI
 WFQNRMRMKQKKRERE EGRVPPAPPGCPKEAAGDASDQSTCTSP EASPSSVTS (SEQ ID NO:
 72)

40 NP_079141.2 homeobox protein NANOG

MSVDPACPQSLPCFEASDCKESSPMVICGPEENYPSLQMSSAEMPHTETVSPLPSSMDL
 LIQDSPDSSTSPKGKQPTSAEKSVAKKEDKVPVKKQKTRTVFSSTQLCVLNDRFQRQKYL
 SLQQMQELSNILNLSYKQVKTW FQNQRMKSKRWQKNNWPKN SNGVTQKASAPTYPSLYSS
 YHQGCLVNPTGNLPMWSNQTWNNSTWSNQTQNIQSWSNHSWNTQTWCTQSWNNQAWNS
 45 PFYNCGEESLQSCMQFQPNSPASDLEAALEAAGEGLNVIQQTTRYFSTPQTMDLFLNYSNM
 QPEDV (SEQ ID NO: 73)

NP_001801.1 major centromere autoantigen B

MGPKRRQLTFREKSRIIQEVEENPDLRKGEIARRFNIPPSTLSTILKNKRAILASERKYG
 50 VASTCRKTNKLSPYDKLEGLLIAWFQQIRAAGLPVKG IILKEKALRIA EELGMDDFTASN
 GWLDRFRRRHGVVSCSGVARARARNAAPRTPAAPASPAAPVSEGS GGSTTGWRAREEQPPS
 VAEGYASQDVFSATETSLWYDFLPDQAAGLCGGDGRPRQATQRLSVLLCANADGSEKLPLP
 VAGKSAKPRAGQAGLPCDYTANSKGGVTTQALAKY LKALDTRMAAESRRVLLLAGRLAAQ
 SLDTSGLRHVQLAFFPPGTVHPLERGVVQQVKGHYRQAMLLKAMA ALEGQDPSGLQLGLT
 55 EALHFVAAAWQAVEPSDIAACFREAGFGGGPNATITTS LKSEGE EEEEEEEEEEEEEEGEGEEE
 EEEGEEEEEGGEGEELGEEEEVEEEGDVDSDEEEEEDEESSEGLEAEDWAQGVVEAGGSF

5 GAYGAQEEAQCPTLHFLEGGEDSDSDSEEEDDEEEDDEDEDDDDDEEDGDEVVPVPSFGEAM
AYFAMVKRYLTSFPIDDRVQSHILHLEHDLVHVTRKNHARQAGVRGLGHQS (SEQ ID NO:
74)

NP_523353.2 male-specific lethal 3 homolog isoform a

10 MSASEGMKFKFHSGEKVLCFEPDPTKARVLYDAKIVDVIVGKDEKGRKPIEYLIHFNGWNRS
WDRWAAEDHVLRTDENRRLQRKLARKAVARLRSTGRKKKRCRLPGVDSVLKGLPTEEKD
ENDENSLSSSSDCSENKDEEISEESDIEEKTEVKEEPELQTRREMEERTITIEIPEVLKKQLEDD
CYYINRRKRLVKLPCQTNITILESIVKHFAINAAFSANERPRHHHVMPHANMNVHYIPAEN
VDLCKEMVDGLRITFDYTLPLVLLYPYEQAQYKKVTSSKFFLPIKESATSTNRSQEELSPSPPL
15 LNPSTPQSTESQPTTGEPATPKRRKAEPEALQSLRRSTRHSANCDR
LSESSASPQPKRRQDTSASMPKLFHLEKKTPVHSRSSSPIPLTPSKEGSAVFAGFEGR
RTNEINEVLSWKLVPDNYPPGDQPPPPSYIYGAQHLLRLFVKLPEILGKMSFSEKNLKA
LKHFDLFLRFLAEYHDDFFPESAYVAACEAHYSTKNPRAIY (SEQ ID NO: 75)

20 NP_001189442.1 max dimerization protein 1 isoform 2

MAAAVRMNIQMLLEAADYLERREREAEHGYASMLPYNNKDRDALKRRNKSCKNNSSSRST
HNEMEKNRRAHLRLCLEKLKGLVPLGPESRHTTLLTKAKLHIKKLEDCDRKAVHQIDQL
QREQRHLKRQLEKLGIERIRMDSIGSTVSSERSDSREIDVDVESTDYLTGDLDWSSSSVSDS
DERGSMQSLGSDEGYSSSTSIKRIKLQDSHKACLGL (SEQ ID NO: 76)

25 NP_055048.1 nucleolar transcription factor 1 isoform a

MNGEADCPTDLEMAAPKGQDRWSQEDMLTLLECMKNNLPSNDSSKFKTTESHMDWEKVA
FKDFSGDMCKLKWVEISNEVRKFRTLTELILDAQEHVKNPYKGKKLKKHPDFPKKPLTPYFR
FFMEKRAKYAKLHPMSNLDLTKILSKKYKELPEKKKMKYIQDFQREKQEFERNLARFRED
30 HPDLIQNAKKSDIPEKPKTPQQLWYTHEKKVYLKVRPDATTKEVKDSLQKQWSQLSDKKRL
KWIHKALEQRKEYEEIMRDYIQKHPELNISEEGITKSTLTKAERQLKDKFDGRPTKPPPNSSYL
YCAELMANMKDVPSTERMVLCSQQWKLLSQKEKDAYHKKCDQKKKDYEVLLRFLESLPE
EEQQRVLGEEKMLNINKKQATSPASKKPAQEGGKGGSEKPKRPVSAMFIFSEEKRRQLQEER
PELSESELTRLLARMWNDLSEKKKAKYKAREAALKAQSERKPGGEREERGKLPESPKRAEEI
35 WQQSVIGDYLARFKNDRVKALKAMEMTWNMEKKEKLMWIKKAAEDQKRYERELSEMR
APPAATNSSKKMKFQGEPPKPPMNGYQKFSQELLSNGELNHLPLKERMVEIGSRWQRISQSQ
KEHYKKLAEEQQKQYKVHLDLWVKSLSPQDRAAYKEYISNKRKSMTKLRGPNPKSSRTTLQ
SKSESEEDDEEDEDDEDEDEEEEDDENGDSSEDDGGDSSESSEDESEDEGDENEEDDEDED
EDDEDEDNESEGSSSSSSSSSGDSSSDSDSN (SEQ ID NO: 77)

40 NP_006212.1 peptidyl-prolyl cis-trans isomerase NIMA-interacting 1

MADEEKLPPGWEKRMSRSSGRVYYFNHITNASQWERPSGNSSSGGKNGQGEPARVRCSHLL
VKHSQSRRPSSWRQEKITRTKEEALELINGYIQKIKSGEEDFESLASQFSDCSSAKARGDLGAF
SRGQMMPKFEDASFALRTGEMSGPVFTDSGIHILRTE (SEQ ID NO: 78)

45 NP_001108.2 pituitary adenylate cyclase-activating polypeptide precursor

MTMCSGARLALLVYGIIMHSSVYSSPAAAGLRFPGRPEEEAYGEDGNPLPDFDGSEPPG
AGSPASAPRAAAAWYRPAGRRDVAHGILNEAYRKVLDQLSAGKHLQSLVARGVGGSLGGG
AGDDAEPLSKRHSDGIFTDSYSRYRKQMAVKKYLA AVLKGKRYKQRVKNKGRRRIAYL (SEQ
50 ID NO: 79)

NP_006226.2 POU domain class 2-associating factor 1

MLWQKPTAPEQAPAPARPYQGVRVKEPVKELLRRKRGHASSGAAPAPTAVVLPHQPLATYT
TVGPSCLDMEGSVSAVTEEAALCAGWLSQPTPATLQPLAPWTPYTEYVPHEAVSCPYSADM
55 YVQPVCPSTVVGPSVLTYSAPPLITNVTTTRSSATPAVGPPLEGPEHQAPLTYFPWPQPLSTL
PTSTLQYQPPAPALPGPQFVQLPISIPVQLQDMEDPRRAASSLTIDKLLLEE

5 DSDAYALNHTLSVEGF (SEQ ID NO: 80)

NP_001185715.1 POU domain, class 2, transcription factor 1 isoform 3

MADGGAASQDESSAAAAAADSARMNNPSETSKPSMESGDGNTGTQTNGLDFQKQPVVPVGG
 AISTAQAQAFGLGHLHQVQLAGTSLQAAAQSLNVQSKSNEESGDSQQPSQPSQQPSVQAAIPQ
 10 TQLMLAGGQITGDLQQLQQLQQQNLNLQQFVLVHPTTNLQPAQFIISQTPQGQQGLLQAQNL
 LTQLPQQSQANLLQSQPSITLTSQPATPTRTIAATPIQTLPQSQSTPKRIDTPSLEEPSDLEEELEQ
 FAKTFKQRRIKLGFTQGDVGLAMGKLYGNDFSQTTISRFEALNLSFKNMCKLKPLLEKWLN
 DAENLSSDSSLSSPSALNSPGIEGLSRRRKKRTSIETNIRVALEKSFLE
 NQKPTSEEITMIADQLNMEKEVIRVWFCNRRQKEKRINPPSSGGTSSSPIKAIFPSPTSL
 15 VATTPSLVTSSAATTTLTVSPVLPLTSAAVTNLSVTGTSDTTSNNTATVISTAPPASSAVT
 SPSLSPSPSASASTSEASSASETSTTQTTSTPLSSPLGTSQVMVTASGLQTAAAAAALQGA
 AQLPANASLAAMAAAAGLNPSLMAPSQFAAGGALLSLNPGTLSGALSPALMSNSTLATIQAL
 ASGGSLPITSLDATGNLVFANAGGAPNIVTAPLFLNPQNLSLLTSNPVSLVSAAAASA
 GNSAPVASLHATSTSAESIQNSLFTVASASGAASTTTTASKAQ (SEQ ID NO: 81)

20

NP_001191890.1 pre-B-cell leukemia transcription factor 1 isoform 2

MDEQPRLMHSAGVGMAGHPGLSQHLQDGAGGTEGEGGRKQDIGDILQQIMTITDQSLDEA
 QARKHALNCHRMKPALFNVLCEIKEKTVLSIRGAQEEPTDPQLMRLDNMLLAEGVAGPEK
 GGSAAAAAASGGAGSDNSVEHSDYRAKLSQIRQIYHTELEKYEQACNEFTTHVMNLL
 25 REQSRTRPISPKEIERMVSIIHRKFSSIQMQLKQSTCEAVMILRSRFLDARRKRRNFNKQATEIL
 NEYFYSHLSNPYPSEEAKEELAKKCGITVSQVSNWFGNKRIRYKKNIGKFQEEANIYAAKTA
 VTATNVSAHGSQANSPTSPNSAGGYSPCYQPDRIQ (SEQ ID NO: 82)

NP_002871.1 RAF proto-oncogene serine/threonine-protein kinase

30 MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSTKTSNTIRVFLP
 NKQRTVVNVNRNGMSLHDCLMKALKVRGLQPECCAVFRLLEHKGKKARLDWNTDAASLI
 GEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLNGFRCQTCGYKFHEHCSTKVPTMC
 VDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSE
 GSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPV
 35 PAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKKGKWHGDVA
 VKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLH
 VQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRLW
 SGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIF
 MVGRGYASPDLSKLYKNCPKAMKRLVADCVKVKEERPLFPQILSSIELLQHSLPKINRSASE
 40 PSLHRAAHTEDINACTLTTSPLRPVF (SEQ ID NO: 83)

NP_001005862.1 receptor tyrosine-protein kinase erbB-2 isoform b

MKLRLPASPETHLDMLRHLVYQGCQVVQGNLELTYPNTASLSFLQDIQEVQGYVLIAHNQV
 RQVPLQRLRIVRGTLQFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGV
 45 LIQRNPQLCYQDTILWKDIFHKNNQLALTIDTNRSRACHPCSPMCKGSRGWGESSEDCQSLT
 RTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLFNHSICELHCPALVTYNTD
 TFESMPNPEGRTYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCA
 RVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFET
 LEEITGYLYISAWPDSLPLDSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLA
 50 LIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPPT
 QCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVAC
 AHYKDPPFCVARCPSGVKPDLSPYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRAS
 PLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQM
 RILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMA
 55 GVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRRGLGSQDLLNWCMQIAKGMSYL
 EDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEHADGGKVPIKWMALESILRRR

5 FTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCW
 MIDSECRPRFREL VSEFSRMARDPQRFVVIQNE DLGPASPLDSTFYRSLLEDDDMGDLVDAEE
 YLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSD
 VFDGDLGMGAAKGLQSLPTHDPSP LQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVR
 PQQPSREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPH
 10 PPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV (SEQ ID NO: 84)

NP_001036064.1 receptor tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor
 MKPATGLWVWVSLVAAGTVQPSDSQSV CAGTENKLSSLSDLEQQYRALRKY YENCEVVM
 GNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGTKLYEDRYALAI FLNRYR
 15 KDG NFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTLVSTNGSSG
 CGRCHKSTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPYVSDCCHRECAGGCSGPKDTD
 CFACMNFND SGACVTQCPQTFVYNPTTFQLEHNFNAKYTYGAFCVKKCPHNFVVDSSSCVR
 ACPSSKMEVEENG IKMCKPCTDICPKACDGIGTGSLSAQTVDSSNIDKFINCTKINGNLIFLV
 TGIHGDOPYNAIEAIDPEKLN VFRTVREITGFLNIQSWPPNMTDFSVFSNLVTIGGRVLYSGLSL
 20 LILKQQGITS LQFQSLKEISAGNIYITDNSNLCYYHTINWTTLFSTINQRIVIRDNRKAENCTAE
 GMVCNHLCSSDGCWGPDPDQCLSCRRFSRGRICIESCNLYDGEFREFENG SICVECDPQCEK
 MEDGLLTCHGPGPDNCTKCSHF KDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCT
 QGCNGPTSHDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRA
 LRRFLETELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGT VYKGIWVPEGETVKIPV
 25 AIKILNETTGPKANVEFMDEALIMASMDPHLVRL LGVCLSPTIQLVTQLMPHGC LLEYVHE
 HKDNIGSQLLL NWCVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLEGD
 EKEYNADGGKMPIKWMALECIHYRK FTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDL
 LEKGERLPQPPICTIDVYMVMVKCWMIDADSRPKFKELAAEF SRMARDPQRYLVIQGDDRM
 KLPSND SKFFQNLLDEEDLEDMMDAEEYLVPQAFNIPPPIYTSRARIDSNRNQFVYRDGGFA
 30 AEQGVSVPYRAPTSTIPEAPVAQGATAE IFDDSCNGTLRKPVAPHVQEDSSTQRY SADPTVF
 APERSPRGELDEEGYMT PMRD KPKQEYLN PVEENPFVSRRKNGDLQALDNPEYHNASNGPP
 KAEDEYVNEPLYLNTFANTLGKAEYLKNNILSMPEKAKKAFDNP DYWNHSLPPRSTLQHPD
 YLQEYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV (SEQ ID NO: 85)

35 NP_000312.2 retinoblastoma-associated protein
 MPPKTPRKTAATAAAAAA EPPAPPPPPPEEDPEQDSGPEDLPLVRLEFEETE EPDFTALCQKL
 KIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEIS
 VHKKFFNLLKEIDTSTKVDNAMSRLKKYDVLFA LFSKLERTCELIYLTQPSSSISTEINSALVL
 KVSWITFLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRR
 40 GQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLS
 KRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPHTPVRTVMNT
 IQQLMMILNSASDQPSENLISYFNNCTVNPKE SILKRVKDIGYIFKEKFAKAVGQGCVEIGSQR
 YKLGVRLYYRVMESMLKSEEERLSIQNF SKLLNDNIFHMSLLACALEVVMATYSRSTSQNLD
 SGTDLSPFWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFD
 45 LIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQAT
 SAFQTQKPLKSTSLSFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMR
 DRHLDQIMMCSMYGICKVKNI DLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSV
 FMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMT
 PRSRILV SIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKH
 50 LPGESKFQOK
 LAEMTSTRTRMQKQKMND SMDTSNKEEK (SEQ ID NO: 86)

NP_002927.2 ribonuclease H1
 MSWLLFLAHRVALAALPCRRGSRGFGMFYAVRRGRKTGVFLTWNECRAQVDRFPAARFKK
 55 FATEDEAWAFVRKSASPEVSEGHENQH GQESEAKASKRLREPLDGDGHESAEPYAKHMKPS
 VEPAPPVSRDTFSYMGDFVVVYTDGCCSSNGRRRPRAGIGVYWGP GHPLNVGIRLPGRQTN

5 QRAEIHAAACKAIEQAKTQNINKLVLYTDSMFTINGITNWVQGWKKNGWKTSAGKEVINKED
FVALERLTQGMDIQWMHVPGHSGFIGNEEADRLAREGAKQSED (SEQ ID NO: 87)

NP_036366.3 RING1 and YY1-binding protein

10 MTMGDKKSPTRPKRQAKPAADEGFWDCSVCTFRNSAEAFKCSICDVRKGTSTRKPRINSQL
VAQQVAQQYATPPPPKKEKKEKVEKQDKEKPEKDKEISPSVTKKNTNKKTKPKSDILKDPPS
EANSIQSANATTKTSETNHTSRPRLKNVDRSTAQQLA VTVGNVTVIITDFKEKTRSSSTSSTV
TSSAGSEQQNQSSSGSESTDKGSSRSSTPKGDM SAVNDESF (SEQ ID NO: 88)

NP_001006121.1 RNA-binding motif protein, Y chromosome, family 1 member B

15 MVEADHPGKLFIGGLNRETNEKMLKAVFGKHGPISEVLLIKDRTSKSRGFAFITFENPAD
AKNAAKDMNGKSLHGKAIKVEQAKKPSFQSGGRRRPPASSRNRSPSGSLRSARGSRGGTRG
WLPSQEGHLDDGGYTPDLKMSYSRGLIPVKRGPSSRSGGPPPKKSAPSAVARNSNSWMGSQG
PMSQRRENYGVPPRRATISSWRNDRMSTRHDGYATNDGNHPSCQETRDYAPPSRGYAYRD
NGHSNRDEHSSRGYRNHRSSRETRDYAPPSRGHAYRDYGHSSRRDESYSGYRNRRSSRETR
20 EYAPPSRGHGYRDYGHSSRRHESYSRGYRNHPSSRETRDYAPPHRDYAYRDYGHSSWDEHSS
RGYSYHDGYGEALGRDHSEHLGSSYRDALQRYGTSHGAPPARGPRMSYGGSTCHAYSNTR
DRYGRSWESYSSCGDFHYCDREHVC RKDQRNPPSLGRVLPDPREAYGSSSYVASIVDGGESR
SEKGDSSRY (SEQ ID NO: 89)

25 NP_036523.1 SAM pointed domain-containing Ets transcription factor

MGSASPGLSSVSPSHLLPDPD TVSRTGLEKAAAGAVGLERRDWSPSPPATPEQGLSAFYL
SYFDMLYPEDSSWAAKAPGASSREEPPEEPEQCPVIDSQAPAGSLDLVPGGLTLEEHSLE
QVQSMVVGEVLKDIETACKLLNITADPMDWSPSNVQKWLLWTEHQYRLPPMGKAFQELAG
KELCAMSEEQFRQRSPLGGDVLHAHLDIWKSAAWMKERTSPGAIHYCASTSEESWTDSEVD
30 SSCSGQPIHLWQFLKELLLKPHSYGRFIRWLNKEKGIFKIEDSAQVARLWGIRKNRPAMNYD
KLSRSIRQYYKKGIIRKPDISQRLVYQFVHPI (SEQ ID NO: 90)

NP_003122.1 serum response factor

35 MLPTQAGAAAALGRGSALGGSLNRTPTGRPGGGGGTRGANGGRVPGNGAGLGPGRLEREA
AAAAATTPAPTAGALYSGSEGDSSESGEEELGAERRGLKRSLSMEIGMVVGGPEASAAATG
GYGPVSGAVSGAKPGKKTRGRVKIKMEFIDNKLRRYTTFSKRKTGIMKKAYELSTLTGTQVL
LLVASETGHVYTFATRKLQPMITSETGKALIQTCLNSPDSPPRSDPTTDQRMSATGFEETDLT
YQVSESDSSGETKDTLKP AFTVTNLPGTTSTIQTAPSTSTTMQVSSGSPFITNYLAPVSASVSP
SAVSSANGTVLKSTGSGPVSSGGLMQLPTSFTLMPGGAVAQQVPVQAIQVHQAPQQASPSR
40 DSSTDLTQTSSSGTVTLPATIMTSSVPTTVGGHMMYPSPHAVMYAPTSGLGDGSLTVLNAFS
QAPSTMQVSHSQVQEPGGVPQVFLTASSGT VQIPVSAVQLHQMAVIGQQAGSSSNLTELQVV
NLDTAHSTKSE (SEQ ID NO: 91)

NP_003131.1 sex-determining region Y protein

45 MQSYASAMLSVFNSDDYSPAVQENIPALRRSSSFLCTESCNSKYQCETGENSKGNVQDRVKR
PMNAFIVWSRDQRRKMALENPRMRNSEISKQLGYQWKMLTEAEKW PFFQEAQKLQAMHR
EKYPNYKYRPRRKAKMLPKNC SLLPADPASVLCSEVQLDNRLYRDDCTKATHSRMEHQLG
HLPPINAASSPQQRDRYSHWTKL (SEQ ID NO: 92)

50 NP_004588.1 small nuclear ribonucleoprotein Sm D2 isoform 1

MSLLNPKPKSEMTPEELQKREEEEFNTGPLSVLTQSVKNNTQVLINCRNNKLLGRVKA FDRH
CNMVLENVKEMWTEVPKSGKGKKKSKPVNKDRYISKMFLRGDSVIVVLRNPLIAGK (SEQ
ID NO: 93)

55 NP_001005291.1 sterol regulatory element-binding protein 1 isoform a

5 MDEPPFSEAALEQALGEPCLDAALLTDIEGEVGAGRGRANGLDAPRAGADRGAMDCTFED
 MLQLINNQDSDFPGLFDPPYAGSGAGGTDPA SPDTSSPGSLSPPPATLSSSLEAFLSGPQAAPS
 PLSPPQPAPTPLKMYPSMPAFSPGPGIKEESVPLSILQTPTPQPLPGALLPQSFPAPAPPQFSSTP
 VLGYPSPPGGFSTGSPPGNTQQPLPGLPLASPPGVPPVSLHTQVQSVVPQQLLTVTAAPTAAP
 VTTTVTSQIQQVPVLLQPHFIKADSLLL TAMKTDGATVKAAGLSPLVSGTTVQTGPLPTLVSG
 10 GTILATVPLVVDAEKL PINRLAAGSKAPASAQSRGEKRTAHNAIEKRYRSSINDKIIELKDLVV
 GTEAKLNKSAVLRKAIDYIRFLQHSNQKLKQENLSLRTAVHKSKSLKDLVSACGSGGNTDVL
 MEGVKTEVEDTLTPPPSDAGSPFQSSPLSLGSRGSGSGSGSDSEPDS PVFEDSKAKPEQRPSL
 HSRGMLDRSRLALCTLVFLCLSCNPLASLLGARGLPSPSDTTSVYHSPGRNVLGTESRDGPG
 WAQWLLPPVWVLLNGLLVLSLVLLFVYGE PVTRPHSGPAVYFWRHRKQADLDLARGDFA
 15 QAAQQLWLALRALGRPLPTSHLDLACSL LWNLIRHLLQRLWVGRWLAGRAGGLQQDCALR
 VDASASARDAALVYHKLHQLHTMGKHTGGHLTATNLALSALNLAECAGDAVSVATLAEIY
 VAAALRVKTS LPRALHFLTRFFLSSARQACLAQSGSVPPAMQWLCHPVGHRFFVDGDWSVL
 STPWESLYSLAGNPVDPLAQVTQLFREHLLERALNCVTQPNPSPGSADGDKEFSDALGYLQL
 LNCSDAAGAPAYSFSSISSMATTTGVDPAKWWASLTAVVIHWLRRDEEAAERLCPLVEH
 20 LPRVLQESERPLPRAALHSFKAARALLGCAKAESGPASLTICEKASGYLQDSLATTPASSSIDK
 AVQLFLCDLLL VVRTSLWRQQQPPAPAPAAQGTSSRPQASALELRGFQRDLSLRLRLAQSFR
 PAMRRVFLHEATARLMAGASPTRTHQLLDRSLRRRAGPGGKGGAVAELEPRPTRREHAEAL
 LLASCYLPPGFLSAPGQRVGMLAEAARTLEKLGDRLLHDCQQMLMRLGGGTTVTSS (SEQ
 ID NO: 94)
 25 NP_006280.3 talin-1
 MVALSLKISIGNVVKTMQFEPSTMVYDACRIIRERIEAPAGPPSDFGLFLSDDDPKKGI
 WLEAGKALDY YMLRNGDTMEYRKKQRPLKIRMLDGT VKTIMVDDSKTVTDMLMTICARIG
 ITNHDEYSLVRELMEEKKEEITGTLRKDKTLLRDEKKMEK LKQKLHTDDELNWL DHGRTL R
 30 EQGVEEHETLLLRRKFFYSDQNVDSRDPVQLNLLYVQARDDILNGSHPV SFDKACEFAGFQC
 QIQFGPHNEQKHKAGFLDLKDFLPKEYVKQKGERKIFQA HKNCGQMSEIEAKVRYVKLARS
 LKTYGV SFFLVKEKMKGKNKLVPRLLGITKECVMRVDEKTKEVIQEWNL TNIKRWAASPKS
 FTLD FGDYQDGYYSVQTTEGEQIAQLIAGYIDIILKKKKSKDHFGL EGDEESTMLEDSVSPKK
 STVLQQQYNRVGKVEHGSVALPAIMRSGASGPENFQVGSMPPAQQQITSGQMHRGHMPPLT
 35 SAQQALTGTINSSMQAVQAAQATLDDFDTL PPLGQDAASKAWRKNKMDESKHEIHSQVDAI
 TAGTASVVNLTAGDPAETDYTAVGCAVTTISSNLTEMSRGVKLLAALLEDEGGSGRPLLQA
 AKGLAGAVSELLRSAQPASAEPRQNLLQAAGNVGQASGELLQQIGESDTPHFQDALMQLA
 KAVASAAAALVLKAKSVAQRTEDSGLQTQVIAAATQCALSTS QLVACTKVVAPTISSPVCQE
 QLVEAGRLVAKAVEGCVSASQAATEDGQLLRGVGAAATAVTQALNELLQHVKAHATGAG
 40 PAGRYDQATDTILTVTENIFSSMGDAGEMVRQARILAQATSDLVNAIKADAEGESDLENSRK
 LLSAAKILADATAKMVEAAKGAAAHDPDSEEQQQRLREAAEGLRMATNAAAQNAIKKKLVQ
 RLEHAAKQAAASATQTIAAAQHAASTPKASAGPQPLL VQSCKAVAEQIPLL VQGVRSQAQ
 PDSPSAQLALIAASQSFLQPGGKMVAAAKASVPTIQDQASAMQLS QCAKNLGTALAE LRTA
 AQKAQEACGPLEMDSALSVVNLEKDLQEVKAAARDGKLKPLPGETMEKCTQDLGNSTKA
 45 VSSAIAQLLGEVAQGNENYAGIAARDVAGGLRSLAQAARGVAALTS DPAVQAIVLDTASDV
 LDKASSLIEEAKKAAGHPGD PESQQRLAQVAKAVTQALNRCV SCLPGQRDVDNALRAVGD
 ASKRLLSDSLPPSTGTFQEAQSRLNEAAAGLNQAATELVQASRGTPQDLARASGRFGQDFST
 FLEAGVEMAGQAPSQEDRAQVVSNLKGISMSSSKLLLA AKALSTDPAAPNLKSQLAAAARA
 VTDSINQLITMCTQQAPGQKECDNALRELETVRELLENPVQPINDMSYFGCLDSVMENSKVL
 50 GEAMTGISQNAKNGNLPEFGDAISTASKALCGFTEAAAQAAYLVGVSDPNSQAGQQGLVEP
 TQFARANQAIQMACQSLGEPGCTQAQVLSAATIVAKHTSALCNSCRLASARTTNPTAKRQFV
 QSAKEVANSTANLVKTIKALDGAFTEENRAQCRAATAPLLEAVDNLSAFASNPEFSSIPAQIS
 PEGRAAMEPIVISAKTMLESAGGLIQTARALAVNPRDPPSWSVLAGHSRTVSDSIKKLITSMR
 DKAPGQLECEAIAALNSCLRDLDQASLA AVSQQ LAPREGISQEALHTQMLTAVQEISHLIEP
 55 LANAARAEASQLGHKVSQMAQYFEPLTLAAVGAASKTLSHPQQMALLDQTKTLAESALQL
 LYTAKEAGGNPKQAAHTQEALEEAVQMMTEAVEDLTTTLNEAASAAGVVGGMVDSITQAI

5 NQLDEGPMGEPEGSFVDYQTTMVRTAKAIAVTVQEMVTKSNTSPEELGPLANQLTSDYGRL
 ASEAKPAAVAAENEEIGSHIKHRVQELGHGCAALVTKAGALQCSPSDAYTKKELIECARRVS
 EKVSHVLAALQAGNRGTQACITAASAVSGIADLDTTIMFATAGTLNREGTETFADHREGILK
 TAKVLVEDTKVLVQNAAGSQEKLAQAAQSSVATITRLADVVKLGAASLGAEDPETQVVLIN
 AVKDVAKALGDLISATKAAAGKVGDDPAVWQLKNSAKVMVTNVTSLKTVKAVEDEATK
 10 GTRALEATTEHIRQELAVFCSPEPPAKTSTPEDFIRMTKGITMATAKAVAAGNSCRQEDVIAT
 ANLSRRAIADMLRACKEAAYHPEVAPDVRLRALHYGRECANGYLELLDHVLLTLQKPSPEL
 KQQLTGHSKRVAAGSVTELIQAAEAMKGTWVDPEDPTVIAENELLGAAAAIEAAAKKLEQL
 KPRAKPKEADESLNFEEQILEAAKSIAAATSALVKAASAAQRELVAQGKVGAI PANALDDGQ
 WSQGLISAARMVAAATNNLCEAANA AVQGHASQEKLISSAKQVAASTAQLLVACKVKADQ
 15 DSEAMKRLQAAGNAVKRASDNLVKAAQKAAAFEEQENETVVVKEKMVG GIIAQIIAAQEEM
 LRKERELEEARKKLAQIRQQQYKFLPSELRDEH (SEQ ID NO: 95)

NP_003185.1 TATA-box-binding protein isoform 1

MDQNNSLPPYAQGLASPGAMTPGIPIFSPMMPYGTGLTPQPIQNTNSLSILEEQQRQQQ
 20 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQAVAAA AVQQSTSQQATQGTSGQ
 APQLFHSQTLTTAPLP GTTPLYPSPMTPMTPITPATPASESSGIVPQLQNIVSTVNLGCKLDLKT
 IALRARNAEYNPKRFAAVIMRIREPRTTALIFSSGKMVCTGAKSEEQSRLAARKYARVVQKL
 GFP AKFLDFKI QNMVGSCDVKFPIRLEGLVLTHQQFSSYEPELFPGLIYRMIKPRIVLLIFVSGK
 VVLTGAKVRAEIYEAFENIYPILKGFRKTT (SEQ ID NO: 96)

25

NP_001165556.1 TATA-box-binding protein isoform 2

MTPGIPIFSPMMPYGTGLTPQPIQNTNSLSILEEQQRQQQQQQQQQQQQQQQQQQQQQQQQQ
 QQQQQQQQQQQQQQQQAVAAA AVQQSTSQQATQGTSGQAPQLFHSQTLTTAPLP GTTPLYPSP
 MTPMTPITPATPASESSGIVPQLQNIVSTVNLGCKLDLKTIALRARNAEYNPKRFAAVIMRIE
 30 PRTTALIFSSGKMVCTGAKSEEQSRLAARKYARVVQKLGFPAKFLDFKI QNMVGSCDVKFPI
 RLEGLVLTHQQFSSYEPELFPGLIYRMIKPRIVLLIFVSGKVVLTGAKVRAE
 IYEAFENIYPILKGFRKTT (SEQ ID NO: 97)

NP_057254.1 T-cell leukemia homeobox protein 2

MEPGMLGPHNLPHHEPISFGIDQILSGPETPGGGLGLGRGGQGHGENGA FS GGYHGASGYGP
 35 AGSLAPLP GSSGVGPGGVIRVPAHRPLVPPPAGGAPAVPGPSGLGGAGGLAGLTFPWMDSG
 RRF AKDRLTAALSPFSGTRRIGHYPYQNRTPPKRKKPRTSFSRSQVLELERRFLRQKYLASAER
 AALAKALRMTDAQVKTWFQNRRTKWRRQTAEEREAERHRAGRLLLHLQQDALPRPLRPPL
 PPDPLCLHNSSLFALQNLQPWAEDNKVASVSGLASVV (SEQ ID NO: 98)

40

NP_000607.1 T-cell surface glycoprotein CD4 isoform 1 precursor

MNRGV PFRHLLLVLQLALLPAATQGGKVVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKI
 LGNQGSFLT KGPSKLNDRADSRRLWDQGNFPLIKNLKI ESDTYICEVEDQKEEVQLLVFG
 LTANS DTHLLQGQSLT LTLESPPGSSPSVQCRSPRGKNIQGGKTL SVSQLELQDSG
 45 TWTCTVLQNQKKVEFKIDIVVLA FQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWWQA
 ERASSSKSWITFDLKNKEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLT LALEA
 KTGK LHQEVN LVVMRATQLQKNLTCEVWGPTSPKLMLS LKLENKEAKVSKREKAVWVLN
 PEAGMWQCLLSDSGQVLLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRHR
 RRQAERMSQIKRLLSEKKTCQC PHRFQKTCSPI (SEQ ID NO: 99)

50

NP_059523.2 telomeric repeat-binding factor 1 isoform 1

MAEDVSSAAPS PRGCADGRDADPTEEQMAETERNDEEQFECQELLE CQVQVGAPEEEEEEE
 EDAGLVAEAEAVAAGWMLDFLCLSLCRAFRDGRSEDFRRTRNSAEAIHGLSSLTACQLRTI
 YICQFLTRIAAGKTLDAQFENDERITPLESALMIWGSIEKEHDKLHEEIQNLIKIQ A
 55 IAVCMENG NFKEAEEVFERIFGDPNSHMPFKSKLLMIISQKDTFHSFFQHFSYNHMMMEKI

- 5 KSYVNYVLSEKSSTFLMKAAAKVVESKRTRTITSQDKPSGNDVEMETEANLDTRKSVSDKQ
SAVTESSEGTVSLLRSHKNLFLSKLQHGTQQQDLNKKERRVGTPQSTKKKKESRRATESRIPV
SKSQPVTPEKHRARKRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSVMLKDR
WRTMKKLKLISSDSED (SEQ ID NO: 100)
- 10 NP_005643.1 telomeric repeat-binding factor 2
MAGGGGSSDGSGRAAGRRASRSSGRARRGRHEPGLGGPAERGAGEARLEEAVNRWVLKFY
FHEALRAFRGSRYGDFRQIRDIMQALLVRPLGKEHTVSRLLRVMQCLSRIEENLDCSFD
EAELTPLESAINVLEMIKTEFTLTEAVVESSRKLVEAAVVICIKNKEFEKASKILKKHMSKDP
TTQKLRNDLLNIIREKNLAHPVIQNFSYETFQKMLRFLESHLDDAEPYLLTMAKKALKSESA
15 ASSTGKEDKQPAPGPVEKPPREPARQLRNPPTTIGMMTLKAAFCTLGAQDSEAAFAKLDQK
DLVLPTQALPASALKNRPRKDESSAPADGEGGSELQPKNKRMTISRLVLEEDSQSTEPS
AGLNSSQEAASAPPSKPTVLNQPLPGEKNPKVPKGKWNSSNGVEEKETWVEEDELQVQAA
PDEDSTTNITKKQKWTVEESEWVKAGVQKYGEGNWAAISKNYPFVNRTAVMIKDRWRTM
KRLGMN (SEQ ID NO: 101)
- 20 NP_060575.1 THAP domain-containing protein 1 isoform 1
MVQSCSAYGCKNRYDKDKPVSFHKFPLTRPSLCKEWEAAVRRKNFKPTKYSSICSEHFTPDC
FKRECNNKLLKENAVPTIFLCTEPHDKKEDLLEPQEQLPPPPLPPPVSQVDAAIGLLM
PPLQTPVNLSVFCDHNYTVEDTMHQRKRHQLLEQQVEKLRKKLKTAAQQRCCRQERQLEKLL
25 EVVHFQKEKDDVSERGYVILPNDYFEIVEVPA (SEQ ID NO: 102)
- NP_002219.1 transcription factor AP-1
MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLT
SPDVGLLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAE
30 LHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGALS
SGGGAPSYGAAGLAFPAQPQQQQQPPHLLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSP
IDMESQERIKAEKRMNRNRIASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVA
QLKQKVMNHVNSGCQLMLTQQLQTF (SEQ ID NO: 103)
- 35 NP_003097.1 transcription factor SOX-2
MYNMMETELKPPGPQQTSGGGGGNSTAAAAGGNQKNSPDRVKRPMNAFMVWSRGQRRK
MAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRLRALHMKEHPDYKYRPRRKTCTL
MKKDKYTLPGGLLAPGGNSMASGVGVGAGLGAGVNQRMDSYAHMNGWSNGSYSMMQD
QLGYPQHPLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYSMSYSQQGTPGM
40 ALGSMGSVVKSEASSSPVVTSSSHSRAPCQAGDLRDMISMYLPGAEVPEPAAPSRLHMSQH
YQSGPVPGTAINGTLP LSHM (SEQ ID NO: 104)
- NP_003100.1 transcription factor Sp1 isoform b
MDEMTAVVKIEKGVGGNNGGNGNGGGAFAFSQARSSSTGSSSSTGGGGQESQPSPLALLAATC
45 SRIESPNENSNNNSQGQPSQSGGTGELDLTATQLSQGANGWQIISSSSGATPTSKEQSGSSTNGSN
GSESSKNRTVSGGQYVVAAPNLQNQQVLTGLPGVMPNIQYQVIPQFQTVDGQQLQFAATG
AQVQQDGSQIQIIPGANQQIITNRGSGGNIIAAMPNLLQQA VPLQGLANNVLSGQTQYVTN
VPVALNGNITLLPVNSVSAATLTPSSQAVTISSSGSQESGSQPVTSGTTISSASLVSSQASSSSFF
TNANSYSTTTTTSNMGIMNFTTSGSSGTNSQGQTPQRVSGLQGS DALNIQQNQTS GGS LQAG
50 QQKEGEQNQQTQQQQIILQPQLVQGGQALQALQAAPLSGQTFTTQAISQETLQNLQQLQAVPN
SGPIIIRTPTVGPNGQVSWQTLQNLQVQNPQAQTITLAPMQGVSLGQTSSSNTTLTPIASAA
SIPAGTVTVNAAQLSSMPGLQTINLSALGTSGIQVHPIQGLPLAIANAPGDHGAQLGLHGAGG
DGIHDDTAGGEEGENSPDAQPQAGRRTREACTCPYCKDSEGRGSGDPGKKKQHICHIQGC
GKVYGKTSHLRAHLRWHTGERPFMCTWSYCGKRFRTRSEDELQRHKRTHHTGEKKFACPEC PK
55 RFMRSDHLSKHIKTHQNKKGPGVALSVGTLPLDSGAGSESGTATPSALITTNMVAMEAIC
PEGIARLANSGINVMQVADLQSNISGNGF (SEQ ID NO: 105)

5

NP_001123645.1 transcriptional activator Myb isoform 1

MARRPRHSIYSSDEDEDFEMCDHDYDGLLPKSGKRHLGKTRWTREEDEKLKKLVEQNGT
 DDWKVIANYLPNRTDVQCQHRWQKVLNPELIKGPWTKEEDQRVIELVQKYGPKRWSVIAK
 HLKGRIGKQCRERWHNHLNPEVKKTSWTEEDRIIYQAHKRLGNRWAEIAKLLPGRTDNAI
 10 KNHWNSTMRRKVEQEGYLQESSKASQPAVATSFQKNSHLMGFAQAPPTAQLPATGQPTVN
 NDYSYYHISEAQNVSSHVPYPVALHVNIVNVPQAAAAIQRHYNDEDPEKEKRIKELELLLM
 STENELKGQQVLPTQNHTCSYPGWHSTTIADHTRPHGDSAPVSCLGEHHSTPSLPADPGSLPE
 ESASPARCMIVHQGTILDNVKNLLEFAETLQFIDSDSSSWCDLSSFEFFEEADFSPSQHHTGKA
 LQLQQREGNGTKPAGEPSPRVKNRMLSESSLDPKVLPPARHSTIPLVILRKKRGQASPLATG
 15 DCSSFIFADVSSSTPKRSPVKSLPFSPSQFLNTSSNHENS DLEMPSLTSTPLIGHKLTVTTPFHRD
 QTVKTQKENTVFRTPAIKRSILESSPRTPTPFKHALAAQEIKYGPLKMLPQTPSHLVEDLQDVI
 KQESDESGIVAEEFQENGPPLLKKIKQEVESPTDKSGNFFCSHHWEGDSLNTQLFTQTSPVADA
 PNILTSSVLMAPASEDEDNVLKAFTVPKNRSLASPLQPCSSWEPASCGKMEEQMTSSSQAR
 KYVNAFSARTLVM (SEQ ID NO: 106)

20

NP_001155128.1 transcriptional activator Myb isoform 4

MARRPRHSIYSSDEDEDFEMCDHDYDGLLPKSGKRHLGKTRWTREEDEKLKKLVEQNGT
 DDWKVIANYLPNRTDVQCQHRWQKVLNPELIKGPWTKEEDQRVIELVQKYGPKRWSVIAK
 HLKGRIGKQCRERWHNHLNPEVKKTSWTEEDRIIYQAHKRLGNRWAEIAKLLPGRTDNAI
 25 KNHWNSTMRRKVEQEGYLQESSKASQPAVATSFQKNSHLMGFAQAPPTAQLPATGQPTVN
 NDYSYYHISEAQNVSSHVPYPVALHVNIVNVPQAAAAIQRHYNDEDPEKEKRIKELELLLM
 STENELKGQQVTQNHTCSYPGWHSTTIADHTRPHGDSAPVSCLGEHHSTPSLPADPGSLPEESA
 SPARCMIVHQGTILDNVKNLLEFAETLQFIDSDSSSWCDLSSFEFFEEADFSPSQHHTGKALQL
 QQREGNGTKPAGEPSPRVKNRMLSESSLDPKVLPPARHSTIPLVILRKKRGQASPLATGDCS
 30 SFIFADVSSSTPKRSPVKSLPFSPSQFLNTSSNHENS DLEMPSLTSTPLIGHKLTVTTPFHRDQT
 VKTQKENTVFRTPAIKRSILESSPRTPTPFKHALAAQEIKYGPLKMLPQTPSHLVEDLQDVIKQ
 ESDESGIVAEEFQENGPPLLKKIKQEVESPTDKSGNFFCSHHWEGDSLNTQLFTQTSPVADAPNI
 LTSSVLMAPASEDEDNVLKAFTVPKNRSLASPLQPCSSWEPASCGKMEEQMTSSSQARKYV
 NAFSARTLVM (SEQ ID NO: 107)

35

NP_443177.1 tumor necrosis factor receptor superfamily member 13C

MRRGPRSLRGRDAPAPTPCVPAECFDLLVRHCVACGLLRTPRPKPAGASSPAPRTALQPQ
 ESGAGAGEAALPLPGLLFGAPALLGLALVLALVLVGLVSWRRRQRRLRGASSAEAPDGDK
 DAPEPLDKVIILSPGISDATAPAWPPPGEDPGTTPPGHSVPVPATELGSTELVTTKTAG
 40 PEQQ (SEQ ID NO: 108)

NP_004587.1 U1 small nuclear ribonucleoprotein A

MAVPETRPNHTIYINNLEKIKKDELKKSLEYAIFSQFGQILDILVSRSLKMRGQAFVIFK
 EVSSATNALRSMQGFPHYDKPMRIQYAKTDSDIIAKMKGT FVERDRKREKRKPKSQETPATK
 45 KAVQGGGATPVVGAVQGPVPGMPPMTQAPRIMHHMPGQPPYMPPPGMIPPPGLAPGQIPPG
 AMPPQQLMPGQMPPAQPLSENPPNHILFLTNLPEETNELMLSMLFNQFPGFKEVRLVPGRHDI
 AFVEFDNEVQAGAARDALQGFKITQNNAMKISFAKK (SEQ ID NO: 109)

NP_001161097.1 voltage-dependent L-type calcium channel subunit alpha-1C isoform 23

MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAALSWQAAIDAAR
 QAKLMGSAGNATISTVSSTQRKRQQYGKPKKQGSTTATRPPRALLCLTLKNPIRRACISIVEW
 KPFEIIIILLTIFANCVALAIYIPFEDDSNATNSNLERVEYLFLLIFTVEAFLKVIAYGLLFHPNAY
 LRNGWNLLDFIIVVGLFSAILEQATKADGANALGGKGAGFDVKALRAFRVLRPLRLVSGVP
 SLQVVLNSIIKAMVPLLHIALLVLFVIIYAIIGLELFMGKMHKTCYNQEGIADVPAEDDPSPCA
 55 LETGHGRQCQNGTVCKPGWDGPKHGITNFDNFAFAMLTVFQCITMEGWTDVLYWMQDAM
 GYELPWVYFVSLVIFGSFFVLNLVLGVLSGEFSKEREKAKARGDFQKLREKQQLEEDLKGYL

- 5 DWITQAEDIDPENEDEGMDEEKPRNMSMPTSETESVNTENVAGGDIEGENCGARLAHRISKS
KFSRYWRRWNRFCRRKCRAAVKSNVFWLVIFLVFLNLTITASEHYNQPNWLTEVQDTAN
KALLALFTAEMLLKMYSLGLQAYFVSLFNRFDCFVVCGGILETILVETKIMSPLGISVLRVLR
LLRIFKITRYWNSLSNLVASLLNSVRSIASLLLLLFLFIIIFSLLGMQLFGGKFNFDQMTRRSTF
DNFPQSLLTVFQILTGEDWNSVMYDGIMAYGGPSFPGMLVCIYFIILFICGNYILLNVFLAIAV
10 DNLADAESLTSAQKEEEEEKERKKLARTASPEKKQELVEKPAVGESKEEKIELKSITADGESP
PATKINMDDLQPNENEDKSPYPNPETTGEEDDEEPEMPVGPRPRPLSELHLKEKAVPMPEASA
FFIFSSNNRFRLLQCHRIVNDTIFTNLILFFILLSSISLAAEDPVQHTSFRNHILFYFDIVFTTIFTIEI
ALKMTAYGAFLHKGSFCRNYFNILDLLVVSLSISFGIQSSAINVVKILRVLRVLRPLRAINRA
KGLKHVVQCVFVAIRTIGNIVIVTTLLQFMFACIGVQLFKGKLYTCSDSSKQTEAECKGNYIT
15 YKDGEVDHPHIIQPRSWENSKFDFDNVLAAMMALFTVSTFEGWPELLYRSIDSHTEDEKGPIN
YRVEISIFFIIYIIIAFFMMNIFVGFVIVTFQEQQEQEYKNCELDKNQRQCVEYALKARPLRRYI
PKNQHQQYKVVWYVNSTYFEYLMFVLILLNTICLAMQHYGQSCFLKIAMNILNMLFTGLFTV
EMILKLIAFKPKHYFCDAWNTFDALIVVGSIVDIAITEVNNAEENSRSISITFFRLFRVMRLVKLL
SRGEGIRTLTWTFIKSFQALPYVALLIVMLFFIYAVIGMQVFGKIALNDTTEINRNNNFQTFPQ
20 AVLLLFRCATGEAWQDIMLACMPGKKCAPESEPSNSTEGETPCGSSFAVFYFISFYMLCAFLII
NLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWAEYDPEAKGRIKHLDVVTLLRRIQPPLGF
GKLCPHRVACKRLVSMNMPLNSDGTVMFNATLFAVVRTALRIKTEGNLEQANEELRAIIKKI
WKRTSMKLLDQVVPAGDDEVTVGKFYATFLIQEYFRKFKKRKEQGLVGKPSQRNALSLQA
GLRTLHDIGPEIRRAISGDLTAEELDKAMKEAVSAASEDDIFRRAGGLFGNHVSYYQSDGRS
25 AFPQTFTTQRPLHINKAGSSQGDTEPSHEKLVDSTFTPSYSSTGSNANINNANNTALGRLPR
PAGYPSTVSTVEGHGPPLSPAIRVQEVAVKLSNRMHCCDMLDGGTFPPALGPRRAPPLHQ
QLQGSLAGLREDTPCIVPGHASLCCSSRVGEWLPAGCTAPQHARCHSRESQAAMAGQEETS
QDETYEVKMNHDTEACSEPSLLSTEMLSYQDDENRQLTLPEEDKRDIRQSPKRGFLRSASLG
RRASFHLECLKRQKDRGGDISQKTVLPLHLVHHQALAVAGLSPLLQRSHSPASFPRPFATPPA
30 TPGSRGWPPQPVPVTLRLEGVESSEKLNSSFPSIHCGSWAETTPGGGGSSAARRVRPVSLMVPS
QAGAPGRQFHGSASSLVEAVLISEGLGQFAQDPKFIEVTTQELADACDMTIEEMESAADNLS
GGAPQSPNGALLPFVNC
RDAGQDRAGGEEDAGCVRARGRPSEELQDSRVYVSSL (SEQ ID NO: 110)
- 35 NP_005446.2 zinc finger Ran-binding domain-containing protein 2 isoform 2
MSTKNFRVSDGDWICPDKKCGNVNFARRTSCNRCGREKTTEAKMMKAGGTEIGKTLAEKS
RGLFSANDWQCKTCSNVNWARRSECNMCTPKYAKLEERTGYGGGFNERENVEYIEREES
DGEYDEFGRKKKKYRGKAVGPASILKEVEDKESEGEEDDEDLSDSKYKLDEDEDDEDADLS
KYNLDASEEEDSNKKKSNRRSRSKSRSSHSRSSSRSSSPSSSRSRSRSRSSSSSSQSRSRSSSRE
40 RSRSRGSKSRSSSRSHRGSSSPRKRYSYSSSSSPERNRKRSRSRSSSSSGDRKK
RRTRSRSPESQVIGENTKQP (SEQ ID NO: 111)
- NP_005185.2 CCAAT/enhancer-binding protein beta
MQRLVAWDPAACLPLPPPPAFKSMEVANFYEADCLAAAYGGKAAPAAPPAARPGPRPPAG
45 ELGSIGDHERAIDFSPYLEPLGAPQAPAPATATDTFEAAPPAPAPAPASSGQHHDFLSDLFSDD
YGGKNCKKPAEYGYVSLGRLGAAKGALHPGCFAPLHPPPPPPPPAELKAEPGFEPADCKRK
EEAGAPGGGAGMAAGFPYALRAYLGYQAVPSGSSGSLSTSSSSSPPGTPSPADAKAPPTACY
AGAAPAPSQVKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAEN
ERLQKKVEQLSRELSTLRNLFKQLPEPLASSGHC (SEQ ID NO: 112)
- 50 NP_061820.1 cytochrome c
MGDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKTGQAPGYSYTAANKNKGIIW
GEDTLMEYLENPKKYIPGTMIFVGIIKKKEERADLIAYLKATNE (SEQ ID NO: 113)
- 55 NP_004505.2 forkhead box protein K2

5 MAAAAAALSGAGTPPAGGGAGGGGAGGGGSPGGWAVARLEGREFEYLMKKRSVTIGRNS
 SQGSVDVSMGHSSFISRRHLEIFTPPGGGGHGGAAPELPPAQPRPDAGGDFYLRCLGKNGVF
 VDGVFQRRGAPPLQLPRVCTFRFPSTNIKITFTALSSEKREKQEASESPVKAVQPHISPLTINIP
 DTMAHLISPLPSPTGTISAANSCPSSPRGAGSSGYKVGRVMPSDLNLMADNSQPENEKEASG
 GDSPKDDSKPPYSYAQLIVQAITMAPDKQLTLNGIYTHITKNYPYYRTADKGWQNSIRHNLS
 10 LNRYFIKVPRSQEEP GKGSFWRIDPASESKLIEQAFKRPRRGVPCFRTPLGPLSSRSAPASPN
 HAGVLSAHSSGAQTPELSREGSPAPLEPEPGAAQPKLAVIQEARFAQSAPGSPLSSQPVLITV
 QRQLPQAIKPVITYTVATPVTSTSTSQPPVVQTVHVHQPAPVSVTSVAGLAPANTYTVSGQAV
 VTPAAVLAPPKAEAQENG DHEVKVKVEPIPAIGHATLGTASRIIQTATTPVQTVTIVQQAP
 LGQHQLPIKTVTQNGTHVASVPTAVHGVNNAASPLHMLATHASASASLPTKRHNNGDQPE
 15 QPELKRIKTEDGEGIVIALSVDTPPAAVREKGVQN (SEQ ID NO: 114)

NP_002986.1 lymphotactin precursor
 MRLILALLGICSLTAYIVEGVGSEVSDKRTCVS LTTQRLPVSRIKTYTITEGSLRAVIF
 ITKRGLKVCADPQATWVRDVVRSM DRKSNTNRNNMIQT KPTGTQQSTNTAVTLTG (SEQ ID
 20 NO: 115)

NP_004166.1 small nuclear ribonucleoprotein Sm D3
 MSIGVPIKVLHEAEGHIVTCETNTGEVYRGK LIEAEDNMNCQMSNITV TYRDGRVAQLEQVY
 IRGSKIRFLILPDMLKNAPMLKSMKNKNQ GSGAGRGKAAILKAQVAARGRGRGMGRGNIFQ
 25 KRR (SEQ ID NO: 116)

NP_001029058.1 stromal cell-derived factor 1 isoform gamma
 MNAKV VVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVAR
 LKNNNRQVCIDPKLKWIQEYLEKALNKGRREEKVGKKEKIGKKKRQKKRKAQKRKN
 30 (SEQ ID NO: 117)

NP_001091046.1 angiogenin precursor
 MVMGLGVLLL VFVLGLGLTPPTLAQDNSRYTHFLTQH YDAKPQGRDDRYCESIMRRRGLTS
 PCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSS FQVTTCKLHGGSPWPPCQYRATAGF
 35 RNVVVACENGLPVHLDQSIFRRP (SEQ ID NO: 118)

NP_005209.1 beta-defensin 1 preproprotein
 MRTSYLLLFTLCLLLSEMASGGNFLTGLGHRSDHYN CVSSGGQCLYSACPIFTKIQGTCY
 RGKAKCCK (SEQ ID NO: 119)
 40

NP_001137288.1 brain-derived neurotrophic factor isoform a preproprotein
 MTILFLTMVISYFGCMKAAPMKEANIRGQGGLAYPGVR THGTLESVNGPKAGSRGLTSLAD
 TFEHVIEELLDEDQKVRPNEENNKDADLYTSRVMLSSQVPLEPPLLFLLEEYKNYLDAANMS
 MRVRRHSDPARRGELSVCD SISEWVTAADKKTAVDMSGGT VTVLEKVPVSKGQLKQYFYE
 45 TKCNPMGYTKEGCRGIDKRHWNSQCRTTQSYVRALTMD SKKRIGWRFIRIDTSCVCTLTIKR
 GR (SEQ ID NO: 120)

NP_665905.1 C-C motif chemokine 23 isoform CKbeta8 precursor
 MKVSVAALSCLMLVTALGSQARVTKDAETEFMMSKLPLENPVLLDRFHATSADCCISYTPR
 50 SIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQVQVCVRMLKLDTRIKTRKN (SEQ
 ID NO: 121)

NP_001720.1 probetacellulin precursor
 MDRAARCSGASSLPLLLALALGLVILHCVVADGNSTRSPETNGLLCGDPEENCAATTTQS

- 5 KRKGHFSRCPKQYKHYCIKGRCRFVVAEQTPSCVCDEGYIGARCERVDLFYLRGDRGQILVI
CLIAVMVVFILVIGVCTCCHPLRKRRKRKKKEEEMETLGKDITPINEDIEETNIA (SEQ ID
NO: 122)
- NP_001029058.1 stromal cell-derived factor 1 isoform gamma
- 10 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVAR
LKNNNRQVCIDPKLKWIQEYLEKALNKGRREEKVGKKEKIGKKKRQKKRKAQKRKN
(SEQ ID NO: 123)
- NP_060575.1 THAP domain-containing protein 1 isoform 1
- 15 MVQSCSAYGCKNRYDKDKPVSFHKFPLTRPSLCKEWEAAVRRKNFKPTKYSSICSEHFTPDC
FKRECNNKLLKENAVPTIFLCTEPHDKKEDLLEPQEQLPPPPLPPPVSQVDAAIGLLM
PPLQTPVNLSVFCDHNYTVEDTMHQKRRIHQLEQQVEKLRKKLKTAAQQRCCRQERQLEKLK
EVDHFQKEKDDVSERGYVILPNDYFEIVEVPA (SEQ ID NO: 124)
- 20 NP_001129687.1 artemin isoform 3 precursor
MELGLGGLSTLSHCPWPRQQAPLGLSAQPALWPTLAALALLSSVAEASLGSAPRSPAPRE
GPPPVLASPAGHLPGGRTARWCSGRARRPPPQPSRPAPPPPAPPSALPRGGRAARAGGPG
SRARAAGARGCRLRSQ LVPVRALGLGHRSDLVRFRCGSGSCRRARSPHDLSLASLLGAGAL
RPPPGSRPVSQPCCRPTRYEAVSFMDVNSTWRTVDRLSATACGLG (SEQ ID NO: 125)
- 25 NP_001121128.1 cysteine and glycine-rich protein 3
MPNWGGGAKCGACEKTVYHAEIQCNGRSFHKTCFHCMACRKALDSTTVAAHESEIYCKV
CYGRRYGPKGIGYGQGAGCLSTDTEHLGLQFQQSPKPARSVTTSNPSKFTAKFGESEKCPR
CGKSVYAAEKVMGGGKPPWHKTCFRCAICGKSLESTNVTDKDGELYCKVCYAKNFGPTGIG
30 FGGLTQQVEKKE (SEQ ID NO: 126)
- NP_002383.2 E3 ubiquitin-protein ligase Mdm2 isoform MDM2
- 35 MVRSRQMCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAKDITYTMKEVLF
YLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIRNLVVVNQQESSD
SGTSVSENRCHEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSEGERQR
KRHKSDSISLSFDESLALCVIREICCERSSSSSESTGTPSNPDLDAGVSEHSGD
WLDQDSVSDQFSVEFEVESLDESDYSLSEEGQELSDDEDDEVYQVTVYQAGESDTSFEEDPEI
SLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFD
VPDCKKTIVNDSRESCVEENDDKITQASQSQSESDYSQPSTSSSIYSSQEDVKEF
40 EREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKP
CPVCRQPIQMIVLTYFP (SEQ ID NO: 127)
- NP_002384.2 protein Mdm4 isoform 1
- 45 MTSFSTSAQCSTSDSACRISPGQINQVRPKLPLLKILHAAGAQQGEMFTVKEVMHYLGQYI
MVKQLYDQQEQHVMVYCGGDLLGELLGRQSFSVKDPSPLYDMLRKNLVTLATATTDAQAQTL
ALAQDHSM DIPSDQLKQSAEESSTSRKRTTEDDIPTLPTSEHKCIHSREDEDLIENLAQDETS
RLDLGFEEWDVAGLPWWFLGNLRSNYTPRSNGSTD LQTNQDVGTAI VSDTTDDLWFLNESV
SEQLGVGIKVEAADTEQTSEEVGKVSDKKVIEVGKNDDLED SKSLSDDTDVEVTSEDEWQC
TECKKFNSPSKRYCFRCWALRKDWYSDCSKLTHSLSTSDITAIPEKENEGNDVPDCRRTISAP
50 VVRPKDAYIKKENS KLFDPCNSVEFLDLAHSSESQETISSMGEQLDNLSEQRTDTENMEDCQ
NLLKPCSLCEKRPRDGNIIHGRTGHLVTCFHCARRLKKAGASCPICKKEIQLVIKVFIA (SEQ
ID NO: 128)
- NP_003055.1 antileukoproteinase precursor

5 MKSSGLFPFLVLLALGTLAPWAVEGSGKSFKAGVCPPKKSAQCLRYKKPECQSDWQCPGKK
RCCPDTCGIKCLDPVDTPNPTRRKPGKCPVTYGGCLMLNPPNFCEMDGQCKRDLKCCMGM
CGKSCVSPVKA (SEQ ID NO: 129)

NP_055408.2 cpG-binding protein isoform 2

10 MEGDGSDPEPPDAGEDSKSENGENAPIYCICRKPDI NCFMIGCDNCNEWFHGDCIRITEK
MAKAIREWYCRECREKDPKLEIRYRHKKSRERDGNERDSSEPRDEGGGRKRPVPDPDLQRR
AGSGTGVGAMLAGRSASPHKSSPQPLVATPSQHHQQQQQQIKRSARMCGECEACRRTEDCG
HCDFCRDMKKFGGPNKIRQKCRLRQCQLRARESYKYFPSSLSPVTPSESLPRPRRPLPTQQQP
QPSQKLGRIREDEGAVASSTVKEPPEATATPEPLSDEDLPLDPDLYQDFCAGAFDDHGLPWM
15 SDTEESPFLDPALRKRAVKVKHVKRREKKSEKKKEERYKRHRQKQKHKDKWKHPERADAK
DPASLPQCLGPGCVRPAQPSSKYCSDDCGMKLAANRIYEILPQRIQQWQQSPCIAEEHGKKLL
ERIRREQQSARTRLQEMERRFHELEAILRAKQQAVREDEESNEGDSDDTDLQIFCVSCGHPIN
PRVALRHMERCYAKYESQTSFGSMYPTRIEGATRLFCDVYNPQSKTYCKRLQVLCPEHSRDP
KVPADDEVCGCPLVRDVFELTGDFCRLPKRQCNRHYCWEKLRRAEVDLERVRVWYKLDEL
20 EQERNVRTAMTNRAGLLALMLHQTIQHDPLTTDLRSSADR (SEQ ID NO: 130)

NP_002926.2 eosinophil cationic protein precursor

MVPKLFTSQICLLLLLGLMGVEGSLHARPPQFTRAQWF AIQHISLNPPRCTIAMRAINNY
RWRCKNQNTFLRTTFANVVNVCGNQSIRCPHNRTLNNCHRSRFRVPLLHCDLINPGAQNISN
25 CTYADRPGRRFYVVACDNRDPRDSPRYVPVPHLDTTI (SEQ ID NO: 131)

NP_001127757.1 estrogen-related receptor gamma isoform 2

MSNKDRHIDSSCSSFIKTEPSSPASLTDSVNHHSPPGGSSDASGSYSSTMNGHQNGLDSP
LYPSAPILGGSGPVRKLYDDCSSTIVEDPQTKCEYMLNSMPKRLCLVCGDIASGYHYGVA
30 SCEACKAFFKRTIQGNIEYSCPATNECEITKRRRKSCQACRFMKCLKVGMLKEGVRLDRVRG
GRQKYKRRIDAENSPYLNQQLVQPAKKPYNKIVSHLLVAEPEKIYAMPDPTVPDSDIKALTTL
CDLADREL VVIIGWAKHIPGFSTLSLADQMSLLQSAWMEILILGVVYRSLSFEDE
LVYADDYIMDEDQSKLAGLLDLNNAILQLVKKYKSMKLEKEEFVTLKAIALANSDSMHIED
VEAVQKLQDVLHEALQDYEAGQHMEDPRRAGKMLMTLPLLRQTSTKAVQHFFYNIKLEGKV
35 PMHKLFLEMLEAKV (SEQ ID NO: 132)

NP_002948.1 retinoic acid receptor RXR-alpha

MDTKHFLPLDFSTQVNSSLTSPTGRGSMAAPSLHPSLGP GIGSPGQLHSPISTLSSPING
MGPPFSVISSPMGPHSMSVPTTPTLGFTGSPQLSSPMNPVSSSEDIKPPLGLNGVLKVP
40 AHPSGNMA SFTKHICAICGDRSSGKH YGVYSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKR
QRNRCQYCRYQKCLAMGMKREAVQEERQRGKDRNENEVESTSSANEDMPVERILEAELAV
EPKTETYVEANMGLNPSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSELPLDDQVILLRAG
WNELLIASFSHRSAVKDGILLATGLHVHRNSAHSAGVG AIFDRVLT ELVSKMRDMQMDKT
ELGCLRAIVLFNPDSKGLSNPAEVEALREKVYASLEAYCKHKYPEQPGRFAKLLLRPALRSI
45 GLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQMT (SEQ ID NO: 133)

NP_115961.2 ribonuclease 7 precursor

MAPARAGFCPLLLLLLLLGLWVAEIPVSAKPKGMTSSQWFKIQHMQPSPQACNSAMKNINKH
TKRCKDLNTFLHEPFSSVAATCQTPKIACKNGDKNCHQSHGAVSLTMCKLTSGKYPNCRYK
50 EKRQNKSYVVACKPPQKKDSQQFHLVPVHLDRVL (SEQ ID NO: 134)

NP_003394.1 transcriptional repressor protein YY1

MASGDTLYIATDGSEMPAEIVELHEIEVETIPVETIETT VVGEEEEEDDDDEDGGGGDHG
GGGGHGHAGHHHHHHHHHHHPPMIALQPLVTDDPTQVHHH QEVLVQTREEVVGDDSDG
55 LRAEDGFEDQILIPVPAPAGGDDDDYIEQTLVTVA AAGKSGGGGGSSSSGGGRVKKGGGKKSG
KKSYSLSGGAGAAGGGGADPGNKKWEQKQVQIKTLEGEFSVTMWSSDEKKDIDHETVVEEQ

5 IIGENSPPDYSEYMTGKKLPPGGIPGIDLSDPKQLAEFARMKPRKIKEDDAPRTIACPHKGCTK
MFRDNSAMRKHLHHTHGPRVHVCAECGKAFVESSKLKRHQLVHTGEKPFQCTFEGCGKRFSL
DFNLRTHVRIHTGDRPYVCPFDGCNKKFAQSTNLKSHILTHAKAKNNQ (SEQ ID NO: 135)

NP_001020539.2 vascular endothelial growth factor A isoform d

10 MTDRQTD TAPSPSYHLLPGRRRTVDAAASRGQGPEPAPGGGVEGVGARGVALKLFVQLLGC
SRFGGAVVRAGEAEPSGAARSASSGREEPQPEEGEEEEEEKEEERGPQWRLGARKPGSWTGE
AAVCADSAPAARAPQALARASGRGGRVARRGAEESGPPHSPSRRGSASRAGPGRASETMNF
LLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQ
EYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTESNITMQIMRIKPHQGQHIGEMSFLQHN
15 KCECRPKKDRARQENPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCD
KPRR (SEQ ID NO: 136)

NP_077742.2 Wilms tumor protein isoform B

20 MQDPASTCVPEPASQHTLRSGPGCLQQPEQQGV RDPGGIWAKLGAAEASAERLQGRRSRGA
SGSEPQQMGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGP
APPPAPPPPPPPPHSFIKQEPSWGGAEPEHEEQCLSAFTVHFSGQFTGTAGACRYGPF GPPPPSQ
ASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTSPSYGHTPSHHAAQFPNHSFKHEDP
MGQQGSLGEQQYSVPPPVYGCHTPTDSC TGSQALLRTPYSSDNLYQMTSQLECM TWNQM
NLGATLKGVAAGSSSSSVKWTEGQSNHSTGYESDNHTTPILCGAQYRIHTHG VFRGIQDVRRV
25 PGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRF
SRSDQLKRHRRTHTGVKPFQCKTCQRKFSRSDHLKTHTRHTHTGEKPFSCRWPSCQKKFARS
DELVRHHNMHQ RNM TKLQLAL (SEQ ID NO: 137)

NP_004371.2 CREB-binding protein isoform a

30 MAENLLDGPPNP KRAKLSSPGFSANDSTDFGSLFDLENDLPDELIPNGGELGLLNSGNLV
PDAASKHKQLSELLRGGSGSSINPGIGNVSASSPVQQGLGGQAQGQPNSANMASLSAMGKSP
LSQGDSSAPSLPKQAASTSGPTPAASQALNPQAQKQVGLATSSPATSTGTGPGICMNANFNQT
HPGLLNSNSGHS LINQASQGQAQVMNGSLGAAGRGRGAGMPYPTPAMQGASSSVLAETLT
QVSPQMTGHAGLNTAQAGGMAKMGITGNTSPFGQPFSQAGGQPMGATGVNPQLASKQSM
35 VNSLPTFPTDIKNTSVTNVPNMSQM QTSVGIVPTQAIATGPTADPEKRKLIQQQLVLLLHAHK
CQRREQANGEVRACSLPHCRTMKNVLN HMTHCQAGKACQVAHCASSRQIISHWKNCTRHD
CPVCLPLKNASDKRNQQTILGSPASGIQNTIGSVGTGQQNATSLSNPNPIDPSSMQRAYAALG
LPYMNQPQTQLQPQVPGQQPAQPQTHQQMRTL NPLGNNPMNIPAGGITTDQQPPNLISESAL
PTSLGATNPLMNDGSNSGNIGTLSTIPTAAPP SSTGVRKGWHEHVTQDLRSHLVHKL VQAIFP
40 TPDPAALKDRRMENLVAYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRLHK
QGILGNQPALPAPGAQPPVIPQAQPVRPPNGPLSLPVNRMQVSQGMNSFNPM S LGNVQLPQA
PMGPRAASPMNH SVQMNSMGSVPGMAISPSRMPQPPNMMGAHTNNMMAQAPAQSQFLPQ
NQFPSSSGAMSVGMGQPPAQTGVSQGQVPGAALPNPLNMLGPQASQLPCPPVTQSPLHPTTP
PASTAAGMP SLQHTTPPGMTTPQPAAPTQPSTPVSSSGQTPTPTPGSVPSATQTQSTPTVQAA
45 AQAQVTPQPQTPVQPPSVATPQSSQQQPTPVHAQPPGTPLSQA AASIDNRVPTPSSVASAETN
SQQPGPDVPVLEMKTETQAEDTEPDPGESKGEPRSEMMEEDLQGASQVKEETDIAEQKSEPM
EVDEKKPEVKVEVKEEEESSNGTASQSTSPSQPRKKIFKPEELRQALMPTLEALYRQDPESL
PFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNR
KTSRVYKFC SKLAEVFEQEIDPVMQSLGYCCGRKYEFSPQTLCCY GKQLCTIPRDAAYSYQ
50 NRYHFCEKCFTEIQGENVT LGDDPSQPQT TISKDQFEKKKNDTLDPEPFVDCKECGRKMHIQ
CVLHYDIIWPSGFVCDNCLKKTGRPRKENKFS AKRLQTTRLGNHLED RVNKFLRRQNHPEA
GEVFVRV VASSDKTVEVKPGMKSRFVDSGEMSESPYRTKALFAFEEIDGVDVCFFGMHVQ
EYGSDCPPPNTRRVYISYLD SIHFFRPRCLRTAVYHEILIGYLEYVKKLGYVTGHIWACPPSEG
DDYIFHCHPPDQKIPKPKRLQE WYKKMLDKAFAERIIHDYKDIFKQATEDRLTSAKELPYFEG
55 DFWPNVLEESIKELEQEEEEERKKEESTAASETTEGSQGD SKNAKKKNNKKTNKNKSSISRAN
KKKPSMPNVSN DLSQKLYATMEKHKEVFFVIHLHAGPVINTLPPIVDPDPLLSCDLMDGRDA

5 FLTLARDKHWEFSSLRRSKWSTLCMLVELHTQGQDRFVYTCNECKHHVETRWHCTVCEDY
 DLCINCYNTKSHAHKMVKWGLGLDDEGSSQGEPQSKSPQESRRLSIQRCIQSLVHACQCRNA
 NCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCKQLIALCCYHAKHCQENKCPVPFCLNIHKH
 LRQQQIQHRLQQAQLMRRRMATMNTRNVPQQSLPSPTSAPPGTPTQQPSTPQTPQPPAQPQP
 SPVSMSPAGFPSVARTQPPTTVSTGKPTSQVPAPPPPAQPPPAAVEAARQIEREAQQQQHLYR
 10 VNINNSMPPGRTGMGTPGSQMAPVSLNVPRPNQVSGPVMPSMPPGQWQQAPLPQQQPMMPG
 LPRPVISMQAQAAVAGPRMPSVQPPRSISPSALQDLLRTLKSPSSPQQQQQVNLILKSNPQLM
 AAFIKQRTAKYVANQPGMQPQPGLQSQPGMQPQPGMHQQPSLQNLNAMQAGVPRPGVPPQ
 QQAMGGLNPQGQALNIMNPGHNPNMASMNPQYREMLRRQLLQQQQQQQQQQQQQQQQQQQ
 QGSAGMAGGMAGHGQFQQPQGGYPPAMQQQQQRMQQHLPLQGSSMGQMAAQMGLG
 15 QMGQPGLGADSTPNIQQALQQRILQQQQMKQQIGSPGQPNPMSPQQHMLSGQPQASHLPQG
 QIATSLSNQVRSPAPVQSPRPQSQPPHSSPSPRIQPQSPHHVSPQTGSPHPGLAVTMASSIDQG
 HLGNPEQSAMLPLQNTPSRSALSSLSLVGDTTGDITLEKFVEGL (SEQ ID NO: 138)

NP_004371.2 CREB-binding protein isoform a

20 MAENLLDGPPNPKRAKLSSPGFSANDSTDFGSLFDLENDLPDELIPNGGELGLLNSGNLV
 PDAASKHKQLSELLRGGSGSSINPGIGNVSASSPVQQGLGGQAQGPNSANMASLSAMGKSP
 LSQGDSSAPSLPKQAASTSGPTPAASQALNPQAQKQVGLATSSPATSTGPGICMNANFNQT
 HPGLLNSNSGHSLINQASQGAQVMNGSLGAAGRGRGAGMPYPTPAMQGASSSVLAETLT
 QVSPQMTGHAGLNTAQAGGMAKMGITGNTSPFGQPFSQAGGQPMGATGVNPQLASKQSM
 25 VNSLPTFPTDIKNTSVTNVPNMSQMQTSVGIVPTQAIATGPTADPEKRKLIQQQLVLLHAHK
 CQRREQANGEVRACSLPHCRTMKNVLNHMTHCQAGKACQVAHCASSRQIISHWKNCTRHD
 CPVCLPLKNASDKRNQQTILGSPASGIQNTIGSVGTGQQNATSLSNPNPIDPSSMQRAYAALG
 LPYMNQPQTQLQPQVPGQQAQPQTHQQMRTLNLPLGNNPMNIPAGGITTDQQPPNLISESAL
 PTLGATNPLMNDGSNSGNIGTLSTIPTAAPPSTGVRKGWHEHVTQDLRSHLVHKLVAIFP
 30 TPDPAALKDRRMENLVAYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRLHK
 QGILGNQPALPAPGAQPPVIPQAQPVRPPNGPLSLPVNRMQVSQGMNSFNPMMSLGNVQLPQA
 PMGPRAASPMNHSVQMNSMGSVPGMAISPSRMPQPPNMMGAHTNNMMAQAPAQSQFLPQ
 NQFPSSSGAMSVGMGQPPAQTGVSQGGQVPGAALPNPLNMLGPQASQLPCPPVTQSPLHPTTP
 PASTAAGMPSLQHTTPPGMTTPQPAAPTQPSTPVSSSGQTPTPTPGSVPSATQTQSTPTVQAA
 35 AQAQVTPQPQTPVQPPSVATPQSSQQQPTPVHAQPPGTPLSQAAASIDNRVPTPSSVASAETN
 SQQPGPDVPVLEMKTETQAEDTEPDGKESKGEPRSEMMEEDLQGASQVKEETDIAEQKSEPM
 EVDEKKPEVKVEVKEEEESSNGTASQSTSPSQPRKKIFKPEELRQALMPTLEALYRQDPESL
 PFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNR
 KTSRVYKFCSKLAEVFEQEIDPVMQSLGYCCGRKYEFSPTLCCYGKQLCTIPRDAAYYSYQ
 40 NRYHFCEKCFTEIQGENVTLGDDPSQPQTTISKDQFEKKKNDTLDPEPFVDCKECGRKMHQI
 CVLHYDIIWPSGFVCDNCLKKTGRPRKENKFSAKRLQTTRLGNHLEDVKNKFLRRQNHPEA
 GEVFVRVVASDKTVEVKPGMKSRFVDSGEMSESPYRTKALFAFEEIDGVDVCFFGMHVQ
 EYGSDCPPPNTRRVYISYLDSEHFFRPRCLRTAVYHEILIGYLEYVKKLGYVTGHIWACPPSEG
 DDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAFAERIIHDYKDIFKQATEDRLTSAKELPYFEG
 45 DFWPNVLEESIKELEQEEEEERKKEESTAASETTEGSQGDSSNAKKKNNKKTNNKSSISRAN
 KKKPSMPNVSNDLQKLYATMEKHKEVFFVIHLHAGPVINTLPPIVDPDPLLSCDLMDGRDA
 FLTLARDKHWEFSSLRRSKWSTLCMLVELHTQGQDRFVYTCNECKHHVETRWHCTVCEDY
 DLCINCYNTKSHAHKMVKWGLGLDDEGSSQGEPQSKSPQESRRLSIQRCIQSLVHACQCRNA
 NCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCKQLIALCCYHAKHCQENKCPVPFCLNIHKH
 50 LRQQQIQHRLQQAQLMRRRMATMNTRNVPQQSLPSPTSAPPGTPTQQPSTPQTPQPPAQPQP
 SPVSMSPAGFPSVARTQPPTTVSTGKPTSQVPAPPPPAQPPPAAVEAARQIEREAQQQQHLYR
 VNINNSMPPGRTGMGTPGSQMAPVSLNVPRPNQVSGPVMPSMPPGQWQQAPLPQQQPMMPG
 LPRPVISMQAQAAVAGPRMPSVQPPRSISPSALQDLLRTLKSPSSPQQQQQVNLILKSNPQLM
 AAFIKQRTAKYVANQPGMQPQPGLQSQPGMQPQPGMHQQPSLQNLNAMQAGVPRPGVPPQ
 55 QQAMGGLNPQGQALNIMNPGHNPNMASMNPQYREMLRRQLLQQQQQQQQQQQQQQQQQQQ
 QGSAGMAGGMAGHGQFQQPQGGYPPAMQQQQQRMQQHLPLQGSSMGQMAAQMGLG

5 QMGQPGLGADSTPNIQQALQQRILQQQQMKQQIGSPGQPNPMSPQQHMLSGQPQASHLPGQ
 QIATSLSNQVRSPAPVQSPRPQSQPPHSSPSPRIQPQSPHHVSPQTGSPHPGLAVTMASSIDQG
 HLGNPEQSAMLPLQLNTPSRALSSELVGDGTTGDTLEKFVEGL (SEQ ID NO: 139)

NP_001116214.1 estrogen receptor isoform 4

10 MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAYEF
 NAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPFLQPH
 GQQVPYYLENESGYTVREAGPPAFYRPNSDNRRQGGRELASTNDKGSMMAMESAKETRYC
 AVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQACRLRKC
 YEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKRSKKN
 15 SLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPG
 FVDLTLHDQVHLLECAWLEILMIGLVWRSMHPGKLLFAPNLLDRNQGKCEGMVEIFDM
 LLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMA
 KAGLTLQQQHQLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHA
 PTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV (SEQ ID NO: 140)

NP_849180.1 hepatocyte nuclear factor 4-alpha isoform a

20 MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTLNAPNSLGVSALC
 AICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKC
 FRAGMKKEAVQNERDRISTRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIA
 25 DVCESMKEQLLVLEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLG
 NDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIFFDPDAKGLSDPGKIKRL
 RSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFMAKIDNLLQEML
 LGGSPSDAPHAHHPLPHLMQEHMGTNVIVANTMPTHLSNGQMSTPETPQPSPPGGSGSEPY
 KLLPGAVATIVKPLSAIPQPTITKQEV (SEQ ID NO: 141)

NP_001420.2 histone acetyltransferase p300

30 MAENVVEPGPPSAKRPKLSSPALSASASDGTDFGSLFDLEHDLDELINSTEGLTNGGD
 INQLQTS LGMVQDAASKHKQLSELLRSGSSPNLNMGVGGPGQVMASQAQQSSPGLGLINSM
 VKSPMTQAGLTSPNMGMGTSGPNQGPQTSTGMMNSPVNQPAMGMNTGMNAGMNPGLMA
 35 AGNGQGIMPVNQVMNGSIGAGRGRQNMQYPNPGMGSAGNLLTEPLQQGSPQMGGQTGLRG
 PQPLKMGMNNPNPYGSPYTQNPQQIGASGLGLQIQTKTVLSNNLSPFAMDKKAVPGGG
 MPNMGQQPAPQVQQPGLVTPVAQGMGSGAHTADPEKRKLIQQQLVLLHAHKCQRREQA
 NGEVRQCNLPHCRTMKNVLNTHMTHCQSGKSCQVAHCASSRQIISHWKNCTRHDPCVCLPL
 KNAGDKRNQQPILTGAPVGLGNPSSLGVGQQSAPNLSTVSQIDPSSIERAYAALGLPYQVNQ
 40 MPTQPQVQAKNQNNQQPGQSPQGMRPMSNMSASPMGVNGGVGVQTPSLLSDSMLHSAINS
 QNPMMSENASVPSLGPMPTAAQPSTTGIRKQWHEDITQDLRNHLVHKLVAIFPTPDPAALK
 DRRMENLVAYARKVEGDMYESANNRAEYYHLLAEKIYKIQKELEEKRRTRLQKQNMLPNA
 AGMVPVSMNPGPNMGQPQPGMTSNGPLPDPSMIRGSVPNQMMPRITPQSGLNQFGQMSMA
 QPPIVPRQTPPLQHHGQLAQPGALNPPMGYGPRMQQPSNQGQFLPQTQFPSQGMNVTNIPLA
 45 PSSGQAPVSQAQMSSSSCPVNSPIMPPGSQGSIIHCPQLPQPALHQNPSPPVPSRTPTPHHTPPS
 IGAQQPPATTIPAPVPTPPAMPPGPQSQUALHPPPRQTPTPTTQLPQQVQPSLPAAPSADQPQQ
 QPRSQQSTAASVPTPTAPLLPPQPATPLSQPAVSIEGQVSNPPSTSSTEVSQAIAEKQPSQEVK
 MEAKMEVDQPEPADTQPEDISESKVEDCKMESTETEERSTELKTEIKEEEDQPSTSATQSSPA
 PGQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVPDQLLGIPDYFDIVKSPMDLSTIKR
 50 KLDTGQYQEPWQYVDDIWL MFNNAWL YNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCC
 GRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTIN
 KEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIWPAGFVCDGCLKKSARTRKENKFS
 AKRLPSTRLGTFLNVRVNDLRRQNHPESGEVTVRVVHASDKTVEVKPGMKARFVDSGEMA
 ESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDVHFFRPKCLRTAV
 55 YHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAV
 SERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEEERKREENTSNESTD

5 VTKGDSKNAKKKNNKKTSTKNKSSLSRGNKKKPGMPNVSNDSLQKLYATMEKHKEVFFVIR
 LIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRRAQWSTMCMLVELHTQS
 QDRFVYTCNECKHHVETRWHCTVCEDYDLCITCYNTKNHDHKMEKLGLGLDDESNNQQA
 AATQSPGDSRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICK
 10 QLIALCCYHAKHCQENKCPVPFCLNIKQKLRQQQLQHRLQQAQMLRRRMASMQRTGVVGQ
 QQGLPSPTPATPTTPTGQQPTTPQTPQPTSQPQPTPPNSMPPYLPRTQAAGPVSQGKAAGQVT
 PPTPPQTAQPPLPGPPPAAVEMAMQIQRAAETQRQMAHVQIFQRPIQHQMPPMTPMAPMGM
 NPPPMTRGPSGHLEPGMGPTGMQQQPPWSQGGLPQPQQQLQSGMPRPAMMSVAQHGQPLN
 MAPQPGLGQVGISPLKPGTVSQQALQNLRLTLRSPSSPLQQQQVLSILHANPQLLAAFIKQRA
 AKYANSNPQPIPGQPGMPQGQPGGLQPPTMPGQQGVHSNPAMQNMNPMQAGVQRAGLPQQ
 15 QPQQQLQPPMGGMSPQAQQMNMNHNTMPSQFRDILRRQQMMQQQQQQGAGPGIGPGMA
 NHNQFQQPQGVGYPPQQQQQRMQHMMQQMQQGNMGQIGQLPQALGAEAGASLQAYQQRL
 LQQQMGSPPVQPNPMSPQQHMLPNQAQSPHLQGGQIPNSLSNQVRSPQPVPSRPQSQPPHSSP
 SPRMQPQPSPHHVSPQTSSPHGLVAAQANPMEQGHFASPDQNSMLSQLASNPGMANLHGA
 SATDLGLSTDNSDLNSNLSQSTLDIH (SEQ ID NO: 142)
 20 NP_001420.2 histone acetyltransferase p300
 MAENVVEPGPPSAKRPKLSSPALSASASDGTDFGSLFDLEHDLDPDELINSTEGLTNGGD
 INQLQTS LGMVQDAASKHKQLSELLRSGSSPNLNMGVGGPGQVMASQAQQSSPGLGLINSM
 VKSPMTQAGLTSPNMGMGTSGPNQGPTQSTGMMNSPVNQPAMGMNTGMNAGMNPGLMA
 25 AGNGQGIMPNQVMNGSIGAGRGRQNMQYPNPGMGSAAGNLLTEPLQQGSPQMGGQTGLRG
 PQPLKMGMMNNPNPYGSPYTQNPQQIGASGLGLQIQTKTVLSNNLSPFAMDKKAVPGGG
 MPNMGQQPAPQVQQPGLVTPVAQGMGSGAHTADPEKRKLIQQQLVLLLHAHKCQRREQA
 NGEVRQCNLPHCRTMKNVLNTHMTHCQSGKSCQVAHCASSRQIISHWKNCTRHDPCVCLPL
 KNAGDKRNQQPILTGAPVGLGNPSSLGVGQQSAPNLSTVSQIDPSSIERAYAAALGLPYQVNQ
 30 MPTQPQVQAKNQNNQQPGQSPQGMSPMSMSASPMGVNGGVGVQTPSLLSDSMLHSAINS
 QNPMMSENASVPSLGPMPTAAQPSTTGIRKQWHEDITQDLRNHLVHKL VQAIPTPDPAALK
 DRRMENLVAYARKVEGDMYESANNRAEYYHLLAEKIYKIQKELEEKRRTRLQKQNMLPNA
 AGMVPVSMNPGPNMGQPQPGMTSNGPLPDPSMIRGSVPNQMMPRITPQSGLNQFGQMSMA
 QPPIVPRQTPPLQHHGQLAQPGALNPPMGYGPRMQQPSNQGQFLPQTQFPSQGMNVTNIPLA
 35 PSSGQAPVSQAQMSSSSCPVNSPIMPPGSQGSIIHCPQLPQPALHQNSPSPVPSRTPTPHHTPPS
 IGAQQPPATTIPAPVPTPPAMPPGPQSQUALHPPPRQTPTPTTQLPQQVQPSLPAAPSADQPQQ
 QPRSQQSTAASVPTPTAPLLPPQATPLSQPAVSIEGQVSNPPSTSSTEVSQAIAEKQPSQEVK
 MEAKMEVDQPEPADTQPEDISESKVEDCKMESTETEERSTELKTEIKEEEDQPSTSATQSSPA
 PGQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVPDQLLGIPDYFDIVKSPMDLSTIKR
 40 KLDTGQYQEPWQYVDDIWL MFNNAWL YNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCC
 GRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTIN
 KEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIWPAGFVCDGCLKKSARTRKENKFS
 AKRLPSTRLGTFLN RVNDFLRRQNHPESEVTVRVVHASDKTVEVKPGMKARFVDSGEMA
 ESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDVHFFRPKCLRTAV
 45 YHEILIGYLEYVKKLGYYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAV
 SERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEEERKREENTSNESTD
 VTKGDSKNAKKKNNKKTSTKNKSSLSRGNKKKPGMPNVSNDSLQKLYATMEKHKEVFFVIR
 LIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRRAQWSTMCMLVELHTQS
 QDRFVYTCNECKHHVETRWHCTVCEDYDLCITCYNTKNHDHKMEKLGLGLDDESNNQQA
 50 AATQSPGDSRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICK
 QLIALCCYHAKHCQENKCPVPFCLNIKQKLRQQQLQHRLQQAQMLRRRMASMQRTGVVGQ
 QQGLPSPTPATPTTPTGQQPTTPQTPQPTSQPQPTPPNSMPPYLPRTQAAGPVSQGKAAGQVT
 PPTPPQTAQPPLPGPPPAAVEMAMQIQRAAETQRQMAHVQIFQRPIQHQMPPMTPMAPMGM
 NPPPMTRGPSGHLEPGMGPTGMQQQPPWSQGGLPQPQQQLQSGMPRPAMMSVAQHGQPLN
 55 MAPQPGLGQVGISPLKPGTVSQQALQNLRLTLRSPSSPLQQQQVLSILHANPQLLAAFIKQRA
 AKYANSNPQPIPGQPGMPQGQPGGLQPPTMPGQQGVHSNPAMQNMNPMQAGVQRAGLPQQ

5 QPQQQLQPPMGGMSPQAQQMNMNHNTMPSQFRDILRRQQMMQQQQQQGAGPGIGPGMA
 NHNQFQQPQGVGYPPQQQQRMQHMMQQMQQGNMGQIGQLPQALGAEAGASLQAYQQRL
 LQQQMGSPPVQPNPMSPQQHMLPNQAQSPHLQGQQIPNSLSNQVRSPQPVPSRPQSQPPHSSP
 SPRMQPQPSPHHVSPQTSSPHPLVAAQANPMEQGHFASPDQNSMLSQLASNPGMANLHGA
 SATDLGLSTDNSDLNSNLSQSTLDIH (SEQ ID NO: 143)

10 NP_005924.2 histone-lysine N-methyltransferase MLL isoform 2 precursor
 MAHSCRWRFPARPGTTGGGGGGGRRGLGGAPRQRPVALLLPVGGGGPGAPPSPPAVA
 AAAAAAGSSGAGVPGGAAAASAASSSSASSSSSSSSASSGPALLRVGPGFDAALQVSAAIGT
 NLRFRFRAVFGESGGGGGSGEDEQFLGFGSDEEVRVRSPTSPSVKTSRPRGRPRSGSDRNS

15 AILSDPSVFSPLNKSETKSGDKIKKKDSKSIKKRGRPPTFPGVKIKITHGKDISELPKGNKEDS
 LKKIKRTPSATFQQATKIKKLKAGKLSPLKSKFKTGKLGKGRGVQIVRRRGRPPSTERIKTPS
 GLLINSELEKPQKVRKDKEGTPPLTKEDKTIVRQSPRRIKPVRIIPSSKRTDATIAKQLLQRAK
 KGAQKKIEKEAAQLQGRKVKTQVKNIRQFIMPVVSASSRIKTPRRFIEDEDYDPPIKIARLES
 TPNSRFSAPSCGSSEKSSAASQHSQMSSDSSRSSSPSVDSTSDSQASEEIQVLPEERSDTPEVH

20 PPLPISQSPENESNDRRSRRYSVSERSFGSRTTKKLSTLQSAPQQQTSSSPPPPLTPPPPLQPAS
 SISDHTPWLMPTIPLASPFLPASTAPMQGKRKSILREPTFRWTSKHSRSEPQYFSSAKYAKE
 GLIRKPIFDNFRPPPLTPEDVGFASGFSASGTAASARLFSPLHSGTRFDMHKRSPLLRAPRFTPS
 EAHSRIFESVTLPSNRTSAGTSSSGVSNRKRKRKVFSPIRSEPRSPSHSMRTRSGRLSSSELSPLT
 PPSSVSSSLSISVSPLATSALNPTFTFSPSHSLTQSGESAENQRPRKQTSAPAEFSSSSPTPLFP

25 WFTPGSQTERGRNKDKAPEELSKDRDADKSVEKDKSRERDREREKENKRESRKEKRKKKGSE
 IQSSSALYPVGRVSKEKVVGEDVATSSSAKKATGRKKSSSHDSGTDITSVTLGDTTAVKTKIL
 IKKGRGNLEKTNLDLGPTAPSLEKEKTLCLSTPSSSTVKHSTSSIGSMLAQADKLPMTDKRVA
 SLLKKAQAQLCKIEKSKSLKQTDQPKAQQQESDSSETSVRGPRIKHVCRAAVALGRKRAVF
 PDDMPTLSALPWEEREKILSSMGNDDKSSIAGSEDAEPLAPPIKPIKPVTRNKAPQEPPVKKGR

30 RSRRCGQCPCGQVPEDCGVCTNCLDKPKFGGRNIKKQCKMRKCQNQLQWMPSKAYLQKQ
 AKAVKKKEKKSKTSEKKDSKESVVKNVVDSSQKPTPSAREDPAKKSSSEPPPRKPVEEKS
 EEGNVSAPGPESKQATTPASRKSSKQVSQPALVIPPQPPTTGPPRKEVPKTTTPSEPKKKQPPPP
 ESGPEQSKQKKVAPRPSIPVKQKPKEKEKPPPVNKKQENAGTLNILSTLSNGNSSKQKIPADGV
 HRIRVDFKEDCEAENVWEMGGLGILTSVPITPRVVCFLCASSGHVEFVYCQVCCEPFHKFCLE

35 ENERPLEDQLENWCCRCKFCHVCGRQHQAQTKQLLECNKCRNSYHPECLGPNYPTKPTKKK
 KVVICTKCVRCKSCGSTTPGKGWDAQWSHDFSLCHDCAKLFAGNFCPLCDKCYDDDDYE
 SKMMQCGKCDRWVHSCENLSDEMYEILSNLPESVAYTCVNCTERHPAEWRLALEKELQIS
 LKQVLTALLNSRTTSHLLRYRQAAPDLNPETEEIPSRSSEPGDPPLVTEVSKQDDQQPLD
 LEGVKRKMDQGNYSVLEFSDDIVKIIQAAINSDDGGQPEIKKANSMVKSSFIRQMEREVFPWFS

40 VKKSRFWEPNKVSSNSGMLPNAVLPPSLDHNYAQWQEREENSHTEQPPLMKKIIPAPKPKGP
 GEPDSPTPLHPPTPILSTDRSREDSPELNPPPGIEDNRQCALCLTYGDDSDANDAGRLLYIGQN
 EWITHVNCALWSAEVFEDDDGSLKNVHMAVIRGKQLRCEFCQKPGATVGCCLTSCTSNYHF
 MCSRAKNCVFLDDKKVYCQRHRDLIKGEVVPENGFEVFRRVFVDFEGISLRRKFLNGLEPEN
 IHMMIGSMTIDCLGILNDLSDCEDKLFPIGYQCSRVYWSTTDARKRCVYTCKIVECRPPVVEP

45 DINSTVEHDENRTIAHSPTSFTSSSKESQNTAEIISPSPDRPPHSQTSKSCYYHVISKVPRI RTP
 SYSPTQRSPGCRPLPSAGSPTPTTHEIVTVGDPLLSSGLRSIGSRRHSTSSLSRQSKLRIMSPMR
 TGNTYSRNNVSSVSTTGATDLESSAKVVDHVLGPLNSSTSLGQNTSTSSNLQRTVVTVGNK
 NSHLDGSSSSEMKSASDLVSKSSSLKGEKTKVLSSKSSEGSAHNVAYPGIPKLAPQVHNTT
 SRELNVSKIGSFAEPSSVSFSSKEALSFPHLHLRGQRNDRDQHTDSTQSANSSPDEDTEVK

50 TLKLSGMSNRSSIINEHMGSSSRDRRQKGGKSKKETFKKHSSKSFLGQVTTGEEGNL
 KPEFMDEVLTPEYMGQRPCNNVSSDKIGDKGLSMPGVKAPPMQVEGSAKELQAPRKRTVK
 VTLTPLK MENESQSKNALKESSPASPLQIESTSPTEPISASENPGDGPVAQPSPNNTSC
 QDSQSNNYQNLPVQDRNLMLPDGPKPQEDGSFKRRYPRRSARARSNMFFGLTPLYGVRSYG
 EEDIPFYSSSTGKKRGKRSAGQVDGADDLSTSEDDLYYYNFTRTVISSGGEERLASHNLFR

55 EEEQCDLPKISQLDGVDDGTESDTSVTATTRKSSQIPKRNGKENG TENLKIDRPED

- 5 AGEKEHVTKSSVGHKNEPKMDNCHSVSRVKTQGQDSLEAQLSSLESSRRVHTSTPSDKNLL
 DTYNTELLKSDSDNNNSDDCGNILPSDIMDFVLKNTPSMQALGESPESSSSSELLNLGEGGLD
 SNREKDMGLFEVFSQQLPTEPVDSSVSSSISAEQFELPLELPDLSVLTTRSPTVPSQNPSRL
 AVISDSGEKRVITITEKSVASSESDPALLSPGVDPTEGHMTPDHFIQGHMDADHISSPPCGSVE
 QGHGNNQDLTRNSSTPGLQVPVSPVPIQNQKYVPNSTDSPGPSQISNAAVQTTPPHLKPATE
 10 KLIVVNQNMQPLYVLQTLPNGVTQKIQLTSSVSSTPSVMEINTSVLGPMGGGLTLTTGLNPS
 LPTSQSLFPSASKGLLPMSSHQHLHSFPAATQSSFPPNISNPPSGLLIGVQPPDPQLLVSESSQ
 RTDLSTTVATPSSGLKKRPISRLQTRKNKKLAPSSTPSNIAPSDVVSNMTLINFTPSQLPNHPSL
 LDLGSLNTSSHRTVPNIIKRSKSSIMYFEPAPLLPQSVGGTAATAAGTSTISQDTSHLTSGSVSG
 LASSSSVLNVVSMQTTTTPTSSASVPGHVTLTNPRLLGTPDIGSISNLLIKASQQSLGIQDQPVA
 15 LPPSSGMFPQLGTSQTPSTAAITAASSICVLPSTQTTGITAASPSGEADEHYQLQHVNQLLASK
 TGIHSSQRDLDSASGPQVSNFTQTVDA PNSMGLEQNKALSSAVQASPTSPGGSPSSPSSGQRS
 ASPSVPGPTKPKPKTKRFQLPLDKGNGKKHKVSHLRTSSSEAHIPDQETTSLSGTGTGPGAEA
 EQQDTASVEQSSQKECGQPAGQVAVLPEVQVTQNPANEQESAEPKTVEEEESNFSSPLMLW
 LQQEQKRKESITEKKPKKGLVFEISSDDGFQICAESIEDAWKSLTDKVQEARSNARLKQLSFA
 20 GVNGLRMLGILHDAVVFLIEQLSGAKHCRNYKFRFHKPEEANEPLNPHGSARAEVHLRKSA
 FDMFNFLASKHRQPPEYNPNDEEEEEVQLKSARRATSMDLPMMPMRFRHLKKTSKEAVGVYR
 SPIHGRGLFCKRNIDAGEMVIEYAGNVIRSIQTDKREKYYDSKGIGCYMFRIDDSEVV DATM
 HGNAARFINHSCEPNCYSRVINIDGQKHIVIFAMRKIYRGEELTYDYKFPIEDASNKLPCNCG
 AKKCRKFLN (SEQ ID NO: 144)
- 25 NP_068370.1 nuclear receptor subfamily 1 group D member 1
 MTTLDSNNNTGGVITYIGSSGSSPSRTSPESLYSDNSNGSFQSLTQGCPTYFPPSPTGSLTQDPA
 RSFGSIPPSLSDDGSPSSSSSSSSSSSSSYNGSPPGSLQVAMEDSSRVSPSKSTSNITKLNGMVLL
 CKVCGDVASGFHYGVHACEGCKGFFRRSIQQNIQYKRCLKNENC SIVRINRNRCQQCRFKKC
 30 LSVGMSRDAVRFGRIKREKQRM LAEMQSAMNLANNQLSSQCPLETSPTQHPTPGPMGPSPP
 PAPVPSPLVGFSQFPQQLTPRSPSPEPTVEDVISQVARAHREIFTYAHDKLGSSPGNFNANHA
 SGSPPATTPHRWENQGCPPAPNDNNTLAAQRHNEALNGLRQAPSSYPPTWPPGPAHHSCHQ
 SNSNGHRLCPTHVYAAPEGKAPANSRQGN SKNVLLACPMNMYPHGRSGRTVQEIWEDFS
 MSFTPAVREVVEFAKHIPGFRDLSQHDQVTLLKAGTFEVL MVRFASLFNVKDQTMFLSRTT
 35 YSLQELGAMGMGDLLSAMFDFSEKLN SLALTEEELGLFTAVVLVSADRSGMENSASVEQLQ
 ETLLRALRALVLKNRPLETSRFTKLLLKL PDLRTLNNMHSEKLLSFRVDAQ (SEQ ID NO:
 145)
- 40 NP_003813.1 nuclear receptor subfamily 5 group A member 2 isoform 2
 MSSNSDTGDLQESLKHGLTPIVSQFKMVNYSYDEDLEELCPVCGDKVSGYHYGLLTCECK
 GFFKRTVQNNKRYTCIENQNCQIDKTQRKRCPYCRFQKCLSVGMKLEAVRADRMRGGRNK
 FGPMYKRDRALKQQKKALIRANGLKLEAMSQVIQAMPSDLTISSAIQNIHSASKGLPLNHAA
 LPPTDYDRSPFVTSPISMTMPPHGS LQGYQTYGHFPSRAIKSEYPDPYTSSPESIMGYSYMDSY
 QTSSPASIPHLILELLKCEPDEPQVQAKIMAYLQQEQANRSKHEKLSTFGLMCKMADQTLFSI
 45 VEWARSSIFFRELKVDDQMKLLQNCWSELLILDHIYRQVVHKGESIFLVTGQQVDYSIIASQ
 AGATLNNLMSHAQELVAKLRSLQFDQREFVCLKFLVLFSLDVKNLENFQLVEGVQE QVNAA
 LLDYTM CNYPQQTEKFGQLLLRLPEIRAISMQAEEYLYYKHLNGDVPYNNLLIEM LHAKRA
 (SEQ ID NO: 146)
- 50 NP_001138773.1 retinoic acid receptor alpha isoform 1
 MASNSSSCPTPGGGHLNGYPVPYAFFFPMLGGLSPPGALTTLQHQLPVSGYSTPSPAT
 IETQSSSSEEIVPSPSPPLPRIYKPCFVCQDKSSGYHYGVSACEGCKGFFRRSIQKNM
 VYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKESVRNDRNKKKKEVPKPECSESYTLT
 PEVGELIEKVRKAHQETFPALCQLGKYTTNNSSEQRVSLDIDLWDKFSELSTKCIKTV
 55 EFAKQLPGFTTLTIADQITLLKAA CLDILIRICTRYTPEQDTMTFSDGLTLNRTQM HNA
 GFGPLTDLVFAFANQLLPLEMDDAETGLLSAICLICGDRQDLEQPDRVDMLQEPLLEALK

5 VYVRKRRPSRPHMFPKMLMKITDLRSISAKGAERVITLKMEIPGSMPLIQEMLENSEGL
DTLSGQPGGGGRDGGGLAPPPGSCPSLSPSSNRSSPATHSP (SEQ ID NO: 147)

NP_002948.1 retinoic acid receptor RXR-alpha

MDTKHFLPLDFSTQVNSSLTSPTRGSMAAPSLHPSLGP GIGSPGQLHSPISTLSSPINGMGPPF
10 SVISSPMGPHSMSVPTTPTLGFSTGSPQLSSPMNPVSSSEDIKPPLGLNGVLKVP AHPSGNMAS
FTKHICAICGDRSSGKH YGVYSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQYC
RYQKCLAMGMKREAVQEERQRGKDRNENEVESTSSANEDMPVERILEAELAVEPKTETYVE
ANMGLNPSSPNDPVTNICQAADKQLFTLVEWAKRIPHSELPLDDQVILLRAGWNELLIASFS
HRSIAVKDGILLATGLHVHRNSAHSAGVGAIFDRVLT ELVSKMRDMQMDKTELGLCLRAIVL
15 FNPDSKGLSNPAEVEALREKVYASLEAYCKHKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFF
FKLIGDTPIDTFLMEMLEAPHQMT (SEQ ID NO: 148)

NP_001017536.1 vitamin D3 receptor isoform VDRB1

MEWRNKKRSDWLSMVLRTAGVEEAFGSEVSVRPHRRAPLGSTYLPPAPSGMEAMAASTSLP
20 DPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRRSMKRKALFTCPFNGDCRITKDN
RRHCQACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEALKDSL RPKLSEEQQRIAIL
LDAHHKTYDPTYSDFCQFRPPVRVNDGGGSHPSRPNSRHTPSFSGDSSSSSCSDHCITSSDMMD
SSSFSNLDLSEEDSDDPSVTLELSQLSMLPHLADLVSYSIQKVIGFAKMIPGFRDLTSEDQIVLL
KSSAIEVIMLRSNESFTMDDMSWTCGNQDYKYRVSDVT KAGHSLELIEPLIKFQVGLKKLNL
25 HEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLSNTLQTYIRCRHPPPGSHLLYAKMIQKLA
DLRSLNEEHSKQYRCLSFQPECSMKLTPLVLEVFGNEIS (SEQ ID NO: 149)

NP_000917.3 progesterone receptor isoform

BMTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLFPRP
30 CQGQDPSDEKTQDQQSLSDVEGAYSRAEATR GAGGSSSSPPEKDSGLLDSVLDTL LAPSGPG
QSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAAAHKVLPR
GLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGKPRALGGAAA
GGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTVMDFIHVPILPL
NHALLAARTRQLLEDES YDGGAGAASAFAPPRSSPCASSTPVAVGDFPDCA YPPDAEPKDDA
35 YPLYSDFQPPALKIKEEEEGAEASARSPSYLVAGANPAAFPDFPLGPPPPLPPRATPSRPGEA
AVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPCKAPGASGCLLP RDGLPSTSAS
AAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPPYLYNLRPDSEASQSPQYSFESLP
QKICLICGDEASGCHYGVLT CGSCKVFFKRAMEGQHNYLCAGRND CIVDKIRRKNC PACRL
RKCCQAGMVLGGRKF KFKFNKVRVVRALDAVALPQPVGVPNESQALSQRFTFSPGQDIQLIPP
40 LINLLMSIEPDVIYAGHDNTKPD TSSSLTSLNQLGERQLLSVVKWSKSLPGFRNLHIDDQITLI
QYSWMSLMVFGLGWRSYKHVSGQMLYFAPDLILNEQRMKESSFYSLCLTMWQIPQEFVKL
QVSQEEFLCMKVLLLLNTIPLEGLRSQTQFEEMRSSYIRELIKAIGLRQKG VVSSSQRFYQLTK
LLDNLHDLVKQLHLYCLNTFIQSRALSVEFP EMMSEVIAAQLPKILAGMVKPLL FHKK (SEQ
ID NO: 150)

45

NP_001073315.1 CREB-binding protein isoform b

MAENLLDGPPNPKRAKLSSPGFSANDSTDFGSLFDLENDLPDELIPNGGELG LLNSGNLVPDA
ASKHKQLSELLRGGSGSSINPGIGNVSASSPVQQGLGGQAQGPNSANMASLSAMGKSPLSQ
GDSSAPSLPKQAASTSGPTPAASQALNPQAQKQVGLATSSPAT SQTGPGICMNANFNQTHPG
50 LLNSNSGHSLINQASQGQAQVMNGSLGAAGRGRGAGMPYPTPAMQGASSSVLAETLTQVSP
QMTGHAGLNTAQAGGMAKMGITGNTSPFGQPFSQAGGQPMGATGVNPQLASKQSMVN SLP
TFPTDIKNTSVTNVPNMSQMOTSVGIVPTQAIATGPTADPEKRKLIQQQLVLLLHAHKCQRRE
QANGEVRACSLPHCRTMKNVLNHMTHCQAGKACQAILGSPASGIQNTIGSVGTGQQNATSL
SNPNPIDPSSMQRAYAALGLPYMNQPQTQLQPQVPGQQPAQPQTHQQMRTL NPLGNNPMNI
55 PAGGITTDQQPPNLISESALPTSLGATNPLMNDGSNSGNIGTLSTIPTAAPP SSTGVRKGWHEH
VTQDLRSHLVHKL VQAIFPTPDPAALKDRRMENLVAYAKKVEGDMYESANSRDEYYHLLA

5 EKIYKIQKELEEKRRSRLHKQGILGNQPALPAPGAQPPVIPQAQPVRPPNGPLSLPVNRMQVS
 QGMNSFNPMISLGNVQLPQAPMGPRASPMNHSVQMNSMGSVPGMAISPSRMPQPPNMMG
 AHTNNMMAQAPAQSQFLPQNQFPSSSGAMSVGMGQPPAQTGVSQGGVPGAALPNPLNMLG
 PQASQLPCPPVTQSPLHPTPPPASTAAGMPSLQHTTTPPGMTTPPQPAAPTQPSTPVSSSGQTPTP
 TPGSVPSATQTQSTPTVQAAAQAQVTPQPQTPVQPPSVATPQSSQQQPTPVHAQPPGTPLSQA
 10 AASIDNRVPTPSSVASAETNSQQPGPDVPVLEMKTETQAEDTEPDPGESKGEPRSEMMEEDL
 QGASQVKEETDIAEQKSEPMEVDEKKPEVKVEVKEEEEESSNGTASQSTSPSQPRKKIFKPEE
 LRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPW
 QYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLGYCCGRKYEFSPTL
 CCYGKQLCTIPRDAAYYSYQNRYPHFCEKCFTEIQGENVTLGDDPSQPQTTISKDQFEKKKND
 15 TLDPEPFVDCKEGRKMHQICVLHYDIIWPSGFVCDNCLKKTGRPRKENKFSAKRLQTTRLG
 NHLEDRVNKFLRRQNHPEAGEVFVRVVASDKTVEVKPGMKSRFVDSGEMSESFYRTKAL
 FAFEEIDGVDVCFFGMHVQEYGSDCPPPNTRRVYISYLDLSIHFFRPRCLRTAVYHEILIGYLEY
 VKKLGYVTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAFAERIIHDYKDI
 FKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEEERKKEESTAASETTEGSQGDSKNA
 20 KKKNNKKTNNKSSISRANKKKPSMPNVSNLDSQKLYATMEKHKEVFFVIHLHAGPVINTLP
 PIVDPDPLLSCDLMDGRDAFLTARDKHWEFSSLRRSKWSTLCMLVELHTQGQDRFVYTCN
 ECKHHVETRWHCTVCEYDLCLCNCYNKSHAHKMKVWGLGLDDEGSSQGEPQSKSPQESR
 RLSIQRCLQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCKQLIALCCYH
 AKHCQENKCPVPFCLNIKHKLRRQQQIQHRLQQAQLMRRRMATMNTRNVPQQSLPSPTSAPP
 25 GTPTQQPSTPQTPQPPAQPPSPVSMSPAGFPSVARTQPPTTVSTGKPTSQVPAPPPPAQPPPA
 AVEAARQIEREAQQQQHLYRVNINNSMPPGRTGMGTGPSQMAPVSLNVPRPNQVSGPVMPS
 MPPGQWQQAPLPQQQPMPLPRPVISMQAQAAVAGPRMPSVQPPRSISPSALQDLLRTLKSP
 SSPQQQQQVLNLIKSNPQLMAAFIKQRTAKYVANQPQMPPGLQSQPGMQPPGMHQQPS
 LQNLNAMQAGVPRPGVPPQQQAMGGLNPQGQALNIMNPGHNPNMASMPNPQYREMLRRQL
 30 LQQQQQQQQQQQQQQQQQQQQGSAGMAGGMAGHGQFQQPQGGGYPPAMQQQQQRMQQHL
 PLQGSSMGQMAAQMGQLGQMGPGLGADSTPNIQQALQQRILQQQQMKQQIGSPGQPNPM
 SPQQHMLSGQPQASHLPQQIATSLSNQVRSPAPVQSPRPQSQPPHSSPSPRIQPQPSPHHVSP
 QTGSPHPGLAVTMASSIDQGH LGNPEQSAMLPLQNTPSRSALSSELSLVGDTTGD TLEKFVEG
 L (SEQ ID NO: 151)
 35 NP_001420.2 histone acetyltransferase p300
 MAENVVEPGPPSAKRPKLSSPALSASASDGTDFGSLFDLEHDL PDELINSTE LGLTNGGD
 INQLQTS LGMVQDAASKHKQLSELLRSGSSPNLNMGVGGPGQVMASQAQQSSPGLGLINSM
 VKSPMTQAGLTSPNMGMGTSGPNQGPTQSTGMMNSPVNQPAMGMNTGMNAGMNPGLMA
 40 AGNGQGIMPVNQVMNGSIGAGRGRQNMQYPNPGMGSAGNLLTEPLQQGSPQMGGQTGLRG
 PQPLKMGMMNNPNPYGSPYTQNPQQQIGASGLGLQIQTKTVLSNNLSPFAMDKKAVPGGG
 MPNMGGQQPAPQVQQPGLVTPVAQGMGSGAHTADPEKRKLIQQQLVLLLHAHKCQRREQA
 NGEVRQC NLPHCRTMKNVLN HMTHCQSGKSCQVAHCASSRQIISHWKNCTRHD CPVCLPL
 KNAGDKRNQQPILTGAPVGLGNPSSLGVGQQSAPNLSTVSQIDPSSIERAYAALGLPYQVNQ
 45 MPTQPQVQAKNQNNQQPGQSPQGM RPMSNMSASPMGVNGGVGVQTPSLLSDSMLHSAINS
 QNPMMSENASVPSLGPMPTAAQPSTTGIRKQWHEDITQDLRNHLVHKL VQAIPTPDPAALK
 DRRMENLVAYARKVEGDMYESANNRAEYYHLLAEKIYKIQKELEEKRRTRLQKQNMLPNA
 AGMVPVSMNPGPNMGQPQPGMTSNGPLPDPSMIRGSVPNQMMPRITPQSGLNQFGQMSMA
 QPPIVPRQTPLQH HGQLAQPGALNPPMGY GPRMQQPSNQGQFLPQTQFPSQGMNV TNIPLA
 50 PSSGQAPVSQAQMSSSSCPVNSPIMPPGSQGSIHCPQLPQPALHQNSPSPVPSRTPTPHHTPPS
 IGAQQPPATTIPAPVPTPPAMPPGPQS QALHPPPRQTPTPTTQLPQQVQPSLPAAPSADQPQQ
 QPRSQQSTAASVPTPTAPLLPPQATPLSQPAVSIEGQVSNPPSTSSSTEVSQAIAEKQPSQEVK
 MEAKMEVDQPEPADTQPEDISESKVEDCKMESTETEERSTELKTEIKEEEDQPSTSATQSSPA
 PGQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKR
 55 KLDTGQYQEPWQYVDDIWL MFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCC
 GRKLEFSPTLCCYGKQLCTIPRDATA YSYQNRYPHFCEKCFNEIQGESVSLGDDPSQPQTTIN

- 5 KEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIWPAGFVCDGCLKKSARTRKENKFS
AKRLPSTRLGTFLENRVNDLRRQNHPESEGEVTVRVVHASDKTVEVKPGMKARFVDSGEMA
ESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDVHFFRPKCLRTAV
YHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAV
SERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEEERKREENTSNESTD
10 VTKGDSKNAKKNNKTSKNKSSLSRGNKKKPGMPNVSNLDSQKLYATMEKHKEVFFVIR
LIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTARDKHLEFSSLRRAQWSTMCMLVELHTQS
QDRFVYTCNECKHHVETRWHCTVCEDYDLCITCYNTKNHDHKMEKLGLGLDDESNNQQA
AATQSPGDSRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICK
QLIALCCYHAKHCQENKCPVPFCLNIKQKLRQQQLQHRLQQAQMLRRRMASMQRTGVVGQ
15 QQGLPSPTPATPTTPTGQQPTTPQTPQPTSQPQPTPPNSMPPYLPRTQAAGPVSQGKAAGQVT
PPTPPQTAQPPLPGPPAAVEMAMQIQRAAETQRQMAHVQIFQRPIQHQMPPMTPMAPMG
NPPPMTRGPSGHLEPGMGPTGMQQQPPWSQGGLPQPQQLOSGMPRPAMMSVAQHGGQPLN
MAPQPGLGQVGISPLKPGTVSQQALQNLLRTLRSPLSQQQVLSILHANPQLLAFAIKQRA
AKYANSNPQPIPGQPGMPQGQPGLPPTMPGQQGVHSNPAMQNMNPMQAGVQRAGLPQQ
20 QPQQQLQPPMGGMSPQAQQMNMNHNTMPSQFRDILRRQQMMQQQQQQGAGPGIGPGMA
NHNQFQQPQGVGYPPQQQQQRMQHHMQQMQQGNMGQIGQLPQALGAEAGASLQAYQQRL
LQQQMGSPPVQPNPMSPQQHMLPNQAQSPHLQGGQIPNSLSNQVRSPQPVPSPRPQSQPPHSSP
SPRMQPQPSPHHVSPQTSSPHGLVAAQANPMEQGHFASPDQNSMLSQLASNPGMANLHGA
SATDLGLSTDNSDLNSNLSQSTLDIH (SEQ ID NO: 152)
- 25 NP_001155201.1 phospholipase A2, membrane associated precursor
MKTLLLLAVIMIFGLLQAHGNLVNFHRMIKLTGKEAALSYGFYGCHCGVGGRGSPKDATD
RCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQCECDKAAATCFARNKT
TYNKKYQYYSNKHCRGSTPRC (SEQ ID NO: 153)
- 30 NP_613075.1 core histone macro-H2A.1 isoform 1
MSSRGGGKKKSTKTSRSAKAGVIFPVGRMLRYIKKGHPKYRIGVGAPVYMAAVLEYLTAEILE
LAGNAARDNKKGRVTPRHILLAVANDEELNQLLKGVTIASGGVLPNIHPELLAKKRGSKGKL
EAIITPPPAKKAKSPSQKKPVSKKAGGKKGARKSKKKQGEVSKAASADSTTEGTPADGFTVL
35 STKSLFLGQKLQVVQADIASIDSDAVVHPTNTDFYIGGEVGNTLEKKGGKEFVEAVLELRKK
NGPLEVAGAAVSAGHGLPAKFVIHCNSPVWGADKCEELLEKTVKNCLALADDKKLKSIAFP
SIGSGRNGFPKQTAAQLILKAISSYFVSTMSSSIKTVYFVLFDSESIGIYVQEMAKLDAN (SEQ
ID NO: 153)
- 40 NP_003521.2 histone cluster 1, H3d
MARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIRRYQKSTEL
LIRKLPFQRLVREIAQDFKTDLRFQSSAVMALQEACEAYLVGLFEDTNLCAIHAKRVTIMPKD
IQLARRIRGERA (SEQ ID NO: 154)
- 45 NP_003504.2 histone H2A type 1-B/E
MSGRGKQGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGNYSERVGAGAPVYLAADVLEYLT
AEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLGRVTIAQGGVLPNIQAVLLPKKTES
HHKAKGK (SEQ ID NO: 155)
- 50 NP_808760.1 histone H2A.J
MSGRGKQGGKVRAKAKSRSSRAGLQFPVGRVHRLLRKGNYAERVGAGAPVYLAADVLEYLT
AEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLKGKVTIAQGGVLPNIQAVLLPKKTES
QKTKSK (SEQ ID NO: 156)
- 55 NP_002097.1 histone H2A.Z

- 5 MAGGKAGKDSGKAKTKAVSRSQRAGLQFPVGRIHRHLKSRTTSHGRVGATAAVYSA AILEY
LTAEVLELAGNASKDLKVKRITPRHLQLAIRGDEELDSLKATIAGGGVIPHIHKS LIG
KKGQQKTV (SEQ ID NO: 157)
- NP_066406.1 histone H2B type 1-B
- 10 MPEPSKSAPAPKKGSKKAITKAQKKDGKKRKR SRKESYSIYVYKVLKQVHPDTGISSKAMGI
MNSFVNDIFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEG TKAVT
KYTSSK (SEQ ID NO: 158)
- NP_066402.2 histone H2B type 1-J
- 15 MPEPAKSAPAPKKGSKKAVTKAQKKDGKKRKR SRKESYSIYVYKVLKQVHPDTGISSKAMG
IMNSFVNDIFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEG TKAVTKYTS
K (SEQ ID NO: 159)
- NP_542160.1 histone H2B type 1-K
- 20 MPEPAKSAPAPKKGSKKAVTKAQKKDGKKRKR SRKESYSVYVYKVLKQVHPDTGISSKAM
GIMNSFVNDIFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEG TKAVTKYTS
AK (SEQ ID NO: 160)
- NP_003518.2 histone H2B type 1-O
- 25 MPDPAKSAPAPKKGSKKAVTKAQKKDGKKRKR SRKESYSIYVYKVLKQVHPDTGISSKAM
GIMNSFVNDIFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEG TKAVTKYTS
SK (SEQ ID NO: 161)
- NP_003484.1 histone H3.1t
- 30 MARTKQTARKSTGGKAPRKQLATKVAR KSAPATGGVKKPHRYRPGTVALREIRRYQKSTEL
LIRKL PFQRLMREIAQDFKTD LRFQSSAVMALQEACESYLVGLFEDTNLCVIHAKRVTIMPKD
IQLARRIRGERA (SEQ ID NO: 162)
- NP_001116847.1 histone H3.2
- 35 MARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIRRYQKSTEL
LIRKL PFQRLVREIAQDFKTD LRFQSSAVMALQEASEAYLVGLFEDTNLC AIHAKRVTIMPKD
IQLARRIRGERA (SEQ ID NO: 163)
- NP_005315.1 histone H3.3
- 40 MARTKQTARKSTGGKAPRKQLATKAARKSAPSTGGVKKPHRYRPGTVALREIRRYQKSTEL
LIRKL PFQRLVREIAQDFKTD LRFQSAAIGALQEASEAYLVGLFEDTNLC AIHAKRVTIMPKDI
QLARRIRGERA (SEQ ID NO: 164)
- NP_001029249.1 histone H4
- 45 MSGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKRISGLIYEETR GV LKVF
LENVIRDAV TYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 165)
- NP_001902.1 cathepsin G preproprotein
- 50 MQPLLLLLAFLPTGAEAGEIIGGRESRPHSRPYMAYLQIQSPAGQSRCGGFLVREDFVL
TAAHCWGSNINVT LGAHNIQRRENTQQHITARRAIRHPQYNQRTIQNDIMLLQLSRRVRR
NRNVNPVALPRAQEGLRPGTLCTVAGWGRVSMRRGTDTLREVQLRVQRDRQCLRIFGSYDP
RRQICVGD RRERKAAFKGDSGGPLL CNNAHGVSYGKSSGVPPEVFTRVSSFLPWIRT TMR
SFKLLDQMETPL (SEQ ID NO: 166)
- 55 NP_002119.1 high mobility group protein B1

- 5 MGKGDPKKPRGKMSSYAFFVQTCREEHKKKHPDASVNFSEFSKKCSERWKTMSAKEKGKF
EDMAKADKARYEREMKTYIPPKGETKKKFKDPNAPKRPPSAFFLFCSEYRPMKIKGEHPGLSIG
DVAKKLGEMWNNTAADDKQPYEKKA AKLKEKYEKDIAAYRAKGKPDAAKKGVVKA EKS
KKKKEEEEDEEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDDDE (SEQ ID NO: 167)
- 10 NP_001997.5 heparin-binding growth factor 2
MVGVGGGDVEDVTPRPGGCQISGRGARGCNGIPGAAAWEAALPRRRPRRHPSVNPRSRAAG
SPRTRGRRTEERPSGSRLGDRGRGRALPGGRLGGRGRGRAPERVGGRRGRGRGTAAAPRAAPA
ARGSRPGPAGTMAAGSITTLPALPEDGGSGAFPPGHFKDPKRLYCKNGGFFLRIHPDGRVDG
VREKSDPHIKLQLQAEERGVSISIKGVCANRYLAMKEDGRLLASKCVTDECFFFERLESNNYN
15 TYRSRKYTSWYVALKRTGQYKLGSKTGPGQKAILFLPMSAKS (SEQ ID NO: 168)
- NP_001155201.1 phospholipase A2, membrane associated precursor
MKTLLLLAVIMIFGLLQAHGNLVNFHRMIKLTGKEAALSYGFYGCHCGVGGRGSPKDATD
RCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQ LCECDKAAATCFARNKT
20 TYNKKYQYYSNKHCRGSTPRC (SEQ ID NO: 169)
- NP_002719.3 bone marrow proteoglycan preproprotein
MKLPLLLALLFGAVSALHLRSETSTFETPLGAKTLPEDEETPEQEMEETPCRELEEEEEEW
GSGSEDASKKDGA VESISVPDMVDKNLTCPEEEDTVKVVGIPGCQTCRYLLVRSLQTFSQ
25 AWFTCRRCYRGNL VSIHNFNINYRIQCSVSALNQGQVWIGGRITGSGRCRRFQWVDGSRWN
FAYWAAHQPSRGGHCVALCTRGGHWRRRAHCLRRLPFICSY (SEQ ID NO: 170)
- NP_008869.1 small nuclear ribonucleoprotein Sm D1
MKLVRFLMKLSHETVTIELKNGTQVHGTITGVDVSMNTHLKA VKMTLKNREP VQLETLSIR
30 GNNIRYFILPDSLPLDTLLVDVEPKVKSKKREAVAGRGRGRGRGRGRGRGRGRGGPRR
(SEQ ID NO: 171)
- NP_060771.3 RNA-binding protein 41 isoform 1
MKRVNSCVKSDEHVLEETEGERQLKSLQHQLDTSVSIEECMSKKESFAPGTMYKPPFGKE
35 AAGTMTLSQFQTLHEKDQETASLRELGLNETEILWKSHVSGEKKTKLRATPEAIQNRLQDIE
ERISERQRILCLPQRFASKQLTRREMEIEKSLFQGADRHSFLKALYYQDEPQKKNKGDPMN
NLESFYQEMIMKKRLEEFQLMRGEPFASHSLVSATSVGDSGTAESP SLLQDKGKQAAQGKGP
SLHVANVIDFSPEQCWTGPKKLTQPIEFVPEDEIQRNRLSEEEIRKIPMFSSYNPGEPNKVLYL
KNLSPRVTERDLVSLFARFQEKKGPIQFRMMTGRMRGQAFITFPNKEIAWQALHLVNGYKL
40 HGKILVIEFGKNKKQRSNLQATSLISCATGSTTEISGS (SEQ ID NO: 172)
- NP_619520.1 putative ATP-dependent RNA helicase DHX30 isoform 1
MFSLDSFRKDRAQHRQRQCKLPPPRLPPMCVNPTPGGTISRASRDLLKEFPQPKNLLNSVIGR
ALGISHAKDKLVYVHTNGPKKKKVT LHIKWPKSVEVEGYGSKKIDAERQAAAAACQLFKG
45 WGLLGPRNELFDAKYRVLADRFGSPADSWWRPEPTMPPTSWRQLNPESIRPGGPGGLSRSL
GREEEDEEEEELEEGTIDVTDFLSMTQQDSHAPLRDSRGSSFEMTDDDSAIRALTQFPLPKNL
LAKVIQIATSSSTAKNLMQFHTVGT KTKLSTLTLLWPCPMTFVAKGRRKAEAENKAAALAC
KKLKSLGLVDRNNEPLTHAMYNLASLRELGETQRRPCTIQVPEPILRKIETFLNHYPVESSWI
APELRLQSDDILPLGKDSGPLSDPITGKPYVPLLEAEVRLS QSLELWRRRGPVWQEAPQLP
50 VDPHRDTILNAIEQHPVVVISGDTGCGKTTRIPQLLLERYVTEGRGARC NVIITQPRRISAVSV
AQRVSHELGPSLRRNVGFQVRLESKPPSRGGALLFCTVGILLRKLQSNPSLEGVSHVIVDEVH
ERDVNTDFLLILLKGLQRLNPALRLVLMSATGDNERFSRYFGGCPVIKVPGFMYPVKEHYLE
DILAKLGKHQYLHRHRHHESEDECALDLDLVTDLVLHIDARGEPPGILCFLPGWQEIKGVQQ
RLQEALGMHESKYLLIPVHSNIPMMDQKAIFQQPPVGVRKIVLATNIAETSITINDIVHVVD SG
55 LHKEERYDLKTKVSCLETVWVSRANVIQRRGRAGRCQSGFAYHLFPRSRLEKMVPFQVPEIL
RTPLENLVLQAKIHMPEKTAVEFLSKAVDSPNIKAVDEAVILLQEIGVLDQREYLTTLGQRLA

5 HISTDPRLAKAIVLAAIFRCLHPLL VVV SCLTRDPFSSSLQNRAEVDKVKALLSHDSGSDHLA
FVRAVAGWEEVLRWQDRSSRENYLEENLLYAPSLRFIHGLIKQFSENIYEAF LVGKPSDCTLA
SAQCNEYSEEEELVKGVL MAGLYPNLIQVRQGK VTRQGKFKPNSVTYRTKSGNILLHKSTIN
REATRLRSRWLT YFMAVKSN GSVFVRDSSQVHPLAVLLLTDGDVHIRDDGRRATISLS DSDL
10 LRLEGDSRTVRL LKELRRALGRMVERSLRSELAALPPSVQEEHGQLLALLAELLRGPCGSFD
VRKTADD (SEQ ID NO: 173)

NP_001129248.1 zinc finger and BTB domain-containing protein 43
MEPGTNSFRVEFPDFSS TILQKLNQQRQQGQLCDVSIVVQGHIFRAHKAVLAASSPYFCDQVL
LKNSRRIVLPDVMNPRVFENILLSSYTGR LVMPAPEIVSYLTAASFLQMWHVVDKCTEVLEG
15 NPTVLCQKLNHGSDHQSPSSSSYNGLVESFELGSGGHTDFPKAQELRDGENEEESTKDELSSQ
LTEHEYLP SNSSTEHDRLSTEMASQDGEEGASDSA EFHYTRPMYSKPSIMAHKRWIHV KPER
LEQACEGMDVHATYDEHQVTE SINTVQTEHTVQPSGVEEDFHIGEKKVEAEFDEQADESNY
DEQVDFY GSSMEEFSGERSDGNLIGHRQE AALAAGYSENIEMVTGIKEEASHLGFSATDKLY
PCQCGKSFT HKSQRDRHMSMHLGLRPY GCGVCGKKFKMKHHLVGHMKIHTGIKPYECNIC
20 AKRFMWRDSFHRHVT SCTKSYEAAKAEQNTTEAN (SEQ ID NO: 174)

NP_001721.2 Krueppel-like factor 5
MATRVLSMSARLGPVPQPPAPQDEPVFAQLK PVLGAANPARDAALFPGEELKHAHHRPQAQ
PAPAQAPQPAQPPATGPRLPPEDLVQTRCEME KYLTPQLPPVPIIPEHKKYRRDSASVVDQFF
25 TDTEGLPY SINMNVFLPDITHLRTGLYKSQRPCVTHIKTEPV AIFSHQSETTAPPPAPTQALPEF
TSIFSSHQTA APEVNNIFIKQELPTPDLHLSVPTQQGHLYQLLNTPDLDMPSSSTNQTAA MDTL
NVSMSAAMAGLNTHTSAVPQTAVKQFQGMPPCTYTMPSQFLPQQATYFPPSPPSSEPGSPDR
QAEMLQNLTPPPSYAATIASKLAIHNP NLPTTLPVNSQNIQPVRYNRRSNPDLEKRRIHYCDY
PGCTKVYTKSSH LKAHLRTHTEGKPYKCTWEGCDWRFARSDDELTRHYRKHTGAKPFQCGV
30 CNRSFSRSDHLALHMKRHQN (SEQ ID NO: 175)

NP_001129687.1 artemin isoform 3 precursor
MELGLGGLSTLSHCPWPRQQAPLGLSAQPALWPTLAALALLSSVAEASLG SAPRSPAPREGP
PPVLASPAGHLP GGRTARWCSGRARRPPPQPSRPAPPPPAPPSALPRGGRAARAGGPGSRAR
35 AAGARGCRLRSQ LVPVRALGLGHRSD ELVRFRCFSGSCRRARSPHDLSLASLLGAGALRPPP
GSRPVSQPCCRPTRYEAVSFMDVNSTWRTVDRLSATACGLG (SEQ ID NO: 176)

NP_113623.1 THAP domain-containing protein 2
MPTNCAAAGCATTYNKHINISFHRFPLDPKRRKEWVRLVRRKNFVPGKHTFLCSKHFEASCF
40 DLTGQTRRLKMDAVPTIFDFCTHIKSMKLKSRNLLKKNNSCSPAGPSNLKSNISSQQV LLEHS
YAFRNPMEAKKRII KLEKEIASLRRKMKTCLQKERRATR RWIKATCLVKNLEANSVLPKGTS
EHMLPTALSSLPLEDFKILEQDQQDKTLLSLNLKQTKSTFI (SEQ ID NO: 177)

NP_001020092.1 60S ribosomal protein L9
45 MKTILSNQTV DIPENV DITLKGRTVIVKGPRGTLRRDFNHINVELSLLGKKKKRLRV DKWWG
NRKELATVRTICSHVQNM IKGVT LGFRYKMRSVYAHFPINVVIQENGSLVEIRNFLGEKYIRR
VRMRPGVACSVSQAQKDELILEGNDIELVSNSAALIQQATT VKNKDIRKFLDGIYVSEKGTV
QQADE (SEQ ID NO: 178)

50 NP_775956.1 E3 SUMO-protein ligase NSE2
MPGRSSSN SGSTGFISFGVESALSSLKNFQACINSGMDTASSVALDLVESQTEVSSEYSMDK
AMVEFATLDRQLNH YVKA VQSTINH VKEERPEKIPDLKLLVEKKFLALQSKNSDADFQNE
KFVQFKQQLKELKKQCGLQADREADGTEGVDEDIIVTQSQTNFTCPITKEEMKKPVKNKVC
GHTYEEDAIVRMIESRQKRKKKAYCPQIGCSHTDIRKSDLIQDEALRRAIENHNKKRHRHSE
55 (SEQ ID NO: 179)

- 5 NP_060667.2 zinc finger protein 64 isoform a
 MNASSEGESFAGSVQIPGGTTVLVELTPDIHICGICKQQFNNLDAFVAHKQSGCQLTGTS
 AAPSTVQFVSEETVPATQTQTTRTITSETQTITVSAPEFVFEHGYQTYLPTESNENQT
 ATVISLPAKSRTKKPTTPPAQKRLNCCYPGCQFKTAYGMKDMERHLKIHTGDKPHKCEVCG
 KCFSRKDKLKTHMRCHTGVKPYKCKTCDYAAADSSSLNKHRLHSDERPFKCQICPYASRNS
 10 SQLTVHLRSHTGDAPFQCWLCSAKFKISSDLKRHMRVHSGEKPFKCEFCNVRCTMKGNLKS
 HIRIKHSGNNFKCPHCDLFGDSKATLRKHSRVHQSEHPEKCSECSYSCSSKAALRIHERIHCTD
 RPFKCNYCSFDTKQPSNLSKHMKKFHGDMVKTEALERKDTGRQSSRQVAKLDAKKSFHCDI
 CDASFMREDSLRSHKRQHSEYSESKNSDVTVLQFQIDPSKQPATPLTVGHLQVPLQPSQVPQF
 SEGRVKIIVGHQVPQANTIVQAAAAAVNIVPPALVAQNPEELPGNSRLQILRQVSLIAPPQSSR
 15 CPSEAGAMTQPAVLLTTHEQTDGATLHQTLIPTASGGPQEGSGNQTFITSSGITCTDFEGLNA
 LIQEGTAEVTVVSDGGQNIAVATTAPPVFSSSSQQELPKQTYSIIQGAHPALLCPADSIPD
 (SEQ ID NO: 180)
- 20 NP_114440.1 POZ-, AT hook-, and zinc finger-containing protein 1 short isoform
 MERVNDASCGPSGCYTYQVSRHSTEMLHNLNQQRKNGGRFCDVLLRVGDESFPAAHRAVLA
 ACSEYFESVFSAQLGDGGAADGGPADVGGATAAPGGGAGGSRELEMHTISSKVFGDILDFA
 YTSRIVVRLESFPELMTAAKFLLMRSVIEICQEVIKQSNVQILVPPARADIMLFRPPGTSDLGFP
 LDMTNGAALAANSNGIAGSMQPEEEAARAAGAAIAGQASLPVLPGVDR LPMVAGPLSPQLL
 TSPFPSVASSAPPLTGKRGRGRPRKANLLDSMFGSPGGLREAGILPCGLCGKVFTDANRLRQH
 25 EAQHGVTS LQLGYIDLPPRLGENGLPISEDPDGRKRSRTRKQVACEICGKIFRDVYHLNRH
 KLSHSGEKPYPSCPVCGLRFKRKDRMSYHVRSHDGSVGKPYICQSCGKGFSPDHLNGHIKQV
 HTSERPHKCQVWVGSSSGLPPLEPLPSDLPSWDFAPALWRSSHSVPDTAFSLSLKKSFPAL
 NLGPAHSSNTLFCPAPPGYLRQGWTTPEGSRAFTQWPVG (SEQ ID NO: 181)
- 30 NP_149105.3 zinc finger CCHC-type and RNA-binding motif-containing protein 1
 MSGGLAPSKSTVYVS NLPFSLTNNDLYRIFSKYGVVKVTIMKDKDTRKSKGVAFILFLD
 KDSAQNCTRAINNKQLFGRVIKASIAIDNGRAAEFIRRRNYFDKSKCYECGESGHL SYAC
 PKNMLGEREPPKKKEKKKKKKAPEPEEEIEEVEESEDGEDPALDSLSQAIAFQQAKIEE
 EQKKWKPSGVPSTSDDSRRPRIKKSTYFSDEEELSD (SEQ ID NO: 182)
- 35 NP_036389.2 HMG box-containing protein 1
 MVWEVKTNQMPNAVQKLLLVM DKRASGMNDSLELLQCNENLPSSPGYNSCDEHME LDDL
 PELQAVQSDPTQSGMYQLSSDVSHQEYPRSSWNQNTSDIPETTYRENEVDWLTEL ANIATSP
 QSPLMQCSFYNRSSPVHIIATSKSLHSYARPPPVSSSSKSEPAFPHHHWKEETPVRHERANSES
 40 ESGIFCMSSLSDDDDLGWCNSWPSTVWHCFLKGTRLCFHKGSNKEWQDVEDFARAEGCDN
 EEDLQMGIHKGYGSDGLKLLSHEESVSFGESVLKLTDFDPTVEDGLLTVECKLDHPFYVKNK
 GWSSFYPSLTVVQH GIPCCVHIGDVCLPPGHPDAINFDDSGVFDTFKSYDFTPMDS SAVYVL
 SSMARQRRASLSCGGPGGQDFARSGFSKNCGSPGSSQLSSNSLYAKAVKNHSSGTVSATSPN
 KCKRPMNAFMLFAKKYRVEYTQMYPGKDNRAISVILGDRWKKMKNEERRMYTLEAKALA
 45 EEQKRLNPDCWKRKRTNSGSQQH (SEQ ID NO: 183)
- NP_115672.2 FLYWCH-type zinc finger-containing protein 1 isoform a
 MPLPEPSEQEGESVKAGQE PPKPGTDVIPAAPRKPREFSKL VLLTASDQDEDGVGSKPQ
 EVHCVLSLEMAGPATLASTLQILPVEEQGGVVQPALEMPEQKCSKLD AAPQSLEFLRTPF
 50 GGRLLVLESFLYKQEKA VGDKVYWKCRQHAELGCRGRAITRGLRATVMRGHCHAPDEQGL
 EARRQREKLPSLALPEGLGEPQGPEGPGGRVEEPLEGVGPWQCPEEPEPTPGLVLSKPALEEE
 EAPRALSLLSLPPKKRSILGLGQARPLEFLRTC YGG SFLVHESFLYKREKA VGDKVYWTCRD
 HALHGCRSRAITQGQRVTVMRGHCHQPDMEGLEARRQQEKAVETLQAGQDGPGS QVD TLL
 RGVDSLLYRRGPGPLTLTRPRPRKRAKVEDQELPTQPEAPDEHQDMDADPGGP EFLKTPLGG
 55 SFLVYESFLYRREKAAGEKVYWTCRDQARMGCRSRAITQGRRTVMRGHCHPPDLGGLEA
 LRQREKRPNTAQRGSPGGPEFLKTPLGG SFLVYESFLYRREKAAGEKVYWTCRDQARMGCR

5 SRAITQGRRVMVMRRHCHPPDLGGLEALRQREHFPNLAQWDSPDPLRPLEFLRTSLGGRFLV
HESFLYRKEKAAGEKVYWMCRDQARLGCRSRAITQGHRIMVMRSHCHQPDLAGLEALRQR
ERLPTTAQQEDPEKIQVQLCFKTCSPESQQIYGDIKDVRLDGESQ (SEQ ID NO: 184)

NP_005645.1 COUP transcription factor 1

10 MAMVVSSWRDPQDDVAGGNPGGPNPAAQAARGGGGGAGEQQQQAGSGAPHTPQTPGQPG
APATPGTAGDKGQGPPGSGQSQQHIECVVCGDKSSGKHYGQFTCEGCKSFFKRSVRRNLTY
TCRANRNCPIDQHHRNQCYCRLKKCLKVGMRRREAVQGRMPPTQPNPGQYALTNGDPLN
GHCYLSGYISLLLRAEPTYPSRYGSQCMQPNNIMGIENICELAAARLLFSAVEWARNIPFFPDQ
ITDQVSLRLTWSELFVLNAAQCSMPLHVAPLLAAAGLHASPMSADRVVAFMDHIRIFQEYV
15 EKLKALHVDSAEYSCLKAIVLFTSDACGLSDAAHIESLQEKSQCALEEYVRSQYPNQPSRFGK
LLLRLPSLRTVSSSVIEQLFFVRLVGKTPIETLIRDMLLSGSSFNWPYMSIQCS (SEQ ID NO:
185)

NP_006457.2 DNA-directed RNA polymerase III subunit RPC6

20 MAEVKVKVQPPDADPVEIENRIIELCHQFPHGITDQVIQNEMPHIEAQQRAVAINRLLSM
GQLDLLRSNTGLLYRIKDSQNAGKMKGSDNQEKL VYQIIEDAGNKGIWSRDIRYKSNLPLTEI
NKILKNLESKKLIKAVKSVAASKKKVYMLYNLQPDRSVTGGAWYSDQDFESEFVEVLNQQC
FKFLQSKAETARESKQNPMIQRNSSFASSHEVWKYICELGISKVELSMEDIETILNTLIYDGKV
EMTIIAAKEGTVGSVDGHMKLYRAVNPIIPTGLVRAPCGLCPVFDDCHEGGEISPSNCIYMT
25 EWLEF (SEQ ID NO: 186)

NP_005333.2 high mobility group protein B3

MAKGDPKKPKGKMSAYAFFVQTCREEHKKKNPEVPVNF AEFSKKCSERWKTMSGKEKSKF
DEMAKADKVRDREMKDYGPAKGGKKKKDPNAPKRPPSGFFLCSEFRPKIKSTNPGISIGD
30 VAKKLGEWNNLNDSEKQPYITKAAKLKEKYEKDVADYKSKGKFDGAKGPAKVARKKVE
EEDEEEEEEEEEEEEEDE (SEQ ID NO: 187)

NP_001165290.1 peroxisome proliferator-activated receptor delta isoform 3

MHQRDLRSSSPPSLDQLQMCGDASGSLNMECRVCGDKASGFHYGVHACEGCKGFFR
35 RTIRMKLEYEKCERSCKIQKKNRNCQYCRFQKCLALGMSHNAIRFGRMPAEKRKL VAGL
TANEGSQYNPQVADLKAFSKHIYNAYLKNFNMTKKKARSILTGKASHTAPFVIHDIETLWQA
EKGLVWKQLVNGLPYKEISVHVYRCQCTTVETVRELTEFAKSIPSFSSFLNDQVTLLKYG
VHEAIFAMLASIVNKDGLLVANGSGFVTREFLRSLRKPFSDIIEPKFEFAVKFNALELDDSDLA
LFIAAIIILCGDRPGLMNVPRVEAIQDTILRALEFHLQANHPDAQYLFPKLLQKMADLRQLVTE
40 HAQMMQRIKKTETETSLHPLLQEIKDMY (SEQ ID NO: 188)

NP_003783.1 endothelial differentiation-related factor 1 isoform alpha

MAESDWDTVTVLRKKGPTAAQAKSKQAILAAQRRGEDVETSKKWAAGQNKQHSITKNTA
KLDRETEELHHDRVTLVGKVIQQGRQSKGLTQKDLATKINEKPQVIADYESGRAIPNNQVL
45 GKIERAIGLKLRGKDIGKPIEKGPRAK (SEQ ID NO: 189)

NP_620410.3 homeobox protein TGIF2LX

MEAAADGPAETQSPVEKDSPAQTQSPAQDTSIMSRNNADTGRVLALPEHKKKRKGNLPAES
VKILRDWMYKHRFKAYPSEEEKQMLSEKTNLSLLQISNWFNARRRILPDMLQQRRNDPIIGH
50 KTGKDAHATHLQSTEASVPAKSGPSGPDNVQSLPLWPLPKGQMSREKQPD PESAPSQKLTGI
AQPKKKVKVSVTSPSSPELVSPEEHADFSFLLLVDAAVQRAAELELEKKQEPNP (SEQ ID
NO: 190)

NP_003131.1 sex-determining region Y protein

55 MQSYASAMLSVFNSDDYSPAVQENIPALRRSSSFLCTESCNSKYQCETGENSKGNVQDRVKR
PMNAFIVWSRDQRRKMALENPRMRNSEISKQLGYQWKMLTEAEKWPFQEAQKLQAMHR

5 EKYPNYKYRPRRKAKMLPKNCSSLPADPASVLCSEVQLDNRLYRDDCTKATHSRMEHQLG
HLPPINAASSPQQRDRYSHWTKL (SEQ ID NO: 191)

NP_000956.2 retinoic acid receptor beta isoform 1

MFDCMDVLSVSPGQILDFYTASPSSCMLQEKALKACFSGLTQTEWQHRHTAQSIETQSTS
10 SEELVPSPSPPLPPRVYKPCFVCQDKSSGYHYGVSAEGCKGFFRRSIQKNMIYTCHRD
KNCVINKVTRNRCQYCRLQKCFEVGMSKESVRNDRNKKKKKETSKECTESYEMTAELDDL
TEKIRKAHQETFPSLCQLGKYTTNSSADHRVRLDLGLWDFSELATKCIKIVEFAKRLPGFT
GLTIADQITLLKAAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTD
LVFTFANQLLPLEMDDTETGLLSAICLICGDRQDLEPTKVDKLQEPLLEALKIYIRKRR
15 PSKPHMFPKILMKITDLRSISAKGAERVITLKMEIPGSMPLIQEMLENSEGHEPLTPSS
SGNTAEHSPSISPSSVENSQSVQ (SEQ ID NO: 191)

NP_064589.2 LIM/homeobox protein Lhx9 isoform 1

MEIVGCRAEDNSCPFRPPAMLFHGISGGHIQGIMEEMERRSKTEARLAKGAQLNGRDAGMPP
20 LSPEKPALCAGCGGKISDRYLLAVDKQWHLRCLKCCECKLALESELTCFAKDGSYICKEDY
YRRFSVQRCARCHLGISASEMVMRARDSVYHLSCFTCSTCNKTLTTGDHFGMKDSLVCRA
HFETLLQGEYPPQLSYTELAAKSGGLALPYFNGTGTVQKGRPRKRKSPALGVDIVNYNSGCN
ENEADHLDRDQQPYPPSQKTKRMRTSFKHHQLRTMKSYFAINHNPDAKDLKQLAQKTGLT
KRVLQVWFQNAKFRNLLRQENGVDKADGTSLPAPPSADSGALTPPGTATTLTDLTNP
25 TITVVTSTSNMDSHESGPSQTTLTNLF (SEQ ID NO: 192)

NP_067545.3 homeobox protein BarH-like 1

MQRPGEPGAARFGPPEGCADHRPHRYRSFMIEEILTEPPGPKGAAPAAAAAAGELLKFGVQ
ALLAARPFHSHLAVLKAEEQAAVFKFPLAPLGCSGLSSALLAAGPGLPGAAGAPHLPLELQLR
30 GKLEAAGPGEPTKAKKGRRSRTVFTELQLMGLEKRFEKQKYLSTPDRIDLAESLGLSQLQV
KTWYQNRRMKWKKIVLQGGGLESPKPKGRPKKNSIPTSEQLTEQERAKDAEKPAEVPGE
SDRSRED (SEQ ID NO: 193)

NP_997704.1 protein kinase C delta type

MAPFLRIAFNSYELGSLQAEDEANQPFCVVKMEALSTERGKTLVQKKPTMYPEWKSTFDA
HIYEGRVIQIVLMRAAEEPVSEVTVGVSVAERCKKNNGKAEFWLDLQPQAKVLMSVQYFL
EDVDCKQSMRSEDEAKFPTMNRRGAIKQAKIHYNHEFIATFFGQPTFCVCKDFVWGLNK
QGYKCRQCNAAIHKKCIDKIIGRCTGTAANSRDTIFQKERFNIDMPHRFKVHNYMSPTFCDH
CGSLLWGLVKQGLKCEDCGMNVHHKCREKVANLCGINQKLLAEALNQVTQRASRRSDSAS
40 SEPVGIIYQGFEKKTGVAGEDMQDNSGTYGKIWEGSSKCNINNFIFHKVLGKGSFGKVLLGEL
KGRGEYFAIKALKKDVVLIDDDVECTMVEKRVLTAAENPFLTHLICTFQTKDHLFFVMEFL
NGGDLMYHIQDKGRFELYRATFYAAEIMCGLQFLHSKGIIYRDLKLDNVLLDRDGHKIADF
GMCKENIFGESRASTFCGTPDYIAPEILQGLKYTFSDVWWSFGVLLYEMLIQSPFHGDDDEDE
LFESIRVDTPHYPRWITKESKDILEKLFEREPTKRLGVTGNIKIHPFFKTINWTLLEKRRLEPPF
45 RPKVKSPRDYSNFDQEFLNEKARLSYSDKNLIDSMDQSAFAGFSFVNPKFEHLLED (SEQ ID
NO: 194)

NP_079507.1 zinc finger and SCAN domain-containing protein 16

MTTALEPEDQKGLLIKAEDHYWGQDSSSQKCSPHRRELYRQHFRKLCYQDAPGPREALTQL
50 WELCRQWLRPECHTKEQILDLLVLEQFLSILPKDLQAWVRAHHPETGEEAVTVLEDLERELD
EPGKQVPGNSERRDILMDKLAPLGRPYESLTVQLHPKKTQLEQEAGKPQRNGDKTRTKNEE
LFQKEDMPKDKEFLGEINDRLNKDTPQHPKSKDIIENEGRSEWQQRRRRYKCEDECCKSFSSH
SSDLSKHRRTHTGEPYKCEDECCKAFIQRSHLIGHHRVHTGVKPYKCKEKGKDFSGRTGLIQ
HQRHTGEPYECDECGRPFRVSSALIRHQRIHTANKLY (SEQ ID NO: 195)

55

NP_001002261.1 zinc finger FYVE domain-containing protein 27 isoform a

5 MQTSEREGSGPELSPSVMPEAPLESPPFPTKSPAFDLFNLVLSYKRLEIYLEPLKDAGDG
 VRYLLRWQMPLCSLLTCLGLNVLFLLTLNEGAWYSVGALMISVPALLGYLQEVCRARLPDSE
 LMRRKYHSVRQEDLQRGRLSRPEAVA EVKSFLIQLEAFLSRLCCTCEAAYRVLHWENPVVSS
 QFYGALLGTVCMPLYLLPLCWVLTLLNSTLFLGNVEFFRVVSEYRASLQQRMNPKQEEHAFE
 SPPPPDVGGKDGLMDSTPALTPTESLSSQDLTPGSVEEAEEAEPDEEFKDAIEETHLVLEDD
 10 EGAPCPAEDELALQDNGFLSKNEVLRSKVSRLTERLRKRYPTNNFGNCTGCSATFSVLKKRR
 SCSNCGNSFCSRCCSFKVPKSSMGATAPEAQRET VFCASCNQTL SK (SEQ ID NO: 196)

NP_001556.2 C-X-C motif chemokine 10 precursor

15 MNQTAILICCLIFLTLSGIQGVPLSRTVRC TCISISNQPVNPRSLEKLEIIPASQFCPRV
 EIIATMKKKG EKRLNPESKA IKNLLKAVSKERSKRSP (SEQ ID NO: 197)

NP_006248.1 protein kinase C theta type

MSPFLRIGLSNFDCGSCQSCQGEAVNPYCAVLVKEYVESENGQMYIQKKPTMYPPWDSTFD
 AHINKGRVMQIIVKGKNVDL ISETTVELYS LAERC RKNN GKTEIWLELKPQGRMLMNARYFL
 20 EMSDTKDMNEFETEGFFALHQR RGA IKQAKVHHVKCHEFTATFFPQPTFC SVCHEFVWGLN
 KQGYQCRQCNA AIHKKCIDKVI AKCTGSAIN SRET MFHKERFKIDMPHRFKVYNYKSPTFCE
 HCGTLLWGLARQGLKCDACGMNVHHR CQTKVANLCGINQKLMAEALAMIESTQQARCLR
 DTEQIFREGPVEIGLPCSIKNEARPPCLPTPGKREPQGISWESPLDEVDMCHLPEPELNKERPS
 LQIKLKIEDFILHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDDDVECTMVEKRVL
 25 SLAWEHPFLTHMFCTFQTKENLFFVMEYLN GGDLMYHIQSCHKFDLSRATFYAAE IILGLQF
 LHSKGIVYRDLKLDNILLDKDGH IKIADFGMCKENMLGDAKTNTFCGTPDYIAPEILLGQKY
 NHSVDWWSFGVLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPRWLEKEAKDLLVKLFVRE
 PEKRLGVRGDIRQHPLFREINWEELE RKEIDPPFRPKVKSPFDCSNFDKEFLNEKPRLSFADRA
 LINSMDQNMFRNFSFMNPGMERLIS (SEQ ID NO: 198)

30

NP_055850.1 zinc fingers and homeoboxes protein 3

MASKRKSTTPCMIPVKT VVLQDASMEAQPAETLPEGPQQDLPPEASAASSEAAQNPSSTD
 GSTLANGHRSTLDGYLYSCKYCDFRSHDMTQFVGHMNSEHTDFNKDPTFVCSGCSFLAKTP
 EGLSLHNATCHSGEASFVWNVAKPDNHVVVEQSIPESTSTPDLAGEPSAEGADGQAEIITKT
 35 PIMKIMKGKAEAKKIHTLKENVPSQPVG EALPKLSTGEME VREGDHSFINGAVPVSQASASS
 AKNPHAANGPLIGTVPVLPAGIAQFLSLQQQPPVHAQH HVHQPLPTAKALPKVMIPLSSIPTY
 NAAMDSNSFLKNSFHKFPYPTKAELCYLTVVTKYPEEQLKIWFTAQRLKQGISWSPEEIEDA
 RKKMFNTVIQSVPPQPTITVLNTPLVASAGNVQH LIQAALPGHVVGQPEGTGGGLLVTQPLMA
 NGLQATSSPLPLTVTSVPKQPGVAPINTVCSNTTSAVKV VNAAQSLLTACPSITSQAFLDASIY
 40 KNKKSHEQLSALKGSFCRNQFPGQSEVEHLTKVTGLSTREVRKWFSDRRYHCRNLKGSRAM
 IPGDHSSIIIDSVPEVSFSPSSKVPEVTCIPTTATLATHPSAKRQSWHQTPDFTPTKYKERAPEQL
 RALESSFAQNPLPLDEELDRLRSETKMTRREIDSWFSERRKKVNAEETKKAEENASQEEEEEA
 AEDEGGEE DLASELRVSGENG SLEMPSSHILAERKVSP IKINLKNLRVTEANGRNEIPGLGAC
 DPEDDES NKLAEQLP GKVSCKKTAQQRHLLRQLFVQTQWPSNQDYDSIMAQTGLPRPEVVR
 45 WFGDSRYALKNGQLK WYEDYKRGNFPPG LLVIAPGNRELLQDY YMTHKMLYEEDLQNL C
 DKTQMSSQQVKQWFAEKMGEETRAVADTG SEDQGP GTGELTAVHKGMGDTYSEVSENSES
 WEPRVPEASSEPFDTSSPQAGRQLETD (SEQ ID NO: 199)

NP_659501.1 SH3 and cysteine-rich domain-containing protein 3

50 MTEKEVLESPKPSFPAETRQSG LQRLKQLLRKGSTGT KEMELPPEPQANGEAVGAGGGPI
 YYIYEEEEEEEEEEEEPPPEPKLVNDKPHKFKDHFFKKPKFCDVCARMIVLNNKFGLRC
 KNCKTNIHEHCQSYVEMQRCFGKIPPGFHRA YSSPLYSNQQYACVKDLSAANRNDPVFETLR
 TGVIMANKERKKGQADKKNPVAAMMEEEPESARPEEGKPQDGNPEGDKKAEKKTPDDKH
 KQPGFQQSHYFVALYRFKALEKDDLD FPPGEKITVIDDSNEEWWRGKIGEKVGFFPPNFII RV
 55 RAGERVHRVTRSFVGNREIGQITLKKDQIVVQKGDEAGGYVKVYTGRKVGLFPTDFLEEI
 (SEQ ID NO: 200)

5

NP_001167539.1 synaptotagmin-like protein 4

MSELLDLSFLSEEEKDLILSVLQRDEEVRKADEKRIRRLKNELLEIKRKGAKRGSSQHYSD
 RTCARCQESLGRSLPKTNTCRGCNHLVCRDCRIQESNGTWRCKVCAKEIELKKATGDWFDYD
 QKVNRFAYRTGSEIIRMSLRHKPAVSKRETVGQSLLHQTQMGGDIWPGRKIIQERQKEPSVLFE
 10 VPKLKSGKSALEAESESLDSFTADSDSTSRRDSLDSGLFPEWKKMSAPKSQVEKETQPGGQ
 NVVFVDEGEMIFKKNTRKILRPSEYTKSVIDLRPEDVVHESGSLGDRSKSVPGLNVDMEEEEE
 EEDIDHLVKLHRQKLARSSMQSGSSMSTIGSMMSIYSEAGDFGNIFVTGRIAFSLKYEQQTQS
 LVVHVKECHQLAYADEAKKRSNPYVKTYLLPDKSRQGKRKTSIKRDTINPLYDETLRYEIP
 SLLAQRTLQFSVWHHGRFGRNTFLGEAEIQMDSWKLDKKLDHCLPLHGKISAESPTGLPSHK
 15 GELVVSLLKYIPASKTPVGGDRKKSKGGEGGELQVWIKEAKNLTAAGGTSDSFVKGYLLP
 MRNKASKRKTTPVMKKTLNPHYNHTFVYNGVRLEDLQHMCLELTVWDREPLASNDLGGV
 RLGVTGISNGEVVDWMDSTGEEVSLWQKMRQYPGSWAEGTLQLRSSMAKQKLGL (SEQ
 ID NO: 201)

20

NP_001078956.1 histone H2A deubiquitinase MYSM1

MAAEEADVDIEGDVVAAGAQPQSGGENTASVLQKDHYLDSSWRTENGLIPWTLTNTISEEN
 RAVIEKMLLEEEYYLSKKSQPEKVWLDQKEDDKKYMKSLLQKTAKIMVHSPTKPASYSVKW
 TIEEKELFEQGLAKFGRRWTKISKLGSRVTLQVKSYARQYFKNKVKCGLDKETPNQKTGHN
 LQVKNEDEKGTAKWTPSCLRGRADPNLNAVKIEKLSDDDEEVDITDEVDELSSQTPQKNSSDL
 25 LLDFPNSKMHEITNQGEFITSQSALFSKSSRGCLQNEKQDETLSSEITLWTEKQSNQDKKSI
 ELNDQKFNELIKNCNKHDGRGIIVDARQLPSPEPCEIQKNLNDNEMLFHSCQMVEESHEEEEL
 KPPEQEIEIDRNIIQEEEEKQAIPEFFEGRQAKTPERYLKIRNYILDQWEICKPKYLNKTSVRPGL
 KNCGDVNCIGRIHTYLELIGAINFGCEQAVYNRPQTVDKVRIRDRKDAVEAYQLAQRLLQSM
 RTRRRRVRDPWGNWCDADLEGQTFEHLAEELAKRREEEEKGRPVKSLKVPRTKSSFDPF
 30 QLIPCNFFSEEKQEPFQVKVASEALLIMDLHAHVSMMAEVIGLLGGRYSEVDKVVVEVCAAEPC
 NSLSTGLQCEMDPVSQTQASETLAVRGFSVIGWYHSHPAFDPNPSLRDIDTQAKYQSYFSRG
 GAKFIGMIVSPYNRNPLPYSQITCLVISEEISPDGSYRLPYKFEVQQMLEEPQWGLVFEKTR
 WIEKYRLSHSSVPMDKIFRRDSDLTCLQKLLECMRKTLSKVTNCFMAEEFLTEIENLFLSNY
 KSNQENGVTENCTKELLM (SEQ ID NO: 202)

35

NP_004562.2 homeobox protein PKNOX1

MMATQTLSDSYQDGQQMQVVTELKTEQDPNCSEPDAEGVSPPPVESQTPMDVDKQAIYRH
 PLFPLLALLFEKCEQSTQGSEGTTSASFDVDIENFVRKQEKEGKPFCEPETDNLMVKAIQV
 LRIHLLLELEKVNELCKDFCSRYIACLKTKMNSETLLSGEPGSPYSPVQSQQIQSAITGTISPQGI
 40 VVPASALQQGNVAMATVAGGTVYQPVTVVTPQGGQVVTQTLSPGTIRIQNSQLQLQLNQDLS
 ILHQDDGSSKNKRGVLPKHATNVMRSWLFQHIGHPYPTDEKKQIAAQTNLTLLQVNNWFI
 NARRRILQPMLDSSCSETPKTKKKTAQNRPVQRFWPDSIASGVAQPPPELTMSEGAVVTITT
 PVNMNVDSLQSLSSDGATLAVQQVMMAGQSEDESVDSTEEDAGALAPAHISGLVLENSDSL
 Q (SEQ ID NO: 203)

45

NP_001027453.1 Krueppel-like factor 10 isoform b

MEERMEMISERPKESSMYSWNKTAEKSDFEAVEALMSMSCSWKSDFKKYVENRPVTPVSDL
 SEEENLLPGTPDFHTIPAFCLTPPYSPSDFEPSQVSNLMAAPSTVHFKSLSDTAKPHIAAPFKE
 EEKSPVSAPKLPAQATSVIRHTADAQLCNHQTCPMKAASILNYQNNFRRRRTHLNVEAARK
 50 NIPCAAVSPNRSKCRNTVADVDEKASAALYDFSVPSETVICRSQPAPVSPQQKSVLVSPPA
 VSAGGVPPMPVICQMVPPLANNPVVTTVPSTPPSQPPAVCPPVVFMTGTQVPKGAVMVFVVP
 QPVVQSSKPPVVPNGTRLSPAPAPGFSPSAKVTPTQIDSSRIRSHICSHPGCGKTYFKSSHLK
 AHTRTHTGEKPFSCSWKGCERRFARSDELRSRHRRTHTGEKKFACPMCDRRFMRSDHLTKHA
 RRHLSAKKLPNWQMEVSKLNDIALPPTPAPTQ (SEQ ID NO: 204)

55

NP_002720.1 hematopoietically-expressed homeobox protein HHEX

5 MQYPHPGPAAGAVGVPLYAPTPLLQPAHPTPFYIEDILGRGPAAPTPAPTLPSPNSSFTSLVSP
YRTPVYEPTPIHPAFSHHSAAALAAAYGPGGFGGPLYFPFRTVNDYTHALLRHDPLGKPLLW
SPFLQRPLHKRKGQVRFSNDQTIELEKKFETQKYLSPPERKRLAKMLQLSERQVKTWQNR
RAKWRRLKQENPQSNKKEELESLSDDQDQDLPSEQNKGASLDSSQCSPSPASQEDLESEIS
EDSDQEV DIEGDKSYFNAG (SEQ ID NO: 205)

10

NP_006352.2 homeobox protein Hox-B13

MEPGNYATLDGAKDIEGLLGAGGGRNLVAHSPLTSHPAAPTLMPAVNYAPLDLPGSAEPPK
QCHPCPGVPQGTSPAPVPYGYFGGGYYSCRVSRSSLKPCAQAATLAAYPAETPTAGEEYPSR
PTEFAFYPGYPGTYQPMASYLDVSVVQTLGAPGEPRHDSLLPVDSYQSWALAGGWNSQMC
15 CQGEQNPPGPFWKAADFADSSGQHPPDACAARRGRKKRIPYSKQGLRELEREYAANKFITKDK
RRKISAATSLSERQITIWFQNR RVKEKKVLAKVKNSATP (SEQ ID NO: 206)

NP_597721.2 zinc finger protein 483 isoform a

MQAVVPLNKMATAISPEPQTLASTEQNEVPRVVTSGEQEAILRGNAADAESFRQRFRWFCYSE
20 VAGPRKALSQWLWCNQLWRPDIHTKEQILELLVFEQFLTILPGEIRIWVKSQHPRESS
EEVVTLIEDLTQMLEEKDPVSQDSTVSQEENSKEDKMVTVCNTESCESITLKDVAVNFS
RGEWKKLEPFQKELYKEVLLENLRNLEFLDFPVSKLELISQLKWVELPWLLEEVSKSSRL
DESALDKIIRCLRDDDHLMEESQQYCGSSEEDHGNQGNKGRVAQNKTGSGSRGKKFD
PDKSPFGHNFKETS DLIKHLRVYLRKKSRRYNESKKPFSFHS DLVLNRKEKTAGEKSRKSN
25 GGVLSHSSALTEHQKRQKIHLGDRSQKCSKCGIIFIRSTLSRRKTPMCEKCRKDSCQEAAL
NKDEGNESGEKTHKCSKCGKAFGYASLT KHRRHTGEKPYMCNECGKAFSDSSSLTPHHRT
HSGEKPFCDDCGKGFTLSAHLIKHQRIHTGEKPYKCKDCGRPFSDSSSLIQHQRIHTGEKPY
TCSNCGKSFSHSSSLSKHQRIHTGEKPYKCGECGKAFRQNSCLTRHQRIHTGEKPYLCNDCG
MTFSHFTSVIYHQRLHSGEKPYKCNQCEKAFPTHSLLSRHQRIHTGVKPYKCKEKGKSFSSQSS
30 SLNEHHRIHTGEKPYECNYCGATFSRSSILVEHLKIHTGRREYECNECEKTFKSNSGLIRHRGF
HSAE (SEQ ID NO: 207)

NP_001502.1 growth-regulated alpha protein precursor

MARAALSAAPSNPRLLRVALLLLLVAAGRRAAGASVATELRCQCLQTLQGIHPKNIQSVNV
35 KSPGPHCAQTEVIATLKNRKAACLPASPIVKKIIEKMLNSDKSN (SEQ ID NO: 208)

NP_001244.1 cell division cycle 5-like protein

MPRIMIKGGVWRNTEDEILKAAVMKYGKNQWSRIASLLHRKSAKQCKARWYEWLDPSIKK
TEWSREEEEKLLHLAKLMPTQWRTIPIIGRTAAQCLEHYEFLLDKAAQRDNEEETDPRK
40 LKPGEIDPNPETKPARPDPIDMDEDELEMLSEARARLANTQGKKAKRKAREKQLEEARRLAA
LQKRRELRAAGIEIQKKRKRKRGV DYN AEIPFEKKPALGFYDTSEENYQALDADFRKLRQQD
LDGELRSEKEGRDRKKDKQHLKRKKESDLPSAILQTSGVSEFTKKRSKLVLPAQISDAELQE
VVKVGQASEIARQTAEESGITNSASSTLLSEYNVTNNSVALRTPRTPASQDRILQEAQNLMAL
TNVDTPKGGGLNTPHESDFSGVTPQRQVVQTPNTVLSTPFRTPSNGAEGLTPRSGTTPKPIV
45 NSTPGRTPLRDKLNINPEDGMADYSDPSYVKQMERESREHLRLGLLGLPAPKNDFEIVLPEN
AEKELEEREIDDTYIEDAADVDARKQAIRDAERVKEMKRMHKA VQKDLPRPSEVNETILRPL
NVEPPLTDLQKSEELIKKEMITMLHYDLLHHPYEPGNGKKGKT VGFGTNNSEHITYLEHNPY
EKFSKEELKKAQDVLVQEME VVKQGM SHGELSSEAYNQVWEECY SQVLYLPGQSR YTRAN
LASKKDRIESLEKRLEINRGHMTTEAKRAAKMEKKMKILLGGYQSRAMGLMKQLNDLWDQ
50 IEQAHLRLRTFEELKKHEDSAIPRRLECLKEDVQRQQEREKELQHRYADLLEKETLKS KF
(SEQ ID NO: 209)

NP_115816.2 ligand-dependent corepressor isoform 1

MQRMIQQFAAEYTSKNSSTQDPSQPNSTKNQSLPKASPVTTSPATAATTQNPVLSKLLMADQD
55 SPLDLTVRKSQSEPSEQDGVLDLSTKKSPCAGSTSLSHSPGCSSTQGNRPGRPQSQRPDGLR
SGDGVPPRSLQDGTREGFGHSTSLKVPLARSLQISEELLSRNQLSTAASLGPSGL

- 5 QNHGQHLILSREASWAKPHYEFNLSRMKFRGNGALSNI SDLPFLAENSAFPKMALQAKQDG
KKDVSHSSPVDLKIPQVRGMDLSWESRTGDQYSYSSLVMGSQTESALSKKLRAILPKQSRKS
MLDAGPDSWGSDAEQSTSGQPYPTSDQEGDPGSKQPRKKRGRYRQYNSEILEEAISVVMMSG
KMSVSKAQSIYGIPHSTLEYKVKERLGT LKNPPKKKMKLMRSEGPDVSVKIELDPQGEAAQS
ANESKNE (SEQ ID NO: 210)
- 10 NP_001502.1 growth-regulated alpha protein precursor
MARAALSAAPSNPRLLRVALLLLLVAAGRRAAGASVATELRCQCLQTLQGIHPKNIQSVNV
KSPGPHCAQTEVIATLKNRKA CLNPASPIVKKIIEKMLNSDKSN (SEQ ID NO: 211)
- 15 NP_005212.1 homeobox protein DLX-5
MTGVFDRRVPSIRSGDFQAPFQTSAA MHHPSQESPTLPES SATDSDYYSP TGGAPHGYCS
PTSASYGKALNPYQYQYHGVNGSAGSYPAKAYADYSYASSYHQYGGAYNRVPSATNQPEK
EVTEPEVRMVNGKPKKVRKPRTIYSSFQLAALQRRFQKTQYLALPERAELAASLGLTQTQVK
IWFQNKRSKIKKIMKNGEMPPEHSPSSSDPMACNSPQSPAVWEPQGSSRSLSHHPHAHPPTS N
20 QSPASSYLENSASWY TSAASSINSHLPPPGSLQHPLALASGTLY (SEQ ID NO: 212)
- NP_001124296.1 transcription elongation factor SPT5 isoform a
MSDSEDSNFSEEEDSERSSDGEEAEVDEERRSAAGSEKEEEPEDEEEEEEEEEEEYDEEEEE
EDDDRPPKKPRHGGFILDEADV DDEYEDEDQWEDGAEDILEKEEIEASNIDNVVLDEDRS
25 GARRLQNLWRDQREEELGEYMKKYAKSSVGETVYGGSD ELSDDITQQQLLPGVKDPNLW
TVKCKIGEERATAISLMRKFIAYQFTDTPLQIKSVVAPEHVKG YIYVEAYKQTHVKQAIEGVG
NLR LGYWNQQMVPIKEMTDVLKVVKEVANLKP KSWVRLKRG IYKDDIAQVDYVEPSQNTI
SLKMIPRIDYDRIKARMSLKDWFAKRKKFKRPPQRLFDAEKIRSLGGDVASDGD FLIFEGNRY
SRKGFLFKSFAMSAVITEGVKPTLSELEKFEDQPEGIDLEV VTESTGKEREHNFQPGDNVEVC
30 EGELINLQGKILSVDGNKITIMPKHEDLKDMLEFPAQELRKYFKMGDHVKVIAGRFE GDTGLI
VRVEENFVILFSDLTMHELKVLPRDLQLCSETASGV DVGGQHEWGELVQLDPQTVGVIVRLE
RETFQVLNMYGKVVTVRHQAVTRKKDNRF AVALDSEQNNIHVKDIVKVIDGPHSGREGEIR
HLFRSFAFLHCKKLVENGGMFVCKTRHLVLAGGSKPRDVTNFTVGGFAPMSPRISSPMHPSA
GGQRGGFGSPGGGSGGMSRGRGRRDNELIGQTVRISQGPYKGYIGVVKDATESTARVELHST
35 CQTISVDRQRLTTVGSRRPGGMTSTYGRTPMYGSQTPMYGSGSRTPMYGSQTPLQDGSRT P
HYGSQTPLHDGSRTPAQSGAWDPNNPNTPSRAEE EYEA FDDDEPTPSPQAYGGTPNPQTPGY
PDPSSPQVNPQYNPQTPGTPAMYNTDQFSPYAAPSPQGSYQPSPPSYHQVAPSPAGYQNT
HSPASYHPTPSPMAYQASPSPPVGYS PMTPGAPSPGGYNPHTPGSGIEQNSSDWVT TDIQVK
VRDTYLDTQVVGQTGVIRSVTGGMCSVYLKDSEK VVSISSEHLEPITPTKNNKV KVLGEDRE
40 ATGVLLSIDGEDGIVRMDLDEQLKILNLRFLGKLLEA (SEQ ID NO: 213)
- NP_001193954.1 POU domain, class 2, transcription factor 2 isoform 1
MVHSSMGAPEIRMSKPLEAEKQGLDSPSEHTDTERNGPD TNHQNPQNKTSPFSVSPTGPS
TKIKAEDPSGDSAPAAPLPPQPAQPHLPQAQLMLTGSQLAGDIQQLQLQQLVLVPGHHL
45 QPPAQFLLPQAQQSQPGLLPTPNLFQLPQQTQGALLTSQPRAGLPTQAVTRPTLPDPLS
HPQPPKCLEPPSHPEEPSDLEELEQFARTFKQRRIKLGFTQGDVGLAMGKLYGNDFSQTT
ISRFEALNLSFKNMCKLKPLLEKWLND AETMSVDSSLPSPNQLSSPSLGFDGLPGRRRKK
RTSIETNVRFALEKSFLANQKPTSEEILLIAEQLHMEKEVIRVWFCNRRQKEKRINPCSA
APMLPSPGKPASYS PHMVTPQGGAGTLPLSQASSSLSTTVTTLSSAVGTLHPSRTAGGGG
50 GGGGAAPPLNSIPSVTPPPPATTNSTNPSPQGS HSAIGLSGLNPSTGPGLWWNPAPYQP (SEQ
ID NO: 214)
- NP_057588.1 39S ribosomal protein L27, mitochondrial
MASVVLALRTRTAVTSLLSPTPATALAVRYASKKSGGSSKNLGGKSSGRRQGIIKKMEGHYV
55 HAGNIIATQRHFRWHPGAHVGVGKNKCLYALEEGIVRYTKEVYVPHPRNTEAVDLITRLPK
GAVLYKTFVHVVPAPKEGTFKLVAML (SEQ ID NO: 215)

5

NP_000177.2 complement factor H isoform a precursor

MRLLAKIICLMLWAICVAEDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLG
 NVIMVCRKGEWVALNPLRKCQKRPCGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQL
 LGEINYRECDTDGWTNDIPICEVVKCLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNSGY
 10 KIEGDEEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKENERFQYKCNMGYEYSE
 RGDVCTESGWRPLPSCEEKSCDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYPATRGNTA
 KCTSTGWIPAPRCTLKPCDYPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEHFETPSGSY
 WDHICTQDGWSPAVPCLRKCYPYLENGYNQNHGRKFVQGKSIDVACHPGYALPKAQT
 VTCMENGWSPTPRCIRVKTCSSIDIENGFISESQYTYALKEKAKYQCKLGYVTADGETSGS
 15 ITCGKDGWSAQPTCIKSCDIPVFMNARTKNDFTWFKLNDTLDYECHDGYESNTGSTTGSIVC
 GYNGWSDLPICYERECLEPKIDVHLVPDRKKDQYKVGEVLKFSCKPGFTIVGPNSVQCYHFG
 LSPDLPICKEQVQSCGPPPELLNGNVKEKTKEEYGHSEVVEYYCNPRFLMKGPNKIQCVDGE
 WTTLPVCIVEESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCSESFTMIGHRSITCIHGVWTQL
 PQCVAIDKLKKCKSSNLIILEEHLKNKKEFDHNSNIRYRCRGKEGWIHTVCINGRWDPEVNCS
 20 MAQIQLCPPPQIPNSHNMTTTLNRYRDGEKVSVLCQENYLIQEGEEITCKDGRWQSIPLCVEK
 IPCSQPPQIEHGTINSSRSSQESYAHGTKLSYTCEGGFRISEENETTCYMGKWSSPPQCEGLPC
 KSPPEISHGVVAHMSDSYQYGEEVITYKCFEGFGIDGPAIAKCLGEKWSHPPSCIKTDCLSLPSF
 ENAIPMGEKKDVYKAGEQVITYTCATYYKMDGASNVTCINSRWTGRPTCRDTSCVNPPTVQ
 NAYIVSRQMSKYPSGERVRYQCRSPYEMFGDEEVMCLNGNWTEPPQCKDSTGKCGPPPID
 25 NGDITSFPLSVYAPASSVEYQCQONLYQLEGNKRITCRNGQWSEPPKCLHPCVISREIMENYNI
 ALRWTAQKQLYSRTGESVEFVCKRGYRLSSRSHTLRTTCWDGKLEYPTCAKR (SEQ ID NO:
 216)

NP_000177.2 complement factor H isoform a precursor

30 MRLLAKIICLMLWAICVAEDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLGNVI
 MVCRKGEWVALNPLRKCQKRPCGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQLLGE
 INYRECDTDGWTNDIPICEVVKCLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNSGYKIE
 GDEEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKENERFQYKCNMGYEYSERGD
 AVCTESGWRPLPSCEEKSCDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYPATRGNTAKCTS
 35 TGWIPAPRCTLKPCDYPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEHFETPSGSYWDHI
 HCTQDGWSPAVPCLRKCYPYLENGYNQNHGRKFVQGKSIDVACHPGYALPKAQTTVTCM
 ENGWSPTPRCIRVKTCSSIDIENGFISESQYTYALKEKAKYQCKLGYVTADGETSGSITCGK
 DGWSAQPTCIKSCDIPVFMNARTKNDFTWFKLNDTLDYECHDGYESNTGSTTGSIVCGYNG
 WSDLPICYERECLEPKIDVHLVPDRKKDQYKVGEVLKFSCKPGFTIVGPNSVQCYHFGLSDDL
 40 PICKEQVQSCGPPPELLNGNVKEKTKEEYGHSEVVEYYCNPRFLMKGPNKIQCVDGEWTTLP
 VCIVEESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCSESFTMIGHRSITCIHGVWTQLPQCV
 AIDKLKKCKSSNLIILEEHLKNKKEFDHNSNIRYRCRGKEGWIHTVCINGRWDPEVNCSMAQI
 QLCPPPQIPNSHNMTTTLNRYRDGEKVSVLCQENYLIQEGEEITCKDGRWQSIPLCVEKIPCSQ
 PPQIEHGTINSSRSSQESYAHGTKLSYTCEGGFRISEENETTCYMGKWSSPPQCEGLPCKSPPEI
 45 SHGVVAHMSDSYQYGEEVITYKCFEGFGIDGPAIAKCLGEKWSHPPSCIKTDCLSLPSFENAIP
 MGEKKDVYKAGEQVITYTCATYYKMDGASNVTCINSRWTGRPTCRDTSCVNPPTVQNAYIV
 SRQMSKYPSGERVRYQCRSPYEMFGDEEVMCLNGNWTEPPQCKDSTGKCGPPPIDNGDITS
 FPLSVYAPASSVEYQCQONLYQLEGNKRITCRNGQWSEPPKCLHPCVISREIMENYNI
 50 ALRWTAQKQLYSRTGESVEFVCKRGYRLSSRSHTLRTTCWDGKLEYPTCAKR (SEQ ID NO: 217)

NP_002105.2 zinc finger protein 40

55 MPRTKQIHPRNLRDKIEEAQKELNGAEVSKKEILQAGVKGTSESLKGVKRKKIVAENHLKKI
 PKSPLRNPLQAKHKQNTTEESSFAVLHSASESHKKQNYIPVKNGKQFTKQNGETPGIIA
 EASKSEESVSPKKPLFLQQPSELRRWRSEGADPAKFSDLDEQCDSSSLSSKTRTDNSECI
 SSHCGTTSPSYTNTAFDVLLKAMEPELSTLSQKGSPPCAIKTEKLRPNKTARSPPKLNSS

5 MDAPNQTSQELVAESQSSCTSYTVHMSAAQKNEQGAMQSASHLYHQHEHFVPKSNQHNQQ
 LPGCSGFTGSLTNLQNQENAKLEQVYNIAVTSSVGLTSPSSRSQVTPQNQQMDSASPLSISPA
 NSTQSPPMPIYNSTHVASVNNQSVEQMCNLLLKDQKPKKQKGKYICEYCNRAKPSVLLKHI
 RSHTGERPYPCVTCGFSFKTKSNLYKHKKSHAHTIKLGLVLQPDAGGLFLSHESPKALSIHSD
 VEDSGESEEAGATDERQHDLGAMELQPVHIIKRMSNAETLLKSSFTSPSPENVIGDFLLQDRS
 10 AESQAVTELPKVVVHHVTVSPLRTDSPKAMDPKPELSSAQKQKDLQVTNVQPLSANMSQGG
 VSRLETNENSHQKGDMPLEGGKQDSHVGTVHAQLQRQQATDYSQEQQKLLSPRSLGSTDS
 GYFSRSESADQTVSPPTPFARRLPSTEQDSGRSNGPSAALVTTSTPSALPTGEKALLLPQMRP
 PLATKTLEERISKLISDNEALVDDKQLDSVKPRRTSLSRGSDSPKSYIFKDSFQFDLKPVGRR
 TSSSSDIPKSPFTPTTEKSKQVFLLSVPSLDCLPITRSNSMPTTGYSAPANIIPPHPLRGSQSFD
 15 DKIGTFYDDVVFVSGPNAPVPQSGHPRTLVRQAAIEDSSANESHVLGTGQSLDESHQGCHAAG
 EAMSVRSKALAQQPHIEKKKSHQGRGTMFECETCRNRYRKLENFENHKKFYCSELHGPKTK
 VAMREPEHSPVPGGLQPQILHYRVAGSSGIWEQTPQIRKRRKMKSVDDEELQQNESGTSPK
 SSEGLQFQNALGCNPSLPKHNV TIRSDQQHKNIQLQNSHIHLVARGPEQTMDPKLSTIMEQQI
 SSAAQDKIELQRHGTGISVIQHTNSLSRPNSFDKPEPFERASPVSFQELNRTGKSGSLKVIGISQ
 20 EESHPSRDGSHPHQLALSDALRGELQESSRKSPSERHVLGQPSRLVRQHNIQVPEILVTEEPDR
 DLEAQCHDQEKSEKFSWPQRSETLSKLPTEKLPPKKKRLRLAEIEHSSSTESSFDSTLSRSLRE
 SSLSHTSSFSASLDIEDVSKTEASPKIDFLNKA EFLMIPAGLNTLNVP GCHREMRRTASEQINC
 TQTSMEVSDLRSKSFDCGSITPPQTTPTELQPPSSPSRVGVTGHVPLLERRRGPLVRQISL NIA
 PDSHLSPVHPTSFQNTALPSVNAVVPYQGPQLTSTSLAEFSANTLHSQTQVKDLQAETSNSST
 25 NVFPVQQLCDINLLNQIHAPPSHQSTQLSLQVSTQGSKPDKN SVLSGSSKSEDCFAPKYQLHC
 QVFTSGPSCSSNPVHSLPNQVISDPVGT DHCVT SATLPTKLIDMSNSHPLLPELRPLGSQVQ
 KVPSSFMLPIRLQSSVPAYCFATLTSLPQILVTQDLNPQICQTNHSVVPIS EEQNSVPTLQKGH
 QNALPNPEKEFLCENVFSEMSQNSSLSESLPITQKISVGRLSPQQESSASSKRMLSPANSLDIA
 MEKHQKRAKDENGAVCATDVRPLEALSSRVNEASKQKKPILVRQVCTTEPLDGVMLEKDV
 30 FSQPEISNEAVNLTNVLPADNSSTGCSKFV VIEPISELQEFENIKSSTSLTLTVRSSPAPSENTHIS
 PLKCTDNNQERKSPGVKNQGDKNIQEQSQQPVTSLSLFN IKDTQQLA FPSLKTTTNFTWCY
 LLRQKSLHLPQKDQKTSAYTDWTVSASNPNPLGLPTKVALALLNSKQNTGKSLYCQAITHS
 KSDLLVYSSKWKSSLSKRALGNQKSTVVEFSNKDASEINSEQDKENSLIKSEPRRIKIFDGGY
 KSNEEYVYVRGRGRGKYICEECGIRCKKPSMLKKHIRTHTDVRPYHCTYCNFSFKTKGNLTK
 35 HMKSKAHSKKCVDLGVS VGLIDEQDTEESDEKQRF SYERSGYDLEESDGPDEDDNENEDDD
 EDSQAESVLSATPSVTASPQHLPSRSSLQDPVSTDEDVRITDCFSGVHTDPMDVLPRALLTRM
 TVLSTAQSDYNRKTLS PGKARQRAARDENDTIPSVDTSRSPCHQMSVDYPESEEILRSSMAG
 KAVAITQSPSSVRLPPAAAEHSPQTAAGMP SVASPHDPQE QKQQITLQPTPGLPSPHTHLFSH
 LPLHSQQQSRTYPNMVPVGGIHVVPAGLT YSTFVPLQAGPVQLTIPAVSVVHRTLGT HRNTV
 40 TEVSGTTNPAGVAELSSVPCIPIGQIRVPGLQNLSTPGLQSLPSLSMETVNIVGLANTNMAPQ
 VHPPLGLALNAVGLQVLTANPSSQSSPAPQA HIPGLQILNIALPTLIPSVSQVAVDAQGAPEMP
 ASQSKACETQPKQTSVASANQVSRTESPQGLPTVQRENAKKVLNPPAPAGDHARLDGLSKM
 DTEKAASANHVKPKPELTSIQGQPASTSQPLLKAHSEVFTKPSGQQTLSPDRQVPRPTALPRR
 QPTVHFSDVSSDDDEDRLVIAT (SEQ ID NO: 218)

45 NP_443177.1 tumor necrosis factor receptor superfamily member 13C
 MRRGPRSLRGRDAPAPTPCVPAECFDLLVRHCVACGLLRTPRPKPAGASSPAPRTALQPQ
 ESGAGAGEAALPLPGLLFGAPALLGLALVLALVLVGLVSWRRRQRRLRGASSAEAPDGDK
 DAPEPLDKVIILSPGISDATAPAWPPPGEDPGTTPPGHSVPVPATELGSTELVTTKTAG
 50 PEQQ (SEQ ID NO: 219)

NP_059523.2 telomeric repeat-binding factor 1 isoform 1
 MAEDVSSAAPSPRGCADGRDADPTEEQMAETERNDEEQFECQELLE CQVQVGAPEEEEEEE
 EDAGLVAEAEAVAAGWMLDFLCLSLCRAFRDGRSEDFRRTRNSAEAIHGLSSLTACQLRTI
 55 YICQFLTRIAAGKTLDAQFENDERITPLESALMIWGSIEKEHDKLHEEIQNLIKIAIAVCMEN
 GNFKEAEEVFERIFGDPNSHMPFKSKLLMIISQKDTFHSFFQHFSYNHMMMEKIKSYVNYVLSE

- 5 KSSTFLMKAAAKVVESKRTRTITSQDKPSGNDVEMETEANLDTRKSVSDKQSAVTESSEGT
SLLRSHKNLFLSKLQHGTQQQDLNKKERRVGTPOSTKKKKESRRATESRIPVSKSQPVTP
HRARKRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSVMLKDRWRTMKKLLI
SSDSED (SEQ ID NO: 220)
- 10 NP_116262.2 ubiquitin-associated and SH3 domain-containing protein B
MAQYGHPSPLGMAAREELYSKVTPRRNRQQRP GTIKHGSALDVLLSMGFPRARAQKALAST
GGRSVQAACDWLFSHVGDPLDDPLPREYVLYLRPTGPLAQKLSDFWQQSKQICGKNKAHN
IFPHITLCQFFMCEDSKVDALGEALQTTVSRWKCKFSAPLPLELYTSSNFIGL FVKEDSAEVLK
KFAADFAAEAASKTEVHVPHKKQLHVTLAYHFQASHLPTLEKLAQNIDVKLGCDWVATIF
15 SRDIRFANHETLQVIYPYTPQNDDLELVP GDFIFMSPMEQTSTSEGWIYGTSLTTGCSGLLPE
NYITKADECSTWIFHGSYSILNTSSSNLTFGDGVLERRPYEDQGLGETTPLTIICQPMQPLRV
NSQPGPQKRCLFVCRHGERMDVVFGKYWLSQCFDAKGRYIRTNLNMPSLPPQRSGGFRDYE
KDAPITVFGCMQARLVGEALLESNTIHDVYCSPSLRCVQTAHNILKGLQQENHLKIRVEPGL
FEWTKWVAGSTLPAWIPSELAAANLSVDTTYRPHIPISKLVVSESYDTYISRSFQVTKEIIEC
20 KSKGNNILIVAHASSLEACTCQLQGLSPQNSKDFVQMVRKIPYLGFCSCCELGETGIWQLTDP
PILPLTHGPTGGFNWRETLLE (SEQ ID NO: 221)NP_001136156.1 zinc finger MYM-type
protein 5 isoform 3
MEKCSVGGLELTEQTPALLGNMAMATSLMDIGDSFGHPACPLVSRSRNSPVEDDDDDDDV
FIESIQPPSISAPAIADQRNFI FASSKNEKPQGNYSVIPSSRD LASQKGNISETIVIDDEEDIETN
25 GGAEKKSSCFIEWGLPGTKNKTNDLDFSTSSLSRSKTKTGVRPFNPGRMNVAGDLFQNGEFA
THHSPDSWISQSASFPSNQKQPGVDSLSPVALLRKQNFQPTAQQLTKPAKITCANCKKPLQ
KGQTAYQRKGS AHLFCSTTCLSSFSHKRTQNTRSIICKKDASTKKANVILPVESSKSFQEFYST
SCLSPCENNWNLLKKG VFNKSRCTICSKLAEIRHEVSVNNVTHKLCSNHCFNKYRLANGLIMN
CCEHCGEYMP SKSTGNNILVIGGQQKR FCCQSCINEYKQMMETKSKKLTASENRKRN AFR
30 NEKQLYGSNTLLKKIEGIEPEKKEKTSQLQLSVECGTDTLLIQENVNLPPSSTSTIADTFQEQL
EKNFEDSIVPVVLSADPGTWPRILNIKQRDTLVENVPPQVRNFNFPKDNTGRKFSETYYTRILP
NGEKTTRSWLLYSTSKDSVFCLYCKLFGGKNQLKNENGCKDWQHLSHILSKHEESEM HVN
NSVKYSKLLKSDLKKNKAIDAAEHRLYENENEKNDGVLLLYT (SEQ ID NO: 222)
- 35 NP_004882.1 39S ribosomal protein L33, mitochondrial isoform a
MFLSAVFFAKSKSKNILVRMVSEAGTGFCFNTKRNRLREKLTLLHYDPVVKQRVLFVEKKKI
RSL (SEQ ID NO: 223)
- NP_008841.2 E3 ubiquitin-protein ligase RBBP6 isoform 1
40 MSCVHYKFSSKLN YDTVTFDGLHISLCDLKKQIMGREKLKAADCDLQITNAQTKEEYTD
ALIPKNSSVIVRRIPIGGVKSTSKTYVISRTEPAMATTKAIDDSSASISLAQLTKTANLAEANAS
EEDKIKAMMSQSGHEYDPINYMKKPLGPPPPSYTCFRCGKPGHYIKNCPTNGDKNFESGPRIK
KSTGIPRSFMMEVKDPNMKGAMLTNTGKYAIPTIDAEAYAIGKKEKPPFLPEEPSSSSEEDDPI
PDELLCLICKDIMTDAVVIPCCGNSYCDECIRTALLE SDEHTCPTCHQNDVSPDALIANKFLRQ
45 AVNNFKNETGYTKRLRKQLPPPPPIPPPRPLIQRN LQPLMRSPISRQQDPLMIPVTSSSTHPAP
SISSLTSNQSSLAPPVSGNPSSAPAPVPDITATVSVHSEKSDGPFRDSDNKILPAAALASEHSK
GTSSIAIT ALMEEKGYQVPVLGTPSLLGQSLLHGQLIPTTGPVRINTARPGGGRPGWEHSNKL
GYLVSPPPQQIRRGERSCYRSINRGRHHSERSQRTQGPSLPATPVFVPVPPPPLYPPPPHTLPLPP
GVPPPQFSPQFPQPPGQPPAGYSVPPPGFPAPANLSTPWVSSGVQTAHSNTIPTTQAPPLSREEF
50 YREQRRLKEEEKKKSKLDEFTNDFAKELMEYKKIQKERRRSFSRSKSPYSGSSYSRSSYTYSK
SRSGSTRSRSYSRSFS
RSHSRYSRSPPYPRRGRGKSRNYRSRSRSHGYHRSRSRSPPYRRYHSRSRSPQAFRGQS
PNKRNVPQGETEREYFNRYREVPPPYDMKAYYGRSVDFRDPFEKERYREWERKYREWYEK
YYKGYAAGAQRPSANRENFSERFLPLNIRNSPFTRGRREDYVGGQSHRSRNIGSNYPE
55 KLSARDGHNQKDNTKSKEKESENAPGDGKGKHKHKKHRKRRKGEESEGFLNPELLETSRKSR
EPTGVEENKTD SLFVLPSRDDATPVRDEPMDAESITFKSVSEKDKRERDKPKAKGDKTKRKN

5 DGS AVSKKENIVKPAKGPQEKVDGERERSPRSEPPIKKAKEETPKTDNTKSSSSSQKDEKITG
 TPRKAHSKSAKEHQETKPVKEEKVKKDYSKDVKSEKLTTEEKAKKPNEKNKPLDNKGEK
 RKRKTEEKGVDKDFESSMKISKLEVTEIVKPSPKRKMEDTEKMDRTPEKDKISLSAPAKKI
 KLNRETGKKIGSTENISNTKEPSEKLESTSSKVKQEKVKGKVRKVTGTGEGSSSTLVDYTSTS
 STGGSPVRKSEEKTDKRTVIKTMEEYNNDNTAPAEDVIIMIQVPQSKWDKDDFESEEDVK
 10 STQPISSVGKPASVIKNVSTKPSNIVKYPEKESEPSEKIQKFTKDVSHETIQHEVKSSKNSASSEK
 GKT KDRDYSVLEKENPEKRKNSTQPEKESNLDRLNEQGNFKSLSQSSKEARTSDKHDSTRAS
 SNKDFTPNRDKKTDYDTREYSSSKRRDEKNELTRRKDSPSRNKDSASGQKNKPREERDLPPK
 GTGDSKKSNSSPSRDRKPHDHKATYDTKRPNEETKSVDKNPCKDREKHVLEARNNKESGN
 KLLYILNPPETQVEKEQITGQIDKSTVKPKPQLSHSSRLSSDLTRETDEAAFEPPDYNESDSEN
 15 VSVKEEESGNISKDLKDKIVEKAKESLDTAAVVQVGISRNQSHSSPSVSPSRSHSPSGSQTRS
 HSSSASSAESQDSKKKKKKKKEKKKHKHKKHKKHKKHAGTEVELEKSQKHKKHKKKKSKK
 NKDKEKEKEKDDQKVKS MTV (SEQ ID NO: 224)

NP_004764.1 zinc finger HIT domain-containing protein 3
 20 MASLKCSTVVCVICLEKPKYRCPACRVPYCSVVCFRKHKEQCNPETRPVEKKIRSALPTK
 TVKPVENKDDDDSIADFLNSDEEEDRVSLQNLKNLGESATLRSLLLNPHLRQLMVNLDQGE
 DKAKLMRAYMQEPLFVEFADCCLGIVEPSQNEES (SEQ ID NO: 225)

NP_001663.2 agouti-signaling protein precursor
 25 MDVTRLLLATLLVFLCFFTANSHLPPEEKLRRDRSLRSNSSVNLLDVPSVSIVALNKKSK
 QIGRKAAEKRRSSKKEASMKKVVRPRTPLSAPCVATRNSCKPPAPACCDPCASCQCRFFRSA
 CSCRVL SLNC (SEQ ID NO: 226)

NP_002334.2 lactotransferrin isoform 1 precursor
 30 MKLVFLVLLFLGALGLCLAGRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSP
 IQCIQAI AENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERRQPRTHYYAVAVVKKGGSF
 QLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVP GADKGQF
 PNL CRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYEL
 LCPDNTRKPVDFKDKCHLARVP SHAVVARSVNGKEDAIWNLLRQAQEKFGKDKSPKFQLFG
 35 SPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAARRARVWCAVGEQ
 ELRKC NQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTAGKCGLVPVLAEN
 YKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMG
 LLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCV PNSNERYYGYTGAFRCLA
 ENAGDVAFVKDVTVLQNTDGNNEAWAKDLKLAD FALLCLDGKRKPVTEARSCHLAMAP
 40 NHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNLLFNDNTECLARLHG
 KTTYEKYLGPQYVAGITNLKKCSTSPLEACEFLRK (SEQ ID NO: 227)

NP_002257.1 importin subunit alpha-2
 45 MSTNENANTPAARLHRFKNKGKDSTEMRRRRRIEVNVELRKAKKDDQMLKRRNVSSFPDDA
 TSPLQENRNNQGT VNWSVDDIVKGINSSNVENQLQATQAARKLLSREKQPPIDNIIRAGLIPK
 FVSFLGR TDCSPIQFESA WALTNIASGTSEQTKAVVDGGAIPAFISLLASPHAHISE
 QAVWALGNIAGDGSVFRDLVIKYGA VDPLLALLAVPDMSSLACGYLRNLTWTL SNLCRNK
 NPAPPIDAVEQILPTLVRL LHDDPEVLADTCWAISYLTGDPNERIGMVVKTGVVPQLVKLL
 GASELPIVTPALRAIGNIVTGTDEQTQVVIDAGALAVFPSLLTNPKTNIQKEATWTMSNITAG
 50 RQDQIQQV VNHGLVPFLVSVLSKADFKTQKEAVWAVTNYTSGGTVEQIVYLVHCGIIEPLM
 NLLTAKDTKIILVILDAISNIFQAAEKLGETEKL SIMIEECGGLDKIEALQNHENESVYKASLSL
 IEKYFSVEEEEDQNVVPETTSEGYTFQVQDGAPGTFNF (SEQ ID NO: 228)

NP_114440.1 POZ-, AT hook-, and zinc finger-containing protein 1 short isoform
 55 MERVNDASCGPSGCYTYQVSRHSTEMLHNLNQQRKNNGGRFCDVLLRVGDESFP AHRAVLA
 ACSEYFESV FSAQLGDGGAADGGPADVGGATAAPGGGAGGSRELEMHTISSKVFGDILDFA

5 YTSRIVVRLESFPELMTAAKFLLMRSVIEICQEVIKQSNVQILVPPARADIMLFRPPGTSDLGFP
 LDMTNGAALAANSNGIAGSMQPEEEAARAAGAAIAGQASLPVLPVLDRLPMVAGPLSPQLL
 TSPFPSVASSAPPLTGKRGRGRPRKANLLDSMFGSPGGLREAGILPCGLCGKVFTDANRLRQH
 EAQHGVTSLLQLGYIDLPPRLGENGLPISEDPDGPRKRSRTRKQVACEICGKIFRDVYHLNRH
 KLSHSGEKPYSCPVCGLRFKRKDRMSYHVRSHDGSVGKPYICQSCGKGFSRDPDLNGHIKQV
 10 HTSERPHKCQVWVGSSSGLPPLPSDLPSWDFAPALWRSSHVPDTAFSLSLKKSFPAL
 NLGPAHSSNTLFCPAPPGYLROGWTTPEGSRAFTQWPVG (SEQ ID NO: 229)

NP_001159896.1 gastricsin isoform 2 preproprotein
 MKWMVVVLVCLQLLEAAVVKVPLKKFKSIRETMKEKGLLGEFLRTHKYDPAWKYRFGDLS
 15 VTYEPMAYMDAAVFGEISIGTPPQNFLVLFDTGSSNLWVPSVYCQSQACTSHSRFNPSESSTY
 STNGQTFSLQYGSGLTGFFGYDTLTVQSIQVPNQEFGLSENEPGTNFVYAQFDGIMGLAYPA
 LSVDEATTAMQGMVQEGALTSPVFSVYLSNLVLESSGLGPLLTPSRAAPPSSTLQLPEKPLEQ
 TWNILTPFTKTLPVSNLSRKVTWAGVGIPVTCLPEAGSGGERRAECGLGVPTTRGPPRSQHH
 SGA (SEQ ID NO: 230)

20 NP_001036053.1 snurportin-1
 MEELSQUALASSFSVSQDLNSTAAPHRLSQYKSKYSSLEQSERRRRLLLELQKSKRLDYVN
 HARRLAEDDWTGMESEENKKDDEEMDIDTVKKLPKHYANQLMLSEWLIDVPSDLGQEWI
 VVVCVPGKRALIVASRGSTSAYTKSGYCVNRFSSLLPGGNRRNSTAKDYTILDCIYNEVNQT
 25 YYVLDVMCWRGHPFYDCQTDFFRYWMHSLPPEEGLGEKTKLNPFFKVFGLKNFPCTPESLC
 DVLSMDFPFEVDGLLFYHKQTHYSPGSTPLVGWLRPYMVSDVLGVAVPAGPLTTKPDYAGH
 QLQQIMEHKKSQKEGMKEKLTHKASENGHYELEHLSTPKLKGSSHSPDHPGCLMEN (SEQ
 ID NO: 231)

30 NP_054798.1 Krueppel-like factor 15
 MVDHLLPVDENFSSPKCPVGYLGDRLVGRRAYHMLPSPVSEDDSDASSPCSCSSPDSQALCS
 CYGGGLGTESQDSILDFLLSQATLGSGGGSGSSIGASSGPVAVWGPWRRAAAPVKGEHFCLPE
 FPLGDPDDVPRPFQPTLEEIEEFLEENMEPGVKEVPEGNSKDLDACSQLSAGPHKSHLHPGSS
 GRERCSPPPGGASAGGAQGGPGGPTPDGPIPVLLQIQPVVPVKQESGTGPASPG
 35 QAPENVKVAQLLVNIQGQTFALVPQVVPSSNLNLPSKFVRIAPVPIAAKPVGSGPLGPGP
 AGLLMGQKFPKNPAAELIKMHKCTFPGCSKMYTKSSHLKAHLRRHTGEKPFACWPGCGW
 RFSRSELSRHRRSHSGVKPYQCPVCEKKFARSDHLSKHIKVHRFPRSSRSVRSVN (SEQ ID
 NO: 232)

40 NP_001006657.1 zinc finger protein 473
 MAEEFVTLKDVGMDFTLGDWEQLGLEQGDTFWDTALDNCQDLFLLDPPRPNLTSHPDGSE
 DLEPLAGGSPEATSPDVTETKNSPLMEDFFEEGFSQEIIEMLSKDGFWNSNFGEACIEDTWLD
 SLLGDPESLLRSDIATNGESPTECKSHELKRGLSPVSTVSTGEDSMVHNVSEKTLTP
 AKSKEYRGEFFSYSDHSQQDSVQEGEKPYQCSECGKSFSGSYRLTQHWITHTREKPTVHQEC
 45 EQGFDRNASLSVYPKTHTGKFKYVCNEYGTTFSQSTYLWHQKTHTGKPKKSQDSDHPPSH
 DTQPGEHQKTHTDKSYNCECGKAFTTRIFHLTRHQKIHTRKRYECSKCQATFNLRKHLIQH
 QKTHAAKTTECECGKIFRHSSLLIEHQALHAGEEPYKCNERNKSGFRHNSTLKIHQRVHSGE
 KPYKCSECGKAFHRHHLNEHRRHTGYRPHKCECVRFSRPSHLMRHQAIHTAEKPYSCA
 ECKETFSDNNRLVQHQMHTVKTPYECQECGERFICGSTLKCHESVHAREKQGGFFVSGKILD
 50 QNPEQKEKCFKCNKCEKTFSCSKYLTQHERIHTRGVKEPFECDQCGKAFGQSTRLIHHQRIHSR
 VRLYKWGEQGKAISSASLIKLSFHTKEHPFKCNECGKTFSSHSAHLSKHQLIHAGENPFKCSK
 CDRVFTQRNYLVQHERTHARKKPLVCNECGKTFRQSSCLSKHQRIHSGEKPYVCDYCGKAF
 GLSAELVRHQRIHTGEKPYVCQECGKAFTQSSCLSIHRRVHTGEKPYRCGECGKAFAQKANL
 TQHQRIHTGEKPYSCNVCGKAFVLSAHLNQHLRVHTQETLYQCQRCQKAFRCHSSLSRHQR
 55 VHNNKQQYCL (SEQ ID NO: 233)

5 NP_002219.1 transcription factor AP-1

MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLT
 SPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAEHSQNT
 LPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFPNGALSSGGGA
 PSYGAAGLAFPAQPQQQQQPPHLPQQMPVQHPRQLALKEEPQTVPEMPGETPPLSPIDMES
 10 QERIKAERKMRNRNRIASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQ
 KVMNHVNSGCQLMLTQQLQTF (SEQ ID NO: 234)

NP_113674.1 zinc finger protein 484 isoform a

MTKSLESVSFKDVTVDFSRDEWQQDLAQKSLYREVMLENYFNLSVGCQVPKPEVIFSL
 15 EQEPCMLDGEIPSQSRPDGDIGFGPLQQRMSSEVSFQSEININLFTRDDPY SILEELWKDDEH
 TRKCGENQNKPLSRVVFINKKTLANDSIFEYKDIGEIVHVNTHLVSSRKRPHNCNSCGKNLEP
 IITLYNRN NATENS DKTIGDGDIFTHLNSHTEVTACECNQCGKPLHHKQALIQQQKIHTRESL
 YLFSDYVNVFSPKSHAF AHESICAE EKQHECHECEAVFTQKSQLDGSQRVYAGICTEYEKDF
 SLKSNRQKTPYEGNYYKCS DYGRAFIQKSDLFRCQRIHSGEKPYEYSECEKNLPQNSNLNIHK
 20 KIHTGGKHFECTECGKAFTRKSTLSMHQKIHTGEKPYVCTECGKA FIRKSHFITHERIHTGEKP
 YECSDCGKSFIKKSQLHVHQRIHTGENPFICSECGKVFTHKTNLIHQKIHTGERPYICTVCGK
 AFTDRSNLIKHQKIHTGEKPYKCSDCGKSFTWKSRLRIHQKCHTGERHYECSECGKA FIKQST
 LSMHQRIHRGEKPYVCTECGKAFFHKSHFITHERIHTGEKPYECSICGKSFTKKSQLHVHQQI
 HTGEKPYRCAECGKAFTDRSNLFTHQKIHTGEKPYKCSDCGKAFTRKSGLHIHQQSHTGERH
 25 YECSECGKAFA RKSTLIMHQRIHTGEKPYICNECGKSF IQKSHLNRHRIHTGEKPYECSDCG
 KSFIKKSQLHEHHRIHTGEKPYICAECGKAFTIRSNLIKHQKIHTKQKPYKCSDLGKALNWKP
 QLSMPQKSDNGEVECSMPQLWCGDSEG DQGQLSSI (SEQ ID NO: 235)

NP_001166146.1 zinc finger protein 347 isoform a

30 MALTQGGQVTFRDVAIEFSQEEWTCLDPAQRTLYRDVMLENYRN LASLAGISCFDL SIISM
 LEQGKEPFTLESQVQIAGNPDGWEWIKAVITALSSEFVMKDLLHKGKSNTGEVFQTVMLER
 QESQDIEGCSFRE VQKNTHGLE YQCRDAEGNYKGVLLTQEGNLTHGRDEHDKRDARNKLIK
 NQLGLSLQSHLP ELQLFQYEGKIYECNQVEKSFNNNSSVSP PQMPYNVKTHISKKYLKDFIS
 SLLLTQGQKANNWGSPYKSNCGMVF PQNSHLASHQRSHTKEKPYKCYECGKA FRTRSNTL
 35 THQVIHTGEKRYKCNECGKVFSRNSQLSQHQKIHTGEKPYKCNECGKVFTQNSHLVRHRGIH
 TGEKPYKCNECGKA FRARSSLAIHQATHSGEKPYKCNECGKVFTQNSHLTNHWRIHTGEKP
 YKCNECGKA FGVRSSLAIHLVIHTGEKPYKCHECGKVFRRN SHLARHQLIHTGEKPYKCNEC
 GKAFRAHSNLTTHQVIHTGEKPYKCNECGKVFTQNSHLANHQRIHTGVKPYMCNECGKA FS
 VYSSLTTHQVIHTGEKPYKCNECGKVFTQNSHLARHRGIHTGEKPYKCNECGKVFRHNSYLS
 40 RHQRIHTGEKPYKYNEYGKA FSEHSNLTTHQVIHTGEKPYKCNECGKVFTQNSHLARHRRV
 HTGGKPYQCNECGKA FSQTSKLARHQ RVHTGEKPYECNQCGKA FSVRSSLTTHQAIHTGKK
 PYKCNECGKVFTQNSHLARHRGIHTGEKPYKCNECGKA FSQTSKLARHQRIHTGEKPYECG
 KPFSICSSLTTHQTIHTGGKPYKCNVWKVLKSEFKPCKPSQNS (SEQ ID NO: 236)

45 NP_065879.1 zinc finger protein 28 homolog

MRGAASASVREPTPLPGRGAPRTKPRAGRGPTVGTPATLALPARGRPRSRNGLASKGQRGA
 APTGPGHRALPSRDTALPQERNKKLEAVGTGIEPKAMSQGLVTFGDVA VDFSQEEWEWLN
 IQRNLYRKVMLENYRN LASLGLCVSKPDVISSLEQGKEPWTVKRKMTRAWCPDLKAVWKI
 KELPLKKDFCEGKLSQAVITERLTSYNLEYSLLGEHW DYDALFETQPGLVTIKNLAVDFRQQ
 50 LHPAQKNFCKNGIWENNSDLGSAGHCVA KPDLVSLLEQEKEPWMVKREL TGSLSFGQRSVH
 ETQELFPKQDSYAEGVTDRTSNTKLDCSSFRENWDS DYVFGRKLAVGQETQFRQEPITHNKT
 LSKERERTYNKSGRWFYLD DSEEKVHN RDSIKNFQKSSVVIKQTGIYAGKKLFCNECKKTF
 TQSSSLTVHQRIHTGEKPYKCNECGKA FSDGSSFARHQ RCHTGKKPYECIECGKA FIQNTSLI
 RHWRYYYHTGEKPFDCIDCGKA FSDHIGLNQHRR IHTGEKPYKCDVCHKSFYRGSSSLTVHQRI
 55 HTGEKPYECDVCRKA FSHHASLTQHQRVHSGEKPFKCKE CGKA FRQNIHLASHLRIHTGEKP
 FECAECGKSFSISSQLATHQRIHTGEKPYECKVCSKAFTQKAHLAQHQKTHHTGEKPYECKEC

- 5 GKAFSQTTHLIQHQRVHTGEKPYKCMCEGKAFGDNSSCTQHQRRLHTGQRPYECIECGKAFK
TKSSLICHRRSHTGEKPYECVCGKAFSHRQSLSVHQRIHSGKKPYECKECCRKTFIQIGHLNQ
HKRVHTGERSYNYKKSRKVFRQTAHLAHHQRIHTGESSTCPSLPSTSNPVDLFPKFLWNPSSL
PSP (SEQ ID NO: 237)
- 10 NP_113674.1 zinc finger protein 484 isoform a
MTKSLESVSFKDVTVDVDFSRDEWQQDLAQKSLYREVMLENYFNLISVGCQVPKPEVIFSLEQ
EEPCMLDGEIPSQSRPDGDIGFGPLQQRMSSEVSFQSEININLFRDDPYSSILEELWKDDEHTR
KCGENQNKPLSRVVFINKKTLANDSIFEYKDIGEIVHVNTHLVSSRKRPNCNSCGKNLEPIIT
LYNRNNATENS DKTIGDGDIFTHLNSHTEVTACECNQCGKPLHHKQALIQQQKIHTRESLYLF
15 SDYVNVFSPKSHAFAHESICAEKQHECHECEAVFTQKSQLDGSQRVYAGICTEYEKDFSLK
SNRQKTPYEGNYKCS DYGRAFIQKSDLFRCQRIHSGEKPYEYSECEKNLPQNSNLNIHKKIH
TGGKHFECTECGKAFTRKSTLSMHQKIHTGEKPYVCTECGKA FIRKSHFITHERIHTGEKPYE
CSDCGKSF IKKSQLHVHQRIHTGENPFICSECGKVFTHKTNLIHQKIHTGERPYICTVCGKAFT
DRSNLIKHQKIHTGEKPYKCSDCGKSFTWKSRLRIHQKCHTGERHYECSECGKA FIQKSTLS
20 MHQRIHRGEKPYVCTECGKAFFHKSHFITHERIHTGEKPYECSICGKSFTKKSQ LHVHQQIHT
GEKPYRCAECGKAFTDRSNLFTHQKIHTGEKPYKCSDCGKAFTRKSGLHIHQQSHTGERHYE
CSECGKAFARKSTLIMHQRIHTGEKPYICNECGKSFIQKSHLNRHRIHTGEKPYECSDCGKSF
IKKSQLHEHHRIHTGEKPYICAECGKAFTIRSNLIKHQKIHTKQKPYKCSDLGKALNWKPQLS
MPQKSDNGEVECSMPQLWCGDSEGDQGQLSSI (SEQ ID NO: 238)
- 25 NP_001159354.1 zinc finger protein 268 isoform c
MDVFVDFTWEEWQLLDPAQKCLYRSVMLENYSNLVSLGYQH TKPDIIFKLEQGEELCMVQ
AQVPNQTCPNTVWKIDDLMDWHQENKDKLGSTAKSFECTTFGKLCLLSTKYLSRQKPHKC
GTHGKSLKYIDFTSDYARNNPNGFQVHGKSFFHSHKHEQT VIGIKYCESIESGKTVNKKSQLM
30 CQQMYMGEKPFGCSCCEKAFSSKSYLLVHQQT HAEKPYGCNECGKDFSSKSYLIVHQRIHT
GEKLHECSECRKTF SFHSQLVIHQRIHTGENPYECCECGKVFSRKDQLVSHQKTHSGQKPYV
CNECGKA FGLKSQLIHERIHTGEKPYECNECQKAFNTKSNLMVHQRTHTGEKPYVCSDCGK
AFTFKSQLIVHQGIHTGVKPYGCIQCGKGFS LKSQLIVHQRSHTGMKPYVCNECGKA FRSKS
YLIHTRTHTGEKLHECNCGKA FSFKSQLIHQRIHTGENPYECHECGKA FSRKYQLISHQRT
35 HAGEKPYECTDCGKA FGLKSQLIHQRTHTGEKPFECSECQKAFNTKSNLIVHQRTHTGEKPY
SCNECGKAFTFKSQLIVHKG VHTGVKPYGCSQCAKTFSLKSQLIVHQRSHTGVKPYGCSECG
KA FRSKSYLIHMRTHHTGEKPHECRECGKSFSFNSQLIVHQRIHTGENPYECSECGKA FN RKD
QLISHQRT HAGEKPYGCSECGKA FSSKSYLIHMRTHSGEKPYECNECGKA FIWKSLLIVHER
THAGVNPYKCSQCEKSFSGLRLLVHQRMHTREKPYECSECGKA FIRNSQLIVHQRT HSGEK
40 PYGCNECGKTFSQKSILSAHQRTHTGEKPCKCTECGKAFCWKSQ LIMHQRT HVDDKH (SEQ
ID NO: 239)
- NP_001166146.1 zinc finger protein 347 isoform a
MAL TQGQVTFRDVAIEFSQEEWTCLDPAQRTLYRDV MLENYRN LASLAGISCFDLSIISM
45 LEQGKEPFTLESQVQIAGNPDGWEWIKAVITALSSEFVMKDLLHKGKSNTGEVFQTVMLER
QESQDIEGCSFRE VQKNTHGLE YQCRDAEGNYKGVLLTQEGNLTHGRDEHDKRDARNKLIK
NQLGLSLQSHLPELQLFQYEGKIYECNQVEKSFNNNSSVSP PQMPYNVKTHISKKYLKDFIS
SLLLTQGQKANNWGSPYKSNGCGMVFPQNSHLASHQRSHTKEKPYKCYECGKA FRTRSNLT
THQVIHTGEKRYK CNECGKVFSRNSQLSQHQKIHTGEKPYK CNECGKVFTQNSHLVRHRGIH
50 TGEKPYK CNECGKA FRARSSLAIHQATHSGEKPYK CNECGKVFTQNSHLTNHWRIHTGEKP
YK CNECGKA FGVRSSLAIHLVIHTGEKPYK CHECGKVFRRN SHLARHQLIHTGEKPYK CNEC
GKA FRAHSNL TTHQVIHTGEKPYK CNECGKVFTQNSHL ANHQRIHTGVKPYMCNECGKA FS
VYSSLTTHQVIHTGEKPYK CNECGKVFTQNSHLARHRGIHTGEKPYK CNECGKVFRHNSYLS
RHQRIHTGEKPYKYNEYGKA FSEHSNL TTHQVIHTGEKPYK CNECGKVFTQNSHLARHRRV
55 HTGGKPYQCNECGKA FSQTSKLARHQRVHTGEKPYECNQCGKA FSVRSSLTTHQAIHTGKK

5 PYKCNECGKVFTQNSHLARHRGIHTGEKPYKCNECGKAFSQTSKLARHQRIHTGEKPYECG
KPFSSICSSLTTHQTIHTGGKPYKCNVWKVLKSEFKPCKPSQNS (SEQ ID NO: 240)

NP_037530.2 zinc finger protein 224

MTTFKEAMTFKDVAVVFTEELGLDLAQRKLYRDVMLENFRNLLSVGHQAFHRDTFHFLR
10 EEKIWMMKTAIQREGNSGDKIQTEMETVSEAGTHQEWSFQQIWEKIASDLTRSQDLMINSSQ
FSKEGDFPCQTEAGLSVIHTRQKSSQNGYKPSFSDVSHFDFHQQLHSGEKSHTCDECGKNF
CYISALRIHQRVHMGEKCYKCDVCGKEFSQSSHLQTHQRVHTGEKPFKCVECGKGFSRRSAL
NVHHKLHTGEKPYNCEECEGKAFFHDSQLQEHQRIHTGEKPFKCDICGKSFCGRSRLNRHSMV
HTAEKPFRCDTCDKSFQRQSRALNSHRMIHTGEKPYKCEECEGKGFIKRRDLYTHHMVHTGEK
15 YNCKEKGKSFWRASCLLKHQRVHSGEKPFKCEECEGKGFIYNSQCYSHQRSHSGEKPYKCE
CGKGYKRRDLDFHQRVHTGEKLYNCKEKGKSFAPCLLKHERLHSGEKPFQCEECEGKRF
TQNSHLHSHQRVHTGEKPYKCEKCGKGYNSKFNLDMHQKVHTGERPYNCKEKGKSGFWAS
CLLKHQRLHSGEKPFKCEECEGKRFTQNSQLHSHQRVHTGEKPYKCDECEGKGFSWSSTRLTH
QRRHSRETPLKCEQHGNIVQNSFSKVQEKVHSVEKPYKCEDCGKGYNRRNLDMHQRVH
20 MGEKTWKCRCEDMCFSSQASSRLHQNVHVGEK (SEQ ID NO: 241)

NP_113674.1 zinc finger protein 484 isoform a

MTKSLESVSFKDVTVDVSRDEWQQDLAQKSLYREVMLENYFNLSVGCQVPKPEVIFSLEQ
EEPCMLDGEIPSQSRPDGDIGFGPLQQRMSEEVSFQSEININLFTRDDPYSILEELWKDDEHTR
25 KCGENQNKPLSRVVFINKKTLANDSIFEYKDIGEIVHVNTHLVSSRKRPNCNSCGKNLEPIIT
LYNRNNATENSDKTIGDGDIFTHLNSHTEVTACECNQCGKPLHHKQALIQQQKIHTRESLYLF
SDYVNVFSPKSHAFAHESICAEKQHECHECEAVFTQKSQLDGSQRVYAGICTEYKDFSLK
SNRQKTPYEGNYYKCSFYGRAFIQKSDLFRCQRIHSGEKPYEYSECEKNLPQNSNLNIHKKI
TGGKHFECTECGKAFTRKSTLSMHQKIHTGEKPYVCTECGKAFFIRKSHFITERIHTGEKPYE
30 CSDCGKSFIIKSQLHVHQRIHTGENPFICSECGKVFTHTKTNLIHQKIHTGERPYICTVCGKAFT
DRSNLIHQKIHTGEKPYKCSDCGKSFTWKSRLRIHQKCHTGERHYECSECGKAFFIKSTLS
MHQRIHRGEKPYVCTECGKAFFHKSHFITERIHTGEKPYECSICGKSFTKKSQHLVHQIHT
GEKPYRCAECGKAFTDRSNLFTHQKIHTGEKPYKCSDCGKAFTRKSGLHIHQSHHTGERHYE
CSECGKAFAKSTLIMHQRIHTGEKPYICNECGKSFIQKSHLNRHRIHTGEKPYECSDCGKSF
35 IKKSQLHEHHRIHTGEKPYICAECGKAFTIRSNLIHQKIHTKQKPYKCSDLGKALNWKPQLS
MPQKSDNGEVECSMPQLWCGDSEGDQGLSSI (SEQ ID NO: 242)

NP_001006657.1 zinc finger protein 473

MAEEFVTLKDVGMDFTLGDWEQLGLEQGDTFWDTALDNCQDLFLLDPPRPNLTSHPDGSE
40 DLEPLAGGSPEATSPDVTETKNSPLMEDFFEEGFSQEIIEMLSKDGFWNSNFGEACIEDTWLD
SLLGDPESSLRSDIATNGESPTECKSHELKRGSLSPVSTVSTGEDSMVHNVSEKTLTPAKSKEY
RGEFFSYSDHSQQDSVQEGEKPYQCSECGKSFSGSYRLTQHWITHTREKPTVHQECEQGFD
NASLSVYPKTHTYGYKFYVCNEYGTTFSQSTYLWHQKTHHTGEKPKSQSDHPPSHDTQPGE
HQKTHTDKSYNCECGKAFTTRIFHLTRHQKIHTRKRYECSKCQATFNLRKHLIHQKTHAA
45 KTTSECQECGKIFRHSSLLIEHQALHAGEEPYKCNERGKSFHRNSTLKIHQRVHSGEKPYKCS
ECGKAFFHRHHLNEHRIHTGYRPHKCQECVRSFSRPSHLMRHQAIHTAEKPYSCAECKETF
SDNNRLVQHQMHTVKTPECEQECGERFICGSTLKCHESVHAREKQGFFVSGKILDQNPQ
KEKCFKCNKCEKTFSCSKYLTQHERIHTRGVKPFECDCGKAFFGQSTRLIHHQRIHSRVRLY
KWGEQGKAISSASLIKLSFHTKEHPFKNECGKTFSSHAHLKHLIHAHENPFKCSKCDRV
50 FTQRNYLVQHERTHARKKPLVNECGKTFRQSSCLSKHQRIHSGEKPYVCDYCGKAFFGLSA
ELVRHQRIHTGEKPYVCQECGKAFTQSSCLSIHRRVHTGEKPYRCGECGKAFAQKANLTQH
QRIHTGEKPYSCNVCCKAFVLSAHLNQHLRVHTQETLYQCQRCQKAFFRCHSSLSRHQRVHN
KQQYCL (SEQ ID NO: 243)

55 NP_065879.1 zinc finger protein 28 homolog

5 MRGAASASVREPTPLPGRGAPRTKPRAGRGPTVGTATLALPARGRPRSRNGLASKGQRG
 APTGPGHRALPSRDTALPQERNKKLEAVGTGIEPKAMSQGLVTFGDVAVDFSQEEWEWLN
 IQRNLYRKVMLENYRNLASLGLCVSKPDVISSLEQGKEPWTVKRKMTRA WCPDLKAVWKI
 KELPLKKDFCEGKLSQAVITERLTSYNLEYSLLGEHWDYDALFETQPGLVTIKNLAVDFRQQ
 LHPAQKNFCKNGIWENNSDLGSAGHCVAKPDLVSLLEQEKEPWMVKREL TGSLSFGQRSVH
 10 ETQELFPKQDSYAEGVTDRTSNTKLDCCSFRENWDSYVFGRLAVGQETQFRQEPITHNKT
 LSKERERTYNKSGRWFYLLDDSEEKVHNRDSIKNFQKSSVVIKQTGIYAGKKLFCNECKKTF
 TQSSSLTVHQRIHTGEKPYKCNECGKAFSDGSSSFARHQ RCHTGKKPYECIECGKA F IQNTSLI
 RHWRYYYHTGEKPFDCIDCGKAFSDHIGLNQHRRIHTGEKPYKCDVCHKSFRY GSSSLTVHQRI
 HTGEKPYECDVCRKAFSHHASLTQHQRVHSGEKPFKCKEKGKAFRQNIHLASHLRIHTGEKP
 15 FECAECGKSFSISSQLATHQRIHTGEKPYECKVCSKAFTQKAHLAQHQKTHTGEKPYECKEC
 GKAFSQTTHLIQHQRVHTGEKPYKCMCEGKAFGDNSSCTQHQR LHTGQRPYECIECGKA FK
 TKSSLICHRRSHTGEKPYECVCGKAFSHRQSLSVHQRIHSGKKPYECKE CKRTFIQIGHLNQ
 HKRVHTGERSYNYKKSRKVFRQTAHLAHHQRIHTGESSTCPSLPSTSNPV DLPKFLWNPSSL
 PSP (SEQ ID NO: 244)

20 NP_001166146.1 zinc finger protein 347 isoform a
 MALTQGGQVTFRDVAIEFSQEEWTCLDPAQRTLYRDVMLENYRN LASLAGISCFDL SIISMLE
 QGKEPFTLESQVQIAGNPDGWEWIKAVITALSSEFVMKDLLHKGKSNTGEVFQTVMLERQES
 QDIEGCSFREYQKNTHGLE YQCRDAEGNYKGVLLTQEGNLTHGRDEHDKRDARNKLIK NQL
 25 GLSLQSHLPQLFQYEGKIYECNQVEKSFNNNSSVSP PQMPYNVKTHISKKYLKDFISSLL
 LTQGGQKANNWGSPYKSNGCGMVFPQNSHLASHQRSHTKEKPYKCYECGKA FRTRSNTLTH
 QVIHTGEKRYKCNECGKVFSRNSQLSQHQKIHTGEKPYKCNECGKVFTQNSHLVRHRGIHTG
 EKPYKCNECGKA FRARSSLAIHQATHSGEKPYKCNECGKVFTQNSHLTNHWRIHTGEKPYK
 CNECGKA FGVRSSLAIHLVIHTGEKPYKCHECGKVFRRNSHLARHQLIHTGEKPYKCNECGK
 30 AFRAHSNLTTHQVIHTGEKPYKCNECGKVFTQNSHLANHQRIHTGVKPYMCNECGKA FSVY
 SSLTTHQVIHTGEKPYKCNECGKVFTQNSHLARHRGIHTGEKPYKCNECGKVFRHNSYLSRH
 QRIHTGEKPYKYNEYGKA FSEHSNLTTHQVIHTGEKPYKCNECGKVFTQNSHLARHRRVHT
 GGKPYQCNECGKA FSQTSKLARHQ RVHTGEKPYECNQCGKA FSVRSSLTTHQAIHTGKKPY
 KCNECGKVFTQNSHLARHRGIHTGEKPYKCNECGKA FSQTSKLARHQRIHTGEKPYECGKPF
 35 SICSSLTTHQTIHTGGKPYKCNVWKVLKSEFKPCKPSQNS (SEQ ID NO: 245)

NP_659570.1 zinc finger protein with KRAB and SCAN domains 5
 MIMTESREVIDLDPPAETSQE QEDLFIVKVEEEDCTWMQEYNPPTFETFYQRFRHFQYHEASG
 PREALSQRLVLCCEWLRPELHTKEQILELLVLEQFLTILPEEFQPVVREHHPESGEEAVAVIEN
 40 IQRELEERRQIVACPDVLP RKMATPGAVQESCSPHPLTVDTQPEQAPQKPRLL EENALPVLQ
 VPSLPLKDSQELTASLLSTGSQKLVKIEEVADVAVSFILEEWGHL DQSQKSLYRDDRKENYG
 SITSMGYESRDNMELIVKQISDDSESHWVAPEHTERSVPQDPDFAEVSDLKGMVQRWQVNP
 TVGKSRQNPSQKRDLD AITDISPKQSTHGERGHRCSDCGKFFLQASNFIQHRRRIHTGEKPFKC
 GECGKSYNQ RVHLTQHQRVHTGEKPYKCQVCGKA FRVSSHLVQHHSVHSGERP YGCNECG
 45 KNFGRHSHLIEHLKRHFREKSQRCSDKRSKNTKLSVKKKISEYSEADMELSGKTQRNV SQVQ
 DFGEGCEFQGKLDRKQGIPMKEILGQPSSKRMNYSEVPYVHKKSSTGERPHKCNECGKSFIQ
 SAHLIQHQRIHTGEKPFRCIECGKSYNQ RVHLTQHQRVHTGEKPYTCPLCGKA FRVRS HL VQ
 HQSVHSGERP FKCNECGKGFGRRSHLAGHLRLHSREKSHQCRECGEIFFQYVSLIEHQVLHM
 GQKNEKNGICEEAYS WNLTVIDDKKIELQE QPYQCDICGKA FGYSSDLIQHYRTHTA EKPYQ
 50 CDICRENVGQCSHTKQH QKIYSSTKSHQCHECGRGFTL KSHLNQHQRRIHTGEKPFQCKE CGM
 NFSWSCSLFKHLRSHERTDPINTLSVEGSL (SEQ ID NO: 246)

NP_114440.1 POZ-, AT hook-, and zinc finger-containing protein 1 short isoform
 55 MERVNDASCGPSGCYTYQVSRHSTEMLHNLNQQRKNNGGRFCDVLLRVGDESFP AHRAVLA
 ACSEYFESVFS AQLGDGGAADGGPADVGGATAAPGGGAGGSRELEMHTISSKVFGDILDFA

5 YTSRIVVRLESFPELMTAAKFLLMRSVIEICQEVIKQSNVQILVPPARADIMLFRPPGTSDLGFP
 LDMTNGAALAANSNGIAGSMQPEEEAARAAGAAIAGQASLPVLPVLDRLPMVAGPLSPQLL
 TSPFPSVASSAPPLTGKRGRGRPRKANLLDSMFGSPGGLREAGILPCGLCGKVFTDANRLRQH
 EAQHGVTSLSLQGYIDLPPRLGENGLPISEDPDGPRKRSRTRKQVACEICGKIFRDVYHLNRH
 KLSHSGEKPYSCPVCGLRFKRKDRMSYHVRSHDGSVGKPYICQSCGKGFSRDPDLNGHIKQV
 10 HTSERPHKCQVWVGSSSGLPPLEPLPSDLPSWDFAPALWRSSHVPDTAFSLSLKKSFPAL
 NLGPAHSSNTLFCPAPPGYL RQGWTTPEGSRAFTQWPVG (SEQ ID NO: 247)

NP_001006657.1 zinc finger protein 473

MAEEFVTLKDVGMDFTLGDWEQLGLEQGDFTWDTALDNCQDLFLLDPPRPNLTSHPDGSE
 15 DLEPLAGGSPEATSPDVTETKNSPLMEDFFEEGFSQEIIEMLSKDGFWNSNFGEACIEDTWLD
 SLLGDPESSLRSDIATNGESPTECKSHELKRGLSPVSTVSTGEDSMVHNVSEKTLTP
 AKSKEYRGEFFSYSDHSQQDSVQEGEKPYQCSECGKSFSGSYRLTQHWITHTREKPTVHQEC
 EQGFDRNASLSVYPKTHGTGYKFCNEYGTTFSQSTYLWHQKTHGTGEKPKSQQSDHPPSH
 DTQPGEHQKTHTDKSYNCECGKAFTTRIFHLTRHQKIHTRKRYECSKCQATFNLRKHLIQH
 20 QKTHAAKTSECQECGKIFRHSSLLIEHQALHAGEEPYKCNERKGSFRHNSTLKIHRVHSGE
 KPYKCSECGKAFHRHHLNEHRRHTGYRPHKCQECVRSFSRPSHLMRHQAIHTAEKPYSCA
 ECKETFSDNNRLVQHQMHTVKTPYECQECGERFICGSTLKCCHESVHAREKQGGFFVSGKILD
 QNPEQKEKCFKCNKCEKTFSCSKYLTQHERIHTRGVVKPFECDCGKAFGQSTRLIHHQRIHSR
 VRLYKWGEQGAISSASLIKLSFHTKEHPFKCNECGKTFSSHAHLSKHQLIHAGENPFKCSK
 25 CDRVFTQRNYLVQHERTHARKKPLVCNECGKTFRQSSCLSKHQRIHSGEKPYVCDYCGKAF
 GLSAELVRHQRIHTGEKPYVCQECGKAFTQSSCLSIHRRVHTGEKPYRCGECGKAFAQKANL
 TQHQRHTGEKPYSCNVCCKAFVLSAHLNQHLRVHTQETLYQCQRCQKAFRCHSSLSRHQR
 VHNKQQYCL (SEQ ID NO: 248)

30 NP_001973.2 receptor tyrosine-protein kinase erbB-3 isoform 1 precursor
 MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVM
 GNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGFVFAIFVMLN
 YNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCP
 PCHEVCKGRCWGPGECDQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTCFA
 35 CRHFNDSGACVPRCPQPLVYNKLTQLEPNPHTKYQYGGVCVASCNHFVVDQTSCVRACP
 PDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSNIDGFVNCTKILGNLDFLITGL
 NGDPWHKIPALDPEKLNVRFTVREITGYLNIQSWPPHMHNFVFSNLTTIGGRSLYNRGFSLLI
 MKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSNLNWKVLRGPTEERLDIKHNRPRRDCV
 AEGKVCDPLCSSGGCWGPGPQCLSCRNYSRGGVCVTHCNFLNGEPREFAEAEFCFSCHPE
 40 CQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHEN
 CTQGCKGPELQDCLGQTLVLIGKTHLTMAITVIAGLVVIFMMLGGTFLYWRGRRIQNKRAM
 RRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCI
 KVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPG
 SSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNV
 45 LLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALSIHFGKYTHQSDVWSYGVTV
 WELMTFGAEPYAGLRLAEVPDLLEKGERLAQPQICTIDVYMMVMVKCWMIDENIRPTFKELA
 NEFTRMARDPPRYLVIKRESGPGIAPGPEPHGLTNKKLEEVELEPELDLDLDLEAEEDNLATT
 TLGSALSPLVGTLNRPRGSQSLLSPSSGYMPMNQGNLGESCQESAVSGSSERCPRPVSLHPMP
 RGCLASESSEGHVTGSEAELEKQVSMCRSRSRSPRPRGDSAYHSQRHSLTPVTPLSPGGL
 50 EEEDVNGYVMPDTHLKGTPSSREGTLSSVGLSSVLGTEEEDEDEEYEMNRRRRHSPPHPPR
 PSSLEELGYEYMDVGSDLASLGSTQSCPLHPVPIMPTAGTTPDEDYEMNRQRDGGGGPGGD
 YAAMGACPASEQGYEEMRAFGPGHQAPHVHYARLKTLSLEATDSAFDNPDYWHSRLFP
 KANAQRT (SEQ ID NO: 249)

55 NP_037530.2 zinc finger protein 224

5 MTTFKEAMTFKDVA VVFTEEELGLDLAQRKLYRDVMLENFRNLLSVGHQAFHRDTFHFLR
 EEKIWMMKTAIQREGNSGDKIQTEMETVSEAGTHQEWSFQQIWEKIASDLTRSQDLMINSSQ
 FSKEGDFPCQTEAGLSVIHTRQKSSQGNGYKPSFSDVSHFDFHQQLHSGEKSHTCDECCKNF
 CYISALRIHQRVHMGEKCYKCDVCGKEFSQSSHLQTHQRVHTGEKPFKCVECGKGFSRRSAL
 NVHHKLHTGEKPYNCEECEGKAFIHDSQLQEHQRIHTGEKPFKCDICGKSFCGRSRLNRHSMV
 10 HTAEKPFRCDTCDKSFRQRSALNSHRMIHTGEKPYKCEECEGKGFIKRRDLYTHH MVHTGEK
 YNCKEKGKSFWRWASCLLKHQRVHSGEKPFKCEECEGKGFIYNSQCYSHQRSHSGEKPYKCV
 CGKGYKRRDLDFHQRVHTGEKLYNCKEKGKSFAPCLLKHRLHSGEKPFQCEECEGKRF
 TQNSHLHSHQRVHTGEKPYKCEKCGKGYNSKFNLDMHQKVHTGERPYNCKEKGKSGFWAS
 CLLKHQRLHSGEKPFKCEECEGKRFTQNSQLHSHQRVHTGEKPYKCDECCKGFSWSSTRLTH
 15 QRRHSRETPLKCEQHGNIVQNSFSKVQEKVHSVEKPYKCEDCGKGYNRRNLDMHQRVH
 MGEKTWKCRECDMCFSSQASSRLHQNVHVGEK (SEQ ID NO: 250)

NP_065879.1 zinc finger protein 28 homolog

MRGAASASVREPTPLPGRGAPRTKPRAGRGPTVGTATLALPARGRPRSRNGLASKGQARGA
 20 APTGPGHRALPSRDTALPQERNKKLEAVGTGIEPKAMSQGLVTFGDVAVDQSQEEWEWLN
 IQRNLYRKVMLENYRNLASLGLCVSKPDVISSLEQGKEPWTVKRKMTRAWCPDLKAVWKI
 KELPLKKDFCEGKLSQAVITERLTSYNLEYSLLGEHWDYDALFETQPGLVTIKNLAVDFRQQ
 LHPAQKNFCKNGIWENNSDLGSAGHCVAKPDLVSLLEQEKEPWMVKREL TGSLSFGQRSVH
 ETQELFPKQDSYAEGVTDRTSNTKLDCSSFRENWDSYVFGRLAVGQETQFRQEPITHNKT
 25 LSKERERTYNKSGRW FYLDDSEEKVHNRDSIKNFQKSSVVIKQTGIYAGKKLFCNECKKTF
 TQSSSLTVHQRIHTGEKPYKCEGKAFSDGSSFAHQHQRCHTGKKPYECIECGKAFIQNTSLI
 RHWRYYYHTGEKPFDCIDCGKAFSDHIGLNQHRRIHTGEKPYKCDVCHKSFYRGSSSLTVHQRI
 HTGEKPYECDVCRKAFSHHASLTQHQRVHSGEKPFKCKEKGKAFRQNIHLASHLRIHTGEK
 FECAECGKSFSISSQLATHQRIHTGEKPYECKVCSKAFTQKAHLAQHQKTHHTGEKPYECKE
 30 GKAFSQTTHLIQHQRVHTGEKPYKCEGKAFGDNSSCTQHQRLLHTGQRPYECIECGKAFK
 TKSSLICHRRSHTGEKPYECVCGKAFSHRQSLSVHQRIHSGKKPYECKEKRKTFIQIGHLNQ
 HKRVHTGERSYNYKKSRKVFRQTAHLAHHQRIHTGESSTCPSLPSTSNPVDLFPKFLWNPSSL
 PSP (SEQ ID NO: 251)

35 NP_115973.2 zinc finger protein 347 isoform b

MALTQGGVTFRDVAIEFSQEEWTCLDPAQRTLYRDVMLENRYRNLASLGISCFDLISIISML
 EQGKEPFTLESQVQIAGNPDGWEWIKAVITALSSEFVMKDLLHKGKSNTEGEVFQTVMLERQ
 ESQDIEGCSFREYQKNTHGLEEQCRDAEGNYKGVLLTQEGNLTHGRDEHDKRDARNKLIK
 QLGLSLQSHLPELQLFQYEGKIYECNQVEKSFNNNSSVSPQMPYNVKTHISKKYKDFISS
 40 LLLTQGGQKANNWGS PYKSNCGMVFPQNSHLASHQRSHTKEKPYKCYECGKAFRTRSNLT
 THQVIHTGEKRYKCEGKVFSRNSQLSQHQKIHTGEKPYKCEGKVFTQNSHLVRHRGIH
 TGEKPYKCEGKAFRRSSLAHQATHSGEKPYKCEGKVFTQNSHLTNHWRIHTGEK
 YKCEGKAFGVRSSLAHLVIHTGEKPYKCEGKVFRNRSHLARHQLIHTGEKPYKCEG
 GKAFRAHSNLTHQVIHTGEKPYKCEGKVFTQNSHLANHQRIHTGVKPYMCNEGKAFS
 45 VYSSLTTHQVIHTGEKPYKCEGKVFTQNSHLARHRGIHTGEKPYKCEGKVFRHNSYLS
 RHQRIHTGEKPYKYNEYGKAFSEHSNLTHQVIHTGEKPYKCEGKVFTQNSHLARHRRV
 HTGGKPYQCNEGKAFSQTSLARHQRVHTGEKPYECNQCGKAFSVRSSLTTHQAIHTGKK
 PYKCEGKVFTQNSHLARHRGIHTGEKPYKCEGKAFSQTSLARHQRIHTGEKPYECG
 KPFSICSSLTTHQTIHTGGKPYKCNVWVKLSEFKPCKPSQNS (SEQ ID NO: 252)

50

NP_001005368.1 zinc finger protein 32

MFGFPTATLLDCHGRYAQNVAFFNMTEAHHKYDHSEATGSSSWDIQNSFRREKLEQKSPD
 SKTLQEDSPGVRQRVYECQECGKSFRQKGSLLTHERIHTGQKPFECTHCGKSFRAGNLVTH
 QRIHTGEKPYQCKEKGKSFQSGSLAVHERLHTGQKPYECAICQRSFRNQSNLAVHRRVHSG
 55 EKP YRCDQCGKAFS QKGS LIVH RVHTGLKPYACTQCRKSFHTRGNCILHGKIHTGETPYLCG
 QCGKSFTQRGSLAVHQRSCSQRLTL (SEQ ID NO: 253)

5

NP_004243.1 Na(+)/H(+) exchange regulatory cofactor NHE-RF1

MSADAAAGAPLPRLCCLEKGPNGYGFHLHGEKGKLGQYIRLVEPGSPAEEKAGLLAGDRLVE
 VNGENVEKETHQQVVSRIIRAALNAVRLLVVDPETDEQLQKLGVQVREELLRAQEAPGQAEP
 PAAAEVQGAGNENEPREADKSHPEQRELRLCTMKKGPSGYGFNLHSDKSKPGQFIRSVDP
 10 DSPAEASGLRAQDRIVEVNGVCMEGKQHGDVVSIRAGGDETKLLVVDRETDEFFKKCRVI
 PSQEHLNGPLPVPFTNGEIQKENSREALAEAALESPPALVRSASSDTSEELNSQDSPPKQDST
 APSSTSSSDPILDFNISLAMAKERAHQKRSSKRAPQMDWSKKNELFSNL (SEQ ID NO: 254)

NP_001159354.1 zinc finger protein 268 isoform c

15 MDVFVDFTWEEWQLLDPAQKCLYRSVMLENYSNLVSLGYQHTKPDIIFKLEQGEELCMVQ
 AQVPNQTCPNTVWKIDDLMDWHQENKDKLGSTAKSFECTTFGKLCLLSTKYLSRQKPHKC
 GTHGKSLKYIDFTSDYARNNPNGFQVHGKSFFHSHKHEQTVIGIKYCESIESGKTVNKKSQLM
 CQQMYMGEKPGFCSCCEKAFSSKSYLLVHQQTTHAEKPYGCNECGKDFSSKSYLIVHQRIHT
 GEKLHECSECRKTFHSFSQLVIHQRIHTGENPYECCECGKVFSRKDQLVSHQKTHSGQKPYV
 20 CNECGKAFGLKSQLIIHERIHTGEKPYECNECQKAFNTKSNLMVHQRTHHTGEKPYVCSDCGK
 AFTFKSQLIVHQGIHTGVKPYGCIQCGKGFSLKSQLIVHQRSHTGMKPYVCNECGKAFRSKS
 YLIIHTRTHHTGEKLHECNCGKAFSFKSQLIIHQRIHTGENPYECHECGKAFSRKYQLISHQRT
 HAGEKPYECTDCGKAFLKSQLIIHQRTHTGEKPFECSECQKAFNTKSNLIVHQRTHHTGEKPY
 SCNECGKAFTFKSQLIVHKGVTGKPYGCSQCAKTFSLKSQLIVHQRSHTGVKPYGCSECG
 25 KAFRSKSYLIIHMRTHHTGEKPHECRECGKSFSFNSQLIVHQRIHTGENPYECSECGKAFNRKD
 QLISHQRTTHAGEKPYGCSECGKAFSSKSYLIIHMRTHSGEKPYECNECGKAFIWKSLLIVHER
 THAGVNPYKCSQCEKSFSGLRLLVHQRMTREKPYECSECGKAFIRNSQLIVHQRTHSGEK
 PYGCNECGKTFSQKSILSAHQRTHTGEKPCKCTECGKAFCWKSQIMHQRTHVDDKH (SEQ
 ID NO: 255)

30

NP_001090.2 prostatic acid phosphatase isoform PAP precursor

MRAAPLLLARAASLSLGLFLLFFWLDRSVLAKELKFVTLVFRHGDSPIDTFPTDPIKESSWP
 QGFGQLTQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNLAALFP
 PEGVSIWNPILLWQPIPVHTVPLSEDQLLYLPFRNCPRFQELESETLKSEEFQKRLHPYKDFIAT
 35 LGKLSGLHGQDLFGIWSKVYDPLYCESVHNFTLPSWATEDMTKLRELSLSLSLYGIHKQ
 KEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMYSAHDTTVSGLQMALDVYNGLLPPYASC
 HLTLYFEKGEYFVEMYRNETQHEPYPLMLPGCSPSCPLERFAELVGPVIPQDWSTECMTT
 NSHQGTEDSTD (SEQ ID NO: 256)

40

NP_001006657.1 zinc finger protein 473

MAEEFVTLKDVGMDFTLGDWEQLGLEQGDTFWDTALDNCQDLFLLDPPRPNLTSHPDGSE
 DLEPLAGGSPEATSPDVTETKNSPLMEDFFEEGFSQEIIEMLSKDGFWNSNFGEACIEDTWLD
 SLLGDPESSLRSDIATNGESPTECKSHELKRGLSPVSTVSTGEDSMVHNVSEKTLTPAKSKEY
 RGEFFSYSDHSQQDSVQEGEKPYQCSECGKSFSGSYRLTQHWITHTREKPTVHQECEQGFD
 45 NASLSVYPKTHHTGYKFYVCNEYGTTFSQSTYLWHQKTHHTGEKPKKSQSDHPPSHDTQPGE
 HQKTHTDKSYNCNECGKAFTTRIFHLTRHQKIHTRKRYECSKCQATFNLRKHLIQHQKTHAA
 KTTSECQECGKIFRHSSLLIEHQALHAGEEPYKCNERGKSFRHNSTLKIHQRVHSGEKPYKCS
 ECGKAFTHRHHLNEHRRHTGYRPHKCQECVRSFSRPSHLMRHQAIHTAEKPYSCAECKETF
 SDNNRLVQHQMHTVKTPECEQECGERFICGSTLKCHESVHAREKQGGFFVSGKILDQNPEQ
 50 KEKCFKCNKCEKTFSCSKYLTQHERIHTRGVKPFECDCGKAFGQSTRLIHHQRIHSRVRLY
 KWGEQGKAISSASLIKLSFHTKEHPFKCNECGKTFSSHSAHLSKHQLIHAGENPFKCSKCDRV
 FTQRNYLVQHERTHARKKPLVCNECGKTFRQSSCLSKHQRIHSGEKPYVCDYCGKAFLGLSA
 ELVRHQRIHTGEKPYVCQECGKAFTQSSCLSIHRRVHTGEKPYRCGECGKAFAQKANLTQH
 QRIHTGEKPYSCNVCCKAFVLSAHLNQHLRVHTQETLYQCQRCQKAFRCHSSLSRHQRVHN
 55 KQQYCL (SEQ ID NO: 257)

5 NP_001159354.1 zinc finger protein 268 isoform c
 MDVFVDFTWEEWQLLDPAQKCLYRSVMLENYSNLVSLGYQHTKPDIIFKLEQGEELCMVQ
 AQVPNTQCPNTVWKIDDLMDWHQENKDKLGSTAKSFECTTFGKLCLLSTKYLSRQKPHKC
 GTHGKSLKYIDFTSDYARNNPNGFQVHGKSFFHSKHEQTVIGIKYCESIESGKTVNKKSQLM
 CQQMYMGEKPFGCSCCEKAFSSKSYLLVHQQTTHAEKPYGCNECGKDFSSKSYLVHQRIHT
 10 GEKLHECSECRKTFHSFSQLVIHQRIHTGENPYECCECGKVFSRKDQLVSHQKTHSGQKPYV
 CNECGKAFGLKSQLIIHERIHTGEKPYECNECGKAFNTKSNLMVHQRTHTGEKPYVCSDCGK
 AFTFKSQLIVHQGIHTGVKPYGCIQCGKGFSLSKSQLIVHQRSHTGMKPYVCNECGKAFRSKS
 YLIIHTRTHTGEKLHECNCGKAFSFKSQLIIHQRIHTGENPYECHECGKAFSRKYQLISHQRT
 HAGEKPYECTDCGKAFGLKSQLIIHQRTHTGEKPFECSECQKAFNTKSNLIVHQRTHTGEKPY
 15 SCNECGKAFTFKSQLIVHKGVTGVTGKPYGCSQCAKTFSLKSQLIVHQRSHTGVKPYGCSECG
 KAFRSKSYLIIHMRTHTGEKPHECRECGKSFSFNSQLIVHQRIHTGENPYECSECGKAFNRKD
 QLISHQRTTHAGEKPYGCSECGKAFSSKSYLIIHMRTHSGEKPYECNECGKAFIWKSLIVHER
 THAGVNPYKCSQCEKSFSGLRLLVHQRMTREKPYECSECGKAFIRNSQLIVHQRTTHSGEK
 PYGCNECGKTFSQKSILSAHQRTHTGEKPKCTECGKAFCWKSQIMHQRTTHVDDKH (SEQ
 20 ID NO: 258)

NP_001192195.1 beta-defensin 4B
 MRVLYLLFSFLFIFLMPLPGVFGGIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKC
 CKKP (SEQ ID NO: 259)

25 NP_001167629.1 zinc finger protein ZFAT isoform 4
 MCKCCNLFSPNQSELLSHVSEKHMEEGVNVDEIIPLRPLSTPEPPNSSKTGDEFLVMKRKRGR
 RPKGSTKKSSTEEELAENIVSPTEDSPLAPEEGNSLPPSSLECSKCCRKFSNTRQLRKHICIIVLN
 LGEEGEAGNESDLELEKKCKEDDREKASKRPRSQKTEKVQKISGKEARQLSGAKKPIISVVL
 30 TAHEAIPGATKIVPVEAGPPETGATNSETTSADLVPRRGYQEYAIQQTPYEQPMKSSRLGPTQ
 LKIFTCEYCNKVFKFKHSLQAHLRIHTNEKPYKCPQCSYASAIKANLNVHLRKHTGEKFACD
 YCSFTCLSKGHLKVHIERVHKKIKQHCRFCKKKYSVDVKNLIKHIRDAHDPQDKKVKEALDEL
 CLMTREGKRQLLYDCHICERKFKNELDRDRHMLVHGDKWPFACELCGHGATKYQALELHV
 RKHPFVYVCAVCRKKFVSSIRLRTHIKEVHGAAQEALVFTSSINQSFCLEPGGDIQQEALGD
 35 QLQLVEEEFALQGVNALKEEACPGDTQLEEGRKEPEAPGEMPAPAVHLASPQAESTALPPCE
 LETTVVSSSDLHSQEVSDDFLLKNDTSSAEAHAAPEKPPDMQHRSSVQTQGEVITLLLSKA
 QSAGSDQESHGAQSPLGEGQNMAVLSAGDPDPSRCLRSNPAAESDLLPPVAGGGDTITHQPD
 SCKAAPEHRSGITAFMKVLNSLQKKQMNTSLCERIRKVYGDLECEYCGKLFWYQVHFDMH
 VRTHTREHLYYCSQCHYSSITKNCLKRHVQKHSNILLKCPTDGDYDSTPDKYKLQAHLKVH
 40 TALDKRSYSCPVEKSFSEDRLIKSHIKTNHPEVSMSTISEVLGRRVQLKGLIGKRAMKCPYC
 DFYFMKNGSDLQRHIWAHEGVKPFKCSLCEYATRKSNNLKAHMNRHSTKTHLCMDGCKK
 FSKSGTLKSHKLLHTADGKQFKCTVCDYTAAQKPQLLRHMEQHVSFKPFRCAHCHYSCNIS
 GSLKRHYNRKHPNEEYANVGTGELAAEVLIQQGGLKCPVCSFVYGTKWEFNRHLKNKHGL
 KVVEIDGDPKWEVTEEEPSSNHTVMIQETVQQASVELAEQHHLVVSSDDVEGIETVTVYTQG
 45 GEASEFIVYVQEAMQPVEEQAVEQPAQEL (SEQ ID NO: 260)

NP_000333.1 band 3 anion transport protein
 MEELQDDYEDMMEENLEQEEYEDPDIPESQMEEPAHDTEATATDYHTTSHPGTHKVYVEL
 QELVMDEKNQELRWMEAARWVQLEENLGENGAWGRPHLSHLTFWSLLELRRVFTKGTVL
 50 LDLQETSLAGVANQLLDRFIFEDQIRPQDREELLRALLLKHSHAGELEALGGVKPAVLTRSG
 DPSQPLLPHSSLETQLFCEQGDGGTEGHSPSGILEKIPPDSEATLVLVGRADFLEQPVLGFR
 LQEAEELEAVELPVPIRFLFVLLGPEAPHIDYTQLGRAAATLMSEVFRIDAYMAQSRGELLH
 SLEGFLDCSLVLPPTDAPSEQALLSLVPVQRELLRRRYQSSPAKPDSSFYKGLDLNGGPDDPL
 QQTGQLFGGLVRDIRRRYPYYLSDITDAFSPQVLA AVIFIYFAALSPAITFGGLLGEKTRNQM
 55 GVSELLISTAVQGILFALLGAQPLL VVGFSGPLLVFEEAFFSFCE
 TNGLEYIVGRVWIGFWLILLVVLVVAFEGSFLVRFISRYTQEIFSFLISLIFIYETFSKL

5 IKIFQDHPLQKTYNYNVLMVVPKPQGGLPNTALLSLVLMAGTFFFAMMLRKFKNSSYFPGKLR
 RVIGDFGVPI SILIMVLVDFFIQDITYTQKLSVPDGFKVSNSSARGWVIHPLGLRSEFPIWMMFA
 SALPALLVFILIFLESQITTLIVSKPERKMVKGSGFHLDLLLVVGMGGVAALFGMPWLSATTV
 RSVTHANALTVMGKASTPGAAAQIQEVKEQRISGLLVAVLVGLSILMEPILSRIPLAVLFGIFL
 YMGVTSLSGIQLFDRILLFKPPKYHPDVPYVKRVKTRWMHLFTGIQIICLAVLVVVKSTPAS
 10 LALPFVLILTVPLRRVLLPLIFRNVELQCLDADDAKATFDEEEG
 RDEYDEVAMPV (SEQ ID NO: 261)

NP_001167629.1 zinc finger protein ZFAT isoform 4

MCKCCNLFSPNQSELLSHVSEKHMEEGVNVDEIIPLRPLSTPEPPNSSKTGDEFLVMKRKRGR
 15 RPKGSTKKSSTEEELAENIVSPTEDSPLAPEEGNSLPPSSLECSKCCRKFSNTRQLRKHICIVLN
 LGEEEGEAGNESDLELEKKCKEDDREKASKRPRSQKTEKVQKISGKEARQLSGAKKPIISVVL
 TAHEAIPGATKIVPVEAGPPETGATNSETTSADLVPRRGYQEYAIQQTPYEQPMKSSRLGPTQ
 LKIFTCEYCNKVFKFKHSLQAHLRIHTNEKPYKCPQCSYASAIKANLVHLRKHTGEKFACD
 YCSFTCLSKGHLKVHIERVHKKIKQHCRFCKKKYSDVKNLIKHIRDAHDPQDKKVKEALDEL
 20 CLMTREGKRQLLYDCHICERKFKNELDRDRHMLVHGDKWPFACELCGHGATKYQALELHV
 RKHPFVYVCAVCRKKFVSSIRLRTHIKEVHGAAQEALVFTSSINQSFCLLEPGGDIQQEALGD
 QLQLVEEEFALQGVNALKEEACPGDTQLEEGRKEPEAPGEMPAPAVHLASPQAESTALPPCE
 LETTVVSSSDLHSQEVVSDDFLLKNDTSSAEAHAAPEKPPDMQHRSSVQTQGEVITLLLSKA
 QSAGSDQESHGAQSPLGEGQNMAVLSAGDPDPSRCLRSNP AEASDLLPPVAGGGDTITHQPD
 25 SCKAAPEHRSGITAFMKVLNSLQKKQMNTSLCERIRKVYGDLECEYCGKLFWYQVHFD MH
 VRTHTREHLYYCSQCHYSSITKNCLKRHV IQKHSNILLKCPTDGCDYSTPDKYKLQAHLKVH
 TALDKRSYSCPVCEKSFSEDRLIKSHIKTNHPEVSMSTISEVLGRRVQLKGLIGKRAMKCPYC
 DFYFMKNGSDLQRHIWAHEGVKPFKCSLCEYATR SKSNLKAHMNRHST E KTHLCDMCGKK
 FKSKGTLKSHKLLHTADGKQFKCTVCDYTAAQKPQLLRHMEQHVSFKPFCAHCHYSCNIS
 30 GSLKRHYNRKHPNEEYANVGTGELAAEVLIQQGGLKCPVCSFVYGTKWEFNRHLKNKHGL
 KVVEIDGDPKWEVTEEEPSSNHTVMIQETVQQASVELAEQHHLVVSSDDVEGIETVTVYTQG
 GEASEFIVYVQEAMQPVEEQAVEQPAQEL (SEQ ID NO: 262)

NP_065914.2 zinc finger protein ZFAT isoform 1

35 METRAAENTAIFMCKCCNLFSPNQSELLSHVSEKHMEEGVNVDEIIPLRPLSTPEPPNSSKTG
 DEFLVMKRKRGRPKGSTKKSSTEEELAENIVSPTEDSPLAPEEGNSLPPSSLECSKCCRKFSNT
 RQLRKHICIVLNLGEEEGEAGNESDLELEKKCKEDDREKASKRPRSQKTEKVQKISGKEARQ
 LSGAKKPIISVVLTAHEAIPGATKIVPVEAGPPETGATNSETTSADLVPRRGYQEYAIQQTPYE
 QPMKSSRLGPTQLKIFTCEYCNKVFKFKHSLQAHLRIHTNEKPYKCPQCSYASAIKANLVH
 40 LRKHTGEKFACDYCSFTCLSKGHLKVHIERVHKKIKQHCRFCKKKYSDVKNLIKHIRDAHDP
 QDKKVKEALDELCLMTREGKRQLLYDCHICERKFKNELDRDRHMLVHGDKWPFACELCGH
 GATKYQALELHVRKHPFVYVCAVCRKKFVSSIRLRTHIKEVHGAAQEALVFTSSINQSFCLLE
 PGGDIQQEALGDQLQLVEEEFALQGVNALKEEACPGDTQLEEGRKEPEAPGEMPAPAVHLA
 SPQAESTALPPCELETTVVSSSDLHSQEVVSDDFLLKNDTSSAEAHAAPEKPPDMQHRSSVQT
 45 QGEVITLLLSKAQSAGSDQESHGAQSPLGEGQNMAVLSAGDPDPSRCLRSNP AEASDLLPPV
 AGGGDTITHQPD SCKAAPEHRSGITAFMKVLNSLQKKQMNTSLCERIRKVYGDLECEYCGK
 LFWYQVHFD MHVRTHTREHLYYCSQCHYSSITKNCLKRHV IQKHSNILLKCPTDGCDYSTPD
 KYKLQAHLKVHTALDKRSYSCPVCEKSFSEDRLIKSHIKTNHPEVSMSTISEVLGRRVQLKGL
 IGKRAMKCPYCDFYFMKNGSDLQRHIWAHEGVKPFKCSLCEYATR SKSNLKAHMNRHSTE
 50 KTHLCDMCGKKFKSKGTLKSHKLLHTADGKQFKCTVCDYTAAQKPQLLRHMEQHVSFKPF
 RCAHCHYSCNISGSLKRHYNRKHPNEEYANVGTGELAAEVLIQQGGLKCPVCSFVYGTKWE
 FNRHLKNKHGLKVVEIDGDPKWETATEAPEEPSTQYLHITEAEEDVQGTQA AVAALQDLRY
 TSESGDRLDPTAVNILQQIHELGAETHDATA LASVVAMAPGTVTVVKQVTEEEPSSNHTVMIQ
 ETVQQASVELAEQHHLVVSSDDVEGIETVTVYTQGGEASEFIVYVQEAMQPVEEQAVEQPA
 55 QEL (SEQ ID NO: 263)

5

Section 2 of Sequence Listing: Amino acid sequence information for exemplary domains of naturally occurring polypeptides having size and charge characteristics of Surf+ Penetrating Polypeptides, and referenced by PDB number and chain in Figures 1 and 2.

10

**AMINO ACID SEQUENCE INFORMATION FOR SPECIFIC DOMAINS
IDENTIFIED BY PDB IDENTIFIER and CHAIN IN FIGURES**

15 2J2S:A histone-lysine N-methyltransferase MLL isoform 1 precursor
GGSVKKGRRSRRCGQCPGCVPEDCGVCTNCLDKPKFGGRNIKKQCKMRKCQNLQWMP
SKAYLQKQAKAVK (SEQ ID NO: 264)

20 1FOS:F transcription factor AP-1
KAERKRMNRNRIAASKSRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVM
NH (SEQ ID NO: 265)

25 1G2S:A C-C motif chemokine 26 precursor
TRGSDISKTCFQYSHKPLPWTWVRSYEFTSNSCSQRAVIFTTKRGKKVCTHPRKKWVQKY
ISLLKTPKQL (SEQ ID NO: 266)

30 1XDT:R proheparin-binding EGF-like growth factor precursor
GSHMRVTLSSKPQALATPNKEEHGKRKKKGKGLGKKRDPCLRKYKDFCIHGECKYVKELR
APSCICHPGYHGERCHGLS (SEQ ID NO: 267)

35 2JX3:A protein DEK isoform 1
FTIAQGKGQKLCEIERIHFFLSKKKTDELRLNLHKLLYNRPGTVSSLKKNVGQFSGFPFEK
GSVQYKKKEEMLKKFRNAMLKSICEVLDLERSGVNSELVKRILNFLMHPKPSGKPLPKSKK
TCSKGSKKER (SEQ ID NO: 268)

40 2HGF:A hepatocyte growth factor isoform 1 preproprotein
GQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNGLPFTCKAFVFD
KARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRN (SEQ ID NO: 269)

45 1KJ6:A beta-defensin 103 precursor
GIINTLQKYCYCRVRGGRCVLSCLPKKEEQIGKCSTRGRKCCRRKK (SEQ ID NO: 270)

50 1TDH:A Endonuclease VIII-like 1
MPEGPELHLASQFVNEACRALVFGGCVEKSSVSRNPEVPFESSAYRISASARGKELRLIL
SPLPGAQPQQEPLALVFRFGMSGFQLVPREELPRHAHLRFYTAPPGPRLALCFVDIRRF
45 GRWDLGGKWQPGRGPCVLQEYQQFRESVLRNLADKAFDRPICEALLDQRFENGIGNYLRA
EILYRLKIPPEKARSVLEALQQHRPSPELTLSQKIRTKLQNPDLLELCHSVPKEVVQLGGRG
YGSESGEEDFAAFRAWLRCYGMPSLQDRHGRTIWFQGDPLAPKGRKSRKKKSKAT
QLSPEDRVEDALPPSKAPSRTRRAKRDLPKRKGRQAASGHCRPRKVKADIPSLEPEGTSAS
(SEQ ID NO: 271)

50 1J3S:A cytochrome c

5 GDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKTGQAPGYSYTAANKNKGIIWG
EDTLMEYLENPKKYIPGTKMIFVGIIKKKEERADLIAYLK KATNE (SEQ ID NO: 272)

1NUN:A fibroblast growth factor 10 precursor
GRHVRSYNHLQGDVRWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSILEITSVEIGVVAV
10 KAINSYYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVALNG
KGAPRRGQKTRRKNTSAHFLPMVVHS (SEQ ID NO: 273)

1EIG:A C-C motif chemokine 24 precursor
VVIPSPCCMFFVSKRIPENRVVSYQLSSRSTCLKAGVIFTTKKGQQSCGDPKQEWVQRYM
15 KNLDAKQKKASPR (SEQ ID NO: 274)

1E8O:B signal recognition particle 14 kDa protein
VLLESEQFLTELTRLFQKCR TSGSVYITLKKYDGRTKPIPKKGTVEGFEPADNKCLLRAT
20 DGKKKISTVVSSKEVNKFQMAYSNLLRANMDGLKKRDKKNKTKKTK (SEQ ID NO: 275)

1Z9I:A epidermal growth factor receptor isoform a precursor
RRRHIVRKRTLRLQLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSG (SEQ ID NO:
276)

25 2HDL:A C-X-C motif chemokine 14 precursor
GSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEK MVIITTKSVSRYRGQEHCLHPKLQSTKR
FIKWYNWNEKRRVYEE (SEQ ID NO: 277)

1JXS:A forkhead box protein K2
30 DSKPPYSYAQLIVQAITMAPDKQLTLNGIYTHITKNYPYYRTADKGWQNSIRHNLSLNRY
FIKVPRSQEEPGKGSFWRIDPASESKLIEQA FRKRRPR (SEQ ID NO: 278)

1UZC:A pre-mRNA-processing factor 40 homolog A
GSQPAKKT YTWNTKEEAKQAFKELLKEKRVPSNASWEQAMKMIINDPRYSALAKLSEKKQ
35 AFNAYKVQTEK (SEQ ID NO: 279)

2Y9A:D small nuclear ribonucleoprotein Sm D3
MSIGVPIKVLHEAEGHIVTCETNTGEVYRGKLIEAEDNMNCQMSNITVTYRDGRVAQLEQV
YIRGSKIRFLILPDMLKNAPMLKSMKNKNQGS GAGRGKAAILKAQVAARGRGRGMGRGNI
40 FQKRR (SEQ ID NO: 280)

2KKR:A ataxin-7 isoform a
GSKFLNKRLSEREFDPDIHCGVIDLDTKKPCTRS LTCKTHSLTQRRAVQGRRKRFDVLLA
EHKNKTREKELIRH (SEQ ID NO: 281)

45 1V66:A E3 SUMO-protein ligase PIAS1
MADSAELKQMVMSLRVSELQVLLGYAGRNKHGRKHELLTKALHLLKAGCSPAVQM KIKE
LYRRRF (SEQ ID NO: 282)

50 1PFM:A platelet factor 4 precursor
MSAKELRCQCVKTT SQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKK
IHKLLLES (SEQ ID NO: 283)

2E5E:A advanced glycosylation end product-specific receptor isoform 2 precursor
55 AMAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPPWDSVARVLP
NGSLFLPAVG IQDEGIFRCQAMNRNGKETKS NYRVRVYQIP (SEQ ID NO: 284)

- 5 2FDB:M fibroblast growth factor 8 isoform B precursor
QVTVQSSPNFTQHVVREQLVTDQLSRRLIRTYQLYSRTSGKHVQVLANKRINAMAEDGDPF
AKLIVETDTFGSRVRVRGAETGLYICMNKKGKLIKSNKGKDCVFTEIVLENNYTALQNA
KYEGLWYMAFTRKGRPRKGSKTRQHQREVHFMKRLPRGHHTTE (SEQ ID NO: 285)
- 10 1UKL:C sterol regulatory element-binding protein 2
RSSINDKIIELKDLVXGTDKXHKSGVLRKAIDYIKYLQQVNHKLRQENXVLKLANQKNKL
(SEQ ID NO: 286)
- 15 3HTU:B charged multivesicular body protein 6
GSRVTEQDKAILQLKQQRDCLRQYQKRIAQQLERERELA (SEQ ID NO: 287)
- 20 2KOL:A stromal cell-derived factor 1 isoform gamma
KPVSLSYRCPCRFESHVARANVKRLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE
YLEKALNK (SEQ ID NO: 288)
- 25 2K8F:A histone acetyltransferase p300
ATQSPGDSRRLSIQRAIQSLVHAAQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICK
QLIALAAYHAKHCQENKCPVPFCLNIKQK (SEQ ID NO: 289)
- 30 3IWN:C U1 small nuclear ribonucleoprotein A
TRPNHTIYINNLNEKIKKDELKKSLSHAIFSRFGQILDILVSRSLKMRGQAFVIFKEVSSA
TNALRSMQGFPPFYDKPMRIQYAKTDSDIK (SEQ ID NO: 290)
- 35 1PUF:B pre-B-cell leukemia transcription factor 1 isoform 2
ARRKRRNFNKQATEILNEYFYSHLSNPYPSEEAKEELAKKCGITVSQVSNWFGNKRIRYK
KNIGKFQEEANIY (SEQ ID NO: 291)
- 40 2L9R:A homeobox protein Nkx-3.1
MGHHHHHHSHMSHTQVIELERKFSHQKYLSEPERAHLAKNLKLTETQVKIWFQNRRYKTK
RKQLSSELG (SEQ ID NO: 292)
- 45 1PUF:A homeobox protein Hox-A9
NNPAANWLHARSTRKKRCPYTKHQTLLEKEFLFNMYLTRDRRYEVARLLNLTERQVKIW
FQNRMRMKMKKINKDRAK (SEQ ID NO: 293)
- 50 2LCE:A B-cell lymphoma 6 protein isoform 1
MGHHHHHHSHMTHSDKPYKCDRCQASFRYKGNLASHKTVHTGEKPYRCNICGAQFNRP
NLKTHTRIHSGEKPX (SEQ ID NO: 294)
- 55 1BC7:C ETS domain-containing protein Elk-4 isoform a
MDSAITLWQFLLQLLQKPQNKHMICWTSNDGQFKLLQAEVVARLWGIRKNKPNMNYDKL
SRALRYYYVKNIKKVNGQKFVYKFVSYPEILNM (SEQ ID NO: 295)
- 60 1YZ8:P pituitary homeobox 3
GSQRRQRTHFTSQQLQQLEATFQRNRYPDMSSTREEIAVWTNLTEARVRVWFKNRRRAKWR
KREEFIVTD (SEQ ID NO: 296)
- 65 1L9L:A granulysin isoform NKG5
XRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVIQGL
VAGETAQQICEDLX (SEQ ID NO: 297)

- 5 1I27:A general transcription factor IIF subunit 1
GPLGSGDVQVTEDAVRRYLTRKPMTTKDLLKKFQTKKTGLSSEQTVNVLAQILKRLNPERK
MINDKMHFSLKE (SEQ ID NO: 298)
- 10 2KDP:A histone deacetylase complex subunit SAP30
SNAGQLCCLREDGERCGRAAGNASFSKRIQKSISQKKVKIELDKSARHLYICDYHKNLIQ
SVRNRKRKGS (SEQ ID NO: 299)
- 15 2RQP:A heterochromatin protein 1-binding protein 3
GPGMASSPRPKMDAILTEAIKACFQKSGASVVAIRKYIIHKYPSLELERRGYLLKQALKR
ELNRGVIKQVKKGASGSFVVVQKSRKT (SEQ ID NO: 300)
- 20 1EOT:A eotaxin precursor
GPASVPTTCCFNLANRRIPLQRLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQD
SMKYLDQKSPTPKP (SEQ ID NO: 301)
- 2L1Q:A liver-expressed antimicrobial peptide 2 precursor
MTPFWRGVSLRPIGASCRDDSECITRLCRKRRCSLSVAQE (SEQ ID NO: 302)
- 25 2W0T:A lethal(3)malignant brain tumor-like protein 2
GSGSEPAVCEMCGIVGTREAFFSKTKRFCSVSCSRSYSSNSKK (SEQ ID NO: 303)
- 30 1J8I:A lymphotactin precursor
XGSEVSDKRTCVSLLTQRLPVSRIKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVV
RSMDRKSNTNRNMIQTKPTGTQQSTNTAVTLTG (SEQ ID NO: 304)
- 35 1H89:A CCAAT/enhancer-binding protein beta
EYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLFKQ
LPE (SEQ ID NO: 305)
- 1J1D:B troponin T, cardiac muscle isoform 2
HFGGYIQKQAQTERKSGKRQTEREKKKKILAERRKVLAIHDLNEDQLREKAKELWQTIYNL
EAEKFDLQEKFKQKYEINVLNRINDNQKVSKTRGKAKVTGRWK (SEQ ID NO: 306)
- 40 1KBH:B CREB-binding protein isoform b
XNRSISPSALQDLLRTLKSPSSPQQQQQVLNILKSNPQLMAAFIKQRTAKYVANQPQGMQ
(SEQ ID NO: 307)
- 45 1T2K:D cyclic AMP-dependent transcription factor ATF-2
KRRKFLERNRAAASRSRQKRKVWVQSLEKKAEDLSSLNGQLQSEVTLLRNEVAQLKQLLL
A (SEQ ID NO: 308)
- 50 1TZS:P cathepsin E isoform a preproprotein
GSLHRVPLRRHPSLKKKLRARSQLEFWKSHNLDM (SEQ ID NO: 309)
- 1VRY:A glycine receptor subunit alpha-1 isoform 1 precursor
LPARVGLGITTTLTTQSSGSRASLPKVSYSYVKAIDIWLAVCLLFVFSALLEYAAVNFVS
RKKKKHRLLEHHHHHHH (SEQ ID NO: 310)
- 55 1ZOQ:C CREB-binding protein isoform b
SALQDLLRTLKSPSSPQQQQQVLNILKSNPQLMAAFIKQRTAKYVAN (SEQ ID NO: 310)

- 5 2D2P:A pituitary adenylate cyclase-activating polypeptide precursor
HSDGIFTDSYSRYRKQMAVKKYLA AVL GKRYKQRVKNKX (SEQ ID NO: 311)
- 10 2F8X:M mastermind-like protein 1
GLPRHSAVMERLRRRIELCRRHHSTCEARYEAVSPERLELERQHTFALHQRCIQAKAKRA
GKH (SEQ ID NO: 312)
- 15 2J5D:A BCL2/adenovirus E1B 19 kDa protein-interacting protein 3
RNTSVMKKGGIFSAEFLKVFLPSLLLSHLLAIGLGIYIGRRLTTS (SEQ ID NO: 313)
- 2K6O:A cathelicidin antimicrobial peptide
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO: 314)
- 20 2KLU:A T-cell surface glycoprotein CD4 isoform 3
GPLVPRGSMALIVLGGVAGLLLFIGLGIFFSVRSRHRRRQAERMSQIKRLLSEKKTSQSP
HRFQKTHSPI (SEQ ID NO: 315)
- 25 2KS1:B epidermal growth factor receptor isoform a precursor
EGCPTNGPKIPSIATGMVGALLLLL VVALGIGL FMRRRHIVRKR (SEQ ID NO: 316)
- 2KZ5:A transcription factor NF-E2 45 kDa subunit isoform 2
MGHHHHHHSHMAKPTARGEAGSRDERRALAMKIPFPTDKIVNLPVDDFNELLARYPLTES
QLALVRDIRRRGKNKVAAQNYRKRKLETIVQ (SEQ ID NO: 317)
- 30 3BEG:B serine/arginine-rich splicing factor 1 isoform 1
GGAPRGRYGPPSRSEN RVVVSGLPPSGSWQDLKDHMREAGDVCYADVYRDGTGVVEFV
RKEDMTYAVRKLDNTKFRSHEGETAYIRVKVDGPRSPSYGRSRSRSRSRSRSRSRS (SEQ ID
NO: 318)
- 35 3FFD:P parathyroid hormone-related protein isoform 2 preproprotein
AVSEHQLLDKGKSIQDLRRRFFLHHLIAEIHTAEIRATSEVSPNSKPSNTKNHPVRFG
SDDEGRYLTQETNKVETYKEQPLKTPGKKKKKGKPGKRKEQEKKKRRTR (SEQ ID NO: 319)
- 40 3G9W:C integrin beta-1 isoform 1D precursor
GPKLLMIHDRREFAKFEKEKMNAKWD TQENPIYKSPINNFKNPNYGRKAGL (SEQ ID NO:
320)
- 45 2PA2:A 60S ribosomal protein L10
GSFDLGRKKAKVDEFPLCGHMVSDEYEQLSSEALEAARICANKYMKVSCGKDGFHIRVRL
HPFHVIRINKMLSCAGADRLQTGMRGAFGKPPQGTVARVHIGQVIMSIRTKLQNKHEHVIEAL
RRAKFKFPGRQKIHISKKWGFTKFNADEFE (SEQ ID NO: 321)
- 50 2L7U:A advanced glycosylation end product-specific receptor isoform 2 precursor
GSAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLP
NGSLFLPAVGIIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPE (SEQ ID NO: 322)
- 55 2RA4:A C-C motif chemokine 13 precursor
MQPDALNVPSTCCFTFSSKKISLQRLKSYVITT SRC PQKAVIFRTKLGKEICADPKEKWV
QNYMKHLGRKAHTLKT (SEQ ID NO: 323)
- 2VXW:A C-C motif chemokine 5 precursor
FSPLSSQSSACCFAYIARPLPRAHIKEYFYTSGKCSNPAVVVFVTRKNRQVCANPEKKWVR

- 5 EYINSLEMS (SEQ ID NO: 324)
- 1BO0:A C-C motif chemokine 7 precursor
XPVGINTSTTCCYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWV
QDFMKHLDKKTQTPKL (SEQ ID NO: 325)
- 10 1QNK:A C-X-C motif chemokine 2
XELRCQCLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNGQKACLNPA SP MVKKIIE
KMLKNGKSN (SEQ ID NO: 326)
- 15 3CO7:C forkhead box protein O1
SKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQIYEW MVKSVPYFKDKGDSNSSAGWK
NSIRHNLSLH SKFIRVQNEGTGKSSWWMLNPEGGKSGKSPRRRAASMDNNSKFAKS (SEQ
ID NO: 327)
- 20 2K86:A forkhead box protein O3
GSSSR RNAWGNLSYADLITRAIESSPDKRLTLSQIYEW MVRCVPYFKDKGDSNSSAGWKNS
IRHNLSLHSR FM RVQNEGTGKSSWWIINPDGGKSGKAPRRRA (SEQ ID NO: 328)
- 25 1E17:A forkhead box protein O4 isoform 1
GSSHHHHHHSSGLVPRGSHMLEDPGAVTGPRKGGSR RNAWGNQSYAELISQAIESAPEKRL
TLAQIYEW MVRTVPYFKDKGDSNSSAGWKNSIRHNLSLH SKFIKVHNEATGKSSWWMLNP
EGGKSGKAPRRRAASMDSSSKLLRGRSKA (SEQ ID NO: 329)
- 30 1NHA:A general transcription factor IIF subunit 1
STPQPPSGKTTPNSGDVQVTEDAVRRYLTRKPMTTKDLLKKFQTKKTGLSSEQTVNVLAQI
LKRLNPERKMINDKMHFSLKE (SEQ ID NO: 330)
- 35 2K7L:A general transcription factor IIF subunit 1
DVQVTEDAVRRYLTRKPMTTKDLLKKFQTKKTGLSSEQTVNVLAQILKRLNPERKMINDK
MHFSLKE (SEQ ID NO: 331)
- 40 1BFF:A heparin-binding growth factor 2
KDPKRLYCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEERG VVSIKGV CANRYLAMKE
DGRLLASKCVTDECFFFERLESNNYNTYRSRKYTSWYVALKRTGQYKLGSKTGPGQKAILF
LPMSAKS (SEQ ID NO: 332)
- 45 1CVS:A heparin-binding growth factor 2
GHFKDPKRLYCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEERG VVSIKGV SANRYLA
MKEDGRLLASKSVTDECFFFERLESNNYNTYRSRKYTSWYVALKRTGQYKLGSKTGPGQK
AILFLPMSAKS (SEQ ID NO: 333)
- 50 3HMS:A hepatocyte growth factor isoform 1 preproprotein
GSYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTR NKGLPFTCK
AFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIR (SEQ ID NO: 334)
- 55 1M36:A histone acetyltransferase MYST3
GSRLPKLYLCEFCLKYMKSR TILQQHMKKCGWF (SEQ ID NO: 335)
- 3R45:A histone H3-like centromeric protein A isoform a
MGSSHHHHHSQDPNSMGPRRRSRKPEAPRRRSPSPTPTPGPSRRGPSLGASSHQHSRRR

- 5 QGWLKEIRKLQKSTHLLIRKL PFSRLAREICVKFTRGVDFNWQAQALLALQEAAEAFLVHLF
EDAYLLTLHAGRVTLFPKDVQLARRIRGLEEGLG (SEQ ID NO: 336)
- 3AN2:A histone H3-like centromeric protein A isoform a
GSHMGPRRRSRKPEAPRRRSPSPTPTPGPSRRGPSLGASSHQHSRRRQGWLKEIRKLQKS
10 THLLIRKL PFSRLAREICVKFTRGVDFNWQAQALLALQEAAEAFLVHLFEDAYLLTLHAG
RVTLFPKDVQLARRIRGLEEGLG (SEQ ID NO: 337)
- 3NQU:A histone H3-like centromeric protein A isoform a
MGPRRRSRKPEAPRRRSPSPTPTPGPSRRGPSLGASSHQHSRRRQGWLKEIRKLQKSTHL
15 LIRKL PFSRLAREICVKFTRGVDFNWQAQALLALQEAAEAFLVHLFEDAYLLTLHAGRVTLF
PKDVQLARRIRGLEEGLG (SEQ ID NO: 338)
- 1B72:A homeobox protein Hox-B1
MEPNTPTARTFDWMKVKNRNPPTAKVSEPGLGSPSGLRNTFTTRQLTELEKEFHFNKYLSR
20 ARRVEIAATLELNETQVKIWFQNRRMKQKKREREGG (SEQ ID NO: 339)
- 2KT0:A homeobox protein NANOG
SKQPTSAENSVAKKEDKVPVKKQKTRTVFSSTQLCVLNDRFQRQKYLSQLQMQELSNILNL
25 SYKQVKTWTFQNQRMKSKRWQKNN (SEQ ID NO: 340)
- 1HLV:A major centromere autoantigen B
MGPKRRQLTFREKSRIIQEVEENPDLRKGEIARRFNIPPSTLSTILKNKRAILASERKYG
VASTCRKTNKLSPYDKLEGLLIAWFQQIRAAGLPVKGIILKEKALRIAEELGMDDFTASN
30 GWLDRFRRRRS (SEQ ID NO: 341)
- 1BW6:A major centromere autoantigen B
MGPKRRQLTFREKSRIIQEVEENPDLRKGEIARRFNIPPSTLSTILKNKRAILASE (SEQ ID
NO: 342)
- 35 3OA6:A male-specific lethal 3 homolog isoform a
MKKHHHHHHMSASEGMKFKFHSGEKVLCPFDPPTKARVLYDAKIVDVIVGKDEKGRKIPE
YLIHFNGWNRSWDRWAAEDHVLRTDENRRLQRKLARKAVARLRSTGRKK (SEQ ID NO:
343)
- 40 1NLW:A max dimerization protein 1 isoform 2
SRSTHNEMEKNRRRAHLRLSLEKLKGLVPLGPDSSRHTTSLSTLTKAKLHIKKLESDRKAV
HQIDQLQREQRHLKRQLEKL (SEQ ID NO: 344)
- 1K99:A nucleolar transcription factor 1 isoform a
45 MKKLKKHPDFPKKPLTPYFRFFMEKRAKYAKLHPEMSNDLTKILSKKYKELPEKKKMKYI
QDFQREKQEFERNLARFREDHPDLIQNAKKLEHHHHHH (SEQ ID NO: 345)
- 2LB3:A peptidyl-prolyl cis-trans isomerase NIMA-interacting 1
KLPPGWEKRMSRSSGRVYYFNHITNASQWERPSGNS (SEQ ID NO: 346)
50
- 2KCF:A peptidyl-prolyl cis-trans isomerase NIMA-interacting 1
GSKLPPGWEKRMSRSSGRVYYFNHITNASQWERPSG (SEQ ID NO: 347)
- 2JOD:B pituitary adenylate cyclase-activating polypeptide precursor
55 FTDSYSRYRKQMAVKKYLA AVLKGKRYKQRVKNK (SEQ ID NO: 348)

- 5 1CQT:I POU domain class 2-associating factor 1
MLWQKPTAPEQAPAPARPYQGVRVKEPVKELLRRKRGHASSGAA (SEQ ID NO: 349)
- 1POG:A POU domain, class 2, transcription factor 1 isoform 3
10 RGSHMRRRKRTSIETNIRVALEKSFLENQKPTSEEITMIADQLNMEKEVIRVWFCNRRQ
KEKRIDI (SEQ ID NO: 350)
- 1B72:B pre-B-cell leukemia transcription factor 1 isoform 2
ARRKRRNFNKQATEILNEYFYSHLSNPYPSEEAKEELAKKCGITVSQVSNWFGNKRIRYK
15 KNIGKFQEEANIYAAKTAVTATNVSAH (SEQ ID NO: 351)
- 3KUC:B RAF proto-oncogene serine/threonine-protein kinase
PSKTSNTIRVFLPNKQRTVVRVRNGMSLHDCLMKKLKVRGLQPECCAVFRLLEHKGKKA
RLDWNTDAASLIGEELQVDFL (SEQ ID NO: 352)
- 20 2JWA:A receptor tyrosine-protein kinase erbB-2 isoform b
GCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRK (SEQ ID NO: 353)
- 2L2T:A receptor tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor
25 STLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRA (SEQ ID NO: 354)
- 2AZE:C retinoblastoma-associated protein
SRILVSI GESFSGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKK (SEQ ID NO: 355)
- 3BSU:A ribonuclease H1
30 GSHMFYAVRRGRKTGVFLTWNECRAQVDRFPAARFKKFATEDEAWAFVRKSAS (SEQ ID
NO: 356)
- 3IXS:B RING1 and YY1-binding protein
GTRPRLKNVDRSTAQQLAVTVGNVTVIITDFKEKTRS (SEQ ID NO: 357)
- 35 2FY1:A RNA-binding motif protein, Y chromosome, family 1 member B
MVEADHPGKLFIGGLNRETNEKMLKAVFGKHGPISEVLLIKDRTSKSRGFAFITFENPAD
AKNAAKDMNGKSLHGKAIKVEQAKKPSFQSGGRRRPPASSRNRSPSGSLEHHHHHHH (SEQ
ID NO: 358)
- 40 1YO5:C SAM pointed domain-containing Ets transcription factor
GSLDALGSQPIHLWQFLKELLLKPHSYGRFIRWLNKEKGIFKIEDSAQVARLWGIRKNRP
AMNYDKLSRSIRQYYKKGIIRKPDISQRLVYQFVHPI (SEQ ID NO: 359)
- 45 1K6O:B serum response factor
GAKPGKKTRGRVKIKMEFIDNKLRRYTTFSKRKTGIMKKAYELSTLTGTQVLLLVASETGH
VYTFATRKLQPMITSETGKALIQTCNLSPDSPRSDPTTDQR (SEQ ID NO: 360)
- 1HBX:A serum response factor
50 SGAKPGKKTRGRVKIKMEFIDNKLRRYTTFSKRKTGIMKKAYELSTLTGTQVLLLVASET
GHVYTFATRKLQPMITSETGKALIQTCNLSPD (SEQ ID NO: 361)
- 1J46:A sex-determining region Y protein
MQDRVKRPMNAFIVWSRDQRRKMALENPRMRNSEISKQLGYQWKMLTEAEKWPFQEAQ
55 KLQAMHREKYYPNYKYRPRRKAKMLPK (SEQ ID NO: 362)

- 5 1J47:A sex-determining region Y protein
MQDRVKRPINAFIVWSRDQRRKMALENPRMRNSEISKQLGYQWKMLTEAEKWPFFQEAQ
KLQAMHREKYPPNYKYRPRRKAKMLPK (SEQ ID NO: 363)
- 10 1B34:B small nuclear ribonucleoprotein Sm D2 isoform 1
MSLLNKPKESEMTPPEELQKREEEEFNTGPLSVLTQSVKNNTQVLINCRNNKKLLGRVKAHDR
HCNMVLENVKEMWTEVPSGKGKKKSKPVNKDRYISKMFLRGDSVIVVLRNPLIAGK
(SEQ ID NO: 364)
- 15 1AM9:A sterol regulatory element-binding protein 1 isoform a
QSRGEKRTAHNAIEKRYRSSINDKIIELKDLVVGTEAKLNKSAVLRKAIDYIRFLQHSNQ
KLKQENLSLRTAVHKSLSLKD (SEQ ID NO: 365)
- 20 3S90:C talin-1
GPLGSASARTANPTAKRQFVQSAKEVANSTANLVKTIKAL (SEQ ID NO: 366)
- 25 1NVP:A TATA-box-binding protein isoform 1
SGIVPQLQNIVSTVNLGCKLDLKTIALRARNAEYNPKRFAAVIMRIREPRTTALIFSSGK
MVCTGAKSEEQSRLAARKYARVVQKLGFPKFLDFKIQNMVGSCDVKFPIRLEGLVLTHQ
QFSSYEPELFPGLIYRMIKPRIVLLIFVSGKVVLTGAKVRAEIYEAFENIYPILKGFRKT
T (SEQ ID NO: 367)
- 30 1CDW:A TATA-box-binding protein isoform 1
SGIVPQLQNIVSTVNLGCKLDLKTIALRARNAEYNPKRFAAVIMRIREPRTTALIFSSGK
MVCTGAKSEENSRLAARKYARVVQKLGFPKFLDFKIQNMVGSCDVKFPIRLEGLVLTHQ
QFSSYEPELFPGLIYRMIKPRIVLLIFVSGKVVLTGAKVRAEIYEAFENIYPILKGFRK (SEQ
ID NO: 368)
- 35 1TGH:A TATA-box-binding protein isoform 1
GSRGSGIVPQLQNIVSTVNLGCKLDLKTIALRARNAEYNPKRFAAVIMRIREPRTTALIF
SSGKMVCTGAKSEEQSRLAARKYARVVQKLGFPKFLDFKIQNMVGSCDVKFPIRLEGLVL
THQQFSSYEPELFPGLIYRMIKPRIVLLIFVSGKVVLTGAKVRAEIYEAFENIYPILKG
FRKTT (SEQ ID NO: 369)
- 40 1JFI:C TATA-box-binding protein isoform 2
GSHMSGIVPQLQNIVSTVNLGCKLDLKTIALRARNAEYNPKRFAAVIMRIREPRTTALIF
SSGKMVCTGAKSEEQSRLAARKYARVVQKLGFPKFLDFKIQNMVGSCDVKFPIRLEGLVL
THQQFSSYEPELFPGLIYRMIKPRIVLLIFVSGKVVLTGAKVRAEIYEAFENIYPILKG
FRKTT (SEQ ID NO: 370)
- 45 1C9B:B TATA-box-binding protein isoform 2
GSGIVPQLQNIVSTVNLGCKLDLKTIALRARNAEYNPKRFAAVIMRIREPRTTALIFSSG
KMVCTGAKSEEQSRLAARKYARVVQKLGFPKFLDFKIQNMVGSCDVKFPIRLEGLVLTH
QQFSSYEPELFPGLIYRMIKPRIVLLIFVSGKVVLTGAKVRAEIYEAFENIYPILKGFRK (SEQ
ID NO: 371)
- 50 3A03:A T-cell leukemia homeobox protein 2
MTSFSRSQVLELERRFLRQKYLASAERAALAKALRMTDAQVKTWFQNRRTKWRRQT
(SEQ ID NO: 372)
- 55 1Q68:A T-cell surface glycoprotein CD4 isoform 1 precursor
RCRHRRRQAERLSQIKRLLSEKKTCQCPHRFQKTCSPI (SEQ ID NO: 373)

- 5 1IV6:A telomeric repeat-binding factor 1 isoform 1
MTPEKHRARKRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSVMLKDRWRTM
KKLKLISDSED (SEQ ID NO: 374)
- 10 1ITY:A telomeric repeat-binding factor 1 isoform 1
TPEKHRARKRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSVMLKDRWRTMK
KKLKLISDSED (SEQ ID NO: 375)
- 15 1W0T:A telomeric repeat-binding factor 1 isoform 1
KRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSVMLKDRWRTMKKLK (SEQ
ID NO: 376)
- 20 1W0U:A telomeric repeat-binding factor 2
KKQKWTVEESEWVKAGVQKYGEGNWAAISKNYPFVNRTAVMIKDRWRTMKRLGMN
(SEQ ID NO: 377)
- 25 2K00:A THAP domain-containing protein 1 isoform 1
MVQSCSAYGCKNRYDKDKPVSFHKFPLTRPSLCKEWEAAVRRKNFKPTKYSSICSEHFTPD
SFKRESNNKLLKENAVPTIFLELVPR (SEQ ID NO: 378)
- 30 1S9K:E transcription factor AP-1
RKRMRNRRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQL (SEQ ID
NO: 379)
- 35 1A02:J transcription factor AP-1
MKAERKMRNRRIAASKSRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQL (SEQ
ID NO: 380)
- 1T2K:C transcription factor AP-1
MKAERKMRNRRIAASKSRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKV
MN (SEQ ID NO: 381)
- 40 1O4X:B transcription factor SOX-2
GSHMPDRVKRPMNAFMVWSRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFID
EAKRLRALHMKEHPDYKYRPRRKTCTLMK (SEQ ID NO: 382)
- 45 2LE4:A transcription factor SOX-2
SDRVKRPMNAFMVWSRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRL
RALHMKEHPDYKYRPRRKTCT (SEQ ID NO: 383)
- 1GT0:D transcription factor SOX-2
DRVKRPMNAFMVWSRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRLR
ALHMKEHPDYKYRPRRKTCT (SEQ ID NO: 384)
- 50 1VA1:A transcription factor Sp1 isoform b
MDPGKKKQHICHIQGCGKVYGKTSHLRAHLRWHTGEX (SEQ ID NO: 385)
- 55 1H88:C transcriptional activator Myb isoform 1
MGHLGKTRWTREDEKLKKLVEQNGTDDWKVIANYPNRTDVQCQHRWQKVLNPELIKG
PWTKEEDQRVIKLVQKYGPKRWSVIAKHLKGRIGKQCRERWHNHLNPEVKKTSWTEEDR
IIYQAHKRLGNRWAEIAKLLPGRTDNAIKNHWNSTMRKV (SEQ ID NO: 386)

- 5 1H8A:C transcriptional activator Myb isoform 4
MEAVIKNRTDVQCQHRWQKVLNPELNKGPWTKEEDQRVIEHVQKYGPKRWSDIAKHLKG
RIGKQCRERWHNHLNPEVKKTSWTEEDRIIYQAHKRLGNRWAEIAKLLPGRTDNAVKNH
WNSTMRRKV (SEQ ID NO: 387)
- 10 2HFG:R tumor necrosis factor receptor superfamily member 13C
GSYSLRGRDAPAPTPCNPAECFDPLVRHCVACGLLRTPRPKPAGASSPAPR (SEQ ID NO:
388)
- 15 1OSX:A tumor necrosis factor receptor superfamily member 13C
MRRGPRSLRGRDAPAPTPCVPAECFDLLVRHCVACGLLRTPRPKPAGASSPAPRTALQPQ
E (SEQ ID NO: 389)
- 20 3L3C:A U1 small nuclear ribonucleoprotein A
RPNHTIYINNLNEKIKKDELKKSLHAIFSRFGQILDILVSRSLKMRGQAFVIFKEVSSAT
NALRSMQGFPPFYDKPMRIQYAKTDSIIAK (SEQ ID NO: 390)
- 25 1FHT:A U1 small nuclear ribonucleoprotein A
AVPETRPNHTIYINNLNEKIKKDELKKSLYAIFSQFGQILDILVSRSLKMRGQAFVIFKE
VSSATNALRSMQGFPPFYDKPMRIQYAKTDSIIAKMKGTFVERDRKREKRKPKSQE (SEQ
ID NO: 391)
- 30 2BE6:D voltage-dependent L-type calcium channel subunit alpha-1C isoform 23
GHMDEVTVGKFYATFLIQEYFRKFKKRKEQGLVGKPS (SEQ ID NO: 392)
- 1N0Z:A zinc finger Ran-binding domain-containing protein 2 isoform 2
GSMSTKNFRVSDGDWICPDKKCGNVNFARRTSCDRCGREKTTGPI (SEQ ID NO: 393)
- 35 1HJB:A CCAAT/enhancer-binding protein beta
VKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVE
QLSRELSTLRNLFKQLPEPLASSGHC (SEQ ID NO: 394)
- 40 2E43:A CCAAT/enhancer-binding protein beta
VKSKAKKTVDAHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVE
QLSRELSTLRNLFKQLPE (SEQ ID NO: 395)
- 45 1CI6:B CCAAT/enhancer-binding protein beta
MEYKMRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLF
KQL (SEQ ID NO: 396)
- 1GTW:A CCAAT/enhancer-binding protein beta
VKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVE
QLSRELSTLRNLFKQLPE (SEQ ID NO: 397)
- 50 2E42:A CCAAT/enhancer-binding protein beta
VKSKAKKTVDKHSDEYKIRRERNNIAARKSRDKAKMRNLETQHKVLELTAENERLQKKVE
QLSRELSTLRNLFKQLPE (SEQ ID NO: 398)
- 55 3NWV:A cytochrome c
GDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKTSQAPGYSYTAANKNKGIIWG
EDTLMEYLENPKKYIPGTMIFVGIIKKKEERADLIAYLKKATNE (SEQ ID NO: 399)

- 5 2C6Y:A forkhead box protein K2
ASMTGGGQQMGRGSDSKPPYSYAQLIVQAITMAPDKQLTLNGIYTHITKNYPYYRTADKGW
QNSIRHNLSLNRYFIKVPRSQEEPGKGSFWRIDPASESKLIEQA FRKRRPR (SEQ ID NO: 400)
- 10 2HDM:A lymphotactin precursor
GSEVSDKRTC VSLTTQRLPCSRIKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDCVR
SMDRKS NTRNNMIQTKPTGTQQSTNTAVTLTG (SEQ ID NO: 401)
- 15 3CW1:D small nuclear ribonucleoprotein Sm D3
MSIGVPIKVLHEAEGHIVTCETNTGEVYRGK LIEAEDNMNCQMSNITVTYRDGRVAQLEQV
YIRGCKIRFLILPDMLKNAPMLKSMKNKNQGS GAGRGKAAILKAQVAARGRGRGMGRGNI
FQKRR (SEQ ID NO: 402)
- 20 2J7Z:A stromal cell-derived factor 1 isoform gamma
KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKW IQE
YLEKALNK (SEQ ID NO: 403)
- 25 2KEE:A stromal cell-derived factor 1 isoform gamma
GSKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWI
QEYLEKALNK (SEQ ID NO: 404)
- 30 2KEC:A stromal cell-derived factor 1 isoform gamma
GMKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKW IQ
EYLEKALNK (SEQ ID NO: 405)
- 1QG7:A stromal cell-derived factor 1 isoform gamma
KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKW IQE
YLEKALN (SEQ ID NO: 406)
- 35 2NWG:A stromal cell-derived factor 1 isoform gamma
MKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKW IQ
EYLEKALN (SEQ ID NO: 407)
- 40 3HP3:A stromal cell-derived factor 1 isoform gamma
MKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKW IQE
YLEKALN (SEQ ID NO: 408)
- 45 1VMC:A stromal cell-derived factor 1 isoform gamma
SDYKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKW IQ
EYLEKALNK (SEQ ID NO: 409)
- 3GV3:A stromal cell-derived factor 1 isoform gamma
LSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKW IQEYLEK
ALN (SEQ ID NO: 410)
- 50 1UN5:A angiogenin precursor
MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSDRCKPINTFIHG NKRSIKAICE
NKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSI
FRRP (SEQ ID NO: 411)
- 55 2PLZ:A beta-defensin 1 preproprotein

- 5 DHYNCVSSGGQCLYSACPIFTRIQTGTCYRGRARCCR (SEQ ID NO: 412)
- 1BND:A brain-derived neurotrophic factor isoform a preproprotein
HSDPARRGQLSVCDSEWVTAADKKTAVDMSGGTVTVLEKVPVSKGQLKQYFYETKCNP
MGYTKEGCRGIDKRHWNSQCRTTQSYVRALTMDSKKRIGWRFIRIDTSCVCTLTIKRGR
10 (SEQ ID NO: 413)
- 1G91:A C-C motif chemokine 23 isoform CKbeta8 precursor
MDRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQVQ
VCMRMLKLDTRIKTRKN (SEQ ID NO: 414)
- 15 1IOX:A probetacellulin precursor
RKGHFSRCPKQYKHYCIKGRCRFVVAEQTPSCVCDEGYIGARCERVDLFX (SEQ ID NO: 415)
- 20 2K01:A stromal cell-derived factor 1 isoform gamma
GMKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCACQIVARLKNNNRQVCIDPKLKWIQ
EYLEKCLNK (SEQ ID NO: 416)
- 25 2JTG:A THAP domain-containing protein 1 isoform 1
MVQSCSAYGCKNRYDKDKPVSFHKFPLTRPSLCKEWEAAVRRKNFKPTKYSSICSEHFTPD
CFKRECNNKLLKENAVPTIFLELVPR (SEQ ID NO: 417)
- 30 2ASK:A artemin isoform 3 precursor
AGGPGSRARAAGARGCRLRSQVLPVRALGLGHRSEDLVRFRCGSCRRARSPHDLSLASL
LGAGALRPPPGSRPVSQPCCRPTRYEAVSFMDVNSTWRTVDRLSATACGLG (SEQ ID NO: 418)
- 35 2O13:A cysteine and glycine-rich protein 3
KCPRCGKSVYAAEKVMGGGKPWHKTCFRCAICGKSLESTNVTDKDGELYCKVCYAKNF
(SEQ ID NO: 419)
- 40 2VJE:A E3 ubiquitin-protein ligase Mdm2 isoform MDM2
SSLPLNAIEPCVICQGRPKNCGIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVL
TYFP (SEQ ID NO: 420)
- 2HDP:A E3 ubiquitin-protein ligase Mdm2 isoform MDM2
SLPLNAIEPCVICQGRPKNCGIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLT
YFP (SEQ ID NO: 421)
- 45 2VJE:B protein Mdm4 isoform 1
EDCQNLLKPCSLCEKRPRDGNIIHGRTGHLVTCFHCARRLKKAGASCPICKKEIQLVIKV
FIA (SEQ ID NO: 422)
- 50 2Z7F:I antileukoproteinase precursor
RRKPGKCPVTYQGCLMLNPPNFCMDGQCKRDLKCCMGMCGKSCVSPVKA (SEQ ID NO: 423)
- 55 3QMB:A cpG-binding protein isoform 2
MHSHHHHSSRENLYFQGQIKRSARMCGECEACRRTEDCGHCDFCRDMKKFGGPNKIRQKC
RLRQCQLRARESYKYFPSS (SEQ ID NO: 424)

- 5 1H1H:A eosinophil cationic protein precursor
MRPPQFTRAQWFAIQHISLNPPRCTIAMRAINNYRWRCKNQNTFLRTTFANVVNVCGNQSI
RCPHNRTLNNCHRSRFRVPLLHCDLINPGAQNISNCRYADRPGRRFYVVACDNRDPRDSPR
YPVVPVHLDTTI (SEQ ID NO: 425)
- 10 1DYT:A eosinophil cationic protein precursor
RPPQFTRAQWFAIQHISLNPPRCTIAMRAINNYRWRCKNQNTFLRTTFANVVNVCGNQSI
RCPHNRTLNNCHRSRFRVPLLHCDLINPGAQNISNCRYADRPGRRFYVVACDNRDPRDSPR
YPVVPVHLDTTI (SEQ ID NO: 426)
- 15 1LO1:A estrogen-related receptor gamma isoform 2
XIPKRLCLVCGDIASGYHYGVASCEACKAFFKRTIQGNIEYSCPATNECEITKRRRKSCQ
ACRFMKALKVGMLKEGVRLDRVRGGRQKYKRRLDSENS (SEQ ID NO: 427)
- 20 1RXR:A retinoic acid receptor RXR-alpha
XTKHICAICGDRSSGKHYGVSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQYC
RYQKALAMGMKREAVQEERQRG (SEQ ID NO: 428)
- 25 2HKY:A ribonuclease 7 precursor
MKPKGMTSSQWFKIQHMQPSPQACNSAMKNINKHTKRCKDLNTFLHEPFSSVAATCQTPKI
ACKNGDKNCHQSHGPVSLTMCKLTSGKYPNCRYKEKRQNKSYVVACKPPQKKDSQQFHL
VPVHLDRLV (SEQ ID NO: 429)
- 30 1UBD:C transcriptional repressor protein YY1
MEPRTIACPHKGCTKMFRDNSAMRKHLHTHGPRVHVCAECGKAFVESSKLKRHQLVHTGE
KPFQCTFEGCGKRFSLDLNLRTHTVRIHTGDRPYVCPFDGCNKKFAQSTNLKSHILTHAKAKN
NQ (SEQ ID NO: 430)
- 35 1KMX:A vascular endothelial growth factor A isoform d
ARQENPCGPCSERRKHLFVQDPQTCKCCKNTDSRCKARQLELNERTCRCDKPRR (SEQ ID
NO: 431)
- 40 2JP9:A Wilms tumor protein isoform B
ASEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRR
HTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGEKPFSCRWPSCQKKFARSDELVRHHNMH
(SEQ ID NO: 432)
- 45 1R8U:B CREB-binding protein isoform a
ATGPTADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRACSLPHCRTMKNVLNHMTHCQ
AGKACQVAHCASSRQIISHWKNCTRHDPCVCLPLKNASDKX (SEQ ID NO: 433)
- 50 1L8C:A CREB-binding protein isoform a
ADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRACSLPHCRTMKNVLNHMTHCQAGKAC
QVAHCASSRQIISHWKNCTRHDPCVCLPLKNASDKX (SEQ ID NO: 434)
- 50 1HCQ:A estrogen receptor isoform 4
MKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSC
QACRLRKCYEVGMMKGGIRKDRRG (SEQ ID NO: 435)
- 55 1HCP:A estrogen receptor isoform 4
MKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSC
QACRLRKCYEVGMMKGG (SEQ ID NO: 436)

- 5 3CBB:A hepatocyte nuclear factor 4-alpha isoform a
ALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCR
LKKCFRAGMKKEAVQNERD (SEQ ID NO: 437)
- 10 3IO2:A histone acetyltransferase p300
ATQSPGDSRRLSIQRAIQSLVHAAQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICK
QLIALAAYHAKHCQENKCPVPFCLNIKQKLRQQQLQHRLQQAQMLRRRMASMQ (SEQ ID
NO: 438)
- 15 1L3E:B histone acetyltransferase p300
MGSGAHTADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRQCNLPHCRTMKNVLNHMTH
CQSGKSCQVAHCASSRQIISHWKNCTRHDPCVCLPLKNAGDK (SEQ ID NO: 439)
- 20 2KKF:A histone-lysine N-methyltransferase MLL isoform 1 precursor
GSKKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCKMRKCQNLQWMPSK
(SEQ ID NO: 440)
- 25 2JYI:A histone-lysine N-methyltransferase MLL isoform 2 precursor
KKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCKMRKCQNLQWMPSK
(SEQ ID NO: 441)
- 30 1A6Y:A nuclear receptor subfamily 1 group D member 1
TKLNGMVLLCKVCGDVASGFHYGVLACEGCKGFFRRSIQQNIQYKRCLKNENCSIVRINRN
RCQQCRFKKCLSVGMSRDAVRFRIPKREKQRM (SEQ ID NO: 442)
- 35 2A66:A nuclear receptor subfamily 5 group A member 2 isoform 2
GEFGDEDLEELCPVCGDKVSGYHYGLLTCEGCKGFFKRTVQNNKRYTCIENQNCQIDKTQR
KRCPYCRFQKCLSVGMKLEAVRADMRGGRNKFPGMYKRDRALKQQKKALIR (SEQ ID
NO: 443)
- 40 1DSZ:A retinoic acid receptor alpha isoform 1
PRIYKPCFVCQDKSSGYHYGVSAEGCKGFFRRSIQKNMVYTCHRDKNCIINKVTRNRCQY
CRLQKCFEVGMSKESVRNDRNKKKK (SEQ ID NO: 444)
- 45 1DSZ:B retinoic acid receptor RXR-alpha
GSFTKHICAICGDRSSGKHYGVSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQ
YCRYQKCLAMGMKREAVQEERQRG (SEQ ID NO: 445)
- 50 1BY4:A retinoic acid receptor RXR-alpha
GSFTKHICAICGDRSSGKHYGVSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQ
YCRYQKCLAMGMKREAVQEER (SEQ ID NO: 446)
- 55 1R0N:A retinoic acid receptor RXR-alpha
FTKHICAICGDRSSGKHYGVSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQYC
RYQKCLAMGMKREAVQAAAA (SEQ ID NO: 447)
- 2NLL:A retinoic acid receptor RXR-alpha
CAICGDRSSGKHYGVSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQYCRYQK
CLAMGM (SEQ ID NO: 448)
- 1KB2:A vitamin D3 receptor isoform VDRB1

- 5 FDRNVPRICGVCGD RATGFHFNAMTCEGCKGFFRRSMKRKALFTCPFNGDCRITKDNRRHC
QACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEEALKDSL RPKLS (SEQ ID NO: 449)
- 1YNW:A vitamin D3 receptor isoform VDRB1
FDRNVPRICGVCGD RATGFHFNAMTCEGCKGFFRRSMKRKALFTCAANGDCRITKDNRRRA
10 CQACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEEALKDSL RPKLS (SEQ ID NO:
450)
- 2C7A:A progesterone receptor isoform B
PQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHNYLCAGRND C IVDKIRRKNC PACR
15 LRKCCQAGMVLGGRKFK (SEQ ID NO: 451)
- 2KA6:A CREB-binding protein isoform b
SPQESRRLSIQR CIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCKQLI
ALCCYHAKHCQENKCPVPFCLNIKHKL RQQQ (SEQ ID NO: 452)
20
- 3P57:P histone acetyltransferase p300
HMSPGDSRRLSIQR CIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICKQ
LIALCCYHAKHCQENKCPVPFCLNIKQKL RQQQLQHRLQQAQMLRRRMASM (SEQ ID NO:
453)
25
- 1N29:A phospholipase A2, membrane associated precursor
ALVNFHRMIKLTTGKEAALS YGYGCHCGVGGRGSPKDATDRCCVTHDCCYKRLEKRG C
GTKFLSYKFSNSGSRITCAKQDSCRSQ LCECDKAAATCFARNKTTYNKKYQYYSNKHCRGS
TPRC (SEQ ID NO: 454)
30
- 1N28:A phospholipase A2, membrane associated precursor
ALVNFHRMIKLTTGKEAALS YGYGCHCGVGGRGSPKDATDRCCVTQDCCYKRLEKRG C
GTKFLSYKFSNSGSRITCAKQDSCRSQ LCECDKAAATCFARNKTTYNKKYQYYSNKHCRGS
TPRC (SEQ ID NO: 455)
35
- 1U35:C core histone macro-H2A.1 isoform 1
MSSRGGGKKKSTKTSRSAKAGVIFPVGRMLRYIKKGHPKYRIGVGAPVYMAAVLEYLTAEIL
ELAVNAARDNKKGRVTPRHILLAVANDEELNQL LKGVTIASGGVLPNIHPELLAKKRGS
(SEQ ID NO: 456)
40
- 3AFA:A histone cluster 1, H3d
GSHMARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIRRYQK
STELLIRKL PFQRLVREIAQDFKTD LRFQSSAVMALQEACEAYLVGLFEDTNLCAIHAKRVTI
MPKDIQLARRIRGERA (SEQ ID NO: 457)
45
- 1U35:A histone cluster 1, H3d
MARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIRRYQKSTE
LLIRKL PFQRLVREIAQDFKTD LRFQSSAVMALQEACEAYLVGLFEDTNLCAIHAKRVTIMP
KDIQLARRIRGERA (SEQ ID NO: 458)
50
- 2F8N:K histone H2A type 1-B/E
MGSSHHHHHHSSGLVPRGSMGRGKQGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGN Y
SERVGAGAPVYLA AVLEYLTAEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGRVT
IAQGGVLPNIQAVLLPKKTESHHKAKGK (SEQ ID NO: 459)
55
- 3A6N:C histone H2A type 1-B/E

- 5 GSHMSGRGKQGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGNYSERVGAGAPVYLA AVL
EYLTA EILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGRVTIAQGGVLPNIQAVLLPK
KTESHKAKGK (SEQ ID NO: 460)
- 2CV5:C histone H2A type 1-B/E
- 10 MSGRGKQGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGNYSERVGAGAPVYLA AVL EYL
TAEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGRVTIAQGGVLPNIQAVLLPKKTE
SHHKAKGK (SEQ ID NO: 461)
- 1P34:C histone H2A type 1-B/E
- 15 SGRGKQGGKTRAKAKTRSSRAGLQFPVGRVHRLLRKGNYAERVGAGAPVYLA AVL EYL
AEILELAGNAARDNKKTRIIPRHLQLAVRNDEELNKLLGRVTIAQGGVLPNIQSVLLPKKTES
AKSAKSK (SEQ ID NO: 462)
- 1ZLA:C histone H2A.J
- 20 SGRGKQGGKTRAKAKTRSSRAGLQFPVGRVHRLLRKGNYAERVGAGAPVYLA AVL EYL
AEILELAGNWERDNKKTRIIPRHLQLAVRNDEELNKLLGRVTIAQGGVLPNIQSVLLPKKTE
SSKSTKSK (SEQ ID NO: 463)
- 1KX3:C histone H2A.J
- 25 SGRGKQGGKTRAKAKTRSSRAGLQFPVGRVHRLLRKGNYAERVGAGAPVYLA AVL EYL
AEILELAGNAARDNKKTRIIPRHLQLAVRNDEELNKLLGRVTIAQGGVLPNIQSVLLPKKTES
SKSKSK (SEQ ID NO: 464)
- 2NQB:C histone H2A.J
- 30 SGRGKGGKVKGKAKSRSNRAGLQFPVGRIHRLLRKGNYAERVGAGAPVYLA AV MEYLAA
EVLELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLSGVTIAQGGVLPNIQAVLLPKKTEK
KA (SEQ ID NO: 465)
- 2PYO:C histone H2A.J
- 35 SGRGKGGKVKGKAKSRSNRAGLQFPVGRIHRLLRKGNYAERVGAGAPVYLA AV MEYLAA
EVLELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLSGVTIAQGGVLPNIQAVLLPKKTE
(SEQ ID NO: 466)
- 1F66:C histone H2A.Z
- 40 MAGGKAGKDSGKAKTKAVSRSQRAGLQFPVGRIHRHLKSRTTSHGRVGATAAVYSAAILE
YLTA EVLELAGNASKDLKVKRITPRHLQLAIRGDEELDSLKATIAGGGVIPHIHKS LIG
KKGQQKTV (SEQ ID NO: 467)
- 1U35:D histone H2B type 1-B
- 45 MPEPSRSTPAPKKGSKKAITKAQKKDGKKRKRGRKESYSIYVYKVLKQVHPDTGISSKAMG
IMNSFVNDIFERIASEASRLAHYNKRSTITSREVQTAVRLLLPGELAKHAVSEGTKAVTKYTS
SK (SEQ ID NO: 468)
- 3A6N:D histone H2B type 1-J
- 50 GSHMPEPAKSAPAPKKGSKKAVTKAQKKDGKKRKRSRKESYSIYVYKVLKQVHPDTGISS
KAMGIMNSFVNDIFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEGTKAV
TKYTSAK (SEQ ID NO: 469)
- 1F66:D histone H2B type 1-J

- 5 MPEPAKSAPAPKKGSKKAVTKTQKKDGKKRRKTRKESYAIYVYKVLKQVHPDTGISSKAM
SIMNSFVNDVFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEGTKAVTKY
TSAK (SEQ ID NO: 470)
- 1KX3:D histone H2B type 1-J
- 10 PEPAKSAPAPKKGSKKAVTKTQKKDGKKRRKTRKESYAIYVYKVLKQVHPDTGISSKAMSI
MNSFVNDVFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEGTKAVTKYTS
AK (SEQ ID NO: 471)
- 1P34:D histone H2B type 1-J
- 15 PEPAKSAPAPKKGSKKAVTKTQKKDGKKRRKSRKESYAIYVYKVLKQVHPDTGISSKAMSI
MNSFVNDVFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEGTKAVTKYTS
AK (SEQ ID NO: 472)
- 2F8N:H histone H2B type 1-J
- 20 MAKSAAPAPKKGSKKAVTKTQKKDGKKRRKTRKESYAIYVYKVLKQVHPDTGISSKAMSIM
NSFVNDVFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEGTKAVTKYTSA
K (SEQ ID NO: 473)
- 2CV5:D histone H2B type 1-K
- 25 MPEPAKSAPAPKKGSKKAVTKAQQKDGKKRRKSRKESYSVYVYKVLKQVHPDTGISSKA
MGIMNSFVNDIFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEGTKAVTK
YTSK (SEQ ID NO: 474)
- 1ZLA:D histone H2B type 1-O
- 30 PDKSAAPAAKKGSKKAVTKTQKKDGKKRRKSRKESYAIYVYKVLKQVHPDTGISSKAMS
IMNSFVNDVFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEGTKAVTKYT
SAK (SEQ ID NO: 475)
- 3A6N:A histone H3.1t
- 35 GSHMARTKQTARKSTGGKAPRKQLATKVARKSAPATGGVKKPHRYRPGTVALREIRRYQK
STELLIRKLPFQRLMREIAQDFKTDLRQSSAVMALQEACESYLVGLFEDTNLCVIAHAKRVTI
MPKDIQLARRIRGERA (SEQ ID NO: 476)
- 3AV1:A histone H3.2
- 40 GSHMARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIRRYQK
STELLIRKLPFQRLVREIAQDFKTDLRQSSAVMALQEASEAYLVGLFEDTNLCVIAHAKRVTI
MPKDIQLARRIRGERA (SEQ ID NO: 477)
- 1F66:A histone H3.2
- 45 MARTKQTARKSTGGKAPRKQLATKAARKSAPATGEVKKPHRYRPGTVALREIRRYQKSTE
LLIRKLPFQRLVREIAQDFKTDLRQSSAVMALQEASEAYLVGLFEDTNLCVIAHAKRVTIMP
KDIQLARRIRGERA (SEQ ID NO: 478)
- 2F8N:A histone H3.2
- 50 MARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIRRYQKSTE
LLIRKLPFQRLVREIAQDFKTDLRQSSAVMALQEASEAYLVGLFEDTNLCVIAHAKRVTIMP
KDIQLARRIRGERA (SEQ ID NO: 479)
- 1P3L:A histone H3.2

- 5 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGESKKPHRYRPGTVALREIRRYQKSTELL
IRKLFPQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVALFEDTNLCAIHAKRVHIMPKD
IQLARRIRGERA (SEQ ID NO: 480)
- 1P3M:A histone H3.2
- 10 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGESKKPHRYRPGTVALREIRRYQKSTELL
IRKLFPQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVALFEDTNLCAIHAKRVIIM
PKDIQLARRIRGERA (SEQ ID NO: 481)
- 1P3B:A histone H3.2
- 15 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGESKKPHRYRPGTVALREIRRYQKSTELL
IRKLFPQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVALFEDTNLCAIHAKRVTIMPKD
IQLARRIRGERA (SEQ ID NO: 482)
- 1ZLA:A histone H3.2
- 20 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIRRYQKSTEL
LIRKLFPQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVALFEDTNLCAIHAKRVHIMPK
DIQLARRIRGERA (SEQ ID NO: 483)
- 1P3A:A histone H3.2
- 25 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGESKKPHRYRPGTVALREIRRYQKSTELL
IRKLFPQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVALFEDTNLCAIHAKHVTIMPKD
IQLARRIRGERA (SEQ ID NO: 484)
- 1P3K:A histone H3.2
- 30 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGESKKPHRYRPGTVALREIRRYQKSTELL
IRKLFPQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVALFEDTNLCAIHAKRVAIMPKD
IQLARRIRGERA (SEQ ID NO: 485)
- 1KX3:A histone H3.2
- 35 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIRRYQKSTEL
LIRKLFPQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVALFEDTNLCAIHAKRVTIMPK
DIQLARRIRGERA (SEQ ID NO: 486)
- 2IO5:B histone H3.2
- 40 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIRRYQKSTEL
LIRKLFPQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVGLFEDTNLCAIHAKRVTIMPK
DIQLARRIRGERA (SEQ ID NO: 487)
- 1P34:A histone H3.2
- 45 ARTKQTARKSTGGKAPRKQLATKAARKSAPATGESKKPHRYRPGTVALREIRRYQKSTELL
IRKLFPQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVALFEDTNLCAIHAKAVTIMPKD
IQLARRIRGERA (SEQ ID NO: 488)
- 3AV2:A histone H3.3
- 50 GSHMARTKQTARKSTGGKAPRKQLATKAARKSAPSTGGVKKPHRYRPGTVALREIRRYQK
STELLIRKLFPQRLVREIAQDFKTDLRFQSSAIGALQEASEAYLVGLFEDTNLCAIHAKRVTI
MPKDIQLARRIRGERA (SEQ ID NO: 489)
- 1ID3:A histone H3.3
- 55 ARTKQTARKSTGGKAPRKQLASKAARKSAPSTGGVKKPHRYKPGTVALREIRRFQKSTELL
IRKLFPQRLVREIAQDFKTDLRFQSSAIGALQESVEAYLVSLFEDTNLAIAHAKRVTIQ

- 5 KKEIKLARRLRGERS (SEQ ID NO: 490)
- 3A6N:B histone H4
GSHMSGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKRISGLIYEETRGRV
LKVFLENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 491)
- 10 1F66:B histone H4
MSGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKRISGLIYEETRGRVLKV
FLENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 492)
- 15 2NQB:B histone H4
ITGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKRISGLIYEETRGRVLK
VFLENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 493)
- 20 2PYO:B histone H4
TGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKRISGLIYEETRGRVLKVF
LENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 494)
- 25 1P3P:B histone H4
SGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGIKRISGLIYEETRGRVLKV
FLENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 495)
- 30 1KX3:B histone H4
SGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKRISGLIYEETRGRVLKVFL
ENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 496)
- 1ID3:B histone H4
SGRGKGGKGLGKGGAKRHRKILRDNIQGITKPAIRRLARRGGVKRISGLIYEEVRAVLKS
FLESVIRDSVTYTEHAKRKTVTSLDVVYALKRQGRTLYGFGG (SEQ ID NO: 497)
- 35 1P3I:B histone H4
SGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKHISGLIYEETRGRVLKVF
LENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 498)
- 40 1P3O:B histone H4
SGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGAKRISGLIYEETRGRVLKVFL
ENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 499)
- 45 1P3G:B histone H4
SGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKEISGLIYEETRGRVLKVFL
ENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 500)
- 50 1P3F:B histone H4
SGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKCISGLIYEETRGRVLKVFL
ENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 501)
- 1P3B:B histone H4
SGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKAISGLIYEETRGRVLKVF
LENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 502)
- 55 3NQJ:B histone H4
MKVLRDNIQGITKPAIRRLARRGGVKRISGLIYEETRGRVLKVFLENVIRDAVTYTEHAKR

5 KTVTAMDVVYALKRQGRPLYGFGG (SEQ ID NO: 503)

1KYN:A cathepsin G preproprotein

IIGGRESRPHSRPYMAYLQIQSPAGQSRCGGFLVREDFVLTAHHCWGSNINVTLGAHNIQ
RRENTQQHITARRAIRHPQYNQRTIQNDIMLLQLSRRVRRNRNVNPVALPRAQEGLRPGT
10 LCTVAGWGRVSMRRGTDTLREVQLRVQRDRQCLRIFGSYDPRRQICVGDRRERKAAFKGD
SGGPLLCNNVAHGIVSYGKSSGVPPEVFTRVSSFLPWIRTTMRSFKLLDQMETPL (SEQ ID
NO: 504)

1AU8:A cathepsin G preproprotein

15 IIGGRESRPHSRPYMAYLQIQSPAGQSRCGGFLVREDFVLTAHHCWGSNINVTLGAHNIQ
RRENTQQHITARRAIRHPQYNQRTIQNDIMLLQLSRRVRRNRNVNPVALPRAQEGLRPGT
LCTVAGWGRVSMRRGTDTLREVQLRVQRDRQCLRIFGSYDPRRQICVGDRRERKAAFKGD
SGGPLLCNNVAHGIVSYGKSSGVPPEVFTRVSSFLPWIRTTMRS (SEQ ID NO: 505)

20 2YRQ:A high mobility group protein B1

GSSGSSGMGKGDPPKPRGKMSSYAFFVQTCREEHKKKHPDASVNFSEFSKKCSERWKTMS
AKEKGKFEDMAKADKARYEREMKTYIPPKGETKKKFKDPNAPKRPPSAFFLFCSEYRPKIK
GEHPGLSIGDVAKKLGEMWNNTAADDKQPYEKKAACLKEKYEKDIAAYRAKG (SEQ ID
NO: 506)

25

2BFH:A heparin-binding growth factor 2

DPKRLYCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEERGVSISIKGVCANRYLAMKED
GRLLASKCVTDECFFFERLESNNYNTYRSRKYTSWYVALKRTGQYKLGSKTGPGQKAILFL
PMSAKS (SEQ ID NO: 507)

30

1AYP:A phospholipase A2, membrane associated precursor

NLVNFHRMIKLTGKEAALSFGYCHCGVGGRGSPKDATDRCCVTHDCCYKRLEKRGK
GTKFLSYKFSNSGSRITCAKQDSCRSQLECDKAAATCFARNKTTYNNKKYQYYSNKHCRGS
TPRC (SEQ ID NO: 508)

35

1H8U:A bone marrow proteoglycan preproprotein

TCRYLLVRSLQTFSQAWFTCRRCYRGNLVSIFNFNINYRIQCSVSALNQGQVWIGGRITG
SGRCRRFQWVDGSRWNFAYWAAHQPSRGGHCVALCTRGGYWRRAHCLRRLPFICSY
(SEQ ID NO: 509)

40

1B34:A small nuclear ribonucleoprotein Sm D1

MKLVRFLMKLSHETVTIELKNGTQVHGTITGVDVSMNTHLKA VKMTLKNREP VQLETLSIR
GNNIRYFILPDSLPLDTLLVDVEPKVKSKKREAVAGRGRGRGRGRGRGRGRGRGGPRR
(SEQ ID NO: 510)

45

2CPX:A RNA-binding protein 41 isoform 1

GSSGSSGEEIRKIPMFSSYNPGEPNKVLYLKNLSRVTERDLVSLFARFQEKKGPPIQFR
MMTGRMRGQAFITFPNKEIAWQALHLVNGYKLYGKILVIEFGKNKKQRSSGPSSG (SEQ ID
NO: 511)

50

2DB2:A putative ATP-dependent RNA helicase DHX30 isoform 1

GSSGSSGASRDLLKEFPQPKNLLNSVIGRALGISHAKDKLVYVHTNGPKKKKVTLHIKWP
KSVEVEGYGSKKIDAERQAAAAACQLFKGWGLLGPRNELFDAKYRVLADRFGSGPSSG
(SEQ ID NO: 512)

55

2CSH:A zinc finger and BTB domain-containing protein 43

- 5 GSSGSSGDKLYPCQCGKSFTTHKSQRDRHMSMHLGLRPYGCGVCGKKFKMKHHLVGHMKI
HTGIKPYECNICAKRFMWRDSFHRHVTSTCKSYEAAKAEQNTTEASGPSSG (SEQ ID NO:
513)
- 2EBT:A Krueppel-like factor 5
10 GSSGSSGPDLEKRRIHYCDYPGCTKVYTKSSHLKAHLRTHHTGEKPYKCTWEGCDWRFARS
DELTRHYRKHTGAKPFQCGVCNRSFSRSDHLALHMKRHQN (SEQ ID NO: 514)
- 2GYR:A artemin isoform 3 precursor
15 GCRLRSQ LVPVRALGLGHRSDDELVRFRFCSGSCRRARSPHDLSLASLLGAGALRPPPGSR
PVSQPCCRPTRYEAVSFMDVNSTWRTVDRLSATACGCLGHHHHHH (SEQ ID NO: 515)
- 2D8R:A THAP domain-containing protein 2
GSSGSSGMPTNCAAAGCATTYNKHINISFHRFPLDPKRRKEWVRLVRRKNFVPGKHTFLCS
KHFEASCFDLTGQTRRLKMDAVPTIFDFCTHISGPSSG (SEQ ID NO: 516)
20
- 2CQL:A 60S ribosomal protein L9
GSSGSSGMKTILSNQTVDIPENV DITLKGRTVIVKGPRGTLRRDFNHINVELSLLGKKKK
RLRVDKWWGNRKELATVRTICSHVQNMIGVTLGSGPSSG (SEQ ID NO: 517)
- 25 2YU4:A E3 SUMO-protein ligase NSE2
GSSGSSGFTCPITKEEMKKPVKNK VCGHTYEEDAIVRMIESRQKRKKKAYCPQIGCSHTD
IRKSDLIQDEALRRAIENHNKKRHRHSESGPSSG (SEQ ID NO: 518)
- 2DMD:A zinc finger protein 64 isoform a
30 GSSGSSGPHKCEVCGKCFSRKDKLKT HMRCHTGVPYKCKTCDYAAADSSSLNKHLRIHS
DERPFKCQICPYASRNSSQLTVHLRSHTGDSGPSSG (SEQ ID NO: 519)
- 2YT9:A POZ-, AT hook-, and zinc finger-containing protein 1 short isoform
GSSGSSGVACEICGKIFRDVYHLNRHKL SHSGEKPYSCPVCGLRFRKRKDRMSYHVRSHDGS
35 VGKPYICQSCGKGFSRPDHLNGHIKQVHSGPSSG (SEQ ID NO: 520)
- 2E5H:A zinc finger CCHC-type and RNA-binding motif-containing protein 1
GSSGSSGMSGGLAPSKSTVYVSNLPFSLTNNDLYRIFSKYGKVVKVTIMKDKDTRKSKGVA
FILFLDKDSAQNCTRAINNKQLFGRVIKASIAI (SEQ ID NO: 521)
40
- 2E6O:A HMG box-containing protein 1
GSSGSSGGTVSATSPNKCKRPMNAFMLFAKKYRVEYTQMYPGKDNRAISVILGDRWKKM
KNEERRMYTLEAKALAEQKRLNPDCWK (SEQ ID NO: 522)
- 45 2RPR:A FLYWCH-type zinc finger-containing protein 1 isoform a
GSSGSSGLRPLEFLRTSLGGRFLVHESFLYRKEKAAGEKVYWMCRDQARLGCRSRAITQGH
RIMVMRSHCHQPDLAGLEALRQRERL (SEQ ID NO: 523)
- 2EBL:A COUP transcription factor 1
50 GSSGSSGIECVVCGDKSSGKHYGQFTCEGCKSFFKRSVRRNLTYTCRANRNCPIDQHHRN
QCQYCRLKKCLKVGMRRREAVQRGSGPSSG (SEQ ID NO: 524)
- 2DK5:A DNA-directed RNA polymerase III subunit RPC6
GSSGSSGDSQNAGKMKGSDNQEKL VYQIIEDAGNKGIWSRDVRYKSNLPLTEINKILKNL
55 ESKKLIKAVKSVAASKKKVYMLYNLSGPSSG (SEQ ID NO: 525)

- 5 2EQZ:A high mobility group protein B3
GSSGSSGMAKGDPPKPKGKMSAYAFFVQTCREEHKKKNPEVPVNFAEFSKKCSERWKTMS
GKEKSKFDEMAKADKVRDREMKDYG (SEQ ID NO: 526)
- 10 2ENV:A peroxisome proliferator-activated receptor delta isoform 3
GSSGSSGMECRVCGDKASGFHYGVHACEGCKGFFRRTIRMKLEYEKCERSCKIQKKNRKNK
CQYCRFQKCLALGMSHNAIRFGSGPSSG (SEQ ID NO: 527)
- 15 1X57:A endothelial differentiation-related factor 1 isoform alpha
GSSGSSGDRVTLEVGVKVIQQGRQSKGLTQKDLATKINEKPQVIADYESGRAIPNNQVLGK
IERAIGLKLRGKDIGKPIEKGPRAKSGPSSG (SEQ ID NO: 528)
- 20 2DMN:A homeobox protein TGIF2LX
GSSGSSGKKRKGNLPAESVKILRDWMYKHRFKAYPSEEEKQMLSEKTNLSLLQISNWFINA
RRRILPDMLQQRNDPSGPSSG (SEQ ID NO: 529)
- 1HRY:A sex-determining region Y protein
VQDRVKRPMNAFIVWSRDQRRKMALENPRMRNSEISKQLGYQWKMLTEAEKWPFFQEAQ
KLQAMHREKYPPNYKYRP (SEQ ID NO: 530)
- 25 1HRA:A retinoic acid receptor beta isoform 1
MPRVYKPCFVCQDKSSGYHYGVSAEGCKGFFRRSIQKNMIYTCHRDKNKCVINKVTRNRC
QYCRLQKCFEVGMSKESVRN (SEQ ID NO: 531)
- 30 2DMQ:A LIM/homeobox protein Lhx9 isoform 1
GSSGSSGKRMRTSFKHHQLRTMKSYFAINHNPDAKDLKQLAQKTGLTKRVLQVWFQNAAR
AKFRRNLLRQENGGVSGPSSG (SEQ ID NO: 532)
- 35 2DMT:A homeobox protein BarH-like 1
GSSGSSGGEPTGKAKKGRRSRTVFTLQMLGLEKRFQKQKYLSTPDRIDLAESLGLSQLQ
VKTWYQNRRMKWKKSGPSSG (SEQ ID NO: 533)
- 40 2YUU:A protein kinase C delta type
GSSGSSGKQAKIHYIKNHEFIATFFGQPTFCVCKDFVWGLNKQGYKCRQCNAAIHKKCI
DKIIGRCTGTAANSRDTSGPSSG (SEQ ID NO: 534)
- 2COT:A zinc finger and SCAN domain-containing protein 16
GSSGSSGRSEWQQRRERRRYKCDECGKSFSHSSDLSKHRRTHHTGEKPYKCDECGKAFIQRSH
LIGHHRVHTGSGPSSG (SEQ ID NO: 535)
- 45 1X4U:A zinc finger FYVE domain-containing protein 27 isoform a
GSSGSSGRYPTNNFGNCTGCSATFSVLKKRRSCSNCGNSFCRCCSFKVPKSSMGATAPE
AQRETVFVCASCNQTLSKSGPSSG (SEQ ID NO: 536)
- 50 1O7Y:A C-X-C motif chemokine 10 precursor
VPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGKRCCLNPESKA
IKNLLKAVSKEMSKRSP (SEQ ID NO: 537)
- 55 2ENN:A protein kinase C theta type
GSSGSSGQRRGAIKQAKVHHVKCHEFTATFFPQPTFCVCFVWGLNKQGYQCRQCNAAI
HKKCIDKVIKCTGSA (SEQ ID NO: 538)

- 5 2DN0:A zinc fingers and homeoboxes protein 3
GSSGSSGASIYKNKKSHEQLSALKGSFCRNQFPGQSEVEHLTKVTGLSTREVRKWFSDRR
YHCRNLKGSRSGPSSG (SEQ ID NO: 539)
- 10 2DB6:A SH3 and cysteine-rich domain-containing protein 3
GSSGSSGEPPKLVNDKPHKFKDHFFKKPKFCDVCARMIVLNNKFGLRCKNCKTNIHEHCQS
YVEMQRCSGPSSG (SEQ ID NO: 540)
- 15 2CSZ:A synaptotagmin-like protein 4
GSSGSSGLLEIKRKGAKRGSQHYSDRTCARCQESLGRLSPKTNTCRGCNHLVCRDCRIQE
SNGTWRCKVCSGPSSG (SEQ ID NO: 541)
- 20 2CU7:A histone H2A deubiquitinase MYSM1
GSSGSSGYSVKWTIEEKELFEQGLAKFGRRWTKISKLIGSRTVLQVKSYPARQYFKNKVKCG
LDKETPNQKTG (SEQ ID NO: 542)
- 25 1X2N:A homeobox protein PKNOX1
GSSGSSGKNKRGVLPKHATNVMRSWLFQHIGHPTYPTEDKKQIAAQTNLTLLQVNNWFINA
RRRILQSGPSSG (SEQ ID NO: 543)
- 30 2EPA:A Krueppel-like factor 10 isoform b
GSSGSSGPQIDSSRIRSHICSHPGCGKTYFKSSHLKAHTRTHTGEKPFSCSWKGCERRFA
RSELSRHRRTTH (SEQ ID NO: 544)
- 35 2E1O:A hematopoietically-expressed homeobox protein HHEX
GSSGSSGKGGQVRFSNDQTIELEKKFETQKYLSPPERKRLAKMLQLSERQVKTWQFQNRRAK
WRRSGPSSG (SEQ ID NO: 545)
- 40 2CRA:A homeobox protein Hox-B13
GSSGSSGRKKRIPYSKGLRELEREYAANKFITKDKRRKISAATSLSERQITWQFQNRRAK
KEKKSGPSSG (SEQ ID NO: 546)
- 45 2CTU:A zinc finger protein 483 isoform a
GSSGSSGKRQKIHLGDRSQKCSKCGIIFIRRSTLSRRKTPMCEKCRKDSCQEALNKDEG
NESGKKTSGPSSG (SEQ ID NO: 547)
- 50 1MGS:A growth-regulated alpha protein precursor
ASVATELRCQCLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNRKAACLNPAPIVK
KIIKMLNSDKSN (SEQ ID NO: 548)
- 55 2DIM:A cell division cycle 5-like protein
GSSGSSGKGGVWRNTEDEILKAAVMKYGKNQWSRIASLLHRKSAKQCKARWYEWLDPSI
KKTEWSGPSSG (SEQ ID NO: 549)
- 2COB:A ligand-dependent corepressor isoform 1
GSSGSSGRGRYRQYNSEILEEASVVMMSGKMSVSKAQSIYGIPHSTLEYKVKERLGTLLKN
PPKKKMKLMR (SEQ ID NO: 550)
- 1MSG:A growth-regulated alpha protein precursor
ASVATELRCQCLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNRKAACLNPAPIVK
KIIKMLNSDKS (SEQ ID NO: 551)

- 5 2DJN:A homeobox protein DLX-5
GSSGSSGRKPRTIYSSFQLAALQRRFQKTQYLALPERAELAASLGLTQTQVKIWFQNKRS
KIKKSGPSSG (SEQ ID NO: 552)
- 10 2E70:A transcription elongation factor SPT5 isoform a
GSSGSSGMSRGRGRRDNELIGQTVRISQGPYKGYIGVVKDATESTARVELHSTCQTISVD
RQRLTTVGSR (SEQ ID NO: 553)
- 15 1HDP:A POU domain, class 2, transcription factor 2 isoform 1
RRKKRTSIETNVRFALEKSFLANQKPTSEEILLIAEQLHMEKEVIRVWFCNRRQKEKRIN
PCX (SEQ ID NO: 554)
- 20 3IY9:O 39S ribosomal protein L27, mitochondrial
ASKKSGGSSKNLGGKSSGRRQGIIKMEGHYVHAGNIIATQRHFRWHPGAHVGVGKNKCL
YALEEGIVRY (SEQ ID NO: 555)
- 2JGX:A complement factor H isoform a precursor
XRKCYFPYLENGYNQNYGRKFVQGKSIDVACHPGYALPKAQTTVTCMENGWSPTPRCIRV
K (SEQ ID NO: 556)
- 25 2JGW:A complement factor H isoform a precursor
XRKCYFPYLENGYNQNHGRKFVQGKSIDVACHPGYALPKAQTTVTCMENGWSPTPRCIRV
K (SEQ ID NO: 557)
- 30 1BBO:A zinc finger protein 40
KYICEECGIRXKKPSMLKKHIRTHTDVRPYHCTYCNFSFKTKGNLTKHMKSKAHSKK (SEQ
ID NO: 558)
- 35 1P0T:0 tumor necrosis factor receptor superfamily member 13C
MRRGPRSLRGRDAPAPTPCVPAECFDLLVRHCVACGLLRTPRKPAGASSPAPRTALQPQ
ESV (SEQ ID NO: 559)
- 40 1BA5:A telomeric repeat-binding factor 1 isoform 1
RKRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSVMLKDRWRTMKKL (SEQ
ID NO: 560)
- 2CPW:A ubiquitin-associated and SH3 domain-containing protein B
GSSGSSGRNRQQRPGTIKHGSALDVLLSMGFPRARAQKALASTGGRSVQTACDWLFSHSGP
SSG (SEQ ID NO: 561)
- 45 2DAS:A zinc finger MYM-type protein 5 isoform 3
GSSGSSGQPTAQQLTKPAKITCANCKKPLQKGQTAYQRKGS AHLFCSTTCLSSFSSGPS
SG (SEQ ID NO: 562)
- 50 3IY9:P 39S ribosomal protein L33, mitochondrial isoform a
AKSKSKNILVRMVSEAGTGFCFNTKRNLREKLTLHYDPVVKQRVLFVEKK (SEQ ID
NO: 563)
- 55 2YSA:A E3 ubiquitin-protein ligase RBBP6 isoform 1
GSSGSSGYTCFRCGKPGHYIKNCPTNGDKNFESGPRIKKSTGIPRSFMMMEVKDPN (SEQ ID
NO: 564)

- 5 2YQQ:A zinc finger HIT domain-containing protein 3
GSSGSSGLKCSTVVCVICLEKPKYRCPACRVPYCSVVCFRKHKEQCNPETSGPSSG (SEQ ID NO: 565)
- 10 2KZA:A agouti-signaling protein precursor
KKVVRPRTPLSAPCVATRNSCKPAAAACCDPCASCYCRFFRSACYCRVLSLNC (SEQ ID NO: 566)
- 15 1Z6V:A lactotransferrin isoform 1 precursor
GRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQA (SEQ ID NO: 567)
- 1QGK:B importin subunit alpha-2
AARLHRFKNKGKDDSTEMRRRRRIEVNVELRKAKKDDQMLKRRNVS (SEQ ID NO: 568)
- 20 2EPR: A POZ-, AT hook-, and zinc finger-containing protein 1 short isoform
GSSGSSGRTRKQVACEICGKIFRDVYHLNRHKLSHSGEKPYSSGPSSG (SEQ ID NO: 569)
- 25 1HTR:P gastricsin isoform 2 preproprotein
AVVKVPLKKFKSIRETMKEKGLLGEFLRTHKYDPAWKYRFGDL (SEQ ID NO: 570)
- 2P8Q:B snurportin-1
HPRLSQYKSKYSSLEQSERRRRLELQKSKRLDYVNHARR (SEQ ID NO: 571)
- 30 2ENT:A Krueppel-like factor 15
GSSGSSGTGEKPFACWPGCGWRFSRDELRSRHRSHSGVKPSGPSSG (SEQ ID NO: 572)
- 2EOY:A zinc finger protein 473
GSSGSSGQKEKCFKCNKCEKTFSCSKYLTQHERIHTRGVKSGPSSG (SEQ ID NO: 573)
- 35 2YTD:A zinc finger protein 473
GSSGSSSGGEKPYKCSECGKAFHRHRTLNEHRRRIHTGYRPSGPSSG (SEQ ID NO: 574)
- 40 1JUN:A transcription factor AP-1
XCGGRIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNX (SEQ ID NO: 575)
- 2EOV:A zinc finger protein 484 isoform a
GSSGSSGTGEKPYKCSDCGKSFTWKSRLRIHQKCHTGERHSGPSSG (SEQ ID NO: 576)
- 45 2EN4:A zinc finger protein 347 isoform a
GSSGSSGTGEKPYKCYECGKAFRTRSNLTTHQVIHTGEKRS GPSSG (SEQ ID NO: 577)
- 2EOH:A zinc finger protein 28 homolog
GSSGSSGSGKKPYECKEKRKTFIQIGHLNQHKRVHTGERSSGPSSG (SEQ ID NO: 578)
- 50 2ENE:A zinc finger protein 347 isoform a
GSSGSSGTGEKPYKCNECGKVFRHNSYLSRHQRIHTGEKPSGPSSG (SEQ ID NO: 579)
- 2YTS:A zinc finger protein 484 isoform a
GSSGSSGTGEKPYICNECGKSFIQKSHLNRHRRRIHTGEKPSGPSSG (SEQ ID NO: 580)
- 55 2EQ0:A zinc finger protein 347 isoform a

- 5 GSSGSSGTGEKPYKCHECGKVFRNSHLARHQLIHTGEKPSGPSSG (SEQ ID NO: 581)
 2EL6:A zinc finger protein 268 isoform c
 GSSGSSGAGVNPYKCSQCEKSFSGKLRLLVHQRMTREKPSGPSSG (SEQ ID NO: 582)
- 10 2EMA:A zinc finger protein 347 isoform a
 GSSGSSGTGEKRYKCNECGKVFSRNSQLSQHQKIHTGEKPSGPSSG (SEQ ID NO: 583)
 2EM9:A zinc finger protein 224
 GSSGSSGTGEKPYNCKECGKSFRWASCLLKHQRVHSGEKPSGPSSG (SEQ ID NO: 584)
- 15 2YTJ:A zinc finger protein 484 isoform a
 GSSGSSGTGEKPYICAECGKAFTIRSNLIKHQKIHTKQKPSGPSSG (SEQ ID NO: 585)
 2EMB:A zinc finger protein 473
 20 GSSGSSGHTRKRYECSKCQATFNLRKHLIQHQKTHAAKSGPSSG (SEQ ID NO: 586)
 2EM2:A zinc finger protein 28 homolog
 GSSGSSSGGEKPFKCKEKGKAFRQNIHLASHLRIHTGEKPSGPSSG (SEQ ID NO: 587)
- 25 2EM4:A zinc finger protein 28 homolog
 GSSGSSGTGQRPYECIECGKAFKTKSSLICHRRSHTGEKPSGPSSG (SEQ ID NO: 588)
 2EN9:A zinc finger protein 28 homolog
 GSSGSSGAGKKLFCNECKKTFTQSSSLTVHQRIHTGEKPSGPSSG (SEQ ID NO: 589)
- 30 2YU8:A zinc finger protein 347 isoform a
 GSSGSSGTGEKPYKCNCEGKVFTQNSHLARHRRVHTGGKPSGPSSG (SEQ ID NO: 590)
 2EMZ:A zinc finger protein with KRAB and SCAN domains 5
 35 GSSGSSSGGERPFKCNECGKGFGRRSHLAGHLRLHSREKSSGPSSG (SEQ ID NO: 591)
 2YTR:A zinc finger protein 347 isoform a
 GSSGSSGTGEKPYKCNCEGKAFSQTSKLARHQRIHTGEKPSGPSSG (SEQ ID NO: 592)
- 40 2EPQ:A POZ-, AT hook-, and zinc finger-containing protein 1 short isoform
 GSSGSSGEKPYSCPVCGLRFKRKDRMSYHVRSHDGSVGKSGPSSG (SEQ ID NO: 593)
 2YU5:A zinc finger protein 473
 GSSGSSGAGENPFKCSKCDRVFTQRNYLVQHERTHARKSGPSSG (SEQ ID NO: 594)
- 45 2YTN:A zinc finger protein 347 isoform a
 GSSGSSGTGKKPYKCNCEGKVFTQNSHLARHRGIHTGEKPSGPSSG (SEQ ID NO: 595)
 2EOQ:A zinc finger protein 224
 50 GSSGSSGTGEKPFKCDICGKSFCGRSRLNRHSMVHTAEKPSGPSSG (SEQ ID NO: 596)
 2L9U:A receptor tyrosine-protein kinase erbB-3 isoform 1 precursor
 MGRTHLTMALTVIAGLVVIFMMLGGTFLYWRGRRHHHHHH (SEQ ID NO: 597)
- 55 2ELY:A zinc finger protein 224
 GSSGSSGTGEKPFKCVCEGKGFSRRSALNVHHKLHTGEKPSGPSSG (SEQ ID NO: 598)

- 5 2EML:A zinc finger protein 28 homolog
GSSGSSGTGEKPYECSVCGKAFSHRQSLSVHQRIHSGKKPSGPSSG (SEQ ID NO: 599)
- 10 2EQ2:A zinc finger protein 347 isoform b
GSSGSSGTGGKPYQCNECGKAFSQTSKLARHQRVHTGEKPSGPSSG (SEQ ID NO: 600)
- 2EPU:A zinc finger protein 32
GSSGSSGTGQKPFECTHCGKSFRAGNLTHTQRIHTGEKSGPSSG (SEQ ID NO: 601)
- 15 1SGH:B Na(+)/H(+) exchange regulatory cofactor NHE-RF1
CLDFNISLAMAKERAHQKRSSKRAPQMDWSKKNELFSNL (SEQ ID NO: 602)
- 20 2EL4:A zinc finger protein 268 isoform c
GSSGSSGTGVKPYGCSQCAKTFSLKSQLIVHQRSHTGVKPSGPSSG (SEQ ID NO: 603)
- 2L3H:A prostatic acid phosphatase isoform PAP precursor
GIHKQKEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMX (SEQ ID NO: 604)
- 25 2YRH:A zinc finger protein 473
GSSGSSGKKPLVCNECGKTFRQSSCLSKHQRIHSGEKPSGPSSG (SEQ ID NO: 605)
- 2EOG:A zinc finger protein 268 isoform c
GSSGSSGVKPYGCSECGKAFRSKSYLIIHMRTHTGEKPSGPSSG (SEQ ID NO: 606)
- 30 1FQQ:A beta-defensin 4B
XIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP (SEQ ID NO: 607)
- 35 2ELU:A zinc finger protein ZFAT isoform 4
GSSGSSGIKQHCRFCKKKYSVDVKNLIKHIRDAHDPQD (SEQ ID NO: 608)
- 1BH7:A band 3 anion transport protein
XQLFDRILLFLFKPPKYHPDVPYVKRVKTWRMHL (SEQ ID NO: 609)
- 40 2ELM:A zinc finger protein ZFAT isoform 4
GSSGSSGHLYYCSQCHYSSITKNCLKRHVIQKHSNIL (SEQ ID NO: 610)
- 2ELS:A zinc finger protein ZFAT isoform 1
GSSGSSGKIFTCEYCNKVFKFKHSLQAHLRIHTNEK (SEQ ID NO: 611)
- 45 (+36)GFP
ASKGERLFRGKVPILVELKGDVNGHKFSVRGKGKGDATRGLTLKFICTTGKLPVPWPTLV
TTLTYGVCFSRYPKHMKRHDFFKSAMPKGYVQERTISFKKDGKYKTRAEVKFEGRTL
VNRILKGRDFKEKGNILGHKLRYNFNSHKVYITADKRKNGIKAKFKIRHNVKDGSVQLADHY
QQNTPIGRGPVLLPRNHYLSTRSKLSKDPKEKRDHMLLEFVTAAGIKHGRDERYK (SEQ
50 ID NO: 663)
- Myc-(+36)GFP-GS10-C4 scFv-His6
MEQKLISEEDLGSASKGERLFRGKVPILVELKGDVNGHKFSVRGKGKGDATRGLTLKFICT
TGKLPVPWPTLVTTLTYGVCFSRYPKHMKRHDFFKSAMPKGYVQERTISFKKDGKYKTR
55 AEVKFEGRTLVRILKGRDFKEKGNILGHKLRYNFNSHKVYITADKRKNGIKAKFKIRHN
VKDGSVQLADHYQQNTPIGRGPVLLPRNHYLSTRSKLSKDPKEKRDHMLLEFVTAAGIKH

5 GRDERYKGHGGGGSGGGGSQVQLQESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAP
GKGLEWVAVISYDGSNKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDRY
FDLWGRGTLVTVSSGGGGSGGGGSQ SALTQPASVSGSPGQSITISCTGTSSDIGAYN
YVSWYQQYPGKAPKLLIYDVSNRPSGISNRFSGSKSGDTASLTISGLQAEDEADYYCSSFAN
SGPLFGGGTKVTVLGGHGH HHHHHH (SEQ ID NO: 664)

10

Myc-(+36)GFP-His6

MEQKLISEEDLGSASKGERLFRGKVPILVELKGDVNGHKFSVRGKGKGDATRGKLT LKFICT
TGKLPVPWPTLVTTLTYGVQCFSRYPKHMKRHDFFKSAMPKGYVQERTISFKKDGKYKTR
AEVKFEGRTL VNRIKLKGRDFKEKGNILGHKLRYNFNSHKVYITADKRKNGIKAKFKIRHN
15 VKDGSVQLADHYQQNTPIGRGPVLLPRNHYLSTRSKLSKDPKEKRDHMLLEFVTAAGIKH
GRDERYKGHGH HHHHHH (SEQ ID NO: 665)

Domain of FGF-10 (residues 64-208 of full length, unprocessed, naturally occurring human FGF-10)

20 GRHVRSYNHLQGDVRWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSILEITSVEIGVVAV
KAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVALNG
KGAPRRGQKTRRKNTSAHFLPMVVHS (SEQ ID NO: 666)

FGF10(Mut4) (variant of 64-208 fragment of full length, unprocessed, naturally occurring human FGF-10)

25 GRHVRSYNHLQGDVAWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSILEIRSVEIGVVAVK
AINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEANGYNTYASFNWQHNGRQMYVALNGK
GAPRRGQKTRRANTS AHFLPMVVHS (SEQ ID NO: 667)

Myc-FGF10(mut4)-GS10-C4 scFv-His6

30 MEQKLISEEDLGSGRHVRSYNHLQGDVAWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSIL
EIRSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEANGYNTYASFNWQH
NGRQMYVALNGKGAPRRGQKTRRANTS AHFLPMVVHSGHGGGGSGGGGSQVQLQESGG
GLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTI
SRDN SKNTLYLQMNSLRAEDTAVYYCARDRYFDLWGRGTLVTVSSGGGGSGGGGSQ SALTQPASVSGSPGQSITISCTGTSSDIGAYN
35 YVSWYQQYPGKAPKLLIYDVSNRPSGISNRFSGSKSGDTASLTISGLQAEDEADYYCSSFANS
GPLFGGGTKVTVLGGHGH HHHHHH (SEQ ID NO: 668)

Myc-FGF10(mut4)-His6

40 MEQKLISEEDLGSGRHVRSYNHLQGDVAWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSIL
EIRSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEANGYNTYASFNWQH
NGRQMYVALNGKGAPRRGQKTRRANTS AHFLPMVVHSGHGH HHHHHH (SEQ ID NO: 669)

45

INCORPORATION BY REFERENCE

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically
50 and individually indicated to be incorporated by reference.

While specific embodiments of the subject disclosure have been discussed, the

- 5 above specification is illustrative and not restrictive. Many variations of the disclosure will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

10

5 **We claim:**

1. A fusion protein comprising
 a Surf+ Penetrating Polypeptide having surface positive charge, net positive
charge, a molecular weight of at least 4 kDa, and a charge per molecular weight ratio
10 of greater than 0.75; and
 an antibody or antibody-mimic moiety (AAM moiety) that binds to an
intracellular target
and inhibits binding between the target and another protein, wherein the AAM moiety
that binds the intracellular target is a single chain Fv (scFv) comprising a variable
15 heavy chain (V_H) domain and a variable light chain (V_L) domain;
wherein the fusion protein penetrates cells and binds to the intracellular target to
inhibit binding between the target and another protein inside the cells.
2. The fusion protein of claim 1, wherein the Surf+ Penetrating Polypeptide is a
20 polypeptide engineered to comprise an overall charge from about +10 to about +40.
3. A fusion protein comprising
 a Surf+ Penetrating Polypeptide, wherein the Surf+ Penetrating Polypeptide is
a domain of a full length, naturally occurring human polypeptide, wherein the domain
25 of the full length, naturally occurring human polypeptide has a molecular weight of at
least 4 kDa and a charge per molecular weight ratio of greater than 0.75, and wherein
the domain of a full length, naturally occurring human polypeptide has a
charge/molecular weight ratio greater than that of the full length, naturally occurring
human polypeptide; and
30 an antibody or antibody-mimic moiety (AAM moiety) that binds to an
intracellular target and inhibits binding between the target and another protein,,
wherein the AAM moiety is a single chain Fv (scFv) comprising a variable heavy
chain (V_H) domain and a variable light chain (V_L) domain;
wherein the fusion protein penetrates cells and binds to the intracellular target to
35 inhibit binding between the target and another protein inside the cells; and

5 wherein the fusion protein does not include the full length, naturally occurring human polypeptide.

4. The fusion protein of claim 3, wherein the domain of a full length, naturally occurring human polypeptide has a theoretical net charge of about +5 to +17 or about
10 +10 to +20.

5. The fusion protein of claim 3 or 4, wherein the domain of a full length, naturally occurring human polypeptide has a charge per molecular weight ratio greater than that of the full length, naturally occurring human polypeptide.
15

6. The fusion protein of any one of claims 3-5, wherein the full length, naturally occurring human polypeptide has a charge per molecular weight ratio of less than 0.75.

20 7. The fusion protein of any one of claims 3-6, wherein the domain of a full length, naturally occurring human polypeptide has a theoretical net charge of about +12.

8. The fusion protein of any one of claims 3-6, wherein the domain of a full
25 length, naturally occurring human polypeptide has a theoretical net charge of about +14.

9. The fusion protein of any one of claims 3-6, wherein the domain of a full length, naturally occurring human polypeptide has a theoretical net charge of about
30 +15.

10. The fusion protein of any one of claims 3-6, wherein the domain of a full length, naturally occurring human polypeptide has a theoretical net charge of about +16.
35

11. The fusion protein of any one of claims 3-10, wherein the domain of a full

5 length, naturally occurring human polypeptide has a molecular weight of at least about 14 kDa.

12. The fusion protein of any one of claims 3-10, wherein the domain of a full
length, naturally occurring human polypeptide has a molecular weight of at least
10 about 15 kDa.

13. The fusion protein of any one of claims 3-12, wherein the domain of a full
length, naturally occurring human polypeptide is less than 150 amino acid residues.

15 14. The fusion protein of any one of claims 3-13, wherein the domain of a full
length, naturally occurring human polypeptide has a charge/molecular weight ratio of
at least 1.0.

15 15. The fusion protein of any one of claims 3-13, wherein the domain of a full
20 length, naturally occurring human polypeptide has a charge/molecular weight ratio of
at least 0.9.

16. The fusion protein of any one of claims 3-15, wherein the domain of a full
length, naturally occurring human polypeptide is that of a full length, naturally
25 occurring fibroblast growth factor receptor 10 (FGF-10).

17. The fusion protein of any one of claims 3-16, wherein the domain is a variant
comprising one, two, three, four, or five amino acid substitutions, deletions, and/or
additions relative to the corresponding domain of the naturally occurring polypeptide.
30

18. The fusion protein of claim 1 or 2, wherein the Surf+ Penetrating Polypeptide
is a domain of a full length, naturally occurring, human fibroblast growth factor
receptor 10 (FGF-10).

35 19. The fusion protein of any of claims 3-18, wherein the domain has the amino
acid sequence set forth in SEQ ID NO: 666.

5

20. The fusion protein of any one of claims 3-19, wherein the domain is a variant comprising one, two, three, four, or five amino acid substitutions, deletions, and/or additions relative to the corresponding domain of the naturally occurring polypeptide.

10 21. The fusion protein of claim 20, wherein the domain is a domain of full length, naturally occurring, human fibroblast growth factor receptor 10 (FGF-10) having one, two, three, or four amino acid substitutions relative to the corresponding domain of the naturally occurring polypeptide.

15 22. The fusion protein of any one of claims 1-21, wherein the Surf+ Penetrating Polypeptide and the AAM moiety are interconnected by a linker.

23. The fusion protein of claim 22, wherein the linker is a flexible linker comprising glycine and serine residues.

20

24. The fusion protein of claim 22 or 23, wherein the linker is cleavable.

25. A fusion protein comprising

25 (a) a polypeptide selected from the group consisting of: agouti-signaling protein precursor, band 3 anion transport protein, B-cell lymphoma 6 protein isoform 1, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, beta-defensin 1 preproprotein, cathepsin E isoform a preproprotein, charged multivesicular body protein 6, cpG-binding protein isoform 2, C-X-C motif chemokine 10 precursor, epidermal growth factor receptor isoform a precursor, histone acetyltransferase MYST3, histone acetyltransferase p300, 30 homeobox protein Nkx-3.1, lethal(3)malignant brain tumor-like protein 2, male-specific lethal 3 homolog isoform a, Na(+)/H(+) exchange regulatory cofactor NHE-RF1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, POU domain class 2- 35 associating factor 1, prostatic acid phosphatase isoform PAP precursor, receptor tyrosine-protein kinase erbB-2 isoform b, receptor tyrosine-protein

5 kinase erbB-3 isoform 1 precursor, receptor tyrosine-protein kinase erbB-4
 isoform JM-a/CVT-2 precursor, RING1 and YY1-binding protein, sterol
 regulatory element-binding protein 2, stromal cell-derived factor 1 isoform
 gamma, talin-1, T-cell surface glycoprotein CD4 isoform 1 precursor,
 transcription factor AP-1, transcription factor NF-E2 45 kDa subunit isoform
 10 2, transcription factor Sp1 isoform b, voltage-dependent L-type calcium
 channel subunit alpha-1C isoform 23, zinc finger protein 224, zinc finger
 protein 268 isoform c, zinc finger protein 28 homolog, zinc finger protein 32,
 zinc finger protein 347 isoform a, zinc finger protein 347 isoform b, or zinc
 finger protein 40, or a domain of any of the foregoing having surface positive
 15 charge, a mass of at least 4kDa and a charge/molecular weight ratio of at least
 0.75 and

(b) an AAM moiety that binds to an intracellular target, wherein the AAM
 moiety is a single chain Fv (scFv) comprising a variable heavy chain (V_H)
 domain and a variable light chain (V_L) domain.

20

26. A fusion protein comprising

(a) a polypeptide comprising an amino acid sequence at least 95% identical to
 any of the amino acid sequences set forth in Section 2 of the sequence listing and
 identified in such sequence listing by PDB identifier, or a domain thereof having
 25 surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio
 of at least 0.75 and

(b) an AAM moiety that binds to an intracellular target, wherein the AAM
 moiety is a single chain Fv (scFv) comprising a variable heavy chain (V_H) domain and
 a variable light chain (V_L) domain.

30

27. The fusion protein of claim 26, wherein (a) comprises a polypeptide
 comprising an amino acid sequence identical to any of the amino acid sequences set
 forth in Section 2 of the sequence listing and identified in such sequence listing by
 PDB identifier, or a domain thereof having surface positive charge, a mass of at least
 35 4 kDa, and a charge/molecular weight ratio of at least 0.75.

5 28. The fusion protein of claim 26 or 27, wherein (a) comprises a polypeptide comprising an amino acid sequence at least 95%-100% identical to an amino acid sequence set forth in Section 2 of the sequence listing and identified in such sequence listing by PDB identifier.

10 29. The fusion protein of any of claims 25-28, wherein the fusion protein penetrates cells and binds to the intracellular target to inhibit binding between the target and another protein inside the cells.

30. A nucleic acid comprising a nucleotide sequence encoding the fusion protein
15 of any one of claims 1-29.

31. A vector comprising the nucleic acid of claim 30.

32. A host cell comprising the vector of claim 31.

20

33. A method of making a fusion protein, comprising
(i) providing the host cell of claim 32 in culture media and culturing the host cell under suitable condition for expression of protein therefrom; and
(ii) expressing the fusion protein.

25

34. The method of claim 33, further comprising isolating the fusion protein from the culture media.

35. A method of inhibiting activity of an intracellular target in a cell, comprising
30 providing the fusion protein of any one of claims 1-29, and
contacting cells that express the target with the complex.

36. A composition comprising the fusion protein of any one of claims 1-29 and a pharmaceutically acceptable carrier.

35

5 37. The fusion protein of any one of claims 1-29, wherein the fusion protein comprises a modification selected from glycosylation, phosphorylation or pegylation.

38. The fusion protein of any one of claims 1-29, wherein the fusion protein is not glycosylated.

10

39. A method of modulating activity of an intracellular target in a cell, comprising providing the fusion protein of any one of claims 1-29, which fusion protein penetrates cells, binds to the intracellular target and inhibits binding between the target and another protein; and

15 contacting cells that express the intracellular target with the complex.

40. A complex comprising

a Surf⁺ Penetrating Polypeptide having a molecular weight of at least 4 kDa and a charge per molecular weight ratio of greater than 0.75 and

20

an AAM moiety;

wherein the Surf⁺ Penetrating Polypeptide is associated with the AAM moiety, wherein the AAM moiety binds to an intracellular target, and wherein the intracellular target is distinct from the Surf⁺ Penetrating Polypeptide.

25 41. A complex comprising

a first portion comprising a Surf⁺ Penetrating Polypeptide and

a second portion comprising an AAM moiety having a molecular weight of at least 4 kDa and a charge per molecular weight ratio of greater than 0.75;

30

wherein the Surf⁺ Penetrating Polypeptide is associated with the AAM moiety, wherein the AAM moiety binds to an intracellular target, and wherein the intracellular target is distinct from the portion comprising the Surf⁺ Penetrating Polypeptide.

42. A complex comprising

5 a first portion consisting of a Surf+ Penetrating Polypeptide having a
molecular weight of at least 4 kDa and a charge per molecular weight ratio of
greater than 0.75 and

 a second portion comprising an AAM moiety;

wherein the Surf+ Penetrating Polypeptide is associated with the AAM moiety,

10 wherein the AAM moiety binds to an intracellular target, and wherein the intracellular
target is distinct from the portion comprising the Surf+ Penetrating Polypeptide.

43. The complex of any of claims 40-42, wherein the complex further comprises a
linker.

15

44. The complex of claim 43, wherein the linker interconnects the first portion and
the second portion.

45. The complex of any of claims 40-44, wherein the Surf+ Penetrating
20 Polypeptide is a human polypeptide.

46. The complex of any of claims 40-44, wherein the Surf+ Penetrating
Polypeptide is a full-length, naturally occurring human polypeptide.

25 47. The complex of any of claims 40-45, wherein the Surf+ Penetrating
Polypeptide is a domain of a full length, naturally occurring human polypeptide.

48. The complex of claim 47, wherein the domain of a full length, naturally
occurring human polypeptide has a charge/molecular weight ratio greater than that of
30 the full length, naturally occurring human polypeptide.

49. The complex of claim 47, wherein the domain has a charge/molecular weight
ratio of at least 0.75 but the full length, naturally occurring human polypeptide has a
charge/molecular weight ratio of less than 0.75.

35

5 50. The complex of any of claims 40-49, wherein the Surf+ Penetrating Polypeptide is a domain of a full length, naturally occurring human protein, and wherein the complex does not include the full length, naturally occurring human protein.

10 51. The complex of claim 50, wherein the Surf+ Penetrating Polypeptide is a domain of a full length, naturally occurring human protein, and wherein the complex does not include sufficient additional amino acid sequence from said full length, naturally occurring human protein contiguous with said domain such that the charge/molecular weight of the first portion would be less than 0.75.

15 52. The complex of any of claims 47-51, wherein the domain is less than 150 amino acid residues.

20 53. The complex of any of claims 41-52, wherein the first portion is less than 150 amino acid residues.

25 54. The complex of any of claims 40-53 wherein the Surf+ Penetrating Polypeptide is a polypeptide having endogenous function as a DNA binding protein or is a domain of a full length polypeptide that has endogenous function as a DNA binding protein.

30 55. The complex of any of claims 40-53, wherein the Surf+ Penetrating Polypeptide is a polypeptide having endogenous function as an RNA binding protein or is a domain of a full length polypeptide, which full length polypeptide has endogenous function as an RNA binding protein.

35 56. The complex of any of claims 40-53 wherein the Surf+ Penetrating Polypeptide is a polypeptide having endogenous function as a heparin binding protein or is a domain of a full length polypeptide, which full length polypeptide has endogenous function as a heparin binding protein.

- 5 57. The complex of any of claims 40-53, wherein the Surf+ Penetrating Polypeptide is a polypeptide having endogenous function as a C-C or C-X-C class of chemokine or is a domain of a full length polypeptide, which full length polypeptide has endogenous function as a C-C or C-X-C class of chemokine.
- 10 58. The complex of any of claims 40-57, wherein the Surf+ Penetrating Polypeptide is not an antibody or an antigen binding fragment of an antibody.
59. The complex of any of claims 40-58, wherein the AAM moiety comprises a full length antibody molecule.
- 15 60. The complex of any of claims 40-58, wherein the AAM moiety comprises an antibody fragment.
61. The complex of claim 60, wherein the antibody fragment is a single chain antibody (scFv), a F(ab')₂ fragment, a Fab fragment, or an Fd fragment.
- 20 62. The complex of any of claims 40-58, wherein the AAM moiety is a camelid antibody, an IgNAR, or an antibody like molecule comprising a target binding domain engineered into an Fc domain of the antibody like molecule.
- 25 63. The complex of any of claims 40-58, wherein the AAM moiety comprises a bispecific antibody.
64. The complex of any of claims 40-58, wherein the AAM moiety comprises an antibody-mimic comprising a protein scaffold.
- 30 65. The complex of claim 64, wherein the AAM moiety comprises a DARPin polypeptide, an Adnectin[®] polypeptide or an Anticalin[®] polypeptide.
- 35 66. The complex of any of claims 40-58, wherein the AAM moiety comprises: a target binding scaffold from Src homology domains (e.g. SH2 or SH3 domains), PDZ

5 domains, beta-lactamase, high affinity protease inhibitors, an EGF-like domain, a Kringle-domain, a PAN domain, a Gla domain, a SRCR domain, a Kunitz/Bovine pancreatic trypsin Inhibitor domain, a Kazal-type serine protease inhibitor domain, a Trefoil (P-type) domain, a von Willebrand factor type C domain, an Anaphylatoxin-like domain, a CUB domain, a thyroglobulin type I repeat, LDL-receptor class A
10 domain, a Sushi domain, a Link domain, a Thrombospondin type I domain, a C-type lectin domain, a MAM domain, a von Willebrand factor type A domain, a Somatomedin B domain, a WAP-type four disulfide core domain, a F5/8 type C domain, a Hemopexin domain, a Laminin-type EGF-like domain, or a C2 domain.

15 67. The complex of any of claims 40-66, wherein the Surf+ Penetrating Polypeptide or the portion comprising the Surf+ Penetrating Polypeptide and the AAM moiety are associated non-covalently.

20 68. The complex of any of claims 40-67, wherein the Surf+ Penetrating Polypeptide or the portion comprising the Surf+ Penetrating Polypeptide and the AAM moiety are associated via a covalent interconnection.

25 69. The complex of claim 68, wherein the Surf+ Penetrating Polypeptide or the portion comprising the Surf+ Penetrating Polypeptide and the AAM moiety are interconnected by a linker.

30 70. The complex of claim 68, wherein the Surf+ Penetrating Polypeptide or the portion comprising the Surf+ Penetrating Polypeptide and the AAM moiety are directly interconnected without a linker.

71. The complex of claim 69, wherein the linker is a peptide linker and the Surf+ Penetrating Polypeptide and the AAM moiety form a fusion protein.

35 72. The complex of claim 69, wherein the linker comprises an amide, an ester, or a disulfide bond.

5 73. The complex of any of claims 69-72, wherein the linker is a cleavable linker.

74. The complex of claim 73, wherein the cleavable linker can be cleaved by a naturally occurring cellular enzyme.

10 75. The complex of claim 74, wherein the cellular enzyme is an endosomal protease or an endosomal esterase.

76. The complex of any of claim 40-75, wherein the Surf+ Penetrating Polypeptide has an overall net charge of +5 to +17.

15

77. The complex of any of claims 40-76, wherein the Surf+ Penetrating Polypeptide is a domain of naturally occurring ataxin-7 isoform a, C-C motif chemokine 24 precursor or cytochrome c, which domain has surface positive charge and a charge/molecular weight ratio greater than that of its corresponding naturally occurring, full length polypeptide.

20

78. The complex of any of claims 40-76, wherein the Surf+ Penetrating Polypeptide is a naturally occurring protein selected from C-C motif chemokine 24 precursor, beta-defensin 103 precursor, cytochrome c, fibroblast growth factor 10 precursor, signal recognition particle 14 kDa protein, C-X-C chemokine 14 precursor or fibroblast growth factor 8 isoform B precursor, or a domain of any of the foregoing, which domain has surface positive charge and a charge/molecular weight ratio of at least 0.75.

25

30 79. The complex of any of claims 40-76, wherein the Surf+ Penetrating Polypeptide is: a full length polypeptide or a domain of C-C motif chemokine 26 precursor; a domain of HB-EGF (proheparin-binding EGF-like growth factor precursor); a domain of protein DEK isoform 1; a domain of hepatocyte growth factor isoform 1 preprotein; a full length polypeptide or a domain of cytochrome c; a full length polypeptide or domain of C-X-C motif chemokine 24 precursor; or a domain of ataxin 7 isoform a.

35

5

80. The complex of any of claims 40-76, wherein the Surf+ Penetrating Polypeptide is a domain of any of the following, which domain has a charge per molecular weight ratio of at least 0.75 but for which the corresponding full length naturally occurring polypeptide has a charge/molecular weight ratio of less than 0.75:

10 histone-lysine N-methyltransferase MLL isoform 1 precursor; transcription factor AP-1; proheparin-binding EGF-like growth factor precursor; protein DEK isoform 1; hepatocyte growth factor isoform 1 preprotein; epidermal growth factor receptor isoform a precursor; forkhead box protein K2; pre-mRNA-processing factor 40 homolog A; ataxin-7 isoform a, E3 SUMO-protein ligase PIAS1; platelet factor 4
15 precursor; advanced glycosylation end product-specific receptor isoform 2 precursor; serol regulatory element-binding protein 2; histone acetyltransferase p300; U1 small nuclear ribonucleoprotein A; pre-B-cell leukemia transcription factor 1 isoform 2; homeobox protein Nkx 3.1; homeobox protein Hox-A9; B-cell lymphoma 6 protein isoform 1; ETS domain-containing protein Elk-4 isoform a; pituitary homeobox 3;
20 granulysin isoform NKG5; general transcription factor IIF subunit 1; histone deacetylase complex subunit SAP30; heterochromatin protein 1-binding protein 3; lethal(3)malignant brain tumor-like protein 2; CCAAT/enhancer-binding protein beta; troponin T, cardiac muscle isoform 2; CREB-binding protein isoform B; cyclic AMP-dependent transcription factor ATF-2; cathepsin E isoform a preprotein; glycine
25 receptor subunit alpha-1 isoform 1 precursor; CREB-binding protein isoform b; pituitary adenylate cyclase-activating polypeptide precursor; mastermind-like protein 1; BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; cathelicidin antimicrobial peptide; epidermal growth factor receptor isoform a precursor; transcription factor NF-E2 45 kDa subunit isoform 2; integrin beta-1 isoform 1D
30 precursor.

81. The complex of any of claims 40-76, wherein the Surf+ Penetrating Polypeptide is a domain of charged multivesicular body protein 6; homeobox protein Nkx3.1; B-cell lymphoma 6 protein isoform 1; lethal(3)malignant brain tumor-like
35 protein 2; cathepsin E isoform a preprotein; BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; cathelicidin antimicrobial peptide.

5

82. The complex of any of claims 40-76, wherein the Surf+ Penetrating Polypeptide is a domain of heparin-binding EGF-like growth factor precursor (HBEGF), which domain has surface positive charge and a molecular weight of about 8.9 kDa.

10

83. The complex of any of claims 40-82, wherein the Surf+ Penetrating Polypeptide is a naturally occurring human polypeptide that is modified to increase its overall net charge.

15

84. The complex of claim 40 or claim 83, wherein the Surf+ Penetrating Polypeptide is a polypeptide engineered to comprise an overall charge from about +10 to about +40.

20

85. The complex of any of claims 40-84, wherein the AAM moiety binds to a target and the target is a kinase, a transcription factor, or an oncoprotein.

86. The complex of any of claims 40-85, wherein the AAM moiety binds to a target and the target is NFAT-2, calcineurin, JAK-1, JAK-2, SOCS1, SOCS3, ras or Erk.

25

87. The complex of any of claims 40-86, wherein the AAM moiety binds to a target which localizes to a subcompartment of a cell.

88. The complex of claim 87, wherein the subcompartment of a cell is: nucleus, mitochondria, cytoplasm, or cytoplasmic face of cell membrane.

30

89. The complex of any of claims 40-88, wherein the complex further comprises one or more tags to facilitate detection or purification of the complex.

35

90. The complex of any of claims 40-89, wherein the complex further comprises a nuclear localization signal.

5 91. The complex of any of claims 40-89, wherein the complex further comprises a mitochondrial matrix localization signal or a peroxisomal targeting sequence.

92. The complex of any of claims 40-91, wherein the complex is a fusion protein comprising the Surf+ Penetrating Polypeptide and the AAM moiety, and wherein the
10 Surf+ Penetrating Polypeptide is N-terminal to the AAM moiety.

93. The complex of any of claims 40-91, wherein the complex is a fusion protein comprising the Surf+ Penetrating Polypeptide and the AAM moiety, and wherein the Surf+ Penetrating Polypeptide is C-terminal to the AAM moiety.

15

94. The complex of claim 92, wherein the fusion protein comprises the general formula:

Surf+ Penetrating Polypeptide portion-linker-AAM moiety.

20 95. The complex of claim 93, wherein the fusion protein comprises the general formula:

AAM moiety-linker-Surf+ Penetrating Polypeptide portion.

96. The complex of claim 94 or 95, wherein the fusion protein comprises one or
25 more tags to facilitate detection or purification of the fusion protein.

97. The complex of any of claims 94-96, wherein the fusion protein comprises a localization signal to promote targeting of the complex or the AAM moiety to a subcompartment of a cell.

30

98. A nucleic acid comprising a nucleotide sequence encoding the fusion protein of any of claims 92-97.

99. A vector comprising the nucleic acid of claim 98.

35

100. A host cell comprising the vector of claim 99.

5

101. A method of making a fusion protein, comprising
- (i) providing the host cell of claim 61 in culture media and culturing the host cell under suitable condition for expression of protein therefrom; and
 - (ii) expressing the fusion protein.

10

102. The method of claim 101, further comprising isolating the fusion protein from the culture media.

15

103. A method of delivering an AAM moiety into a cell, comprising
- providing the complex of any of claims 40-97 and
- contacting cells with the complex.

20

104. A method of inhibiting activity of an intracellular target in a cell, comprising
- providing a complex comprising
- a first portion comprising a Surf+ Penetrating Polypeptide and
- a second portion comprising an AAM moiety, which AAM moiety
- binds to and inhibits the intracellular target;
- contacting cells that express the target with the complex.

25

105. A method of inhibiting Hif1-alpha activity, STAT-5 activity or ras activity in a cell of a subject in need thereof comprising
- administering to the subject a complex comprising a Surf+ Penetrating Polypeptide and an AAM moiety, which AAM moiety binds to and inhibits activity of Hif1-alpha, STAT-5 or ras.

30

106. The method of any of claims 103-105, wherein the Surf+ Penetrating Polypeptide and the AAM moiety are associated by a noncovalent or covalent linkage.

35

107. The method of any of claims 104-106, wherein the Surf+ Penetrating Polypeptide is a human polypeptide.

5

108. The method of claim 107, wherein the Surf+ Penetrating Polypeptide is a naturally occurring human polypeptide.

10

109. The method of claim 108, wherein the Surf+ Penetrating Polypeptide is a domain of a full length, naturally occurring human polypeptide.

15

110. The method of claim 109, wherein the domain of the full length, naturally occurring human polypeptide has a charge/molecular weight ratio greater than that of the full length, naturally occurring human polypeptide.

20

111. The method of claim 109 or 110, wherein the domain has a charge/molecular weight ratio of at least 0.75 but the full length, naturally occurring human polypeptide has a charge/molecular weight ratio of less than 0.75.

112. The method of any of claims 109-111, wherein the domain is less than 150 amino acid residues.

25

113. The method of any of claims 104-112, wherein the Surf+ Penetrating Polypeptide is a human polypeptide having endogenous function as a DNA binding protein or it a domain of a full length polypeptide that has endogenous function as a DNA binding protein.

30

114. The method of any of claims 104-112, wherein the Surf+ Penetrating Polypeptide is a human polypeptide having endogenous function as a RNA binding protein or it a domain of a full length polypeptide that has endogenous function as a RNA binding protein.

35

115. The method of any of claims 104-112, wherein the Surf+ Penetrating Polypeptide is a human polypeptide having endogenous function as a heparin binding protein or it a domain of a full length polypeptide that has endogenous function as a heparin binding protein.

5

116. The method of any of claims 104-115, wherein the AAM moiety comprises a full length antibody molecule.

10

117. The method of any of claims 104-115, wherein the AAM moiety comprises an antibody fragment.

118. The method of claim 117, wherein the antibody fragment is a single chain antibody (scFv), a F(ab')₂ fragment, a Fab fragment, or an Fd fragment.

15

119. The method of any of claims 104-115, wherein the AAM moiety is a camelid antibody, an IgNAR, or an antibody like molecule having a targeting binding domain engineered into an Fc domain of the antibody like molecule.

20

120. The method of any of claims 104-115, wherein the AAM moiety comprises a bispecific antibody.

121. The method of any of claims 104-115, wherein the AAM moiety comprises an antibody-like protein scaffold.

25

122. The method of claim 121, wherein the AAM moiety comprises a DARPin polypeptide, an Adnectin[®] polypeptide or an Anticalin[®] polypeptide.

30

123. The method of any of claims 104-115, wherein the AAM moiety comprises: a target binding scaffold from Src homology domains (e.g. SH2 or SH3 domains), PDZ domains, beta-lactamase, high affinity protease inhibitors, an EGF-like domain, a Kringle-domain, a PAN domain, a Gla domain, a SRCR domain, a Kunitz/Bovine pancreatic trypsin Inhibitor domain, a Kazal-type serine protease inhibitor domain, a Trefoil (P-type) domain, a von Willebrand factor type C domain, an Anaphylatoxin-like domain, a CUB domain, a thyroglobulin type I repeat, LDL-receptor class A domain, a Sushi domain, a Link domain, a Thrombospondin type I domain, a C-type lectin domain, a MAM domain, a von Willebrand factor type A domain, a

35

5 Somatomedin B domain, a WAP-type four disulfide core domain, a F5/8 type C domain, a Hemopexin domain, a Laminin-type EGF-like domain, or a C2 domain.

124. The method of any of claims 104-123, wherein the Surf+ Penetrating Polypeptide and the AAM moiety are associated non-covalently.

10

125. The method of any of claims 104-123 wherein the Surf+ Penetrating Polypeptide and the AAM moiety are associated via a covalent interconnection.

126. The method of claim 125, wherein the Surf+ Penetrating Polypeptide and the
15 AAM moiety are interconnected by a linker.

127. The method of claim 125, wherein the Surf+ Penetrating Polypeptide and the AAM moiety are directly interconnected without a linker.

20 128. The method of claim 126, wherein the linker is a peptide linker and the Surf+ Penetrating Polypeptide and the AAM moiety form a fusion protein.

129. The method of claim 126, wherein the linker comprises an amide, an ester, or a disulfide bond.

25

130. The method of claim 126, 128 or 129, wherein the linker is a cleavable linker.

131. The method of claim 130, wherein the cleavable linker can be cleaved by a naturally occurring cellular enzyme.

30

132. The method of claim 131, wherein the cellular enzyme is an endosomal protease or an endosomal esterase.

133. A composition comprising the complex of any of claims 40-117 and a
35 pharmaceutically acceptable carrier.

5 134. The complex of any of claims 40-117, wherein the complex can penetrate a cell.

135. The complex of any of claims 40-117, wherein the complex binds to the target via the AAM moiety.

10

136. The complex of any of claims 40-117, wherein the complex comprises a modification selected from glycosylation, phosphorylation or pegylation.

137. The complex of any of claims 40-135, wherein the complex is not
15 glycosylated.

138. A fusion protein comprising
a Surf+ Penetrating Polypeptide and
an AAM moiety that binds an intracellular target.

20

139. A fusion protein comprising
a first polypeptide portion comprising a Surf+ Penetrating Polypeptide and
a second polypeptide portion comprising an AAM moiety that binds to an
intracellular target.

25

140. The fusion protein of claim 138 or 139, wherein the Surf+ Penetrating Polypeptide is a human polypeptide.

141. The fusion protein of claim 138 or 139, wherein the Surf+ Penetrating
30 Polypeptide is a naturally occurring human polypeptide.

142. The fusion protein of any of claims 138-141, wherein the Surf+ Penetrating Polypeptide is a domain of a full length, naturally occurring human polypeptide.

5 143. The fusion protein of claim 142, wherein the domain of a full length, naturally occurring human polypeptide has a charge/molecular weight ratio greater than that of the full length, naturally occurring human polypeptide.

10 144. The fusion protein of claim 142, wherein the domain has a charge/molecular weight ratio of at least 0.75 but the full length, naturally occurring human polypeptide has a charge/molecular weight ratio of less than 0.75.

145. The fusion protein of any of claims 142-144, wherein the domain is less than 150 amino acid residues.

15 146. The fusion protein of any of claims 138-145, wherein the Surf+ Penetrating Polypeptide is a human polypeptide having endogenous function as a DNA binding protein or it a domain of a full length polypeptide that has endogenous function as a DNA binding protein.

20 147. The fusion protein of any of claims 138-145, wherein the Surf+ Penetrating Polypeptide is a human polypeptide having endogenous function as a RNA binding protein or it a domain of a full length polypeptide that has endogenous function as a RNA binding protein.

25 148. The fusion protein of any of claims 138-145, wherein the Surf+ Penetrating Polypeptide is a human polypeptide having endogenous function as a heparin binding protein or it a domain of a full length polypeptide that has endogenous function as a heparin binding protein.

30 149. The fusion protein of any of claims 138-148, wherein the AAM moiety comprises a full length antibody molecule.

35 150. The fusion protein of any of claims 138-148, wherein the AAM moiety comprises an antibody fragment.

5 151. The fusion protein of claim 150, wherein the antibody fragment is a single chain antibody (scFv), a F(ab')₂ fragment, a Fab fragment, or an Fd fragment.

152. The fusion protein of any of claims 138-148, wherein the AAM moiety is a camelid antibody, an IgNAR, or an antibody like molecule having a target binding
10 domain engineered into an Fc domain of the antibody like molecule.

153. The fusion protein of any of claims 138-148, wherein the AAM moiety comprises a bispecific antibody.

15 154. The fusion protein of any of claims 138-148 wherein the AAM moiety comprises an antibody-mimic comprising a protein scaffold.

155. The fusion protein of claim 154, wherein the AAM moiety comprises a DARPin polypeptide, an Adnectin[®] polypeptide or an Anticalin[®] polypeptide.
20

156. The fusion protein of any of claims 138-148, wherein the AAM moiety comprises: a target binding scaffold from Src homology domains (e.g. SH2 or SH3 domains), PDZ domains, beta-lactamase, high affinity protease inhibitors, an EGF-like domain, a Kringle-domain, a PAN domain, a Gla domain, a SRCR domain, a
25 Kunitz/Bovine pancreatic trypsin Inhibitor domain, a Kazal-type serine protease inhibitor domain, a Trefoil (P-type) domain, a von Willebrand factor type C domain, an Anaphylatoxin-like domain, a CUB domain, a thyroglobulin type I repeat, LDL-receptor class A domain, a Sushi domain, a Link domain, a Thrombospondin type I domain, a C-type lectin domain, a MAM domain, a von Willebrand factor type A
30 domain, a Somatomedin B domain, a WAP-type four disulfide core domain, a F5/8 type C domain, a Hemopexin domain, a Laminin-type EGF-like domain, or a C2 domain.

157. The fusion protein of any of claims 138-156, wherein the Surf+ Penetrating
35 Polypeptide or the portion comprising the Surf+ Penetrating Polypeptide and the AAM moiety are interconnected by a linker.

5

158. The fusion protein of any of claims 138-156, wherein the Surf+ Penetrating Polypeptide or the portion comprising the Surf+ Penetrating Polypeptide and the AAM moiety are directly interconnected without a linker.

10 159. The fusion protein of claim 157, wherein the linker is a cleavable linker.

160. A complex comprising

(a) a polypeptide selected from the group consisting of: agouti-signaling protein precursor, band 3 anion transport protein, B-cell lymphoma 6 protein isoform 1, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, beta-defensin 1 preproprotein, cathepsin E isoform a preproprotein, charged multivesicular body protein 6, cpG-binding protein isoform 2, C-X-C motif chemokine 10 precursor, epidermal growth factor receptor isoform a precursor, histone acetyltransferase MYST3, histone acetyltransferase p300, homeobox protein Nkx-3.1, lethal(3)malignant brain tumor-like protein 2, male-specific lethal 3 homolog isoform a, Na(+)/H(+) exchange regulatory cofactor NHE-RF1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, POU domain class 2-associating factor 1, prostatic acid phosphatase isoform PAP precursor, receptor tyrosine-protein kinase erbB-2 isoform b, receptor tyrosine-protein kinase erbB-3 isoform 1 precursor, receptor tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor, RING1 and YY1-binding protein, sterol regulatory element-binding protein 2, stromal cell-derived factor 1 isoform gamma, talin-1, T-cell surface glycoprotein CD4 isoform 1 precursor, transcription factor AP-1, transcription factor NF-E2 45 kDa subunit isoform 2, transcription factor Sp1 isoform b, voltage-dependent L-type calcium channel subunit alpha-1C isoform 23, zinc finger protein 224, zinc finger protein 268 isoform c, zinc finger protein 28 homolog, zinc finger protein 32, zinc finger protein 347 isoform a, zinc finger protein 347 isoform b, and zinc finger protein 40 and

(b) an AAM moiety;

5 wherein the AAM moiety binds to an intracellular target distinct from the polypeptide associated with the AAM moiety in said complex and/or the complex is a fusion protein.

161. A complex comprising

- 10 (a) a polypeptide selected from the group consisting of: agouti-signaling protein precursor, band 3 anion transport protein, B-cell lymphoma 6 protein isoform 1, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, beta-defensin 1 preproprotein, cathepsin E isoform a preproprotein, charged multivesicular body protein 6, cpG-binding protein isoform 2, C-X-C motif
- 15 chemokine 10 precursor, epidermal growth factor receptor isoform a precursor, histone acetyltransferase MYST3, histone acetyltransferase p300, homeobox protein Nkx-3.1, lethal(3)malignant brain tumor-like protein 2, male-specific lethal 3 homolog isoform a, Na(+)/H(+) exchange regulatory cofactor NHE-RF1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,
- 20 peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, POU domain class 2-associating factor 1, prostatic acid phosphatase isoform PAP precursor, receptor tyrosine-protein kinase erbB-2 isoform b, receptor tyrosine-protein kinase erbB-3 isoform 1 precursor, receptor tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor, RING1 and YY1-binding protein, sterol
- 25 regulatory element-binding protein 2, stromal cell-derived factor 1 isoform gamma, talin-1, T-cell surface glycoprotein CD4 isoform 1 precursor, transcription factor AP-1, transcription factor NF-E2 45 kDa subunit isoform 2, transcription factor Sp1 isoform b, voltage-dependent L-type calcium channel subunit alpha-1C isoform 23, zinc finger protein 224, zinc finger
- 30 protein 268 isoform c, zinc finger protein 28 homolog, zinc finger protein 32, zinc finger protein 347 isoform a, zinc finger protein 347 isoform b, or zinc finger protein 40, or a domain of any of the foregoing having surface positive charge, a mass of at least 4kDa and a charge/molecular weight ratio of at least 0.75 and
- 35 (b) an AAM moiety;

5 wherein the AAM moiety binds to an intracellular target distinct from the polypeptide associated with the AAM moiety in said complex and/or the complex is a fusion protein.

162. A complex comprising

10 (a) a polypeptide comprising an amino acid sequence at least 95% identical to any of the amino acid sequences set forth in Section 2 of the sequence listing and identified in such sequence listing by PDB identifier, or a domain thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75 and

15 (b) an AAM moiety;

wherein the AAM moiety binds to an intracellular target distinct from the polypeptide associated with the AAM moiety in said complex and/or the complex is a fusion protein.

20 163. The complex of claim 162, wherein (a) comprises a polypeptide comprising an amino acid sequence identical to any of the amino acid sequences set forth in Section 2 of the sequence listing and identified in such sequence listing by PDB identifier, or a domain thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75.

25

164. The complex of claim 162 or 163, wherein (a) comprises a polypeptide comprising an amino acid sequence at least 95%-100% identical to an amino acid sequence set forth in Section 2 of the sequence listing and identified in such sequence listing by PDB identifier.

30

165. A complex comprising

(a) a polypeptide comprising an amino acid sequence at least 95% identical to any of the amino acid sequences set forth in Section 1 of the sequence listing and identified in such sequence listing by GenBank accession number, or a domain thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75 and

35

5 (b) an AAM moiety;

wherein the AAM moiety binds to an intracellular target distinct from the polypeptide associated with the AAM moiety in said complex and/or the complex is a fusion protein.

10 166. The complex of claim 165, wherein (a) comprises a polypeptide comprising an amino acid sequence identical to any of the amino acid sequences set forth in Section 1 of the sequence listing and identified in such sequence listing by GenBank accession number, or a domain thereof having surface positive charge, a mass of at least 4 kDa, and a charge/molecular weight ratio of at least 0.75.

15

167. The complex of claim 165 or 166, wherein (a) comprises a polypeptide comprising an amino acid sequence at least 95%-100% identical to an amino acid sequence set forth in Section 1 of the sequence listing and identified in such sequence listing by GenBank accession number.

20

Figure 1

PDB ID	PDB chain	Subseq Start	Subseq End	Protein Name	charge/MW	MW	charge	AA	% FL	# AA	Refseq	charge/MW	MW	charge
2I2S	A	1146	1214	histone-lysine N-methyltransferase MILL isoform 1 precursor	1.86	8.05	15	72	1.74	3972	NP_001184033.1	0.24	432.03	102
1FOS	F	254	315	transcription factor AP-1	1.78	7.30	13	62	18.73	331	NP_002219.1	0.11	35.67	4
1G2S	A	24	94	C-C motif chemokine 26 precursor	1.55	8.40	13	71	75.53	94	NP_006063.1	1.22	10.65	13
				proheparin-binding EGF-like growth factor precursor	1.35	8.90	12	79	36.54	208	NP_001936.1	0.52	23.07	12
2IX3	A	78	208	protein DEK isoform 1	1.26	15.07	19	131	34.93	375	NP_003463.1	0.14	42.67	6
2HGF	A	31	127	hepatocyte growth factor isoform 1 preproprotein	1.23	11.38	14	97	13.32	728	NP_000592.3	0.10	83.13	8
1K16	A	23	67	beta-defensin 103 precursor	2.13	5.16	11	45	67.16	67	NP_001075020.1	1.56	7.70	12
1TDH	A			Endonuclease VIII-like 1	0.51	40.85	21	364	93.33	390	NP_078684.2	0.53	43.68	23
1I3S	A	2	105	cytochrome c	0.77	11.62	9	104	99.05	105	NP_061820.1	0.77	11.75	9
1NUN	A	64	208	fibroblast growth factor 10 precursor	1.01	16.78	17	145	69.71	208	NP_004456.1	0.68	23.44	16
1E1G	A	27	99	C-C motif chemokine 24 precursor	1.20	8.31	10	73	61.34	119	NP_002982.2	0.99	13.13	13
1E8O	B	2	107	signal recognition particle 14 kDa protein	1.24	12.09	15	106	77.94	136	NP_003125.3	1.03	14.57	15
1Z9I	A	669	721	epidermal growth factor receptor isoform a precursor	1.28	6.23	8	53	4.38	1210	NP_005219.2	-0.09	134.27	-12
2HDL	A	34	111	C-X-C motif chemokine 14 precursor	1.37	9.48	13	78	70.27	111	NP_004878.2	1.22	13.08	16
1IXS	A	256	353	forkhead box protein K2	0.78	11.54	9	98	14.85	660	NP_004505.2	0.22	69.06	15
1UZC	A	354	423	pre-mRNA-processing factor 40 homolog A	0.85	8.24	7	71	7.53	930	NP_060362.3	0.02	105.92	2
2Y9A	D	1	126	small nuclear ribonucleoprotein Sm D3	0.86	13.92	12	126	100.00	126	NP_004166.1	0.86	13.92	12
2KKR	A	330	401	ataxin-7 isoform a	1.03	8.74	9	74	8.07	892	NP_000324.1	0.50	95.45	48

Figure 1 (continued)

1V66	A	1	65	E3 SUMO-protein ligase PIAS1	1.07	7.45	8	65	9.98	651	NP_057250.1	-0.03	71.83	-2
1PFM	A	38	101	platelet factor 4 precursor	1.18	7.61	9	68	63.37	101	NP_002610.1	0.37	10.84	4
				advanced glycosylation end product-specific receptor isoform 2										
2E5E	A	23	121	precursor	0.80	11.20	9	101	23.57	420	NP_001193858.1	-0.09	44.77	-4
				fibroblast growth factor 8										
2FDB	M	23	186	isoform B precursor	0.85	18.87	16	164	76.28	215	NP_006110.1	0.81	24.71	20
				steroid regulatory element-binding protein										
1UKL	C	343	403	2	0.98	7.12	7	61	5.35	1141	NP_004590.2	0.10	123.68	12
				charged multivesicular body protein 5										
3HTU	B	11	48	stromal cell-derived factor 1 isoform gamma	1.07	4.69	5	39	18.91	201	NP_078867.2	-0.21	23.48	-5
				histone acetyltransferase p300										
2KOL	A	22	89	U1 small nuclear ribonucleoprotein A	1.25	7.98	10	68	57.14	119	NP_001029058.1	1.68	13.71	23
				pre-B-cell leukemia transcription factor 1 isoform 2										
2K8F	A	1723	1809	homeobox protein Nkx- 3.1	1.41	9.94	14	90	3.60	2414	NP_001420.2	0.11	264.15	30
3IWN	C	6	96	homeobox protein Hox- A9	0.76	10.53	8	91	32.27	282	NP_004587.1	0.38	31.28	12
				homeobox protein Hox- A9										
1PUF	B	233	305	B-cell lymphoma 6 protein isoform 1	0.80	8.73	7	73	21.04	347	NP_001191890.1	0.10	38.43	4
				ETS domain-containing protein Elk-4 isoform a										
2L9R	A	129	189	pituitary homeobox 3	0.96	8.35	8	69	26.07	234	NP_006158.2	0.19	26.35	5
				granulysin isoform NKG5										
1PUF	A	194	270		1.45	9.62	14	77	28.31	272	NP_689952.1	0.13	30.17	4
2LCE	A	536	602		0.93	8.62	8	74	9.49	706	NP_001124317.1	0.09	78.84	7
1BC7	C	1	93		0.80	11.20	9	93	21.58	431	NP_001964.2	0.02	46.90	1
1YZ8	P	62	121		0.83	8.47	7	68	19.87	302	NP_005020.1	0.25	31.83	8
1L9L	A	63	136		1.27	8.66	11	74	51.03	145	NP_006424.2	0.49	16.37	8

Figure 1 (continued)

1127	A	449	517	general transcription factor IIF subunit 1	0.84	8.36	7	73	13.35	517	NP_002087.2	0.00	58.24	0
2KDP	A	61	131	histone deacetylase complex subunit SAP30	1.48	8.11	12	71	32.27	220	NP_003855.1	0.34	23.31	8
2RQP	A	153	237	heterochromatin protein 1-binding protein 3	1.45	9.67	14	88	15.37	553	NP_057371.2	0.57	61.20	35
1EOT	A	24	97	eotaxin precursor	1.32	8.36	11	74	76.29	97	NP_002977.1	1.12	10.73	12
211Q	A	38	77	liver-expressed antimicrobial peptide 2 precursor	0.87	4.59	4	40	51.95	77	NP_443203.1	0.91	8.81	8
2WOT	A	82	124	lethal(3)malignant brain tumor-like protein 2	0.87	4.60	4	43	6.10	705	NP_113676.2	-0.08	79.11	-6
118I	A	22	114	lymphotactin precursor	0.88	10.27	9	93	81.58	114	NP_002986.1	0.72	12.52	9
1H89	A	273	336	CCAAT/enhancer-binding protein beta	0.90	7.80	7	64	18.55	345	NP_005185.2	0.11	36.10	4
111D	B	183	288	troponin T, cardiac muscle isoform 2	1.09	12.81	14	105	36.81	288	NP_001001430.1	-0.46	34.59	-16
1KBH	B	2020	2078	CREB-binding protein isoform b	0.91	6.56	6	59	2.45	2404	NP_001073315.1	0.10	260.98	27
1T2K	D	354	414	cyclic AMP-dependent transcription factor ATF-2	1.26	7.12	9	61	12.08	505	NP_001871.2	0.02	54.54	1
1T2S	P	19	53	cathepsin E isoform a preproprotein	1.66	4.21	7	35	8.84	396	NP_001901.1	-0.37	42.79	-16
1VRV	A	278	341	glycine receptor subunit alpha-1 isoform 1 precursor	0.82	8.51	7	76	14.00	457	NP_001139512.1	0.15	52.62	8
1ZOQ	C	2027	2073	CREB-binding protein isoform b	0.95	5.27	5	47	1.96	2404	NP_001073315.1	0.10	260.98	27
2D2P	A	132	169	pituitary adenylate cyclase-activating polypeptide precursor	1.96	4.59	9	39	21.59	176	NP_001108.2	0.53	18.83	10
2F8X	M	12	74	mastermind-like protein 1	1.07	7.51	8	63	6.20	1016	NP_055572.1	0.04	108.05	4
215D	A	146	190	BCL2/adenovirus E1B 19 kDa protein-interacting protein 3	1.02	4.92	5	45	23.20	194	NP_004043.2	-0.09	21.54	-2

Figure 1 (continued)

2K6O	A	134	170	cathelicidin antimicrobial peptide	1.34	4.49	6	37	21.76	170	NP_004336.2	0.41	19.30	8
				T-cell surface										
2K1U	A	119	185	glycoprotein CD4 isoform 3	1.40	7.85	11	70	36.22	185	NP_001181946.1	0.73	20.68	15
				epidermal growth factor receptor isoform a precursor	1.27	4.73	6	44	3.64	1210	NP_005219.2	-0.09	134.27	-12
2KS1	B	634	677	transcription factor NF-E2										
2KZ5	A	214	293	45 kDa subunit isoform 2	0.76	10.54	8	91	21.45	373	NP_001129495.1	-0.39	41.47	-16
				serine/arginine-rich										
38EG	B	105	219	splicing factor 1 isoform 1	0.85	12.99	11	115	46.37	248	NP_008855.1	0.72	27.74	20
				parathyroid hormone-related protein isoform 2										
3FFD	P	37	144	preproprotein	1.03	12.56	13	108	61.71	175	NP_945315.1	0.70	19.90	14
				integrin beta-1 isoform										
3G9W	C	752	801	1D precursor	0.81	6.18	5	52	6.24	801	NP_391988.1	-0.19	88.88	-17
				60S ribosomal protein										
2PA2	A	34	182	L10	0.76	17.16	13	151	69.63	214	NP_006004.2	1.02	24.60	25
				advanced glycosylation end product-specific receptor isoform 2 precursor										
2L7U	A	23	125	precursor	0.78	11.55	9	105	24.52	420	NP_001193858.1	-0.09	44.77	-4
				C-C motif chemokine 13 precursor	1.26	8.73	11	76	76.53	98	NP_005399.1	1.09	10.99	12
2RA4	A	24	98											
2VXW	A	24	91	C-C motif chemokine 5 precursor	0.76	7.91	6	69	74.73	91	NP_002976.2	0.60	9.99	6
				C-C motif chemokine 7 precursor										
1B00	A	24	99	precursor	1.00	8.96	9	76	76.77	99	NP_006264.2	0.89	11.20	10
1QNK	A	39	107	C-X-C motif chemokine 2	1.06	7.54	8	69	64.49	107	NP_002080.1	1.14	11.39	13
3CO7	C	151	266	forkhead box protein O1	0.91	13.13	12	117	17.71	655	NP_002006.2	-0.09	69.66	-6
2K86	A	151	251	forkhead box protein O3	0.86	11.69	10	103	15.01	673	NP_963853.1	-0.27	71.27	-19
				forkhead box protein O4 isoform 1	0.78	16.58	13	150	24.95	505	NP_005929.2	-0.28	53.68	-15
1E17	A	86	211											
				general transcription factor IIF subunit 1	0.86	9.33	8	82	15.86	517	NP_002087.2	0.00	58.24	0
1NHA	A	436	517											
2K7L	A	451	517	general transcription factor IIF subunit 1	0.89	7.89	7	67	12.96	517	NP_002087.2	0.00	58.24	0

Figure 1 (continued)

1BFF	A	160	288	heparin-binding growth factor 2	0.81	14.77	12	129	44.79	288	NP_001997.5	1.04	30.77	32
1CVS	A	157	288	heparin-binding growth factor 2	0.80	15.08	12	132	45.83	288	NP_001997.5	1.04	30.77	32
3HMS	A	28	126	hepatocyte growth factor isoform 1 preproprotein	1.10	11.77	13	101	13.60	728	NP_000592.3	0.10	83.13	8
1M36	A	532	563	histone acetyltransferase MYST3	1.49	4.04	6	33	1.60	2004	NP_001092883.1	-0.24	225.02	-53
3R45	A	1	140	histone H3-like centromeric protein A isoform a	0.90	17.80	16	156	100.00	140	NP_001800.1	1.06	15.99	17
3AN2	A	1	140	histone H3-like centromeric protein A isoform a	1.04	16.27	17	143	100.00	140	NP_001800.1	1.06	15.99	17
3NQU	A	1	140	histone H3-like centromeric protein A isoform a	1.06	15.99	17	140	100.00	140	NP_001800.1	1.06	15.99	17
1B72	A	171	266	homeobox protein Hox-B1	0.88	11.42	10	97	31.89	301	NP_002135.2	-0.03	32.19	-1
2KT0	A	74	157	homeobox protein NANOG	1.29	10.05	13	84	27.54	305	NP_079141.2	-0.03	34.62	-1
1HLV	A	1	129	major centromere autoantigen B	0.92	15.14	14	131	21.54	599	NP_001801.1	-0.98	65.17	-64
1BW6	A	1	56	major centromere autoantigen B	0.92	6.53	6	56	9.35	599	NP_001801.1	-0.98	65.17	-64
3OA6	A	1	101	male-specific lethal 3 homolog isoform a	0.84	13.07	11	110	19.39	521	NP_523353.2	0.07	59.82	4
1NLW	A	60	136	max dimerization protein 1 isoform 2	0.96	9.42	9	80	35.00	220	NP_001189442.1	0.16	25.12	4
1K99	A	103	192	nucleolar transcription factor 1 isoform a	0.97	12.36	12	99	11.78	764	NP_055048.1	-0.18	89.40	-16
2LB3	A	6	41	peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	0.95	4.22	4	36	22.09	163	NP_006212.1	0.16	18.24	3
2KCF	A	6	39	peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	0.96	4.17	4	36	20.86	163	NP_006212.1	0.16	18.24	3

Figure 1 (continued)

2IOD	B	137	169	pituitary adenylate cyclase-activating polypeptide precursor	2.48	4.03	10	33	18.75	176	NP_001108.2	0.53	18.83	10
1CQT	I	1	44	POU domain class 2-associating factor 1	1.23	4.86	6	44	17.19	256	NP_006226.2	-0.36	27.43	-10
1POG	A	338	398	POU domain, class 2, transcription factor 1 isoform 3	0.86	8.17	7	67	8.68	703	NP_001185715.1	-0.07	72.08	-5
1B72	B	233	319	pre-B-cell leukemia transcription factor 1 isoform 2	0.80	10.05	8	87	25.07	347	NP_001191890.1	0.10	38.43	4
3KUC	B	51	131	RAF proto-oncogene serine/threonine-protein kinase	0.75	9.29	7	81	12.50	648	NP_002871.1	0.27	73.05	20
2IWA	A	611	654	receptor tyrosine-protein kinase erbB-2 isoform b	1.27	4.73	6	44	3.59	1225	NP_001005862.1	-0.23	134.85	-31
2L2T	A	642	685	receptor tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor	1.68	4.76	8	44	3.41	1292	NP_001036064.1	-0.12	145.19	-18
2AZE	C	829	874	retinoblastoma-associated protein	0.98	5.11	5	46	4.96	928	NP_000312.2	0.04	106.16	4
3BSU	A	27	76	ribonuclease H1	0.97	6.18	6	53	17.48	286	NP_002927.2	0.25	32.06	8
3IXS	B	144	176	RING1 and YY1-binding protein	0.98	4.10	4	37	14.47	228	NP_036366.3	0.56	24.82	14
2FY1	A	1	109	RNA-binding motif protein, Y chromosome, family 1 member B	0.78	12.78	10	116	21.98	496	NP_001006121.1	0.57	55.83	32
1YO5	C	243	335	SAM pointed domain-containing Ets transcription factor	1.04	11.57	12	97	27.76	335	NP_036523.1	-0.16	37.52	-6
1K6O	B	133	235	serum response factor	1.04	11.53	12	103	20.28	508	NP_003122.1	0.02	51.59	1
1HEX	A	132	223	serum response factor	1.17	10.28	12	92	18.11	508	NP_003122.1	0.02	51.59	1
1I46	A	56	140	sex-determining region Y protein	1.32	10.63	14	85	41.67	204	NP_003131.1	0.50	23.88	12
1I47	A	56	140	sex-determining region Y protein	1.32	10.61	14	85	41.67	204	NP_003131.1	0.50	23.88	12

Figure 1 (continued)

1B34	B	1	118	small nuclear ribonucleoprotein Sm D2 isoform 1	0.81	13.53	11	118	100.00	118	NP_004588.1	0.81	13.53	11
				steroid regulatory element-binding protein 1 isoform a	1.06	9.47	10	82	6.97	1177	NP_001005291.1	0.04	124.63	5
3590	C	1512	1546	taln-1	1.22	4.10	5	40	1.38	2541	NP_006280.3	-0.13	269.76	-35
1NVP	A	159	339	TATA-box-binding protein isoform 1	0.78	20.41	16	181	53.39	339	NP_003185.1	0.34	37.70	13
1CDW	A	159	337	TATA-box-binding protein isoform 1	0.79	20.20	16	179	52.80	339	NP_003185.1	0.34	37.70	13
1TGH	A	155	339	TATA-box-binding protein isoform 1	0.82	20.77	17	185	54.57	339	NP_003185.1	0.34	37.70	13
1IFI	C	135	319	TATA-box-binding protein isoform 2	0.77	20.82	16	185	57.99	319	NP_001165556.1	0.39	35.66	14
1C9B	B	138	317	TATA-box-binding protein isoform 2	0.79	20.27	16	180	56.43	319	NP_001165556.1	0.39	35.66	14
3A03	A	162	216	T-cell leukemia homeobox protein 2	1.47	6.82	10	55	19.37	284	NP_057254.1	0.55	30.25	17
				T-cell surface glycoprotein CD4 isoform 1 precursor	2.14	4.68	10	38	8.30	458	NP_000607.1	0.45	51.11	23
1Q68	A	421	458	telomeric repeat-binding factor 1 isoform 1	1.05	8.58	9	70	15.95	439	NP_059523.2	-0.14	50.24	-7
1IV6	A	370	439	telomeric repeat-binding factor 1 isoform 1	1.07	8.45	9	69	15.72	439	NP_059523.2	-0.14	50.24	-7
1ITY	A	371	439	telomeric repeat-binding factor 1 isoform 1	1.51	6.62	10	53	12.07	439	NP_059523.2	-0.14	50.24	-7
1W0T	A	379	431	telomeric repeat-binding factor 1 isoform 1	1.07	6.55	7	55	11.00	500	NP_005643.1	0.18	55.55	10
1W0U	A	446	500	THAP domain-containing protein 1 isoform 1	0.79	10.17	8	87	38.50	213	NP_060575.1	0.20	24.94	5
2K00	A	1	82	transcription factor AP-1	1.80	6.12	11	52	15.71	331	NP_002219.1	0.11	35.67	4
159K	E	257	308	transcription factor AP-1	1.68	6.57	11	56	16.92	331	NP_002219.1	0.11	35.67	4
1A02	J	253	308	transcription factor AP-1	1.78	7.30	13	62	18.73	331	NP_002219.1	0.11	35.67	4
1T2K	C	253	314	transcription factor SOX-2	1.31	10.69	14	88	26.50	317	NP_003097.1	0.38	34.31	13
1O4X	B	38	121											

Figure 1 (continued)

2LE4	A	39	118	transcription factor SOX-2	1.31	9.89	13	81	25.24	317	NP_003097.1	0.38	34.31	13
1GT0	D	39	118	transcription factor SOX-2	1.33	9.81	13	80	25.24	317	NP_003097.1	0.38	34.31	13
1VA1	A	612	647	transcription factor Sp1 isoform b	1.40	4.29	6	37	4.63	778	NP_003100.1	0.01	79.89	1
1H88	C	37	193	transcriptional activator Myb isoform 1	0.78	19.13	15	159	20.63	761	NP_001123645.1	-0.07	85.47	-6
1H8A	C	70	193	transcriptional activator Myb isoform 4	0.78	15.45	12	128	16.36	758	NP_001155128.1	-0.07	85.16	-6
2HFG	R	4	54	tumor necrosis factor receptor superfamily member 13C	0.75	5.31	4	51	27.72	184	NP_443177.1	0.11	18.86	2
1OSX	A	1	61	tumor necrosis factor receptor superfamily member 13C	0.92	6.53	6	61	33.15	184	NP_443177.1	0.11	18.86	2
3I3C	A	7	96	U1 small nuclear ribonucleoprotein A	0.77	10.43	8	90	31.91	282	NP_004587.1	0.38	31.28	12
1FHT	A	2	117	U1 small nuclear ribonucleoprotein A	0.81	13.54	11	116	41.13	282	NP_004587.1	0.38	31.28	12
2BE6	D	1600	1633	voltage-dependent L-type calcium channel subunit alpha-1C isoform 23	0.92	4.36	4	37	1.55	2198	NP_001161097.1	-0.04	245.94	-11
1N0Z	A	1	40	zinc finger Ran-binding domain-containing protein 2 isoform 2	0.80	5.00	4	45	12.50	320	NP_005446.2	0.63	36.32	23
1HJB	A	259	345	CCAAT/enhancer-binding protein beta	0.98	10.22	10	87	25.22	345	NP_005185.2	0.11	36.10	4
2E43	A	259	336	CCAAT/enhancer-binding protein beta	0.97	9.30	9	78	22.61	345	NP_005185.2	0.11	36.10	4
1C16	B	273	334	CCAAT/enhancer-binding protein beta	1.04	7.73	8	63	17.97	345	NP_005185.2	0.11	36.10	4
1GTW	A	259	336	CCAAT/enhancer-binding protein beta	1.07	9.36	10	78	22.61	345	NP_005185.2	0.11	36.10	4
2E42	A	259	336	CCAAT/enhancer-binding protein beta	1.07	9.33	10	78	22.61	345	NP_005185.2	0.11	36.10	4
3NWV	A	2	105	cytochrome c	0.77	11.65	9	104	99.05	105	NP_061820.1	0.77	11.75	9
2CGY	A	256	353	forkhead box protein K2	0.78	12.79	10	111	14.85	660	NP_004505.2	0.22	69.06	15

Figure 1 (continued)

2HDM	A	23	114	lymphotactin precursor	0.88	10.18	9	92	80.70	114	NP_002986.1	0.72	12.52	9
				small nuclear										
3CW1	D	1	126	ribonucleoprotein Sm D3	0.86	13.93	12	126	100.00	126	NP_004166.1	0.86	13.92	12
				stromal cell-derived										
2I7Z	A	22	89	factor 1 isoform gamma	1.13	7.96	9	68	57.14	119	NP_001029058.1	1.68	13.71	23
				stromal cell-derived										
2KEE	A	21	89	factor 1 isoform gamma	1.11	8.11	9	70	57.98	119	NP_001029058.1	1.68	13.71	23
				stromal cell-derived										
2KEC	A	22	89	factor 1 isoform gamma	1.10	8.15	9	70	57.14	119	NP_001029058.1	1.68	13.71	23
				stromal cell-derived										
1QG7	A	22	88	factor 1 isoform gamma	1.02	7.84	8	67	56.30	119	NP_001029058.1	1.68	13.71	23
				stromal cell-derived										
2NWG	A	22	88	factor 1 isoform gamma	1.00	7.98	8	68	56.30	119	NP_001029058.1	1.68	13.71	23
				stromal cell-derived										
3HP3	A	22	88	factor 1 isoform gamma	1.00	7.97	8	68	56.30	119	NP_001029058.1	1.68	13.71	23
				stromal cell-derived										
1VMC	A	19	89	factor 1 isoform gamma	0.96	8.33	8	71	59.66	119	NP_001029058.1	1.68	13.71	23
				stromal cell-derived										
3GV3	A	26	88	factor 1 isoform gamma	0.94	7.44	7	63	52.94	119	NP_001029058.1	1.68	13.71	23
				stromal cell-derived										
1UN5	A	25	147	angiogenin precursor	0.76	14.43	11	125	84.35	147	NP_001091046.1	0.60	16.55	10
				beta-defensin 1										
2PLZ	A	33	68	preproprotein	0.99	4.05	4	36	52.94	68	NP_005209.1	0.67	7.42	5
				brain-derived										
				neurotrophic factor										
1BND	A	129	247	isoform a preproprotein	0.81	13.51	11	119	48.18	247	NP_001137288.1	0.25	27.82	7
				C-C motif chemokine 23										
				isoform CKbeta8										
1G91	A	44	120	precursor	0.79	8.85	7	77	64.17	120	NP_665905.1	0.52	13.41	7
				precursor										
1IOX	A	62	111	probetacellulin precursor	0.85	5.90	5	50	28.09	178	NP_001720.1	0.25	19.75	5
				stromal cell-derived										
2K01	A	22	89	factor 1 isoform gamma	1.10	8.17	9	70	57.14	119	NP_001029058.1	1.68	13.71	23
				THAP domain-containing										
2ITG	A	1	82	protein 1 isoform 1	0.78	10.20	8	87	38.50	213	NP_060575.1	0.20	24.94	5
				artemin isoform 3										
2ASK	A	116	228	precursor	1.00	11.96	12	113	49.56	228	NP_001129687.1	0.89	23.62	21
				cysteine and glycine-rich										
2O13	A	119	176	protein 3	0.94	6.41	6	58	29.90	194	NP_001121128.1	0.48	20.97	10

Figure 1 (continued)

2VJE	A	434	497	E3 ubiquitin-protein ligase Mdm2 isoform MDM2	1.27	7.08	9	64	12.88	497	NP_002383.2	-0.68	55.99	-38
2HDP	A	435	497	E3 ubiquitin-protein ligase Mdm2 isoform MDM2	1.29	7.00	9	63	12.68	497	NP_002383.2	-0.68	55.99	-38
2VJE	B	428	490	protein Mdm4 isoform 1	0.99	7.06	7	63	12.86	490	NP_002384.2	-0.49	54.86	-27
2Z7F	I	83	132	antileukoproteinase precursor	1.09	5.51	6	50	37.88	132	NP_003055.1	0.84	14.33	12
3QMB	A	162	222	cpG-binding protein isoform 2	0.95	9.50	9	79	9.30	656	NP_055408.2	0.17	75.71	13
1H1H	A	28	160	eosinophil cationic protein precursor	0.89	15.70	14	134	83.12	160	NP_002926.2	0.71	18.38	13
1DYT	A	28	160	eosinophil cationic protein precursor	0.90	15.57	14	133	83.12	160	NP_002926.2	0.71	18.38	13
				estrogen-related receptor gamma isoform 2	1.17	11.12	13	98	22.53	435	NP_001127757.1	-0.04	48.58	-2
1RXR	A	130	212	retinoic acid receptor RXR-alpha	1.12	9.79	11	83	17.97	462	NP_002948.1	0.04	50.81	2
2HKY	A	29	156	ribonuclease 7 precursor	1.09	14.68	16	129	82.05	156	NP_115961.2	0.92	17.44	16
1UBD	C	293	414	transcriptional repressor protein YY1	0.92	14.16	13	124	29.47	414	NP_003394.1	-0.45	44.71	-20
1KMX	A	317	371	vascular endothelial growth factor A isoform d	1.08	6.48	7	55	14.82	371	NP_001020539.2	0.10	40.74	4
2IP9	A	386	503	Wilms tumor protein isoform B	1.32	14.45	19	119	22.96	514	NP_077742.2	0.27	55.96	15
1RSU	B	341	440	CREB-binding protein isoform a	0.89	11.26	10	100	4.10	2442	NP_004371.2	0.12	265.34	31
1L8C	A	345	440	CREB-binding protein isoform a	0.92	10.83	10	95	3.89	2442	NP_004371.2	0.12	265.34	31
1HCQ	A	180	262	estrogen receptor isoform 4	1.03	9.69	10	84	13.95	595	NP_001116214.1	0.06	66.21	4
1HCP	A	180	254	estrogen receptor isoform 4	0.80	8.75	7	76	12.61	595	NP_001116214.1	0.06	66.21	4
3CBB	A	58	135	hepatocyte nuclear factor 4-alpha isoform a	1.44	9.03	13	78	16.81	464	NP_849180.1	-0.02	51.62	-1

Figure 1 (continued)

3I02	A	1723	1836	histone acetyltransferase p300	1.47	12.96	19	114	4.72	2414	NP_001420.2	0.11	264.15	30
1I3E	B	323	423	histone acetyltransferase p300	0.79	11.40	9	101	4.18	2414	NP_001420.2	0.11	264.15	30
2KKF	A	1147	1203	histone-lysine N-methyltransferase MLL isoform 1 precursor	1.80	6.66	12	59	1.44	3972	NP_001184033.1	0.24	432.03	102
2IYI	A	1147	1203	histone-lysine N-methyltransferase MLL isoform 2 precursor	1.84	6.52	12	57	1.44	3969	NP_005924.2	0.24	431.75	103
1A6Y	A	123	216	nuclear receptor subfamily 1 group D member 1	1.47	10.88	16	94	15.31	614	NP_068370.1	0.13	66.80	9
2A66	A	33	141	nuclear receptor subfamily 5 group A member 2 isoform 2	0.91	13.18	12	113	22.02	495	NP_003813.1	0.05	56.46	3
1DSZ	A	82	167	retinoic acid receptor alpha isoform 1	1.47	10.20	15	86	18.61	462	NP_001138773.1	0.08	50.77	4
1DSZ	B	128	212	retinoic acid receptor RXR-alpha	1.10	9.97	11	85	18.40	462	NP_002948.1	0.04	50.81	2
1BY4	A	128	209	retinoic acid receptor RXR-alpha	1.04	9.63	10	82	17.75	462	NP_002948.1	0.04	50.81	2
1RON	A	130	206	retinoic acid receptor RXR-alpha	1.18	9.36	11	81	16.67	462	NP_002948.1	0.04	50.81	2
2NLL	A	135	200	retinoic acid receptor RXR-alpha	1.16	7.73	9	66	14.29	462	NP_002948.1	0.04	50.81	2
1KB2	A	66	175	vitamin D3 receptor isoform VDRB1	0.85	12.92	11	110	23.06	477	NP_001017536.1	-0.07	53.88	-4
1YNW	A	66	175	vitamin D3 receptor isoform VDRB1	0.86	12.76	11	110	23.06	477	NP_001017536.1	-0.07	53.88	-4
2C7A	A	563	640	progesterone receptor isoform B	1.15	8.66	10	78	8.36	933	NP_000917.3	-0.07	98.98	-7
2KA6	A	1725	1816	CREB-binding protein isoform b	1.43	10.51	15	92	3.83	2404	NP_001073315.1	0.10	260.98	27
3P57	P	1725	1835	histone acetyltransferase p300	1.47	12.93	19	112	4.56	2414	NP_001420.2	0.11	264.15	30
1N29	A	22	144	phospholipase A2, membrane associated precursor	1.08	13.87	15	124	85.42	144	NP_001155201.1	0.99	16.08	16

Figure 1 (continued)

1N28	A	22	144	phospholipase A2, membrane associated precursor	1.08	13.87	15	124	85.42	144	NP_001155201.1	0.99	16.08	16
1U35	C	1	120	core histone macro- H2A.1 isoform 1	1.08	12.96	14	120	32.52	369	NP_613075.1	0.66	39.18	26
3AFA	A	1	136	histone cluster 1, H3d	1.28	15.68	20	139	100.00	136	NP_003521.2	1.30	15.40	20
1U35	A	1	136	histone cluster 1, H3d	1.30	15.40	20	136	100.00	136	NP_003521.2	1.30	15.40	20
2F8N	K	1	130	histone H2A type 1-B/E	1.11	16.16	18	149	100.00	130	NP_003504.2	1.20	14.13	17
3A6N	C	1	130	histone H2A type 1-B/E	1.18	14.42	17	133	100.00	130	NP_003504.2	1.20	14.13	17
2CV5	C	1	130	histone H2A type 1-B/E	1.20	14.13	17	130	100.00	130	NP_003504.2	1.20	14.13	17
1P34	C	2	130	histone H2A type 1-B/E	1.22	13.93	17	129	99.23	130	NP_003504.2	1.20	14.13	17
1ZLA	C	2	129	histone H2A.J	1.13	14.15	16	129	100.00	129	NP_808760.1	1.21	14.02	17
1KX3	C	2	129	histone H2A.J	1.22	13.88	17	128	99.22	129	NP_808760.1	1.21	14.02	17
2NQB	C	2	124	histone H2A.J	1.13	13.23	15	123	94.57	129	NP_808760.1	1.21	14.02	17
2PYO	C	2	122	histone H2A.J	1.01	12.90	13	120	93.02	129	NP_808760.1	1.21	14.02	17
1F66	C	1	128	histone H2A.Z	1.03	13.55	14	128	100.00	128	NP_002097.1	1.03	13.55	14
1U35	D	1	126	histone H2B type 1-B	1.29	13.99	18	126	100.00	126	NP_066406.1	1.29	13.95	18
3A6N	D	1	126	histone H2B type 1-J	1.27	14.18	18	129	100.00	126	NP_066402.2	1.29	13.90	18
1F66	D	1	126	histone H2B type 1-J	1.29	13.95	18	126	100.00	126	NP_066402.2	1.29	13.90	18
1KX3	D	2	126	histone H2B type 1-J	1.30	13.82	18	125	99.21	126	NP_066402.2	1.29	13.90	18
1P34	D	2	126	histone H2B type 1-J	1.30	13.80	18	125	99.21	126	NP_066402.2	1.29	13.90	18
2F8N	H	5	126	histone H2B type 1-J	1.39	13.62	19	123	96.83	126	NP_066402.2	1.29	13.90	18
2CV5	D	1	126	histone H2B type 1-K	1.30	13.89	18	126	100.00	126	NP_542160.1	1.30	13.89	18
1ZLA	D	2	126	histone H2B type 1-O	1.31	13.76	18	125	99.21	126	NP_003518.2	1.29	13.91	18
3A6N	A	1	136	histone H3.1t	1.27	15.79	20	139	100.00	136	NP_003484.1	1.29	15.51	20
3AV1	A	1	136	histone H3.2	1.28	15.67	20	139	100.00	136	NP_001116847.1	1.30	15.39	20
1F66	A	1	136	histone H3.2	1.23	15.47	19	136	100.00	136	NP_001116847.1	1.30	15.39	20
2F8N	A	1	136	histone H3.2	1.30	15.39	20	136	100.00	136	NP_001116847.1	1.30	15.39	20
1P3L	A	2	136	histone H3.2	1.24	15.37	19	135	99.26	136	NP_001116847.1	1.30	15.39	20
1P3M	A	2	136	histone H3.2	1.24	15.34	19	135	99.26	136	NP_001116847.1	1.30	15.39	20

Figure 1 (continued)

1P3B	A	2	136	histone H3.2	1.24	15.33	19	135	99.26	136	NP_001116847.1	1.30	15.39	20
1Z1A	A	2	136	histone H3.2	1.31	15.31	20	135	99.26	136	NP_001116847.1	1.30	15.39	20
1P3A	A	2	136	histone H3.2	1.18	15.31	18	135	99.26	136	NP_001116847.1	1.30	15.39	20
1P3K	A	2	136	histone H3.2	1.24	15.30	19	135	99.26	136	NP_001116847.1	1.30	15.39	20
1KX3	A	2	136	histone H3.2	1.31	15.27	20	135	99.26	136	NP_001116847.1	1.30	15.39	20
2IO5	B	2	136	histone H3.2	1.31	15.26	20	135	99.26	136	NP_001116847.1	1.30	15.39	20
1P34	A	2	136	histone H3.2	1.18	15.25	18	135	99.26	136	NP_001116847.1	1.30	15.39	20
3AV2	A	1	136	histone H3.3	1.28	15.61	20	139	100.00	136	NP_005315.1	1.30	15.33	20
1ID3	A	2	136	histone H3.3	1.44	15.24	22	135	99.26	136	NP_005315.1	1.30	15.33	20
3A6N	B	1	103	histone H4	1.55	11.65	18	106	100.00	103	NP_001029249.1	1.58	11.37	18
1F65	B	1	103	histone H4	1.58	11.37	18	103	100.00	103	NP_001029249.1	1.58	11.37	18
2NQ8	B	1	103	histone H4	1.58	11.36	18	103	100.00	103	NP_001029249.1	1.58	11.37	18
2PYO	B	2	103	histone H4	1.60	11.25	18	102	99.03	103	NP_001029249.1	1.58	11.37	18
1P3P	B	2	103	histone H4	1.60	11.25	18	102	99.03	103	NP_001029249.1	1.58	11.37	18
1KX3	B	2	103	histone H4	1.60	11.24	18	102	99.03	103	NP_001029249.1	1.58	11.37	18
1ID3	B	18	103	histone H4	1.60	11.24	18	102	83.50	103	NP_001029249.1	1.58	11.37	18
1P3I	B	2	103	histone H4	1.52	11.22	17	102	99.03	103	NP_001029249.1	1.58	11.37	18
1P3O	B	2	103	histone H4	1.61	11.21	18	102	99.03	103	NP_001029249.1	1.58	11.37	18
1P3G	B	2	103	histone H4	1.43	11.21	16	102	99.03	103	NP_001029249.1	1.58	11.37	18
1P3F	B	2	103	histone H4	1.52	11.18	17	102	99.03	103	NP_001029249.1	1.58	11.37	18
1P38	B	2	103	histone H4	1.52	11.15	17	102	99.03	103	NP_001029249.1	1.58	11.37	18
3NQJ	B	21	103	histone H4	1.16	9.52	11	84	80.58	103	NP_001029249.1	1.58	11.37	18
				cathepsin G										
1KYN	A	21	255	preproprotein	0.82	26.76	22	235	92.16	255	NP_001902.1	0.69	28.84	20
1AU8	A	21	244	cathepsin G	0.90	25.44	23	224	87.84	255	NP_001902.1	0.69	28.84	20
2YRQ	A	1	166	high mobility group protein B1	0.92	19.63	18	173	77.21	215	NP_002119.1	-0.20	24.89	-5
28FH	A	161	288	heparin-binding growth factor 2	0.75	14.64	11	128	44.44	288	NP_001997.5	1.04	30.77	32

Figure 1 (continued)

1AYP	A	21	144	phospholipase A2, membrane associated precursor	1.08	13.92	15	124	86.11	144	NP_001155201.1	0.99	16.08	16
1H8U	A	106	222	bone marrow proteoglycan preproprotein	1.16	13.80	16	117	52.70	222	NP_002719.3	-0.08	25.20	-2
1B34	A	1	119	small nuclear ribonucleoprotein Sm D1	1.20	13.28	16	119	100.00	119	NP_008869.1	1.20	13.28	16
2CPX	A	289	393	RNA-binding protein 41 isoform 1	0.85	12.95	11	115	25.42	413	NP_060771.3	0.13	47.10	6
2DB2	A	40	152	putative ATP-dependent RNA helicase DHX30 isoform 1	0.78	12.76	10	119	9.46	1194	NP_619520.1	0.13	133.93	18
2CSH	A	367	467	zinc finger and BTB domain-containing protein 43	0.90	12.26	11	110	21.63	467	NP_001129248.1	-0.48	52.63	-25
2EBT	A	363	457	Krüppel-like factor 5 precursor	0.86	11.62	10	100	20.79	457	NP_001721.2	0.14	50.79	7
2GYR	A	130	228	artemin isoform 3	0.78	11.55	9	105	43.42	228	NP_001129687.1	0.89	23.62	21
2D8R	A	1	88	THAP domain-containing protein 2	0.82	11.02	9	99	38.60	228	NP_113623.1	0.99	26.26	26
2CQL	A	1	87	60S ribosomal protein L9	1.01	10.93	11	100	45.31	192	NP_001020092.1	0.59	21.86	13
2YU4	A	161	247	E3 SUMO-protein ligase NSE2	0.75	10.61	8	94	35.22	247	NP_775956.1	0.04	27.93	1
2DMD	A	174	257	zinc finger protein 64 isoform a	0.86	10.47	9	96	12.33	681	NP_060667.2	0.21	74.64	16
2YT9	A	355	437	POZ-, AT hook-, and zinc finger-containing protein 1 short isoform	0.87	10.39	9	95	15.46	537	NP_114440.1	0.16	57.60	9
2ESH	A	1	87	zinc finger CCHC-type and RNA-binding motif- containing protein 1	0.98	10.15	10	94	40.09	217	NP_149105.3	0.16	24.59	4
2E6O	A	422	503	HMG box-containing protein 1	0.90	9.98	9	87	15.95	514	NP_036389.2	-0.23	57.64	-13
2RPR	A	594	673	FLYWCH-type zinc finger- containing protein 1 isoform a	0.80	9.96	8	87	11.19	715	NP_115672.2	0.12	80.03	10

Figure 1 (continued)

2EBL	A	84	164	COUP transcription factor 1	1.21	9.88	12	89	19.15	423	NP_005645.1	0.15	46.15	7
				DNA-directed RNA polymerase III subunit RPC6										
2DK5	A	78	155	high mobility group protein B3	0.81	9.85	8	91	24.68	316	NP_006457.2	-0.14	35.68	-5
2EQZ	A	1	79	peroxisome proliferator-activated receptor delta isoform 3	0.82	9.79	8	86	39.50	200	NP_005333.2	0.13	22.98	3
2ENV	A	26	112	endothelial differentiation-related factor 1 isoform alpha	1.12	9.78	11	88	21.64	402	NP_001165290.1	0.28	45.76	13
1X57	A	71	148	homeobox protein TGIF2LX	0.84	9.55	8	91	52.70	148	NP_003783.1	0.67	16.37	11
2DMN	A	51	120	sex-determining region Y protein	0.84	9.53	8	83	29.05	241	NP_620410.3	0.15	26.67	4
1HRY	A	56	131	retinoic acid receptor beta isoform 1	0.95	9.49	9	76	37.25	204	NP_003131.1	0.50	23.88	12
1HRA	A	75	153	LIM/homeobox protein Lhx9 isoform 1	1.17	9.42	11	80	17.63	448	NP_000956.2	0.02	50.34	1
2DMQ	A	268	334	homeobox protein BarH-like 1	1.44	9.00	13	80	16.88	397	NP_064589.2	0.30	43.97	13
2DMT	A	133	199	protein kinase C delta type	1.12	8.96	10	80	26.38	254	NP_067545.3	0.40	27.30	11
2YUU	A	149	218	zinc finger and SCAN domain-containing protein 16	0.89	8.95	8	83	10.36	676	NP_997704.1	0.04	77.50	3
2COT	A	222	291	zinc finger FYVE domain-containing protein 27 isoform a	0.81	8.66	7	77	20.11	348	NP_079507.1	0.10	40.79	4
1X4U	A	346	416	C-X-C motif chemokine 10 precursor	0.92	8.65	8	84	17.07	416	NP_001002261.1	-0.26	46.34	-12
1O7Y	A	22	98	protein kinase C theta type	1.16	8.62	10	77	78.57	98	NP_001556.2	1.01	10.88	11
2ENN	A	144	213	zinc fingers and homeoboxes protein 3	0.95	8.45	8	77	9.92	706	NP_006248.1	0.02	81.86	2
2DN0	A	494	557		1.07	8.37	9	76	6.69	956	NP_055850.1	-0.21	104.65	-22

Figure 1 (continued)

2DB6	A	80	142	SH3 and cysteine-rich domain-containing protein 3	0.84	8.32	7	74	17.31	364	NP_659501.1	-0.05	41.51	-2
2CSZ	A	43	106	synaptotagmin-like protein 4	1.10	8.20	9	76	9.54	671	NP_001167539.1	0.21	76.02	16
2CU7	A	115	181	histone H2A deubiquitinase MYSM1	1.10	8.16	9	72	8.09	828	NP_001078956.1	-0.23	95.03	-22
1X2N	A	258	319	homeobox protein PKNOX1	0.86	8.11	7	73	14.22	436	NP_004562.2	-0.40	47.60	-19
2EPA	A	342	412	Krüppel-like factor 10 isoform b	1.11	8.10	9	72	15.14	469	NP_001027453.1	0.33	51.42	17
				hematopoietically-expressed homeobox protein HHEX										
2E10	A	138	194	homeobox protein Hox-B13	1.24	8.04	10	70	21.11	270	NP_002720.1	-0.03	30.02	-1
2CRA	A	216	273	zinc finger protein 483 isoform a	1.63	7.97	13	70	20.42	284	NP_006352.2	0.29	30.67	9
2CTU	A	379	438	growth-regulated alpha protein precursor	1.27	7.88	10	73	8.06	744	NP_597721.2	0.26	85.09	22
1MGS	A	35	107	cell division cycle 5-like protein	0.76	7.86	6	73	68.22	107	NP_001502.1	0.97	11.30	11
2DIM	A	7	64	ligand-dependent corepressor isoform 1	0.90	7.81	7	70	7.23	802	NP_001244.1	0.03	92.25	3
2COB	A	343	405	growth-regulated alpha protein precursor	1.15	7.80	9	70	14.55	433	NP_115816.2	0.23	47.00	11
1MSG	A	35	106	homeobox protein DLX-5	0.77	7.75	6	72	67.29	107	NP_001502.1	0.97	11.30	11
2DJN	A	138	194	transcription elongation factor SPT5 isoform a	1.42	7.73	11	70	19.72	289	NP_005212.1	0.25	31.54	8
2E70	A	690	757	POU domain, class 2, transcription factor 2 isoform 1	0.78	7.67	6	71	6.26	1087	NP_001124296.1	-0.45	120.99	-54
				39S ribosomal protein L27, mitochondrial										
1HDP	A	297	359	complement factor H isoform a precursor	0.92	7.63	7	63	13.15	479	NP_001193954.1	0.06	51.21	3
3IY9	O	31	99	complement factor H isoform a precursor	1.33	7.50	10	69	46.62	148	NP_057588.1	1.00	16.07	16
2IGX	A	386	446	complement factor H isoform a precursor	0.86	7.00	6	61	4.96	1231	NP_000177.2	-0.09	139.07	-12
2IGW	A	386	446	complement factor H isoform a precursor	0.86	6.97	6	61	4.96	1231	NP_000177.2	-0.09	139.07	-12

Figure 1 (continued)

1BBO	A	2087	2143	zinc finger protein 40	1.78	6.74	12	57	2.10	2718	NP_002105.2	0.02	296.85	6
				tumor necrosis factor receptor superfamily member 13C	0.89	6.72	6	63	34.24	184	NP_443177.1	0.11	18.86	2
1POT	0	1	63	telomeric repeat-binding factor 1 isoform 1	1.50	6.65	10	53	12.07	439	NP_059523.2	-0.14	50.24	-7
1BA5	A	378	430	ubiquitin-associated and SH3 domain-containing protein B	0.91	6.57	6	64	8.17	649	NP_116262.2	-0.07	72.69	-5
2CPW	A	26	78	zinc finger MYM-type protein 5 isoform 3	1.11	6.32	7	62	7.32	669	NP_001136156.1	0.12	74.81	9
2DAS	A	229	277	39S ribosomal protein L33, mitochondrial isoform a	1.48	6.08	9	52	80.00	65	NP_004882.1	1.44	7.62	11
3IY9	P	9	60	E3 ubiquitin-protein ligase RBBP6 isoform 1	0.84	5.97	5	55	2.73	1792	NP_008841.2	0.50	201.56	101
2YSA	A	158	206	zinc finger HIT domain-containing protein 3	0.84	5.95	5	56	29.03	155	NP_004764.1	-0.17	17.61	-3
2YQQ	A	2	46	agouti-signaling protein precursor	1.39	5.76	8	53	40.15	132	NP_001663.2	1.03	14.51	15
2KZA	A	80	132	lactotransferrin isoform 1 precursor	1.57	5.74	9	49	6.62	710	NP_002334.2	0.14	78.18	11
1Z6V	A	21	67	importin subunit alpha-2	1.86	5.37	10	44	8.32	529	NP_002257.1	-0.22	57.86	-13
1QGK	B	11	54	POZ-, AT hook-, and zinc finger-containing protein 1 short isoform	0.97	5.15	5	48	6.52	537	NP_114440.1	0.16	57.60	9
2EPR	A	350	384	gastricsin isoform 2 preproprotein	1.17	5.12	6	43	13.65	315	NP_001159896.1	-0.09	34.21	-3
1HTR	P	17	59	snurportin-1	1.60	5.01	8	40	11.11	360	NP_001036053.1	-0.15	41.14	-6
2P8Q	B	25	64	Krueppel-like factor 15	0.80	5.01	4	48	8.41	416	NP_054798.1	0.11	43.99	5
2ENT	A	346	380	zinc finger protein 473	1.20	4.98	6	46	3.79	871	NP_001006657.1	0.20	100.18	20
2EOY	A	557	589	zinc finger protein 473	0.81	4.93	4	46	3.79	871	NP_001006657.1	0.20	100.18	20
2YTD	A	426	458	transcription factor AP-1	0.82	4.91	4	44	12.08	331	NP_002219.1	0.11	35.67	4
1IUN	A	276	315	zinc finger protein 484 isoform a	1.02	4.90	5	46	3.87	852	NP_113674.1	0.22	98.22	22
2EOV	A	519	551											

Figure 1 (continued)

2EN4	A	278	317	zinc finger protein 347 isoform a	1.02	4.90	5	46	4.76	840	NP_001166146.1	0.54	95.84	52
2EOH	A	780	812	zinc finger protein 28 homolog	1.02	4.89	5	46	3.80	868	NP_065879.1	0.53	98.70	52
2ENE	A	593	625	zinc finger protein 347 isoform a	0.82	4.89	4	46	3.93	840	NP_001166146.1	0.54	95.84	52
2YTS	A	715	747	zinc finger protein 484 isoform a	0.82	4.86	4	46	3.87	852	NP_113674.1	0.22	98.22	22
2EQ0	A	453	485	zinc finger protein 347 isoform a	0.82	4.85	4	46	3.93	840	NP_001166146.1	0.54	95.84	52
2EL6	A	746	780	zinc finger protein 268 isoform c	1.04	4.82	5	46	4.05	864	NP_001159354.1	0.44	98.81	43
2EMA	A	313	345	zinc finger protein 347 isoform a	0.83	4.81	4	46	3.93	840	NP_001166146.1	0.54	95.84	52
2EM9	A	367	399	zinc finger protein 224	0.83	4.80	4	46	4.67	707	NP_037530.2	0.40	82.28	33
2YIJ	A	771	803	zinc finger protein 484 isoform a	1.05	4.76	5	46	3.87	852	NP_113674.1	0.22	98.22	22
2EMB	A	342	373	zinc finger protein 473	1.47	4.76	7	44	3.67	871	NP_001006657.1	0.20	100.18	20
2EM2	A	584	616	zinc finger protein 28 homolog	0.84	4.74	4	46	3.80	868	NP_065879.1	0.53	98.70	52
2EM4	A	724	756	zinc finger protein 28 homolog	0.84	4.74	4	46	3.80	868	NP_065879.1	0.53	98.70	52
2EN9	A	415	447	zinc finger protein 28 homolog	1.06	4.73	5	46	3.80	868	NP_065879.1	0.53	98.70	52
2YU8	A	649	681	zinc finger protein 347 isoform a	1.06	4.73	5	46	3.93	840	NP_001166146.1	0.54	95.84	52
2EMZ	A	625	660	zinc finger protein with KRAB and SCAN domains 5	1.06	4.73	5	46	4.29	839	NP_659570.1	0.00	96.90	0
2YTR	A	761	793	zinc finger protein 347 isoform a	0.85	4.72	4	46	3.93	840	NP_001166146.1	0.54	95.84	52
2EPQ	A	378	411	POZ-, AT hook-, and zinc finger-containing protein 1 short isoform	1.06	4.72	5	45	6.33	537	NP_114440.1	0.16	57.60	9
2YU5	A	669	699	zinc finger protein 473	0.85	4.71	4	44	3.56	871	NP_001006657.1	0.20	100.18	20
2YTN	A	733	765	zinc finger protein 347 isoform a	1.06	4.71	5	46	3.93	840	NP_001166146.1	0.54	95.84	52

Figure 1 (continued)

2EQQ	A	283	315	zinc finger protein 224	0.85	4.71	4	46	4.67	707	NP_037530.2	0.40	82.28	33
				receptor tyrosine-protein kinase erbB-3 isoform 1 precursor										
2L9U	A	637	670		0.85	4.69	4	40	2.53	1342	NP_001973.2	-0.15	148.09	-22
2ELY	A	227	259	zinc finger protein 224	0.86	4.67	4	46	4.67	707	NP_037530.2	0.40	82.28	33
				zinc finger protein 28										
2EML	A	750	784	homolog	0.86	4.67	4	46	4.03	868	NP_065879.1	0.53	98.70	52
				zinc finger protein 347										
2EQ2	A	676	708	isoform b	0.86	4.64	4	46	3.93	839	NP_115973.2	0.54	95.77	52
2EPU	A	100	131	zinc finger protein 32	0.87	4.59	4	45	11.72	273	NP_001005368.1	0.68	31.03	21
				Na(+)/H(+) exchange regulatory cofactor NHE-RF1										
1SGH	B	321	358		0.87	4.58	4	39	10.61	358	NP_004243.1	-0.23	38.87	-9
				zinc finger protein 268										
2EL4	A	580	617	isoform c	1.09	4.58	5	46	4.40	864	NP_001159354.1	0.44	98.81	43
				prostatic acid phosphatase isoform PAP precursor										
2L3H	A	248	286		1.32	4.55	6	39	10.10	386	NP_001090.2	-0.20	44.56	-9
2YRH	A	699	729	zinc finger protein 473	1.11	4.52	5	44	3.56	871	NP_001006657.1	0.20	100.18	20
				zinc finger protein 268										
2EOG	A	608	640	isoform c	0.89	4.52	4	44	3.82	864	NP_001159354.1	0.44	98.81	43
1FQQ	A	24	64	beta-defensin 4B	1.38	4.33	6	41	64.06	64	NP_001192195.1	0.99	7.04	7
				zinc finger protein ZFAT										
2ELU	A	340	369	isoform 4	0.96	4.18	4	37	2.62	1145	NP_001167629.1	0.05	128.66	6
				band 3 anion transport protein										
1BH7	A	803	835		1.21	4.15	5	33	3.62	911	NP_000333.1	-0.31	101.79	-32
				zinc finger protein ZFAT										
2ELM	A	756	785	isoform 4	0.97	4.14	4	37	2.62	1145	NP_001167629.1	0.05	128.66	6
				zinc finger protein ZFAT										
2ELS	A	269	297	isoform 1	0.98	4.08	4	36	2.33	1243	NP_065914.2	-0.04	139.03	-6

Figure 2

PDB ID	PDB chain	Subseq Start	Subseq End	Protein Name	charge/MW	MW	charge	# AA	% FL	# AA	Refseq	charge/MW	MW	charge
2KZA	A	80	132	agouti-signaling protein precursor	1.39	5.76	8	53	40.15	132	NP_001663.2	1.03	14.51	15
1BH7	A	803	835	band 3 anion transport protein	1.21	4.15	5	33	3.62	911	NP_000333.1	-0.31	101.79	-32
2LCE	A	536	602	B-cell lymphoma 6 protein isoform 1	0.93	8.62	8	74	9.49	706	NP_001124317.1	0.09	78.84	7
2J5D	A	146	190	BCL2/adenovirus E1B 19 kDa protein-interacting protein 3	1.02	4.92	5	45	23.20	194	NP_004043.2	-0.09	21.54	-2
2PLZ	A	33	68	beta-defensin 1 preproprotein	0.99	4.05	4	36	52.94	68	NP_005209.1	0.67	7.42	5
2K6O	A	134	170	cathelicidin antimicrobial peptide	1.34	4.49	6	37	21.76	170	NP_004336.2	0.41	19.30	8
1TZS	P	19	53	cathepsin E isoform a preproprotein	1.66	4.21	7	35	8.84	396	NP_001901.1	-0.37	42.79	-16
3HTU	B	11	48	charged multivesicular body protein 6	1.07	4.69	5	39	18.91	201	NP_078867.2	-0.21	23.48	-5
3QMB	A	162	222	cpG-binding protein isoform 2	0.95	9.50	9	79	9.30	656	NP_055408.2	0.17	75.71	13
1O7Y	A	22	98	C-X-C motif chemokine 10 precursor	1.16	8.62	10	77	78.57	98	NP_001556.2	1.01	10.88	11
2KS1	B	634	677	epidermal growth factor receptor isoform a precursor	1.27	4.73	6	44	3.64	1210	NP_005219.2	-0.09	134.27	-12
1M36	A	532	563	histone acetyltransferase MYST3	1.49	4.04	6	33	1.60	2004	NP_001092883.1	-0.24	225.02	-53
3P57	P	1726	1835	histone acetyltransferase p300	1.47	12.93	19	112	4.56	2414	NP_001420.2	0.11	264.15	30
2L9R	A	129	189	homeobox protein Nkx-3.1	0.96	8.35	8	69	26.07	234	NP_006158.2	0.19	26.35	5
2W0T	A	82	124	lethal(3)malignant brain tumor-like protein 2	0.87	4.60	4	43	6.10	705	NP_113676.2	-0.08	79.11	-6
3OA6	A	1	101	male-specific lethal 3 homolog isoform a	0.84	13.07	11	110	19.39	521	NP_523353.2	0.07	59.82	4

Figure 2 (continued)

1SGH	B	321	358	Na(+)/H(+) exchange regulatory cofactor NHE- RF1	0.87	4.58	4	39	10.61	358	NP_004243.1	-0.23	38.87	-9
21B3	A	6	41	peptidyl-prolyl cis-trans isomerase NIMA- interacting 1	0.95	4.22	4	36	22.09	163	NP_006212.1	0.16	18.24	3
2KCF	A	6	39	peptidyl-prolyl cis-trans isomerase NIMA- interacting 1	0.96	4.17	4	36	20.86	163	NP_006212.1	0.16	18.24	3
1CQT	I	1	44	POU domain class 2- associating factor 1	1.23	4.86	6	44	17.19	256	NP_006226.2	-0.36	27.43	-10
213H	A	248	286	prostatic acid phosphatase isoform PAP precursor	1.32	4.55	6	39	10.10	386	NP_001090.2	-0.20	44.56	-9
21WA	A	611	654	receptor tyrosine-protein kinase erbB-2 isoform b	1.27	4.73	6	44	3.59	1225	NP_001005862.1	-0.23	134.85	-31
219U	A	637	670	receptor tyrosine-protein kinase erbB-3 isoform 1 precursor	0.85	4.69	4	40	2.53	1342	NP_001973.2	-0.15	148.09	-22
212T	A	642	685	receptor tyrosine-protein kinase erbB-4 isoform JM-a/CVT-2 precursor	1.68	4.76	8	44	3.41	1292	NP_001036064.1	-0.12	145.19	-18
31XS	B	144	176	RING1 and YY1-binding protein	0.98	4.10	4	37	14.47	228	NP_036366.3	0.56	24.82	14
1UKL	C	343	403	sterol regulatory element-binding protein 2	0.98	7.12	7	61	5.35	1141	NP_004590.2	0.10	123.68	12
2KOL	A	22	89	stromal cell-derived factor 1 isoform gamma	1.25	7.98	10	68	57.14	119	NP_001029058.1	1.68	13.71	23
3S90	C	1512	1546	talin-1	1.22	4.10	5	40	1.38	2541	NP_006280.3	-0.13	269.76	-35
1Q68	A	421	458	T-cell surface glycoprotein CD4 isoform 1 precursor	2.14	4.68	10	38	8.30	458	NP_000607.1	0.45	51.11	23
1JUN	A	276	315	transcription factor AP-1	0.82	4.91	4	44	12.08	331	NP_002219.1	0.11	35.67	4
2KZ5	A	214	293	transcription factor NF-E2 45 kDa subunit isoform 2	0.76	10.54	8	91	21.45	373	NP_001129495.1	-0.39	41.47	-16
1VA1	A	612	647	transcription factor Sp1 isoform b	1.40	4.29	6	37	4.63	778	NP_003100.1	0.01	79.89	1

Figure 2 (continued)

2BE6	D	1600	1633	voltage-dependent L-type calcium channel subunit alpha-1C isoform 23	0.92	4.36	4	37	1.55	2198	NP_001161097.1	-0.04	245.94	-11
2EM9	A	367	399	zinc finger protein 224	0.83	4.80	4	46	4.67	707	NP_037530.2	0.40	82.28	33
2EOQ	A	283	315	zinc finger protein 224	0.85	4.71	4	46	4.67	707	NP_037530.2	0.40	82.28	33
2ELY	A	227	259	zinc finger protein 224	0.86	4.67	4	46	4.67	707	NP_037530.2	0.40	82.28	33
2EL6	A	746	780	zinc finger protein 268 isoform c	1.04	4.82	5	46	4.05	864	NP_001159354.1	0.44	98.81	43
2EL4	A	580	617	zinc finger protein 268 isoform c	1.09	4.58	5	46	4.40	864	NP_001159354.1	0.44	98.81	43
2EOG	A	608	640	zinc finger protein 268 isoform c	0.89	4.52	4	44	3.82	864	NP_001159354.1	0.44	98.81	43
2EOH	A	780	812	zinc finger protein 28 homolog	1.02	4.89	5	46	3.80	868	NP_065879.1	0.53	98.70	52
2EM2	A	584	616	zinc finger protein 28 homolog	0.84	4.74	4	46	3.80	868	NP_065879.1	0.53	98.70	52
2EM4	A	724	756	zinc finger protein 28 homolog	0.84	4.74	4	46	3.80	868	NP_065879.1	0.53	98.70	52
2EN9	A	415	447	zinc finger protein 28 homolog	1.06	4.73	5	46	3.80	868	NP_065879.1	0.53	98.70	52
2EML	A	750	784	zinc finger protein 28 homolog	0.86	4.67	4	46	4.03	868	NP_065879.1	0.53	98.70	52
2EPU	A	100	131	zinc finger protein 32	0.87	4.59	4	45	11.72	273	NP_001005368.1	0.68	31.03	21
2EN4	A	278	317	zinc finger protein 347 isoform a	1.02	4.90	5	46	4.76	840	NP_001166146.1	0.54	95.84	52
2ENE	A	593	625	zinc finger protein 347 isoform a	0.82	4.89	4	46	3.93	840	NP_001166146.1	0.54	95.84	52
2EQ0	A	453	485	zinc finger protein 347 isoform a	0.82	4.85	4	46	3.93	840	NP_001166146.1	0.54	95.84	52
2EMA	A	313	345	zinc finger protein 347 isoform a	0.83	4.81	4	46	3.93	840	NP_001166146.1	0.54	95.84	52
2YU8	A	649	681	zinc finger protein 347 isoform a	1.06	4.73	5	46	3.93	840	NP_001166146.1	0.54	95.84	52
2YTR	A	761	793	zinc finger protein 347 isoform a	0.85	4.72	4	46	3.93	840	NP_001166146.1	0.54	95.84	52
2YTN	A	733	765	zinc finger protein 347 isoform a	1.06	4.71	5	46	3.93	840	NP_001166146.1	0.54	95.84	52

Figure 2 (continued)

2EQ2	A	676	708	zinc finger protein 347 isoform b	0.86	4.64	4	46	3.93	839	NP_115973.2	0.54	95.77	52
1B80	A	2087	2143	zinc finger protein 40	1.78	6.74	12	57	2.10	2718	NP_002105.2	0.02	296.85	6
2EOY	A	557	589	zinc finger protein 473	1.20	4.98	6	46	3.79	871	NP_001006657.1	0.20	100.18	20
2YTD	A	426	458	zinc finger protein 473	0.81	4.93	4	46	3.79	871	NP_001006657.1	0.20	100.18	20
2EMB	A	342	373	zinc finger protein 473	1.47	4.76	7	44	3.67	871	NP_001006657.1	0.20	100.18	20
2YU5	A	669	699	zinc finger protein 473	0.85	4.71	4	44	3.56	871	NP_001006657.1	0.20	100.18	20
2YRH	A	699	729	zinc finger protein 473	1.11	4.52	5	44	3.56	871	NP_001006657.1	0.20	100.18	20
2EOV	A	519	551	zinc finger protein 484 isoform a	1.02	4.90	5	46	3.87	852	NP_113674.1	0.22	98.22	22
2YTS	A	715	747	zinc finger protein 484 isoform a	0.82	4.86	4	46	3.87	852	NP_113674.1	0.22	98.22	22
2YTJ	A	771	803	zinc finger protein 484 isoform a	1.05	4.76	5	46	3.87	852	NP_113674.1	0.22	98.22	22
				zinc finger protein with KRAB and SCAN domains										
2EMZ	A	625	660	5	1.06	4.73	5	46	4.29	839	NP_659570.1	0.00	96.90	0
2ELS	A	269	297	zinc finger protein ZFAT isoform 1	0.98	4.08	4	36	2.33	1243	NP_065914.2	-0.04	139.03	-6
2ELU	A	340	369	zinc finger protein ZFAT isoform 4	0.96	4.18	4	37	2.62	1145	NP_001167629.1	0.05	128.66	6
2ELM	A	756	785	zinc finger protein ZFAT isoform 4	0.97	4.14	4	37	2.62	1145	NP_001167629.1	0.05	128.66	6
				zinc finger Ran-binding domain-containing protein 2 isoform 2										
1NOZ	A	1	40		0.80	5.00	4	45	12.50	320	NP_005446.2	0.63	36.32	23